(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 July 2023 (27.07.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/141302 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61P 25/00* (2006.01)
A61K 31/7115 (2006.01) *A61K 31/713* (2006.01)
A61K 31/712 (2006.01) *C12N 15/11* (2006.01)
A61K 31/7125 (2006.01)

(21) International Application Number:
PCT/US2023/011286

(22) International Filing Date:
20 January 2023 (20.01.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/301,416 20 January 2022 (20.01.2022) US

(71) Applicant: **BOLDEN THERAPEUTICS, INC.** [US/US]; 225 Dyer Street, Floor 2, Providence, Rhode Island 02903 (US).


(72) Inventors: **PAGE, John**; c/o Bolden Therapeutics, Inc., 225 Dyer Street, Floor 2, Providence, Rhode Island 02903 (US). **VALAT, Anne**; c/o Bolden Therapeutics, Inc., 225 Dyer Street, Floor 2, Providence, Rhode Island 02903 (US). **AGRAWAL, Sudhir**; c/o Bolden Therapeutics, Inc., 225 Dyer Street, Floor 2, Providence, Rhode Island 02903 (US). **BROWN, Duncan**; c/o Bolden Therapeutics, Inc., 225 Dyer Street, Floor 2, Providence, Rhode Island 02903 (US).

(74) Agent: **DAUKSS, Dana M.** et al.; CHOATE, HALL & STEWART LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

(54) Title: MUSK-TARGETING OLIGONUCLEOTIDES



(57) Abstract: The present disclosure provides, among other things, MuSK-targeting oligonucleotide compositions that alter the splicing of MuSK transcripts through exon skipping, and methods of treating diseases with said compositions.

[Continued on next page]

WO 2023/141302 A1

TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

MUSK-TARGETING OLIGONUCLEOTIDES

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 63/301,416, filed January 20, 2022, the contents of which is hereby incorporated by reference in its entirety.

BACKGROUND

[0002] Neurodegenerative diseases represent a major public health challenge, expected to impact one in five people in their lifetimes. Alzheimer's disease (AD) is the most common cause of age-related dementia. There is a critical and urgent need for therapeutics to prevent and treat AD and other neurodegenerative conditions.

[0003] Skeletal muscle has the ability to regenerate after injury. Muscle regeneration is dependent upon resident stem cells, referred to as muscle satellite cells. In mature muscle tissue, satellite cells constitute a small, scattered population of mitotically and physiologically quiescent cells. Satellite cells are also implicated in normal muscle growth and maintenance throughout life, indicating that they could be exploited to treat muscle wasting conditions.

[0004] Skeletal muscle makes up about 35% of body weight and is essential for metabolism, locomotion, and breathing, which highlights its importance in human health. Muscle wasting reduces mobility, metabolism, and quality of life for the majority of cancer patients, elderly patients, and many others with no history of neuromuscular dysfunction. In addition, muscular dystrophies are an often fatal group of genetic diseases leading to severe muscle loss, including Duchenne Muscular Dystrophy which affects children.

[0005] Neurogenesis and muscle regeneration are dependent on neural stem cells (NSCs) and muscle satellite cells. A roadblock to development of treatments of neurodegeneration and muscle wasting is that the signaling that regulates neural stem cells and satellite cells and their regeneration is poorly understood. Accordingly, there is a need for compositions and methods for promoting neurogenesis and muscle regeneration.

SUMMARY

[0006] Among other things, the present disclosure provides an insight that presence and/or activity of a particular form(s) of the muscle-specific tyrosine kinase (MuSK) protein, specifically lacking a functional Ig3 domain, may achieve or contribute to beneficial biological events including, for example, neurogenesis and/or muscle regeneration.

[0007] The present disclosure provides certain technologies for enhancing neurogenesis, including in particular in adult humans. In some embodiments, technologies provided herein may be useful in medicine, including specifically treatment of diseases, disorders or conditions associated with neurodegeneration, or otherwise with low or reduced neuronal activity (e.g., neuronal activity in an adult hippocampus and/or in subventricular zone(s)). For example, in some embodiments, technologies provided herein may be useful in the treatment of one or more of Alzheimer's Disease (AD), Parkinson's disease, dementia (e.g., Frontotemporal dementia), stroke, Major Depressive Disorder (MDD), bipolar disorder, Schizophrenia, Post-Traumatic Stress Disorder (PTSD), substance-related and addictive disorders (*e.g.,* chronic cocaine use and lifelong cigarette smoking), Temporal-Lobe Epilepsy, Hippocampal Sclerosis, Niemann Pick Type C, Diabetes-mediated hippocampal neuronal loss, brain injury (e.g., traumatic and/or anoxic brain injury), and Huntington's disease.

[0008] Bone morphogenetic protein (BMP) signaling regulates at least two important NSC decision points: 1) quiescence, where proliferating stem cells exit the cell cycle and return to replenish a reserve pool that can supply fresh stem cells; and; 2) differentiation into mature progeny (Mira et al., 2010). The present disclosure contemplates that manipulating the BMP pathway in NSCs is an attractive target for regulating neurogenesis in the adult brain. Additionally, BMP signaling regulates skeletal muscle stem cell activity in both normal and pathological states. The present disclosure provides technologies for increasing level and/or activity of MuSK form(s) that functionally participate in neurogenesis and/or muscle regeneration, including, in some embodiments, by reducing alternative splicing that would otherwise generate MuSK form(s) that do not so participate. In some embodiments, such increase is in a relevant tissue such as muscle. Alternatively or additionally, in some embodiments, such increase is in a tissues such as a brain tissue (*e.g.,* hippocampal and/or subventricular) and/or lung tissue.

[0009] Among other things, the present disclosure provides an insight that presence and/or activity of a particular form(s) of the muscle-specific tyrosine kinase (MuSK) protein, specifically lacking a functional Ig3 domain, may achieve or contribute to neurogenesis in adult humans, or otherwise provide neurological benefit(s). The MuSK transcript can be alternatively spliced, including to generate at least one form (*i.e.*, ΔIg3-MuSK) that lacks the Ig3 domain. The present disclosure appreciates that increasing presence and/or level of ΔIg3-MuSK, and/or of other functional form(s) in which its Ig3 domain is altered (*e.g.*, mutated, blocked, etc.) or removed, may provide benefits as described herein.

[0010] In some embodiments, the present disclosure provides technologies for increasing level and/or activity of one or more forms of MuSK whose Ig3 domain is altered (*e.g.*, mutated, blocked, removed, etc.) for example so that it fails to effectively participate in interaction(s) with BMP. In some embodiments, the present disclosure provides technologies for reducing $Ig3^+$ MuSK, for example by reducing level and/or activity of one or more forms of MuSK whose Ig3 domain effectively participates in interaction(s) with BMP.

[0011] In some embodiments, an agent that targets the MuSK Ig3 domain, as described herein (*e.g.*, a MuSK-targeting oligonucleotide), so that level and/or activity of a MuSK/BMP complex is reduced is useful in contexts of neurogenesis and/or muscle regeneration and/or of muscle growth.

[0012] In some embodiments, provided agent(s) may enhance muscle growth. In some embodiments, muscle growth occurs in uninjured tissue. In some embodiments, muscle growth occurs in injured tissue. In some embodiments, enhanced and/or increased muscle growth is determined by a decrease in satellite cell number and/or increase in muscle fiber size. In this regard, muscle growth can be characterized by a decrease in satellite cell number and/or increase in muscle fiber size, which is indicative of satellite cells differentiating and fusing into/augmenting existing muscle fibers and forming new muscle fibers.

[0013] Embodiments of the present invention provide methods of enhancing neurogenesis and/or muscle regeneration and/or growth, for example in a subject in need thereof, by administering a composition that downregulates MuSK Ig3 domain protein expression, MuSK Ig3 domain gene expression, and/or MuSK Ig3 activation of BMP signaling, thereby upregulating muscle satellite cells which results in enhancement of muscle

regeneration and/or growth. In some embodiments, such a composition can comprise and/or deliver a MuSK-targeting oligonucleotide (*e.g.*, a MuSK Ig3-targeting exon-skipping oligonucleotide).

[0014] In some embodiments, enhancing neurogenesis is used in the context of treating a disease or disorder associated with reduced Adult Hippocampal Neurogenesis (AHN). As AHN occurs throughout life in humans and is dramatically reduced in AD (Moreno-Jimenez et al., 2019; Steiner et al., 2019), the present disclosure provides compositions and methods for promoting AHN, enhancing cognitive function and combating neurodegeneration (*e.g.*, Alzheimer's disease).

[0015] In some embodiments, enhancing neurogenesis is used in the context of treating a disease or disorder associated with reduced Subventricular Zone Neurogenesis. As NSCs reside in the subventricular zone (SVZ) lining the lateral ventricles and generate astrocytes and oligodendrocytes that support the existing circuitry as well as neurons in the olfactory bulb that are critical for olfactory discrimination. The present disclosure provides compositions and methods for compensating for the degeneration of neurons in the SVZ through enhancing endogenous neurogenesis. In some embodiments, the present disclosure provides compositions and methods for treating diseases specifically associated with striatal neurogenesis such as Parkinson's disease (which could benefit both from increasing AHN and striatal neurogenesis in the SVZ; Pitcher et al. 2012; Sterling et al. 2013) and Huntington's disease (Sassone et al., 2018). In some embodiments, the present disclosure provides compositions and methods for treating other diseases including addiction (*e.g.*, chronic cocaine use and lifelong cigarette smoking).

[0016] In some embodiments, a subject of interest can be at risk of, or afflicted with, a disease or disorder including, but not limited to, neuromuscular dysfunction, neurodegenerative disorder, cardiac disorder (*e.g.*, myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting. Alternatively or additionally, in some embodiments, a subject of interest can be at risk of, or afflicted with a disease or disorder associated with lung damage, including, for example, idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), pneumonia, and/or certain infections, including viral infections including coronaviral infections such as COVID19.

[0017] Exemplary neuromuscular dysfunctions or disorders that can be treated by technologies of the present invention include, but are not limited to, Becker muscular dystrophy, Congenital muscular dystrophy, Distal muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral muscular dystrophy, Limb-girdle muscular dystrophy, Myotonic muscular dystrophy, and Oculo-pharyngeal muscular dystrophy.

[0018] In some embodiments, enhancing muscle growth is used in the context of treating a disease or disorder associated with muscle atrophy or muscle wasting. Muscle atrophy or muscle wasting may be observed in connection with various diseases and conditions described herein, such as neuromuscular disorders, or direct or indirectly caused by prolonged inactivity, bed rest, hospitalization, aging, malnutrition, cancer cachexia, chronic inflammatory diseases, etc.. Example chronic inflammatory diseases include rheumatoid arthritis, chronic heart failure, and chronic obstructive pulmonary disease (COPD).

[0019] Duration of hospitalization and type and severity of the illness can affect the extent of muscle wasting in a subject, and muscle wasting is common in patients suffering from sepsis, organ failure, hyperglycemia, and diseases associated with chronic and systemic inflammation or oxidative stress. Additionally, hospitalization requiring complete immobilization/bed rest contributes significantly to muscle wasting.

[0020] Additional disorders associated with muscle atrophy/wasting include disorders associate with decreased mobility, such as rheumatoid arthritis, osteoarthritis, and injury. (2016 Powers, Scott K., et al. *Medicine and science in sports and exercise* 48(11): 2307). Thus, in some embodiments, the present disclosure provides therapies for preventing/treating muscle wasting or muscle atrophy related to or as a result of a number of diseases or conditions described herein.

[0021] In some embodiments, methods of the present invention can also be used when a subject is in need of enhanced muscle regeneration and muscle growth following surgery, trauma and/or prolonged immobilization (*e.g.*, from bed-rest or casting). As muscle stem cell activity is known to decrease with age, methods of the present invention can also be

used to prevent or reverse sarcopenia in patients that are otherwise healthy and could lead to significant improvements in quality of life and autonomy.

[0022] Embodiments of the present invention also provide methods of preventing or treating neurodegenerative diseases (*e.g.,* AD) and/or muscle fibrosis, *e.g.,* in a subject in need thereof, by administering a composition that downregulates the MuSK Ig3 domain protein expression, the MuSK Ig3 domain gene expression, and/or the MuSK Ig3 activation of BMP signaling. The composition can comprise, *e.g.,* a MuSK-targeting oligonucleotide (*e.g.,* a MuSK Ig3-targeting exon- skipping oligonucleotide). The subject can be at risk of, or afflicted with, various neurodegenerative diseases, such as Alzheimer's Disease (AD), Parkinson's disease, dementia (e.g., Frontotemporal dementia), stroke, Major Depressive Disorder (MDD), bipolar disorder, Schizophrenia, Post-Traumatic Stress Disorder (PTSD), substance-related and addictive disorders (*e.g.,* chronic cocaine use and lifelong cigarette smoking), Temporal-Lobe Epilepsy, Hippocampal Sclerosis, Niemann Pick Type C, Diabetes-mediated hippocampal neuronal loss, brain injury (e.g., traumatic and/or anoxic brain injury), and Huntington's disease or muscle fibrosis resulting from a disease or condition including, but not limited to, trauma, heritable disease, muscle disorder and aging. The trauma can result from, for example, radiation treatment, crush injury, laceration, and amputation. The heritable disease or muscle disorder include, but are not limited to, Congenital Muscular Dystrophy, Duchenne Muscular Dystrophy, Becker's Muscular Dystrophy; Amyotrophic Lateral Sclerosis (ALS), and age-associate sarcopenia.

[0023] The present invention features, *inter alia*, an oligonucleotide composition comprising plurality of oligonucleotides, the oligonucleotide composition being characterized in that, when it is contacted with a MuSK transcript in a transcript splicing system, relative amounts of transcripts that do and do not include Ig3 domain-encoding sequences are altered as compared with such relative amounts observed under reference conditions selected from the group consisting of absence of the composition, presence of a reference composition, and combinations thereof.

[0024] In some embodiments, the oligonucleotides mediate skipping of at least one exon of the MuSK gene. In some embodiments, the exon skipping lowers levels of mRNAs encoding MuSK protein form that participate in BMP signaling compared with levels

observed absent the exon skipping. In some embodiments, the MuSK protein form participating in BMP signaling is or comprises a MuSK protein form that forms a MuSK/BMP complex.

[0025] In some embodiments, the exon skipping reduces the level and/or activity of a MuSK/BMP complex. In some embodiments, at least one skipped exon is selected from the group consisting of exons 3, 4, 6, and 7. In some embodiments, the relative amounts are amounts of transcripts including exons 6 and 7 relative to those lacking exons 6 and 7. In some embodiments, relative amounts are amounts of transcripts including exons 3 and 4 relative to those lacking exons 6 and 7.

[0026] In some embodiments, the alteration comprises skipping one or more of exons 6 and 7 of MuSK. In some embodiments, the alteration comprises skipping one or more of exons 3 and 4 of MuSK. In some embodiments, the alteration comprises skipping one or more of exons 6 and 7 of MuSK, but skipping none of exons 3 and 4 of MuSK.

[0027] In some embodiments, MuSK splicing is altered in that level of MuSK transcripts including exons 6 and 7 is decreased or level of MuSK protein forms including sequences encoded by exons 6 and 7 is decreased, or both. In some embodiments, MuSK splicing is altered in that level of MuSK transcripts including exons 3 and 4 is decreased or level of MuSK protein forms including sequences encoded by exons 3 and 4 is decreased, or both. In some embodiments, MuSK splicing is altered in that level of MuSK transcripts including exons 6 and 7 is increased or level of MuSK protein forms including sequences encoded by exons 6 and 7 is increased, or both. In some embodiments, MuSK splicing is altered in that level of MuSK transcripts including exons 3 and 4 is increased or level of MuSK protein forms including sequences encoded by exons 3 and 4 is increased, or both. In some embodiments, MuSK splicing is altered in that level of MuSK transcripts including exons 3 and 4 remains substantially unchanged and level of MuSK transcripts including exons 6 and 7 is decreased. In some embodiments, MuSK splicing is altered in that level of MuSK protein forms including sequences encoded by exons 3 and 4 remains substantially unchanged and l level of MuSK protein forms including sequences encoded by exons 6 and 7 is decreased. In some embodiments, MuSK splicing is altered in that total level of MuSK

transcripts remained substantially unchanged and level of MuSK transcripts including exons 6 and 7 is decreased.

[0028] In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 10%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 50%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 80%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 100%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 120%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 150%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 180%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 200%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 250%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 300%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 350%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 400%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 450%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including

exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 500%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 600%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 700%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 800%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 900%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by about 1000%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is increased by at least 1000%.

[0029] In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 10%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 50%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 80%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 100%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 120%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 150%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 180%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 200%. In

some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 250%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 300%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 350%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 400%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 450%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 500%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 600%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 700%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 800%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 900%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by about 1000%. In some embodiments, MuSK splicing is altered in that ratio of MuSK transcripts including exons 3 and 4 to MuSK transcripts including exons 6 and 7 is decreased by at least 1000%.

[0030] In some embodiments, prior to contact with one or more exon-skipping oligonucleotides as described herein, ratio of MuSK transcripts including exons 3 and 4 (i.e., total MuSK transcripts) to MuSK transcripts in a cell or system including exons 6 and 7 is between about 1:1 and 1:0.1. In some embodiments, prior to contact with one or more exon-skipping oligonucleotides as described herein, ratio of MuSK transcripts including exons 3 and 4 (i.e., total MuSK transcripts) to MuSK transcripts in a cell or system including exons 6 and 7 is about 1:1, 1:0.9, 1:0.8, 1:0.7, 1:0.6, 1:0.5, 1:0.4, 1:0.3, 1:0.2, or 1:0.1. In some

embodiments, prior to contact with one or more exon-skipping oligonucleotides as described herein, ratio of MuSK transcripts including exons 3 and 4 (i.e., total MuSK transcripts) to MuSK transcripts in a cell or system including exons 6 and 7 is about 1:0.8.

[0031] In some embodiments, after contact with one or more exon-skipping oligonucleotides as described herein, ratio of MuSK transcripts including exons 3 and 4 (i.e., total MuSK transcripts) to MuSK transcripts in a cell or system including exons 6 and 7 is between about 1:0.9 and 1:0.0001. In some embodiments, after contact with one or more exon-skipping oligonucleotides as described herein, ratio of MuSK transcripts including exons 3 and 4 (i.e., total MuSK transcripts) to MuSK transcripts in a cell or system including exons 6 and 7 is about 1:0.9, 1:0.8, 1:0.7, 1:0.6, 1:0.5, 1:0.4, 1:0.3, 1:0.2, or 1:0.1, 1:0.05, 1:0.01, 1:0.001, or 1:0001. In some embodiments, after contact with one or more exon-skipping oligonucleotides as described herein, ratio of MuSK transcripts including exons 3 and 4 (i.e., total MuSK transcripts) to MuSK transcripts in a cell or system including exons 6 and 7 is between about 1:0.9 and 1:0.8, 1:08 and 1:0.7, 1:0.7 and 1:0.6, 1:0.6 and 1:0.5, 1:0.5 and 1:0.4, 1:0.4 and 1:0.3, 1:0.3 and 1:0.2, 1:0.2 and 1:0.1, 1:0.1 and 1:0.05, 1:0.05 and 1:0.01, 1:0.01 and 1:0.001, or 1:0.001 and 1:0001. In some embodiments, after contact with one or more exon-skipping oligonucleotides as described herein, ratio of MuSK transcripts including exons 3 and 4 (i.e., total MuSK transcripts) to MuSK transcripts in a cell or system including exons 6 and 7 is between about 1:0.9 and 1:0.5.

[0032] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 2 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both.

[0033] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 3 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both. In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by

exons 6 and 7, or both, decreases at a level at least 4 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both.

[0034] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 5 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both. In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 10 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both.

[0035] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0036] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 70% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0037] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 80% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0038] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both,

decreases by greater than 90% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0039] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 30%.

[0040] In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 20%. In some embodiments, the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 10%. In some embodiments, the base sequence of the oligonucleotide comprises a sequence having no more than 5 mismatches from a 18-25 base long portion of the MuSK gene or its complement.

[0041] In some embodiments, the oligonucleotides correspond to positions 83776-83800 and on 83854-83878 of the MuSK gene sequence represented in SEQ ID NO: 77.

[0042] In some embodiments, the oligonucleotides described herein target a region on the MuSK genomic sequence within a region defined by nucleotides 83841-83905 and 83962-84032 on the MuSK gene sequence represented in SEQ ID NO: 77.

[0043] In some embodiments, oligonucleotides target a region on the MuSK genomic sequence within or comprising at least a portion of sequence ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATT GACTCAAGAC (region 1, SEQ ID: 126). In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is at least 10%, 15%, 20%, 25%,

30%, 35%, 40%, 45%, or 50% identical to region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to no more than 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to at least 15 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 15-30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 15 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 16 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 17 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 18 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 19 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 20 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 21 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 22 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 23 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 24 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 25 consecutive bases of region 1, SEQ ID: 126. In some embodiments,

oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 26 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 27 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 28 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 29 consecutive bases of region 1, SEQ ID: 126. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 30 consecutive bases of region 1, SEQ ID: 126.

[0044] In some embodiments, oligonucleotides target a region on the MuSK genomic sequence within or comprising at least a portion of sequence GGGGAGAAGTTCAGTACTGCCAAGGCTGCAGCCACCATCAGCATAGCAGGTAGG ATGCCCCTTCACATTTG (region 2, SEQ ID 211). In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% identical to region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to no more than 30 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to at least 15 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 15-30 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 15 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 16 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 17 consecutive bases of region 2,

SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 18 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 19 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 20 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 21 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 22 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 23 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 24 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 25 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 26 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 27 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 28 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 29 consecutive bases of region 2, SEQ ID: 211. In some embodiments, oligonucleotides target a portion of MuSK transcript comprising a sequence that is identical to 30 consecutive bases of region 2, SEQ ID: 211.

[0045] In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to a sequence within or comprising at least a portion of ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATT GACTCAAGAC (region 1, SEQ ID: 126). In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to a sequence that is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% identical to region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to

a portion of region 1 (SEQ ID: 126) that includes at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 95% identical to a portion of region 1 (SEQ ID: 126) that includes at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 10 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 11 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 12 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 13 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 14 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 15 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 16 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 17 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 18 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 19 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 20 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 21 consecutive bases of region 1 (SEQ ID: 126). In

some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 22 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 23 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 24 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 25 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 26 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 27 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 28 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 29 consecutive bases of region 1 (SEQ ID: 126). In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 30 consecutive bases of region 1 (SEQ ID: 126).

[0046] In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to no more than 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 15-30 consecutive bases of region 1, SEQ ID: 126.

[0047] In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 15 consecutive bases of region 1,

SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 16 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 17 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 18 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 19 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 20 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 21 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 22 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 23 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 24 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 25 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 26 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 27 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 28 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 29 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 30 consecutive bases of region 1, SEQ ID: 126.

[0048] In some embodiments, an oligonucleotide has a length of 30 bases. In some embodiments, an oligonucleotide has a length of 29 bases. In some embodiments, an oligonucleotide has a length of 28 bases. In some embodiments, an oligonucleotide has a length of 27 bases. In some embodiments, an oligonucleotide has a length of 26 bases. In some embodiments, the oligonucleotide has a length of 25 bases. In some embodiments, the oligonucleotide has a length of 24 bases. In some embodiments, the oligonucleotide has a

length of 23 bases. In some embodiments, the oligonucleotide has a length of 22 bases. In some embodiments, the oligonucleotide has a length of 21 bases. In some embodiments, the oligonucleotide has a length of 20 bases. In some embodiments, the oligonucleotide has a length of 19 bases. In some embodiments, the oligonucleotide has a length of 18 bases. In some embodiments, the oligonucleotide has a length of 17 bases. In some embodiments, the oligonucleotide has a length of 16 bases. In some embodiments, the oligonucleotide has a length of 15 bases.

[0049] In some embodiments, the oligonucleotide has a length of less than about 50 bases. In some embodiments, the oligonucleotide has a length of less than about 40 bases. In some embodiments, the oligonucleotide has a length of less than about 30 bases. In some embodiments, the oligonucleotide has a length of more than about 10 bases. In some embodiments, the oligonucleotide has a length of more than about 15 bases. In some embodiments, the oligonucleotide has a length of more than about 20 bases. In some embodiments, the base sequence of the oligonucleotide comprises from 5' to 3':

SEQ ID	Oligo ID	5' to 3' Sequence
1	Bld1	GCTAGGGTGGTCTTTTAGAAATGCA
2	Bld2	GGTCAAGCTAGGGTGGTCTTTTAGA
3	Bld3	CTGCAGGAAATGGTCAAGCTAGGGT
4	Bld4	GAAGTGGTGAGTGACGCTCCTGCAG
5	Bld5	GTTAGGAAGACAGAAGTGGTGAGTG
6	Bld6	ATCCTGGCAAAAACTGTTAGGAAGA
7	Bld7	GTGGGATTCAGGAGCCCGCAGGATC
8	Bld8	GGTGACATTGTGGGATTCAGGAGCC
9	Bld9	GGAGCCAAAGGTGACATTGTGGGAT
10	Bld10	GGTCACAAAGGAGCCAAAGGTGACA
11	Bld11	ACAGTGCAGGGTCACAAAGGAGCCA
12	Bld12	CTGTTGCTGTACAGTGCAGGGTCAC
13	Bld13	GGGACAGGAATGCCTGTTGCTGTAC

14	Bld14	CAGGTGATGGTGGGGACAGGAATGC
15	Bld15	CCGTTTTCAATCCAGGTGATGGTGG
16	Bld16	TGACACTCACAGCATTTCCGTTTTC
17	Bld17	AAGTCCCCACACACATGACACTCAC
18	Bld18	GGTCTTCCCCAGACAAGTCCCCACA
19	Bld19	ACTATGTCAGTAGATTTGAAGGGAA
20	Bld20	TCCCACTATACTATGTCAGTAGATT
21	Bld21	TCAGTCAAGGATTTCCCACTATACT
22	Bld22	AAAAGAACTCAGTCAAGGATTTCCC
23	Bld23	GTAAAGGAAAATAAAAGAACTCAGT
24	Bld24	AACCTGACAGAGTAAAGGAAAATAA
25	Bld25	GGACCCAGAAGAAACCTGACAGAGT
26	Bld26	CACTCTCTTGAATGGACCCAGAAGA
27	Bld27	CACTCGGTCTTTCACACTCTCTTGA
28	Bld28	GTCTTGAGTCAATCACTCGGTCTTT
29	Bld29	GATAAACAGCTGCAGTCTTGAGTCA
30	Bld30	AGTCCTGGCTTGGTGATAAACAGCT
31	Bld31	ATGTGTAGAGTCCTGGCTTGGTGAT
32	Bld32	GTAGCTATGCATGTGTAGAGTCCTG
33	Bld33	TGCTTATTGGTAGCTATGCATGTGT
34	Bld34	ACTTCTCCCCATGCTTATTGGTAGC
35	Bld35	CCTTGGCAGTACTGAACTTCTCCCC
36	Bld36	CCTGCTATGCTGATGGTGGCTGCAG
37	Bld37	GGGCATCCTACCTGCTATGCTGATG
38	Bld38	GCAAATGTGAAGGGGCATCCTACCT
127	Bld51	TTGAATGGACCCAGAAGAAA
128	Bld52	CTTGAATGGACCCAGAAGAA

129	Bld53	TCTTGAATGGACCCAGAAGA
130	Bld54	CTCTTGAATGGACCCAGAAG
131	Bld55	TCTCTTGAATGGACCCAGAA
132	Bld56	CTCTCTTGAATGGACCCAGA
133	Bld57	ACTCTCTTGAATGGACCCAG
134	Bld58	CACTCTCTTGAATGGACCCA
135	Bld59	ACACTCTCTTGAATGGACCC
136	Bld60	CACACTCTCTTGAATGGACC
137	Bld61	TCACACTCTCTTGAATGGAC
138	Bld62	TTCACACTCTCTTGAATGGA
139	Bld63	TTTCACACTCTCTTGAATGG
140	Bld64	CTTTCACACTCTCTTGAATG
141	Bld65	TCTTTCACACTCTCTTGAAT
142	Bld66	GTCTTTCACACTCTCTTGAA
159	Bld25-1	CCAGAAGAAACCTGACAGAGTAAAG
160	Bld25-2	ACCCAGAAGAAACCTGACAGAGTAA
161	Bld25-3	ATGGACCCAGAAGAAACCTGACAGA
162	Bld25-4	GAATGGACCCAGAAGAAACCTGACA
163	Bld25-5	CTTGAATGGACCCAGAAGAAACCTG
164	Bld26-1	CTCTTGAATGGACCCAGAAGAAACC
165	Bld26-2	CTCTCTTGAATGGACCCAGAAGAAA
166	Bld26-3	CACACTCTCTTGAATGGACCCAGAA
167	Bld26-4	TTCACACTCTCTTGAATGGACCCAG
177	Bld25-A	ACCCAGAAGAAACCTGACAGAGT
178	Bld25-B	CCAGAAGAAACCTGACAGAGT
179	Bld25-C	GGACCCAGAAGAAACCTGACAGA
180	Bld25-D	ACCCAGAAGAAACCTGACAGA

181	Bld25-E	GGACCCAGAAGAAACCTGACA
182	Bld25-5-A	GAATGGACCCAGAAGAAACCTGA
183	Bld25-5-B	ATGGACCCAGAAGAAACCTGA
184	Bld25-5-C	TTGAATGGACCCAGAAGAAACCT
185	Bld25-5-D	GAATGGACCCAGAAGAAACCT
186	Bld25-5-E	TTGAATGGACCCAGAAGAAAC
187	Bld26-2-A	CTCTTGAATGGACCCAGAAGAAA
188	Bld26-2-B	CTTGAATGGACCCAGAAGAAA
189	Bld26-2-C	CTCTCTTGAATGGACCCAGAAGA
190	Bld26-2-D	CTCTCTTGAATGGACCCAGAA
191	Bld26-B	CTCTTGAATGGACCCAGAAGA
192	Bld26-C	CACTCTCTTGAATGGACCCAGAA, or
193	Bld26-D	CACTCTCTTGAATGGACCCAG

[0050] In some embodiments, the oligonucleotide is complementary to a nucleotide sequence that is at least 90% identical to any one of SEQ ID NOs: 39-76 and and 212-253.

[0051] In some embodiments, the oligonucleotides comprise one or more types of base modifications, sugar modification, and internucleotidic linkage modifications. In some embodiments, the oligonucleotides comprise non-natural sugar moieties, or non-natural internucleotidic linkages, or both.

[0052] In some embodiments, the oligonucleotides comprise internucleotidic linkage modifications. In some embodiments, the internucleotidic linkages of the oligonucleotide comprises natural phosphate, phosphorothioate, or phosphodithioate linkages. In some embodiments, each internucleotidic linkages of the oligonucleotide is a phosphorothioate linkage. In some embodiments, each internucleotidic linkage of the oligonucleotide is a natural phosphate linkage. In some embodiments, oligonucleotide comprises at least one natural phosphate linkage and at least one phosphodithioate linkage. In some embodiments, at least 50%, 60%, 70%, 80%, 90%, 94%, or 95% of internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 50%, 60%,

70%, 80%, 90%, 94%, or 95% of internucleotidic linkages of an oligonucleotide are natural phosphate linkages.

[0053] In some embodiments, the oligonucleotides comprise sugar modification. In some embodiments, the modified sugar moiety has a 2'-modification. In some embodiments, the modified sugar moiety comprises a bicyclic sugar modification. In some embodiments, the modified sugar moiety comprises a 2'-modification, wherein a 2'-modification is 2'-OR^1, wherein R^1 is optionally substituted C_{1-6} alkyl. In some embodiments, the modified sugar moiety comprises a 2'-modification, wherein a 2'-modification is 2'-MOE. In some embodiments, the modified sugar moiety comprises a 2'-modification, wherein a 2'-modification is 2'-OMe. In some embodiments, each sugar of the oligonucleotide is a 2'-MOE modified sugar. In some embodiments, an oligonucleotide comprises 2'-OH sugar (RNA sugar). In some embodiments, an oligonucleotide comprise 2'-H sugar (DNA sugar). In some embodiments, an oligonucleotide comprises 2'-MOE sugar. In some embodiments, an oligonucleotide comprises 2'-OMe sugar. In some embodiments, an oligonucleotide comprises 2'-MOE, 2'-OMe, 2'-OH, 2'-H sugar, or any combination thereof. In some embodiments, an oligonucleotide comprises at least one 2'-MOE sugar and at least one 2'-OH sugar (RNA sugar). In some embodiments, an oligonucleotide comprises at least one 2'-MOE sugar and at least one 2'-H sugar (DNA sugar).

[0054] In some embodiments, the oligonucleotide has the structure from 5' to 3'of:

SEQ-ID	Oligo ID	Oligonucleotide structure, 5' to 3'
78	Bld1	G*C*T *A*G*G *G*T*G *G*T*C *T*T*T *T*A*G *A*A*A *T*G*C *A
79	Bld2	G*G*T *C*A*A *G*C*T *A*G*G *G*T*G *G*T*C *T*T*T *T*A*G *A
80	Bld3	C*T*G *C*A*G *G*A*A *A*T*G *G*T*C *A*A*G *C*T*A *G*G*G *T
81	Bld4	G*A*A *G*T*G *G*T*G *A*G*T *G*A*C *G*C*T *C*C*T *G*C*A *G
82	Bld5	G*T*T *A*G*G *A*A*G *A*C*A *G*A*A *G*T*G *G*T*G *A*G*T *G
83	Bld6	A*T*C *C*T*G *G*C*A *A*A*A *A*C*T *G*T*T *A*G*G *A*A*G *A
84	Bld7	G*T*G *G*G*A *T*T*C *A*G*G *A*G*C *C*C*G *C*A*G *G*A*T *C

85	Bld8	G*G*T *G*A*C *A*T*T *G*T*G *G*G*A *T*T*C *A*G*G *A*G*C *C
86	Bld9	G*G*A *G*C*C *A*A*A *G*G*T *G*A*C *A*T*T *G*T*G *G*G*A *T
87	Bld10	G*G*T *C*A*C *A*A*A *G*G*A *G*C*C *A*A*A *G*G*T *G*A*C *A
88	Bld11	A*C*A *G*T*G *C*A*G *G*G*T *C*A*C *A*A*A *G*G*A *G*C*C *A
89	Bld12	C*T*G *T*T*G *C*T*G *T*A*C *A*G*T *G*C*A *G*G*G *T*C*A *C
90	Bld13	G*G*G *A*C*A *G*G*A *A*T*G *C*C*T *G*T*T *G*C*T *G*T*A *C
91	Bld14	C*A*G *G*T*G *A*T*G *G*T*G *G*G*G *A*C*A *G*G*A *A*T*G *C
92	Bld15	C*C*G *T*T*T *T*C*A *A*T*C *C*A*G *G*T*G *A*T*G *G*T*G *G
93	Bld16	T*G*A *C*A*C *T*C*A *C*A*G *C*A*T *T*T*C *C*G*T *T*T*T *C
94	Bld17	A*A*G *T*C*C *C*C*A *C*A*C *A*C*A *T*G*A *C*A*C *T*C*A *C
95	Bld18	G*G*T *C*T*T *C*C*C *C*A*G *A*C*A *A*G*T *C*C*C *C*A*C *A
96	Bld19	A*C*T *A*T*G *T*C*A *G*T*A *G*A*T *T*T*G *A*A*G *G*G*A *A
97	Bld20	T*C*C *C*A*C *T*A*T *A*C*T *A*T*G *T*C*A *G*T*A *G*A*T *T
98	Bld21	T*C*A *G*T*C *A*A*G *G*A*T *T*T*C *C*C*A *C*T*A *T*A*C *T
99	Bld22	A*A*A *A*G*A *A*C*T *C*A*G *T*C*A *A*G*G *A*T*T *T*C*C *C
100	Bld23	G*T*A *A*A*G *G*A*A *A*A*T *A*A*A *A*G*A *A*C*T *C*A*G *T
101	Bld24	A*A*C *C*T*G *A*C*A *G*A*G *T*A*A *A*G*G *A*A*A *A*T*A *A
102	Bld25	G*G*A *C*C*C *A*G*A *A*G*A *A*A*C *C*T*G *A*C*A *G*A*G *T
103	Bld26	C*A*C *T*C*T *C*T*T *G*A*A *T*G*G *A*C*C *C*A*G *A*A*G *A
104	Bld27	C*A*C *T*C*G *G*T*C *T*T*T *C*A*C *A*C*T *C*T*C *T*T*G *A
105	Bld28	G*T*C *T*T*G *A*G*T *C*A*A *T*C*A *C*T*C *G*G*T *C*T*T *T
106	Bld29	G*A*T *A*A*A *C*A*G *C*T*G *C*A*G *T*C*T *T*G*A *G*T*C *A
107	Bld30	A*G*T *C*C*T *G*G*C *T*T*G *G*T*G *A*T*A *A*A*C *A*G*C *T
108	Bld31	A*T*G *T*G*T *A*G*A *G*T*C *C*T*G *G*C*T *T*G*G *T*G*A *T

109	Bld32	G*T*A *G*C*T *A*T*G *C*A*T *G*T*G *T*A*G *A*G*T *C*C*T *G
110	Bld33	T*G*C *T*T*A *T*T*G *G*T*A *G*C*T *A*T*G *C*A*T *G*T*G *T
111	Bld34	A*C*T *T*C*T *C*C*C *C*A*T *G*C*T *T*A*T *T*G*G *T*A*G *C
112	Bld35	C*C*T *T*G*G *C*A*G *T*A*C *T*G*A *A*C*T *T*C*T *C*C*C *C
113	Bld36	C*C*T *G*C*T *A*T*G *C*T*G *A*T*G *G*T*G *G*C*T *G*C*A *G
114	Bld37	G*G*G *C*A*T *C*C*T *A*C*C *T*G*C *T*A*T *G*C*T *G*A*T *G
115	Bld38	G*C*A *A*A*T *G*T*G *A*A*G *G*G*G *C*A*T *C*C*T *A*C*C *T
143	Bld51	T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A
144	Bld52	C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A
145	Bld53	T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A
146	Bld54	C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G
147	Bld55	T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A
148	Bld56	C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A
149	Bld57	A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G
150	Bld58	C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A
151	Bld59	A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C
152	Bld60	C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C
153	Bld61	T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C
154	Bld62	T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A
155	Bld63	T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G
156	Bld64	C*T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G
157	Bld65	T*C*T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T
158	Bld66	G*T*C*T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A
168	Bld25-1	C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T*A*A*A*G*

169	Bld25-2	A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T*A*A*
170	Bld25-3	A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*
171	Bld25-4	G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*
172	Bld25-5	C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*
173	Bld26-1	C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*
174	Bld26-2	C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*
175	Bld26-3	C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*
176	Bld26-4	T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*
194	Bld25-A	A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T
195	Bld25-B	C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T
196	Bld25-C	G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A
197	Bld25-D	A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A
198	Bld25-E	G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A
199	Bld25-5-A	G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A
200	Bld25-5-B	A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A
201	Bld25-5-C	T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T
202	Bld25-5-D	G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T
203	Bld25-5-E	T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C
204	Bld26-2-A	C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A
205	Bld26-2-B	C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A
206	Bld26-2-C	C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A
207	Bld26-2-D	C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A
208	Bld26-B	C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A
209	Bld26-C	C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A, or

210	Bld26-D	C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G.

wherein * represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar.

[0055] In some embodiments, an oligonucleotide composition comprising a mixture of two or more oligonucleotides according to any one of the embodiments.

[0056] In some embodiments, the composition comprises oligonucleotides that targets regions of the MuSK gene that correspond to positions 83776-83800 and on 83854-83878 of SEQ ID NO: 77.

[0057] In some embodiments, a pharmaceutical composition comprises a therapeutically effective amount of an oligonucleotide, and at least one pharmaceutically acceptable inactive ingredient selected from pharmaceutically acceptable diluents, pharmaceutically acceptable excipients, and pharmaceutically acceptable carriers, wherein the oligonucleotide is an oligonucleotide of any one of the embodiments.

[0058] In some embodiments, the oligonucleotides are formulated a nanocarrier. In some embodiments, the oligonucleotides are formulated in lipid nano-particles (LNPs). In some embodiments, the oligonucleotides are covalently conjugated to an additional moiety selected from lipids (for example, cholesterol), peptides, aptamers, antibodies, and sugars (for example, N-acetylgalactosamine (GalNAc). In some embodiments, the oligonucleotides are covalently conjugated to N-acetylgalactosamine (GalNAc).

[0059] In another aspect, the disclosure features, a method of altering relative amounts of MuSK spliced transcripts, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of previous embodiments.

[0060] In some embodiments, the disclosure features the alteration of MuSK spliced transcripts being characterized in that, the ratio of MuSK transcripts containing Ig3 domain-encoding sequences to MuSK transcription containing no Ig3 domain-encoding sequences is increased. In some embodiments, the alteration of MuSK spliced transcripts being characterized in that, the ratio of MuSK transcripts containing Ig3 domain-encoding

sequences to MuSK transcription containing no Ig3 domain-encoding sequences decreases. In some embodiments, the alteration of MuSK spliced transcripts being characterized in that, MuSK transcripts containing Ig3 domain-encoding sequences decreases and level of total MuSK transcripts remains substantially the same.

[0061] In some embodiments, the alteration of MuSK spliced transcripts is characterized in that, the level of MuSK transcripts including exons 6 and 7 decreases or level of MuSK protein forms including sequences encoded by exons 6 and 7 decreases, or both.

[0062] In some embodiments, the alteration of MuSK spliced transcripts being characterized in that, level of MuSK transcripts including exons 6 and 7 is increased or level of MuSK protein forms including sequences encoded by exons 6 and 7 is increased, or both. In some embodiments, the alteration of MuSK spliced transcripts is characterized in that, the level of MuSK transcripts including exons 3 and 4 decreases or level of MuSK protein forms including sequences encoded by exons 3 and 4 decreases, or both. In some embodiments, the alteration of MuSK spliced transcripts is characterized in that, the level of MuSK transcripts including exons 3 and 4 is increased or level of MuSK protein forms including sequences encoded by exons 3 and 4 is increased, or both.

[0063] In some embodiments, the alteration of MuSK spliced transcripts being characterized in that, the level of MuSK transcripts including exons 3 and 4 remains substantially the same, or level of MuSK protein forms including sequences encoded by exons 3 and 4 remains substantially the same, or both. In some embodiments, the alteration of MuSK spliced transcripts is characterized that, the level of MuSK transcripts including exons 3 and 4 remains substantially the same, or level of MuSK protein forms including sequences encoded by exons 3 and 4 remains substantially the same, or both; and level of MuSK transcripts including exons 6 and 7 decreases or level of MuSK protein forms including sequences encoded by exons 6 and 7 decreases, or both.

[0064] In another aspect, the disclosure features, a method of treating a subject suffering from one or more features of neurodegenerative diseases, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of the previous embodiments.

[0065] In another aspect, the disclosure features, a method of increasing neurogenesis, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of the previous embodiments.

[0066] In another aspect, the disclosure features, a method of treating a subject suffering from one or more features of neuromuscular dysfunction or a muscular dystrophy, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of the previous embodiments.

[0067] In another aspect, the disclosure features, a method of increasing muscle regeneration and/or muscle growth, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of the previous embodiments.

[0068] In another aspect, the disclosure features, a method of treating muscle fibrosis, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of the previous embodiments.

[0069] In some embodiments, the subject is at risk of, or afflicted with, a disease or disorder selected from the group consisting of: neuromuscular dysfunction, neurodegenerative disorder, cardiac disorder, and diseases characterized by muscle wasting. In some embodiments, the neurodegenerative disorder is selected from the group consisting of Alzheimer's Disease (AD), Parkinson's disease, dementia (e.g., Frontotemporal dementia), stroke, Major Depressive Disorder (MDD), bipolar disorder, Schizophrenia, Post-Traumatic Stress Disorder (PTSD), substance-related and addictive disorders (e.g., chronic cocaine use and lifelong cigarette smoking), Temporal-Lobe Epilepsy, Hippocampal Sclerosis, Niemann Pick Type C, Diabetes-mediated hippocampal neuronal loss, brain injury (e.g., traumatic and/or anoxic brain injury), and Huntington's disease. In some embodiments, the neurodegenerative disease is Alzheimer's Disease (AD).

[0070] In some embodiments, the neuromuscular dysfunction is a muscular dystrophy selected from the group consisting of: Becker, Congenital, Distal, Duchenne, Emery-

Dreifuss, Facioscapulohumeral, Limb-girdle, Myotonic, and Oculo-pharyngeal muscular dystrophy. In another aspect, the disclosure features,

[0071] In some embodiments, the cardiac disorder is myocardial infarction or cardiomyopathy. In some embodiments, the subject is in need of enhanced muscle regeneration and/or growth following a condition selected from the group consisting of: surgery, trauma and prolonged immobilization. In some embodiments, the prolonged immobilization results from bed-rest or casting. In some embodiments, the subject is at risk of, or afflicted with, sarcopenia. In some embodiments, the subject is at risk of, or afflicted with, muscle fibrosis resulting from a disease or condition selected from the group consisting of: trauma, heritable disease, muscle disorder, and aging. In some embodiments, the trauma is the result of a condition selected from the group consisting of: radiation treatment, crush injury, laceration, and amputation.

[0072] In some embodiments, the heritable disease or muscle disorder selected from the group consisting of: Congenital Muscular Dystrophy, Duchenne Muscular Dystrophy, Becker's Muscular Dystrophy; Amyotrophic Lateral Sclerosis (ALS), and age-associate sarcopenia.

[0073] In some embodiments, the composition is delivered to the CNS. In some embodiments, the composition is delivered to the cerebrospinal fluid. In some embodiments, the composition is delivered to the muscle. In some embodiments, the composition is delivered to the liver. In some embodiments, the composition can be formulated for systemic or localized administration. In some embodiments, the composition is formulated for delivery by a route selected from intravenous injection, intravenous infusion, intramuscular injection, intrathecal administration, oral administration, buccal administration, inhalation, nasal administration, topical administration, ophthalmic administration or otic administration.

[0074] In some embodiments, the composition is formulated for delivery by intramuscular administration. In some embodiments, the composition is formulated for delivery by intravenous administration. In some embodiments, the composition is formulated for delivery by oral administration.

BRIEF DESCRIPTION OF THE DRAWING

[0075] For the purpose of illustration, certain embodiments of the presentinvention are shown in the drawings described below. Like numerals in the drawings indicate like elements throughout. It should be understood, however, that the invention is not limited to the precise arrangements, dimensions, and instruments shown. In thedrawings:

[0076] **FIG. 1** is a schematic representation of an interaction between BMP and Ig3 domain of MuSK and its implications in BMP signaling and neurogenesis and cognition.

[0077] **FIG. 2** is a schematic representation of the full-length and MuSKΔIg3 transcripts and encoded proteins and exemplary primer design to selectively detect total MuSK and full-length MuSK transcripts.

[0078] **FIG. 3** shows relative MuSK expression measured by qPCR using Taqman or SYBR green technology in LHCN-M2 cells.

[0079] **FIG. 4** is a schematic representation of "region 1" and "region 2" of exon 7 of MuSK transcript.

[0080] **FIG. 5** shows an alignment of the ASOs Bld1-Bld18 on the genetic sequence of MuSK.

[0081] **FIG. 6** shows microscopic acquisitions of LHCN-M2 24h after being transfected with the ASOs Bld1-Bld4, Bld6, Bld7, Bld9, Bld11, Bld12, Bld13, Bld14, Bld15, Bld16, Bld17, and untreated control at 100nM (scale 100nm).

[0082] **FIG. 7** shows relative MuSK expression measured by qPCR of LHCN-M2 cells transfected with ASOs Bld1-Bld18 at 50 and 100 nM. **Panel A** shows total MuSK expression (*i.e.,* of MuSK34, a primer spanning exon/exon junction 3-4) and **Panel B** shows expression of MuSK exons 6-7 (*i.e.,* using MuSK67, a primer spanning exon/exon junction 6-7). All samples are normalized to the housekeeping genes GAPDH and YWHAZ and to controls.

[0083] **FIG. 8** shows alignment of the ASOs Bld1-Bld18 on the genetic sequence of MuSK and their effect on MuSK expression. Green: no effect or increase in MuSK

expression (MuSK expression comprised between 90 and 300% of the untreated condition). Orange: moderate decrease in MuSK expression (MuSK expression comprised between 40 and 70% of the untreated condition). Red: high decrease in MuSK expression (MuSK expression below 40% of the untreated condition). Red areas indicate regions important for the expression of MuSK where ASOs induced a decrease of MuSK67 >80%.

[0084] **FIG. 9** shows an alignment of the ASOs Bld19-Bld38 on the genetic sequence of MuSK.

[0085] **FIG. 10** shows microscopic acquisitions of LHCN-M2 24 h after being transfected with the ASOs Bld 19-22, Bld29-34, and untreated control at 100 nM (scale 100nm).

[0086] **FIG. 11** shows relative MuSK expression measured by qPCR of LHCN-M2 cells transfected with ASOs (control, Bld19-Bld28) at 50 and 100 nM. **Panel A** shows MuSK34 expression and **panel B** shows MuSK67 expression. All samples are normalized to the housekeeping genes GAPDH and YWHAZ and to controls.

[0087] **FIG. 12** shows the alignment of the ASOs Bld19-Bld38 on the genetic sequences and their effect on MuSK expression. Green: no effect or increase in MuSK expression (MuSK expression comprised between 90 and 300% of the untreated condition). Orange: moderate decrease in MuSK expression (MuSK expression comprised between 40 and 70% of the untreated condition). Red: high decrease in MuSK expression (MuSK expression below 40% of the untreated condition). Red areas indicate regions important for the expression of MuSK where ASOs induced a decrease of MuSK67 >80%. Purple areas indicate regions that can be targeted to selectively inhibit MuSK67 expression (with lower effect on other exons).

[0088] **FIG. 13** shows relative MuSK expression in response to various doses of ASOs (Bld25 (**panel A**), Bld26 (**panel B**), Bld27 (**panel C**), Bld28 (**panel D**), Bld35 (**panel E**), Bld38 (**panel F**)). MuSK34 (in blue) and MuSK67 (in red) expressions were measured by qPCR and normalized to housekeeping genes and to the controls. The estimated IC is indicated on each graph. The 5 tested doses were 2.5, 5, 25, 125, and 400 nM.

[0089] **FIG. 14** shows relative MuSK expression in response to various doses of ASOs (Bld25 (**panel A**), Bld26 (**panel B**)). MuSK34 (in blue) and MuSK67 (in red) expressions were measured by qPCR and normalized to housekeeping genes and to the controls. The 4 tested doses were 5, 7.5, 12.5 and 25 nM.

[0090] **FIG. 15** shows relative MuSK expression in response to combination of ASOs Bld25 and Bld26 at 12.5 nM final concentration compared to an untreated control. MuSK34 (in blue) and MuSK67 (in red) expressions were measured by qPCR and normalized to housekeeping genes and to controls.

[0091] **FIG. 16** shows migration of PCR products from exon 3 to exon 9 on gel electrophoresis. cDNA of ASO-treated cells (Bld25, i.e., "hu7-10 or Bld26, i.e., "hu73") was amplified by PCR and deposited on gel electrophoresis to be migrated (**panel A**). Predicted products are presented in **panel B** and **panel B'**.

[0092] **FIG. 17** shows an alignment of sequences of various target portion of "region 1". ASOs Bld25, Bld26, and Bld51-Bld66 target various portions of "region 1."

[0093] **FIG. 18** shows the relative change of gene expression of total MuSK (MuSK34) and MuSK containing Ig3 domain (MuSK67) for ASOs Bld51-Bld66 at a concentration of 12.5 nM (**Panel A**) and at a concentration of 100 nM (**Panel B**).

[0094] **FIG. 19** shows an alignment of ASOs Bld25-1, Bld25-2, Bld25, Bld25-3, Bld25-4, BLd25-5, Bld26-1, Bld26-2, Bld26, Bld26-3, Bld26-4, Bld27, Bld28, Bld35, Bld 38 on various target portions of "region 1" and "region 2" of exon 7 of human MuSK.

[0095] **FIG. 20** shows MuSK gene expression analyzed in qPCR. **Panel A** shows relative gene expression of MuSKIg3 (MuSK67) and **Panel B** shows relative gene expression of total MuSK (MuSK34).

[0096] **FIG. 21** shows MuSK gene expression from only the ASOs which showed relative expression of MuSK67 of less than 50% and total MuSK (MuSK34) of greater than 60% compared to the control. **Panel A** shows relative gene expression of MuSKIg3 (MuSK67) and **Panel B** shows relative gene expression of total MuSK (MuSK34).

[0097] **FIG. 22** shows a comparison of Bld25-5 to Bld25 after transfection with ASO for 24 hours (**Panels A** and **B**) and 48 hours (**Panels C** and **D**).

[0098] **FIG. 23** shows an alignment of ASOs Bld25, Bld25-A, Bld25-B, Bld25-C, Bld25-D, Bld25-E, Bld25-5, Bld25-5-A, Bld25-5-B, Bld25-5-C, Bld25-5-D, Bld25-5-E, Bld26-2, Bld26-2-A, Bld26-2-B, Bld26-2-C, Bld26-2-D, Bld26, Bld26-B, Bld26-C, Bld26-D, on various target portions of "region 1" of exon 7 of human MuSK.

[0099] **FIG. 24** shows relative gene expression (MuSK34 and MuSK67) for ASOs Bld25-A, Bld25-B, Bld25-C, Bld25-D, and Bld25-E.

[0100] **FIG. 25** shows relative gene expression (MuSK34 and MuSK67) for ASOs Bld25-5-A, Bld25-5-B, Bld25-5-C, Bld25-5-D, and Bld25-5-E.

[0101] **FIG. 26** shows a graphical representation of the 3 variants of MuSK RNA. Full length and ΔIg3 indicate the lengths of the full-length sequence and the sequence comprising a deletion of exon 6, 7, respectively, amplified by PCR from exon 3 to exon 9.

[0102] **FIG. 27** shows the gel migration of pcr products from cells treated with Bld25 and Bld25-5 and intensity of bands from Bld25 and Bld25-5 products.

[0103] **FIG. 28** shows that the sequence of the band lower band positioned, where Δ6,7 variant 1 (687 bases) was expected, was indeed the sequence of this splice variant.

[0104] **FIG. 29** shows images of HCN-M2 cells being treated for 48h with 10nM of siRNA against MuSK and were then stained for MuSK protein on days 2, 3, 4, and 5 following siRNA treatment.

DEFINITIONS

[0105] For convenience, the meaning of some terms and phrases used in the specification, examples, and appended claims, are provided below. Unless stated otherwise, or implicit from context, the following terms and phrases include the meanings provided below.

[0106] These definitions are provided to aid in describing particular embodiments, and are not intended to limit the claimed invention, because the scope of the invention is limited only by the claims.

[0107] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. If there is an apparent discrepancy between the usage of a term in the art and its definition provided herein, the definition provided within the specification shall prevail.

[0108] *About or Approximately:* The term "about" or "approximately", when used herein in reference to a value, refers to a value that is similar, in context to the referenced value. In general, those skilled in the art, familiar with the context, will appreciate the relevant degree of variance encompassed by "about" in that context. For example, in some embodiments, the term "about" may encompass a range of values that within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the referred value.

[0109] *Administration:* As used herein, the term "administration" typically refers to the administration of a composition to a subject or system, for example to achieve delivery of an agent (e.g., an agonizing agent) that is, or is included in or otherwise delivered by, the composition. Those of ordinary skill in the art will be aware of a variety of routes that may, in appropriate circumstances, be utilized for administration to a subject, for example a human. For example, in some embodiments, administration may be ocular, oral, buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, etc), enteral, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (*e.g.,* intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (*e.g.,* by intratracheal instillation), vaginal, vitreal, etc. In some embodiments, an agent (*e.g.,* an agonizing agent) is delivered to the central nervous system (CNS), *e.g.,* delivered via intracerebroventricular administration. In some embodiments, administration may involve only a single dose. In some embodiments, administration may involve application of a fixed number of doses. In some embodiments,

administration may involve dosing that is intermittent (*e.g.*, a plurality of doses separated in time) and/or periodic (*e.g.*, individual doses separated by a common period of time) dosing. In some embodiments, administration may involve continuous dosing (*e.g.*, perfusion) for at least a selected period of time.

[0110] *Agent:* In general, the term "agent", as used herein, may be used to refer to a compound or entity of any chemical class including, for example, a polypeptide, nucleic acid, saccharide, lipid, small molecule, metal, or combination or complex thereof. In appropriate circumstances, as will be clear from context to those skilled in the art, the term may be utilized to refer to an entity that is or comprises a cell or organism, or a fraction, extract, or component thereof. Alternatively or additionally, as context will make clear, the term may be used to refer to a natural product in that it is found in and/or is obtained from nature. In some instances, again as will be clear from context, the term may be used to refer to one or more entities that is man-made in that it is designed, engineered, and/or produced through action of the hand of man and/or is not found in nature. In some embodiments, an agent may be utilized in isolated or pure form; in some embodiments, an agent may be utilized in crude form. In some embodiments, potential agents may be provided as collections or libraries, for example that may be screened to identify or characterize active agents within them. In some cases, the term "agent" may refer to a compound or entity that is or comprises a polymer; in some cases, the term may refer to a compound or entity that comprises one or more polymeric moieties. In some embodiments, the term "agent" may refer to a compound or entity that is not a polymer and/or is substantially free of any polymer and/or of one or more particular polymeric moieties. In some embodiments, the term may refer to a compound or entity that lacks or is substantially free of any polymeric moiety.

[0111] *Agonist*: Those skilled in the art will appreciate that the term "agonist" may be used to refer to an agent (i.e., an "agonizing agent"), condition, or event whose presence, level, degree, type, or form correlates with increased level or activity of another agent (i.e., the agonized agent or the target agent). In general, an agonist may be or include an agent of any chemical class including, for example, small molecules, polypeptides, nucleic acids, carbohydrates, lipids, metals, and/or any other entity that shows the relevant activating activity. In some embodiments, an agonist may be direct (in which case it exerts its influence directly upon its target); in some embodiments, an agonist may be indirect (in which case it

exerts its influence by other than binding to its target; e.g., by interacting with a regulator of the target, so that level or activity of the target is altered). In some embodiments, an agonist is a binding agent that is a protein (e.g., an antibody) or a nucleic acid (e.g., an antisense oligonucleotide) that binds a target (e.g., a protein or nucleic acid) so that level, form, and/or or activity of the target is altered. In some embodiments, the altered level, form and/or activity is an increased level of altered protein expressed from the target nucleic acid sequence. Those skilled in the art, reading the present disclosure, will appreciate that, in some embodiments, an agonizing agent may bind to (and potentially agonize) a binding target, which binding causes an increase in level or activity of a further agonized target. To give a specific example, in some embodiments, an agonizing agent that binds to a nucleic acid target may alter level and/or activity of that target, and in some specific embodiments may agonize an activity of that nucleic acid target (e.g., by increasing its modification, splicing, 5' cap formation, and/or 3' end formation, transport, and/or translation, etc, so that a level of a desired product – e.g., mRNA, is increased) and/or may agonize a downstream target, such as a polypeptide encoded by such nucleic acid target. To give one particular such example, in some embodiments, an agonizing agent may be or comprise an oligonucleotide that binds to a primary transcript and alters its splicing pattern so that level and/or activity of a particular spliced form (e.g., mature mRNA) is increased, which may, in turn achieved increased level of a product (e.g., a polypeptide) that is or is encoded by such particular spliced form.

[0112] *Antagonist:* Those skilled in the art will appreciate that the term "antagonist", as used herein, may be used to refer to an agent (i.e., an "antagonizing agent"), condition, or event whose presence, level, degree, type, or form correlates with decreased level or activity of another agent (i.e., the inhibited agent, or target). In general, an antagonist may be or include an agent of any chemical class including, for example, small molecules, polypeptides, nucleic acids, carbohydrates, lipids, metals, and/or any other entity that shows the relevant inhibitory activity. In some embodiments, an antagonist may be direct (in which case it exerts its influence directly upon its target); in some embodiments, an antagonist may be indirect (in which case it exerts its influence by other than binding to its target; e.g., by interacting with a regulator of the target, so that level or activity of the target is altered). In some embodiments, an antagonist is binding agent that is a protein (e.g., an antibody) or a nucleic acid (e.g., an antisense oligonucleotide) that binds a target (e.g., a protein or nucleic acid) so that the level,

form, and/or activity of the target is altered. In some embodiments, the altered level, form and/or activity is a decreased level of altered protein expressed from the target nucleic acid sequence. Those skilled in the art, reading the present disclosure, will appreciate that, in some embodiments, an antagonizing agent may bind to (and potentially antagonize) a binding target, which binding causes a decrease in level or activity of a further antagonized target. To give a specific example, in some embodiments, an antagonizing agent that binds to a nucleic acid target may alter level and/or activity of that target, and in some specific embodiments may antagonize an activity of that nucleic acid target (e.g., by decreasing its modification, splicing, 5' cap formation, and/or 3' end formation, transport, and/or translation, etc, so that a level of an undesired product – e.g., mRNA, is suppressed) and/or may antagonize a downstream target, such as a polypeptide encoded by such nucleic acid target. To give one particular such example, in some embodiment, an antagonizing agent may be or comprise an oligonucleotide that binds to a primary transcript and alters its splicing pattern so that level and/or activity of a particular spliced form (e.g., mature mRNA) is suppressed, which may, in turn achieved decreased level of a product (e.g., a polypeptide) that is or is encoded by such particular spliced form.

[0113] *Antibody agent*: As used herein, the term "antibody agent" refers to an agent that specifically binds to a particular antigen (*e.g.,* that may be or comprise an epitope of a protein of interest - e.g., a MuSK protein). In some embodiments, the term encompasses any polypeptide or polypeptide complex that includes immunoglobulin structural elements sufficient to confer specific binding. Exemplary antibody agents include, but are not limited to monoclonal antibodies or polyclonal antibodies. In some embodiments, an antibody agent may include one or more constant region sequences that are characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, an antibody agent may include one or more sequence elements are humanized, primatized, chimeric, etc, as is known in the art. In many embodiments, the term "antibody agent" is used to refer to one or more of the art-known or developed constructs or formats for utilizing antibody structural and functional features in alternative presentation. For example, embodiments, an antibody agent utilized in accordance with the present invention is in a format selected from, but not limited to, intact IgA, IgG, IgE or IgM antibodies; bi- or multi- specific antibodies (e.g., Zybodies®, etc); antibody fragments such as Fab fragments, Fab' fragments, F(ab')2 fragments, Fd'

fragments, Fd fragments, and isolated CDRs or sets thereof; single chain Fvs; polypeptide-Fc fusions; single domain antibodies (e.g., shark single domain antibodies such as IgNAR or fragments thereof); cameloid antibodies; masked antibodies (e.g., Probodies®); Small Modular ImmunoPharmaceuticals ("SMIPs™"); single chain or Tandem diabodies (TandAb®); VHHs; Anticalins®; Nanobodies® minibodies; BiTE®s; ankyrin repeat proteins or DARPINs®; Avimers®; DARTs; TCR-like antibodies;, Adnectins®; Affilins®; Trans-bodies®; Affibodies®; TrimerX®; MicroProteins; Fynomers®, Centyrins®; and KALBITOR®s. In some embodiments, an antibody may lack a covalent modification (e.g., attachment of a glycan) that it would have if produced naturally. In some embodiments, an antibody may contain a covalent modification (e.g., attachment of a glycan, a payload [e.g., a detectable moiety, a therapeutic moiety, a catalytic moiety, etc], or other pendant group [e.g., poly-ethylene glycol, etc.]. In many embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes one or more structural elements recognized by those skilled in the art as a complementarity determining region (CDR); in some embodiments an antibody agent is or comprises a polypeptide whose amino acid sequence includes at least one CDR (e.g., at least one heavy chain CDR and/or at least one light chain CDR) that is substantially identical to one found in a reference antibody. In some embodiments an included CDR is substantially identical to a reference CDR in that it is either identical in sequence or contains between 1-5 amino acid substitutions as compared with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that it shows at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that it shows at least 96%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that at least

one amino acid within the included CDR is substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR. In some embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes structural elements recognized by those skilled in the art as an immunoglobulin variable domain. In some embodiments, an antibody agent is a polypeptide protein having a binding domain which is homologous or largely homologous to an immunoglobulin-binding domain.

[0114] *Antibody:* As used herein, the term "antibody" refers to an immunoglobulin or a derivative thereof containing an immunoglobulin domain capable of binding to an antigen (*e.g.,* that may be or comprise an epitope of a protein of interest - *e.g.,* a MuSK protein). The antibody can be of any species, *e.g.,* human, rodent, rabbit, goat, chicken, etc. The antibody may be a member of any immunoglobulin class, including any of the human classes: IgG, IgM, IgA, IgD, and IgE, or subclasses thereof such as IgG1, IgG2, etc. In various embodiments of the invention the antibody is a fragment such as an Fab', $F(ab')_2$, scFv (single-chain variable) or other fragment that retains an antigen binding site, or a recombinantly produced scFv fragment, including recombinantly produced fragments. See, e.g., Allen, T., *Nature Reviews Cancer*, Vol.2, 750-765, 2002, and references therein. The antibody can be monovalent, bivalent or multivalent. The antibody may be a chimeric or "humanized" antibody in which, for example, a variable domain of rodent origin is fused to a constant domain of human origin, thus retaining the specificity of the rodent antibody. The domain of human origin need not originate directly from a human in the sense that it is first synthesized in a human being. Instead, "human" domains may be generated in rodents whose genome incorporates human immunoglobulin genes. See, e.g., Vaughan, et al., (1998), *Nature Biotechnology*, 16: 535-539. The antibody may be partially or completely humanized. An antibody may be polyclonal or monoclonal, though for purposes of the present invention monoclonal antibodies are generally preferred. Methods for producing antibodies that specifically bind to virtually any molecule of interest are known in the art. For example, monoclonal or polyclonal antibodies can be purified from blood or ascites fluid

of an animal that produces the antibody (e.g., following natural exposure to or immunization with the molecule or an antigenic fragment thereof), can be produced using recombinant techniques in cell culture or transgenic organisms, or can be made at least in part by chemical synthesis. In some embodiments, the antibody can act as an antagonist, e.g., by binding to a target antigen, resulting in a decreased level or activity of said antigen. In some embodiments, the antibody can act as an agonist, e.g., by binding to a target antigen, resulting in an increased level or activity of said antigen.

[0115] *Antisense:* The term "antisense" is used herein to refer to a nucleic acid whose nucleotide sequence is complementary to part or all of a sequence found in a coding strand nucleic acid. Typically, a "coding strand" nucleic acid is one whose sequence includes part or all of an open reading frame or other stretch of residues that encodes part or all of a polypeptide. In some embodiments, the term "antisense" may particularly be used herein in reference to an oligonucleotide that binds specifically to a coding strand (i.e., to a target sequence within such coding strand). In some embodiments, a coding strand may include both coding and non-coding sequences (e.g., to give but one example, may be a transcript, such as a primary transcript. that includes both intron and exon sequences). Those skilled in the art, reading the present disclosure, will appreciate that, in some embodiments, an oligonucleotide may be considered or referred to as an "antisense" oligonucleotide when some or all of its sequence is complementary to non-coding portion(s) of its target strand. In some embodiments, an antisense oligonucleotide binds to coding sequences in a target sense strand; in some embodiments, an antisense oligonucleotide binds to non-coding sequences in a target coding strand. In some embodiments, an antisense oligonucleotide binds to both coding and non-coding sequences in a target coding strand. In some embodiments, an antisense oligonucleotide is characterized in that, when bound to its target sequence in a coding strand (e.g., a transcript), it alters post-transcriptional processing (e.g., one or more of modification, splicing, 5' cap formation, and/or 3' end formation, 5' cap formation, and/or 3' end formation, transport, and/or translation) of such coding strand. In some particular embodiments, an antisense oligonucleotide alters splicing of its target coding strand, Alternatively or additionally, in some embodiments, an antisense-coding strand complex is or can be degraded, e.g., by RNase H.

[0116] *Approximately:* As used herein, the terms "approximately" or "about" in reference to a number are generally taken to include numbers that fall within a range of 5%, 10%, 15%, or 20% in either direction (greater than or less than) of the number unless otherwise stated or otherwise evident from the context (except where such number would be less than 0% or exceed 100% of a possible value).

[0117] *Binding agent*: In general, the term "binding agent" is used herein to refer to any entity that binds to a target of interest as described herein. In many embodiments, a binding agent of interest is one that binds specifically with its target in that it discriminates its target from other potential binding partners in a particular interaction context. In general, a binding agent may be or comprise an entity of any chemical class (e.g., polymer, non-polymer, small molecule, polypeptide, carbohydrate, lipid, nucleic acid, etc). In some embodiments, a binding agent is a single chemical entity. In some embodiments, a binding agent is a complex of two or more discrete chemical entities associated with one another under relevant conditions by non-covalent interactions. For example, those skilled in the art will appreciate that in some embodiments, a binding agent may comprise a "generic" binding moiety (e.g., one of biotin/avidin/streptavidin and/or a class-specific antibody) and a "specific" binding moiety (e.g., an antibody or aptamers with a particular molecular target) that is linked to the partner of the generic biding moiety. In some embodiments, such an approach can permit modular assembly of multiple binding agents through linkage of different specific binding moieties with the same generic binding poiety partner. In some embodiments, binding agents are or comprise polypeptides (including, *e.g.,* antibodies or antibody fragments). In some embodiments, binding agents are or comprise small molecules. In some embodiments, binding agents are or comprise nucleic acids (*e.g.,* antisense oligonucleotides). In some embodiments, binding agents are aptamers. In some embodiments, binding agents are polymers; in some embodiments, binding agents are not polymers. In some embodiments, binding agents are non-polymeric in that they lack polymeric moieties. In some embodiments, binding agents are or comprise carbohydrates. In some embodiments, binding agents are or comprise lectins. In some embodiments, binding agents are or comprise peptidomimetics. In some embodiments, binding agents are or comprise scaffold proteins. In some embodiments, binding agents are or comprise mimeotopes. In some embodiments, binding agents are or comprise stapled peptides. In

certain embodiments, binding agents are or comprise nucleic acids, such as DNA or RNA (*e.g.*, antisense oligonucleotides).

[0118] *Complementary*: As used herein, in accordance with its art-accepted meaning, "complementary" refers to the capacity for precise pairing between particular bases, nucleosides, nucleotides or nucleic acids. For example, adenine (A) and uridine (U) are complementary; adenine (A) and thymidine (T) are complementary; and guanine (G) and cytosine (C), are complementary and are referred to in the art as Watson-Crick base pairings. If a nucleotide at a certain position of a first nucleic acid sequence is complementary to a nucleotide located opposite in a second nucleic acid sequence when the strands are aligned in anti-parallel orientation, the nucleotides form a complementary base pair, and the nucleic acids are complementary at that position. The percent complementarity of a first nucleic acid to a second nucleic acid may be evaluated by aligning them in antiparallel orientation for maximum complementarity over a window of evaluation, determining the total number of nt in both strands that form complementary base pairs within the window, dividing by the total number of nt within the window, and multiplying by 100. For example, AAAAAAAA and TTTGTTAT are 75% complementary since there are 12 nt in complementary base pairs out of a total of 16 nt. When computing the number of complementary nt needed to achieve a particular % complementarity, fractions are rounded to the nearest whole number. A position occupied by non-complementary nucleotides constitutes a mismatch, i.e., the position is occupied by a non-complementary base pair. In certain embodiments a window of evaluation has the length described herein for duplex portions or target portions. Complementary sequences include base-pairing of a polynucleotide comprising a first nucleotide sequence to a polynucleotide comprising a second nucleotide sequence over the entire length of both nucleotide sequences (if the same length) or over the entire length of the shorter sequence (if different lengths). Such sequences can be referred to as "perfectly complementary" (100% complementarity) with respect to each other herein. Nucleic acids that are at least 70% complementary over a window of evaluation are considered "substantially complementary" over that window. In certain embodiments complementary nucleic acids are at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% complementary over the window of evaluation. Where a first sequence is referred to as "substantially complementary" with respect to a second sequence herein, the two sequences may be perfectly complementary or

they may comprise one or more unmatched bases upon hybridization, *e.g.,* up to about 5%, 10%, 15%, 20%, or 25% unmatched bases upon hybridization, *e.g.,* 1, 2, 3, 4, 5, or 6 mismatched base pairs upon hybridization for a duplex up to 30 base pairs, while retaining the ability to hybridize under the conditions most relevant to their intended use. It should be understood that where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs are not regarded as mismatches or unpaired nucleotides with regard to the determination of percent complementarity. For example, the two strands of a dsRNA comprising one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is perfectly complementary to the shorter oligonucleotide and a 2 nucleotide overhang, may be referred to as "perfectly complementary" herein. "Complementary" sequences, as used herein may include one or more non-Watson-Crick base pairs and/or base pairs formed from non-natural and other modified nucleotides, in so far as the requirements with respect to their ability to hybridize are fulfilled. Such non-Watson-Crick base pairs include, but are not limited to, G:U Wobble or Hoogsteen base pairing. Those of ordinary skill in the art are aware that guanine, cytosine, adenine, and uracil can be replaced by other bases without substantially altering the base pairing properties of a polynucleotide comprising a nucleotide bearing such bases, according to the so-called "wobble" rules (see, e.g., Murphy, FV IV & V Ramakrishnan, V., Nature Structural and Molecular Biology 11: 1251 - 1252 (2004)). For example, a nucleotide comprising inosine as its base can base pair with nucleotides containing adenine, cytosine, or uracil. Thus, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of an Inhibitory RNA described herein by a nucleotide containing, for example, inosine. It will be understood that the terms "complementary", "perfectly complementary", and "substantially complementary" can be used with respect to the base matching between any two nucleic acids, *e.g.,* the base matching between the sense strand and the antisense strand of a double stranded nucleic acid, or portion thereof. "Hybridize", as used herein, refers to the interaction between two nucleic acid sequences (which in some embodiments may be part of the same nucleic acid molecule and in other embodiments may be or include part(s) of different nucleic acid molecules) comprising or consisting of complementary portions such that a duplex structure (i.e., an intramolecular or intermolecular duplex) is formed that is

stable under the particular conditions of interest, as will be understood by the ordinary skilled artisan.

[0119] *Comprising:* The term "comprising" means that other elements can also be present in addition to the defined elements presented. The use of "comprising" indicates inclusion rather than limitation.

[0120] *Consisting of:* The term "consisting of" refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment. As used herein the term "consisting essentially of" refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the invention.

[0121] *Combination therapy:* As used herein, the term “combination therapy” refers to those situations in which a subject is simultaneously exposed to two or more therapeutic regimens (e.g., two or more therapeutic agents). In some embodiments, the two or more regimens may be administered simultaneously; in some embodiments, such regimens may be administered sequentially (*e.g.,* all “doses” of a first regimen are administered prior to administration of any doses of a second regimen); in some embodiments, such agents are administered in overlapping dosing regimens. In some embodiments, “administration” of combination therapy may involve administration of one or more agent(s) or modality(ies) to a subject receiving the other agent(s) or modality(ies) in the combination. For clarity, combination therapy does not require that individual agents be administered together in a single composition (or even necessarily at the same time), although in some embodiments, two or more agents, or active moieties thereof, may be administered together in a combination composition, or even in a combination compound (e.g., as part of a single chemical complex or covalent entity).

[0122] *Comparable:* As used herein, the term “comparable” refers to two or more agents, entities, situations, sets of conditions, etc., that may not be identical to one another but that are sufficiently similar to permit comparison there between so that one skilled in the art will appreciate that conclusions may reasonably be drawn based on differences or similarities observed. In some embodiments, comparable sets of conditions, circumstances, individuals,

or populations are characterized by a plurality of substantially identical features and one or a small number of varied features. Those of ordinary skill in the art will understand, in context, what degree of identity is required in any given circumstance for two or more such agents, entities, situations, sets of conditions, etc to be considered comparable. For example, those of ordinary skill in the art will appreciate that sets of circumstances, individuals, or populations are comparable to one another when characterized by a sufficient number and type of substantially identical features to warrant a reasonable conclusion that differences in results obtained or phenomena observed under or with different sets of circumstances, individuals, or populations are caused by or indicative of the variation in those features that are varied.

[0123] *Domain:* The term "domain" as used herein refers to a section or portion of an entity. In some embodiments, a "domain" is associated with a particular structural and/or functional feature of the entity so that, when the domain is physically separated from the rest of its parent entity, it substantially or entirely retains the particular structural and/or functional feature. Alternatively or additionally, a domain may be or include a portion of an entity that, when separated from that (parent) entity and linked with a different (recipient) entity, substantially retains and/or imparts on the recipient entity one or more structural and/or functional features that characterized it in the parent entity. In some embodiments, a domain is a section or portion of a molecule (e.g., a small molecule, carbohydrate, lipid, nucleic acid, or polypeptide). In some embodiments, a domain is a section of a polypeptide (*e.g.,* the Ig3 domain of a MuSK protein); in some such embodiments, a domain is characterized by a particular structural element (e.g., a particular amino acid sequence or sequence motif, a-helix character, b-sheet character, coiled-coil character, random coil character, etc.), and/or by a particular functional feature (e.g., binding activity, enzymatic activity, folding activity, signaling activity, etc.).

[0124] *Dosing regimen:* Those skilled in the art will appreciate that the term "dosing regimen" may be used to refer to a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time. In some embodiments, a given therapeutic agent has a recommended dosing regimen, which may involve one or more doses. In some embodiments, a dosing regimen comprises a plurality of doses each of which is separated in time from other doses. In some embodiments, individual doses are separated from one another by a time period of the same length; in some

embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses. In some embodiments, all doses within a dosing regimen are of the same unit dose amount. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount different from the first dose amount. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount same as the first dose amount. In some embodiments, a dosing regimen is correlated with a desired or beneficial outcome when administered across a relevant population (*i.e.*, is a therapeutic dosing regimen).

[0125] *Expression:* As used herein, "expression" of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (*e.g.*, by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5' cap formation, and/or 3' end formation); (3) transport of an RNA transcript (*e.g.*, from nucleus to cytoplasm; and/or (4) translation of an RNA into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein.

[0126] *Isolated or Partially Purified:* The term "isolated" or "partially purified" as used herein refers, in the case of a nucleic acid or polypeptide, to a nucleic acid or polypeptide separated from at least one other component (*e.g.*, nucleic acid or polypeptide) that is present with the nucleic acid or polypeptide as found in its natural source and/or that would be present with the nucleic acid or polypeptide when expressed by a cell, or secreted in the case of secreted polypeptides. A chemically synthesized nucleic acid or polypeptide or one synthesized using *in vitro* transcription/translation is considered "isolated." The terms "purified" or "substantially purified" refer to an isolated nucleic acid or polypeptide that is at least 95% by weight the subject nucleic acid or polypeptide, including, for example, at least 96%, at least 97%, at least 98%, at least 99% or more. In some embodiments, the antibody, antigen-binding portion thereof, or chimeric antigen receptor (CAR) described herein is isolated. In some embodiments, the antibody, antibody reagent, antigen- binding portion thereof, or CAR described herein is purified.

[0127] *Engineered:* As used herein, "engineered" refers to the aspect of having been manipulated by the hand of man. For example, an antibody, antibody reagent, antigen-binding portion thereof, CAR or bispecific antibody is considered to be "engineered" when the sequence of the antibody, antibody reagent, antigen-binding portion thereof, CAR or bispecific antibody is manipulated by the hand of man to differ from the sequence of an antibody as it exists in nature. As is common practice and is understood by those in the art, progeny and copies of an engineered polynucleotide and/or polypeptide are typically still referred to as "engineered" even though the actual manipulation was performed on a prior entity.

[0128] *Fragment:* A "fragment" of a material or entity as described herein has a structure that includes a discrete portion of the whole, but lacks one or more moieties found in the whole. In some embodiments, a fragment consists of such a discrete portion. In some embodiments, a fragment consists of or comprises a characteristic structural element or moiety found in the whole. In some embodiments, a polymer fragment comprises or consists of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more monomeric units (e.g., residues) as found in the whole polymer. In some embodiments, a polymer fragment comprises or consists of at least about 5%, 10%, 15%, 20%, 25%, 30%, 25%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of the monomeric units (e.g., residues) found in the whole polymer. The whole material or entity may in some embodiments be referred to as the "parent" of the fragment.

[0129] *Gene*: As used herein, the term "gene" refers to a DNA sequence in a chromosome that codes for a product (*e.g.,* an RNA product and/or a polypeptide product). In some embodiments, a gene includes coding sequence (*i.e.,* sequence that encodes a particular product); in some embodiments, a gene includes non-coding sequence. In some particular embodiments, a gene may include both coding (*e.g.,* exonic) and non-coding (*e.g.,* intronic) sequences. In some embodiments, a gene may include one or more regulatory elements that, for example, may control or impact one or more aspects of gene expression (*e.g.,* cell-type-specific expression, inducible expression, etc.).

[0130] *Gene product or expression product*: As used herein, the term "gene product" or "expression product" generally refers to an RNA transcribed from the gene (pre-and/or post-processing) or a polypeptide (pre- and/or post-modification) encoded by an RNA transcribed from the gene. In some embodiments, a gene product may be or comprise a particular processed form of an RNA transcript (*e.g.*, a particular edited form, a particular splice form, a particular capped form, etc).

[0131] *Homology*: As used herein, the term "homology" refers to the overall relatedness between polymeric molecules, *e.g.*, between nucleic acid molecules (*e.g.*, DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be "homologous" to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. In some embodiments, polymeric molecules are considered to be "homologous" to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% similar.

[0132] *Identity*: As used herein, the term "identity" refers to the overall relatedness between polymeric molecules, *e.g.*, between nucleic acid molecules (*e.g.*, DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be "substantially identical" to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. Calculation of the percent identity of two nucleic acid or polypeptide sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (*e.g.*, gaps can be introduced in one or both of a first and a second sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of a reference sequence. The nucleotides at corresponding positions are then compared. When a position in the first sequence is occupied by the same residue (e.g., nucleotide or amino acid) as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the


length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17), which has been incorporated into the ALIGN program (version 2.0). In some exemplary embodiments, nucleic acid sequence comparisons made with the ALIGN program use a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleotide sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.

[0133] *Improve*, "*increase*", *"inhibit"* or "*reduce":* As used herein, the terms "improve", "increase", "inhibit', "reduce", or grammatical equivalents thereof, indicate values that are relative to a baseline or other reference measurement. In some embodiments, an appropriate reference measurement may be or comprise a measurement in a particular system (e.g., in a single individual, a single cell, or cell population) under otherwise comparable conditions absent presence of (e.g., prior to and/or after) a particular agent or treatment, or in presence of an appropriate reference agent (e.g., a positive control agent or a negative control agent). In some embodiments, an appropriate reference measurement may be or comprise a measurement in comparable system known or expected to respond in a particular way, in presence of the relevant agent or treatment. Those skilled in the art will appreciate that an "improvement", "increase", "reduction", etc typically refers to a statistically significant change. Moreover, those skilled in the art will understand from context what magnitude of change may be relevant. For example, in some embodiments, a change may be a "fold" change – *i.e.,* so that a "changed" value represents a 1.1, 1.2, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50 or more (e.g., 500, 1000 times) (including all integers and decimal points in between and above 1), e.g., 1.5, 1.6, 1.7. 1.8, etc.)-fold difference relative to the relevant reference. Alternatively or additionally, in some embodiments, a "change" may be a "percentage" change, so that a "changed" value represents a1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% increase

or decrease, including all integers and decimal points in between), relative to the relevant reference.

[0134] *Linked:* As used herein, the term "linked", when used with respect to two or more moieties, means that the moieties are physically associated or connected with one another to form a molecular structure that is sufficiently stable so that the moieties remain associated under the conditions in which the linkage is formed and, preferably, under the conditions in which the new molecular structure is used, *e.g.*, physiological conditions. In certain preferred embodiments of the invention the linkage is a covalent linkage. In other embodiments the linkage is noncovalent. Moieties may be linked either directly or indirectly. When two moieties are directly linked, they are either covalently bonded to one another or are in sufficiently close proximity such that intermolecular forces between the two moieties maintain their association. When two moieties are indirectly linked, they are each linked either covalently or noncovalently to a third moiety, which maintains the association between the two moieties. In general, when two moieties are referred to as being linked by a "linker" or "linking moiety" or "linking portion", the linkage between the two linked moieties is indirect, and typically each of the linked moieties is covalently bonded to the linker. The linker can be any suitable moiety that reacts with the two moieties to be linked within a reasonable period of time, under conditions consistent with stability of the moieties (which may be protected as appropriate, depending upon the conditions), and in sufficient amount, to produce a reasonable yield.

[0135] *Internucleotidic linkage*: As used herein, the phrase "internucleotidic linkage" refers generally to the phosphorus-containing linkage between nucleotide units of an oligonucleotide, and is interchangeable with "inter-sugar linkage" and "phosphorus atom bridge," as used above and herein. In some embodiments, an internucleotidic linkage is a phosphodiester linkage, as found in naturally occurring DNA and RNA molecules. In some embodiments, an internucleotidic linkage is a "modified internucleotidic linkage" wherein each oxygen atom of the phosphodiester linkage is optionally and independently replaced by an organic or inorganic moiety. In some embodiments, such an organic or inorganic moiety is selected from but not limited to =S, =Se, =NR', –SR', –SeR', $–N(R')_2$, $B(R')_3$, –S–, –Se–, and –N(R')–, wherein each R' is independently as defined and described below. In some embodiments, an internucleotidic linkage is a phosphotriester linkage, phosphorothioate


diester linkage ( ), or modified phosphorothioate triester linkage. It is understood by a person of ordinary skill in the art that the internucleotidic linkage may exist as an anion or cation at a given pH due to the existence of acid or base moieties in the linkage. In some embodiments, an internucleotide linkage may be a chiral linkage.

[0136] *Long-term Administration*: As used herein, the term "long-term" administration means that the therapeutic agent or drug is administered for a period of at least 12 weeks. This includes that the therapeutic agent or drug is administered such that it is effective over, or for, a period of at least 12 weeks and does not necessarily imply that the administration itself takes place for 12 weeks, *e.g.,* if sustained release compositions or long acting therapeutic agent or drug is used. Thus, the subject is treated for a period of at least 12 weeks. In many cases, long-term administration is for at least 4, 5, 6, 7, 8, 9 months or more, or for at least 1, 2, 3, 5, 7 or 10 years, or more.

[0137] *Moiety*: Those skilled in the art will appreciate that a “moiety” is a defined chemical group or entity with a particular structure and/or or activity, as described herein.

[0138] *Nanoparticle:* As used herein, the term “nanoparticle” refers to a particle having a diameter of less than 1000 nanometers (nm). In some embodiments, a nanoparticle has a diameter of less than 300 nm, as defined by the National Science Foundation. In some embodiments, a nanoparticle has a diameter of less than 100 nm as defined by the National Institutes of Health. In some embodiments, nanoparticles are micelles in that they comprise an enclosed compartment, separated from the bulk solution by a micellar membrane, typically comprised of amphiphilic entities which surround and enclose a space or compartment (*e.g.*, to define a lumen). In some embodiments, a micellar membrane is comprised of at least one polymer, such as for example a biocompatible and/or biodegradable polymer.

[0139] *Nucleic acid*: As used herein, in its broadest sense, refers to any compound and/or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a nucleic acid is a compound and/or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester linkage. As will be clear from context, in some embodiments, "*nucleic acid*" refers to an individual nucleic acid residue (e.g., a

nucleotide and/or nucleoside); in some embodiments, "*nucleic acid*" refers to an oligonucleotide chain comprising individual nucleic acid residues. In some embodiments, a "*nucleic acid*" is or comprises RNA; in some embodiments, a "*nucleic acid*" is or comprises DNA. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleic acid analogs. In some embodiments, a nucleic acid analog differs from a nucleic acid in that it does not utilize a phosphodiester backbone. For example, in some embodiments, a nucleic acid is, comprises, or consists of one or more "*peptide nucleic acids*", which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention. Alternatively or additionally, in some embodiments, a nucleic acid has one or more phosphorothioate and/or 5'-N-phosphoramidite linkages rather than phosphodiester bonds. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxy guanosine, and deoxycytidine). In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3 -methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5 -propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 0(6)-methylguanine, 2-thiocytidine, methylated bases, intercalated bases, and combinations thereof). In some embodiments, a nucleic acid comprises one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) as compared with those in natural nucleic acids. In some embodiments, a nucleic acid has a nucleotide sequence that encodes a functional gene product such as an RNA or protein. In some embodiments, a nucleic acid includes one or more introns. In some embodiments, nucleic acids are prepared by one or more of isolation from a natural source, enzymatic synthesis by polymerization based on a complementary template (*in vivo* or *in vitro*), reproduction in a recombinant cell or system, and chemical synthesis. In some embodiments, a nucleic acid is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 1 10, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000 or more residues long. In

some embodiments, a nucleic acid is partly or wholly single stranded; in some embodiments, a nucleic acid is partly or wholly double stranded. In some embodiments a nucleic acid has a nucleotide sequence comprising at least one element that encodes, or is the complement of a sequence that encodes, a polypeptide. In some embodiments, a nucleic acid has enzymatic activity.

[0140] *Oligonucleotide:* As used herein, the term "oligonucleotide" refers to a polymer or oligomer of nucleotide monomers, containing any combination of nucleobases, modified nucleobases, sugars, modified sugars, phosphate bridges, or modified phosphorus atom bridges (also referred to herein as "internucleotidic linkage", defined further herein). Oligonucleotides can be single-stranded or double-stranded. A single-stranded oligonucleotide can have double-stranded regions and a double-stranded oligonucleotide can have single-stranded regions. Example oligonucleotides include, but are not limited to structural genes, genes including control and termination regions, self-replicating systems such as viral or plasmid DNA, single-stranded and double-stranded siRNAs and other RNA interference reagents (RNAi agents or iRNA agents), shRNA, antisense oligonucleotides, ribozymes, microRNAs, microRNA mimics, supermirs, aptamers, antimirs, antagomirs, Ul adaptors, triplex-forming oligonucleotides, G-quadruplex oligonucleotides, RNA activators, immuno-stimulatory oligonucleotides, and decoy oligonucleotides. Double-stranded and single-stranded oligonucleotides that are effective in inducing RNA interference are also referred to as siRNA, RNAi agent, or iRNA agent, herein. In some embodiments, these RNA interference inducing oligonucleotides associate with a cytoplasmic multi-protein complex known as RNAi-induced silencing complex (RISC). In many embodiments, single-stranded and double-stranded RNAi agents are sufficiently long that they can be cleaved by an endogenous molecule, e.g., by Dicer, to produce smaller oligonucleotides that can enter the RISC machinery and participate in RISC mediated cleavage of a target sequence, e.g. a target mRNA.

[0141] *Operably linked*: As used herein, the term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control element "operably linked" to a functional element is associated in such a way that expression and/or activity of the functional element is achieved under conditions compatible with the control element. In some embodiments,

"operably linked" control elements (e.g., promoters, enhancers, etc.) are contiguous (e.g., covalently linked) with the coding elements of interest; in some embodiments, control elements act in trans- or cis- with the coding functional element of interest.

[0142] *Patient:* As used herein, the term "patient" refers to any organism to which a provided composition (*e.g.,* an agonizing agent such as an ASO) is or may be administered, *e.g.*, for experimental, diagnostic, prophylactic, cosmetic, and/or therapeutic purposes. Typical patients include animals (*e.g.*, mammals such as mice, rats, rabbits, non-human primates, and/or humans). In some embodiments, a patient is a human. In some embodiments, a patient is suffering from or susceptible to one or more disorders or conditions. In some embodiments, a patient displays one or more symptoms of a disorder or condition. In some embodiments, a patient has been diagnosed with one or more disorders or conditions. In some embodiments, the disorder or condition is Alzheimer's disease or other disease characterized by neurodegeneration. In some embodiments, the disorder or condition is muscular dystrophy or other disease characterized by neuromuscular dysfunction. In some embodiments, the patient is receiving or has received certain therapy to diagnose and/or to treat a disease, disorder, or condition.

[0143] *Pharmaceutical composition:* As used herein, the term "pharmaceutical composition" refers to an active agent (*e.g.,* MuSK-targeting oligonucleotide), formulated together with one or more pharmaceutically acceptable carriers. In some embodiments, active agent is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, *e.g.,* those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, for example, by subcutaneous, intramuscular, intravenous, intraperitoneal, intrathecal, intravenous, intraventricular or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin, lungs, or oral cavity; intravaginally or intrarectally, for

example, as a pessary, cream, or foam; sublingually; ocularly; transdermally; or nasally, pulmonary, and to other mucosal surfaces.

[0144] *Pharmaceutically acceptable:* As used herein, the phrase "pharmaceutically acceptable" refers to those compounds, materials, compositions and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0145] *Pharmaceutically acceptable carrier:* As used herein, the term "pharmaceutically acceptable carrier" means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffered solutions; polyesters, polycarbonates and/or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations.

[0146] *Pharmaceutically acceptable salt:* The term "pharmaceutically acceptable salt", as used herein, refers to salts of such compounds that are appropriate for use in pharmaceutical contexts, *i.e.*, salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable

benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, *et al.* describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). In some embodiments, pharmaceutically acceptable salt include, but are not limited to, nontoxic acid addition salts, which are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, *p*-toluenesulfonate, undecanoate, valerate salts, and the like. In some embodiments, a provided compound comprises one or more acidic groups, e.g., an oligonucleotide, and a pharmaceutically acceptable salt is an alkali, alkaline earth metal, or ammonium (e.g., an ammonium salt of $N(R)_3$, wherein each R is independently defined and described in the present disclosure) salt. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. In some embodiments, a pharmaceutically acceptable salt is a sodium salt. In some embodiments, a pharmaceutically acceptable salt is a potassium salt. In some embodiments, a pharmaceutically acceptable salt is a calcium salt. In some embodiments, pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate. In some embodiments, a provided compound comprises more than one acid groups, for example, an oligonucleotide may comprise two or more acidic groups (e.g., in natural phosphate linkages and/or modified internucleotidic linkages). In some embodiments, a pharmaceutically acceptable salt, or generally a salt, of such a compound comprises two or more cations, which can be the same or different. In some embodiments, in a

pharmaceutically acceptable salt (or generally, a salt), all ionizable hydrogen (e.g., in an aqueous solution with a pKa no more than about 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2; in some embodiments, no more than about 7; in some embodiments, no more than about 6; in some embodiments, no more than about 5; in some embodiments, no more than about 4; in some embodiments, no more than about 3) in the acidic groups are replaced with cations. In some embodiments, each internucleotidic linkage, e.g., phosphate group, independently exists in its salt form (e.g., if sodium salt, −O−P(O)(ONa)−O−). In some embodiments, a pharmaceutically acceptable salt is a sodium salt of an oligonucleotide. In some embodiments, a pharmaceutically acceptable salt is a sodium salt of an oligonucleotide, wherein each acidic phosphate and modified phosphate group, if any, exists as a salt form (all sodium salt).

[0147] *Polypeptide:* As used herein, the term "polypeptide," which is interchangeably used herein with the term "protein," refers to a polymer of at least three amino acid residues. In some embodiments, a polypeptide comprises one or more, or all, natural amino acids. In some embodiments, a polypeptide comprises one or more, or all non-natural amino acids. In some embodiments, a polypeptide comprises one or more, or all, D-amino acids. In some embodiments, a polypeptide comprises one or more, or all, L-amino acids. In some embodiments, a polypeptide comprises one or more pendant groups or other modifications, *e.g.*, modifying or attached to one or more amino acid side chains, at the polypeptide's N-terminus, at the polypeptide's C-terminus, or any combination thereof. In some embodiments, a polypeptide comprises one or more modifications such as acetylation, amidation, aminoethylation, biotinylation, carbamylation, carbonylation, citrullination, deamidation, deimination, eliminylation, glycosylation, lipidation, methylation, pegylation, phosphorylation, sumoylation, or combinations thereof. In some embodiments, a polypeptide may participate in one or more intra- or inter-molecular disulfide bonds. In some embodiments, a polypeptide may be cyclic, and/or may comprise a cyclic portion. In some embodiments, a polypeptide is not cyclic and/or does not comprise any cyclic portion. In some embodiments, a polypeptide is linear. In some embodiments, a polypeptide may comprise a stapled polypeptide. In some embodiments, a polypeptide participates in non-covalent complex formation by non-covalent or covalent association with one or more other polypeptides (*e.g.,* as in an antibody). In some embodiments, a polypeptide has an amino

acid sequence that occurs in nature. In some embodiments, a polypeptide has an amino acid sequence that does not occur in nature. In some embodiments, a polypeptide has an amino acid sequence that is engineered in that it is designed and/or produced through action of the hand of man. In some embodiments, the term "polypeptide" may be appended to a name of a reference polypeptide, activity, or structure; in such instances it is used herein to refer to polypeptides that share the relevant activity or structure and thus can be considered to be members of the same class or family of polypeptides. For each such class, the present specification provides and/or those skilled in the art will be aware of exemplary polypeptides within the class whose amino acid sequences and/or functions are known; in some embodiments, such exemplary polypeptides are reference polypeptides for the polypeptide class or family. In some embodiments, a member of a polypeptide class or family shows significant sequence homology or identity with, shares a common sequence motif (*e.g.*, a characteristic sequence element) with, and/or shares a common activity (in some embodiments at a comparable level or within a designated range) with a reference polypeptide of the class; in some embodiments with all polypeptides within the class). For example, in some embodiments, a member polypeptide shows an overall degree of sequence homology or identity with a reference polypeptide that is at least about 30-40%, and is often greater than about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more and/or includes at least one region (*e.g.*, a conserved region that may in some embodiments comprise a characteristic sequence element) that shows very high sequence identity, often greater than 90% or even 95%, 96%, 97%, 98%, or 99%. Such a conserved region usually encompasses at least 3-4 and often up to 20 or more amino acids; in some embodiments, a conserved region encompasses at least one stretch of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more contiguous amino acids. In some embodiments, a useful polypeptide may comprise a fragment of a parent polypeptide. In some embodiments, a useful polypeptide as may comprise a plurality of fragments, each of which is found in the same parent polypeptide in a different spatial arrangement relative to one another than is found in the polypeptide of interest (*e.g.*, fragments that are directly linked in the parent may be spatially separated in the polypeptide of interest or vice versa, and/or fragments may be present in a different order in the polypeptide of interest than in the parent), so that the polypeptide of interest is a derivative of its parent polypeptide. In some embodiments, the polypeptide described herein (or a nucleic acid encoding such a polypeptide) can be a

functional fragment of one of the amino acid sequences described herein. As used herein, a "functional fragment" is a fragment or segment of a peptide which retains at least 50% of the wildtype reference polypeptide's activity according to the assays described below herein. A functional fragment can comprise conservative substitutions of the sequences disclosed herein. In some embodiments, the polypeptide described herein can be a variant of a sequence described herein. In some embodiments, the variant is a conservatively modified variant. Conservative substitution variants can be obtained by mutations of native nucleotide sequences, for example. A "variant," as referred to herein, is a polypeptide substantially homologous to a native or reference polypeptide, but which has an amino acid sequence different from that of the native or reference polypeptide because of one or a plurality of deletions, insertions or substitutions. Variant polypeptide-encoding DNA sequences encompass sequences that comprise one or more additions, deletions, or substitutions of nucleotides when compared to a native or reference DNA sequence, but that encode a variant protein or fragment thereof that retains activity. A wide variety of PCR-based site-specific mutagenesis approaches are known in the art and can be applied by the ordinarily skilled artisan. In the various embodiments described herein, it is further contemplated that variants (naturally occurring or otherwise), alleles, homologs, conservatively modified variants, and/or conservative substitution variants of any of the particular polypeptides described are encompassed. As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid and retains the desired activity of the polypeptide. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles consistent with the disclosure.

[0148] *Prevent* or *prevention:* as used herein when used in connection with the occurrence of a disease, disorder, and/or condition, refers to reducing the risk of developing the disease, disorder and/or condition and/or to delaying onset of one or more characteristics or symptoms of the disease, disorder or condition. Prevention may be considered complete

when onset of a disease, disorder or condition has been delayed for a predefined period of time.

[0149] *Recombinant*: As used herein, the term "recombinant" is intended to refer to polypeptides that are designed, engineered, prepared, expressed, created, manufactured, and/or or isolated by recombinant means, such as polypeptides expressed using a recombinant expression vector transfected into a host cell; polypeptides isolated from a recombinant, combinatorial human polypeptide library; polypeptides isolated from an animal (e.g., a mouse, rabbit, sheep, fish, etc.) that is transgenic for or otherwise has been manipulated to express a gene or genes, or gene components that encode and/or direct expression of the polypeptide or one or more component(s), portion(s), element(s), or domain(s) thereof; and/or polypeptides prepared, expressed, created or isolated by any other means that involves splicing or ligating selected nucleic acid sequence elements to one another, chemically synthesizing selected sequence elements, and/or otherwise generating a nucleic acid that encodes and/or directs expression of the polypeptide or one or more component(s), portion(s), element(s), or domain(s) thereof. In some embodiments, one or more of such selected sequence elements is found in nature. In some embodiments, one or more of such selected sequence elements is designed *in silico*. In some embodiments, one or more such selected sequence elements results from mutagenesis (*e.g., in vivo* or *in vitro*) of a known sequence element, *e.g.,* from a natural or synthetic source such as, for example, in the germline of a source organism of interest (*e.g.,* of a human, a mouse, etc.).

[0150] *Small molecule:* As used herein, the term "small molecule" means a low molecular weight organic and/or inorganic compound. In general, a "small molecule" is a molecule that is less than about 5 kilodaltons (kD) in size. In some embodiments, a small molecule is less than about 4 kD, 3 kD, about 2 kD, or about 1 kD. In some embodiments, the small molecule is less than about 800 daltons (D), about 600 D, about 500 D, about 400 D, about 300 D, about 200 D, or about 100 D. In some embodiments, a small molecule is less than about 2000 g/mol, less than about 1500 g/mol, less than about 1000 g/mol, less than about 800 g/mol, or less than about 500 g/mol. In some embodiments, a small molecule is not a polymer. In some embodiments, a small molecule does not include a polymeric moiety. In some embodiments, a small molecule is not and/or does not comprise a protein or polypeptide (e.g., is not an oligopeptide or peptide). In some embodiments, a small molecule

is not and/or does not comprise a polynucleotide (e.g., is not an oligonucleotide). In some embodiments, a small molecule is not and/or does not comprise a polysaccharide; for example, in some embodiments, a small molecule is not a glycoprotein, proteoglycan, glycolipid, *etc.*). In some embodiments, a small molecule is not a lipid. In some embodiments, a small molecule is a modulating agent (e.g., is an inhibiting agent or an activating agent). In some embodiments, a small molecule is biologically active. In some embodiments, a small molecule is detectable (e.g., comprises at least one detectable moiety). In some embodiments, a small molecule is a therapeutic agent. Those of ordinary skill in the art, reading the present disclosure, will appreciate that certain small molecule compounds described herein may be provided and/or utilized in any of a variety of forms such as, for example, crystal forms, salt forms, protected forms, pro-drug forms, ester forms, isomeric forms (e.g., optical and/or structural isomers), isotopic forms, etc. Those of skill in the art will appreciate that certain small molecule compounds have structures that can exist in one or more steroisomeric forms. In some embodiments, such a small molecule may be utilized in accordance with the present disclosure in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers; in some embodiments, such a small molecule may be utilized in accordance with the present disclosure in a racemic mixture form. Those of skill in the art will appreciate that certain small molecule compounds have structures that can exist in one or more tautomeric forms. In some embodiments, such a small molecule may be utilized in accordance with the present disclosure in the form of an individual tautomer, or in a form that interconverts between tautomeric forms. Those of skill in the art will appreciate that certain small molecule compounds have structures that permit isotopic substitution (e.g., ^{2}H or ^{3}H for H;, ^{11}C, ^{13}C or ^{14}C for 12C; , ^{13}N or ^{15}N for 14N; ^{17}O or ^{18}O for 16O; ^{36}Cl for XXC; ^{18}F for XXF; 131I for XXXI; etc). In some embodiments, such a small molecule may be utilized in accordance with the present disclosure in one or more isotopically modified forms, or mixtures thereof. In some embodiments, reference to a particular small molecule compound may relate to a specific form of that compound. In some embodiments, a particular small molecule compound may be provided and/or utilized in a salt form (e.g., in an acid-addition or base-addition salt form, depending on the compound); in some such embodiments, the salt form may be a pharmaceutically acceptable salt form. In some embodiments, where a small molecule compound is one that exists or is found in nature, that compound may be provided

and/or utilized in accordance in the present disclosure in a form different from that in which it exists or is found in nature. Those of ordinary skill in the art will appreciate that, in some embodiments, a preparation of a particular small molecule compound that contains an absolute or relative amount of the compound, or of a particular form thereof, that is different from the absolute or relative (with respect to another component of the preparation including, for example, another form of the compound) amount of the compound or form that is present in a reference preparation of interest (e.g., in a primary sample from a source of interest such as a biological or environmental source) is distinct from the compound as it exists in the reference preparation or source. Thus, in some embodiments, for example, a preparation of a single stereoisomer of a small molecule compound may be considered to be a different form of the compound than a racemic mixture of the compound; a particular salt of a small molecule compound may be considered to be a different form from another salt form of the compound; a preparation that contains only a form of the compound that contains one conformational isomer ((Z) or (E)) of a double bond may be considered to be a different form of the compound from one that contains the other conformational isomer ((E) or (Z)) of the double bond; a preparation in which one or more atoms is a different isotope than is present in a reference preparation may be considered to be a different form; etc.

[0151] *Specific binding:* As used herein, the term "specific binding" refers to an ability to discriminate between possible binding partners in the environment in which binding is to occur. A binding agent that interacts with one particular target when other potential targets are present is said to "*bind specifically*" to the target (*e.g.*, a target amino acid or nucleic acid sequence on a target protein/gene of interest) with which it interacts. In some embodiments, specific binding is assessed by detecting or determining degree of association between the binding agent and its partner; in some embodiments, specific binding is assessed by detecting or determining degree of dissociation of a binding agent-partner complex; in some embodiments, specific binding is assessed by detecting or determining ability of the binding agent to compete an alternative interaction between its partner and another entity. In some embodiments, specific binding is assessed by performing such detections or determinations across a range of concentrations.

[0152] *Specificity*: As is known in the art, "specificity" is a measure of the ability of a particular ligand to distinguish its binding partner from other potential binding partners.

[0153] *Subject:* As used herein, the term "subject" refers an organism, typically a mammal (*e.g.,* a human, in some embodiments including prenatal human forms). In some embodiments, a subject is suffering from a relevant disease, disorder or condition (*e.g.,* Alzheimer's disease (AD), muscular dystrophy or other disease characterized by neurodegeneration or neuromuscular dysfunction). In some embodiments, a subject is susceptible to a disease, disorder, or condition. In some embodiments, a subject displays one or more symptoms or characteristics of a disease, disorder or condition. In some embodiments, a subject does not display any symptom or characteristic of a disease, disorder, or condition. In some embodiments, a subject is someone with one or more features characteristic of susceptibility to or risk of a disease, disorder, or condition. In some embodiments, a subject is a patient. In some embodiments, a subject is an individual to whom diagnosis and/or therapy is and/or has been administered.

[0154] *Substantially:* As used herein, the term "substantially" refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term "substantially" is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

[0155] *Substantial identity:* as used herein refers to a comparison between amino acid or nucleic acid sequences. As will be appreciated by those of ordinary skill in the art, two sequences are generally considered to be "substantially identical" if they contain identical residues in corresponding positions. As is well known in this art, amino acid or nucleic acid sequences may be compared using any of a variety of algorithms, including those available in commercial computer programs such as BLASTN for nucleotide sequences and BLASTP, gapped BLAST, and PSI-BLAST for amino acid sequences. Exemplary such programs are described in Altschul et al., Basic local alignment search tool, J. Mol. Biol., 215(3): 403-410, 1990; Altschul et al., Methods in Enzymology; Altschul et al., Nucleic Acids Res. 25:3389-3402, 1997; Baxevanis et al., Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley, 1998; and Misener, et al, (eds.), Bioinformatics Methods and Protocols (Methods in Molecular Biology, Vol. 132), Humana Press, 1999. In addition to identifying

identical sequences, the programs mentioned above typically provide an indication of the degree of identity. In some embodiments, two sequences are considered to be substantially identical if at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more of their corresponding residues are identical over a relevant stretch of residues. In some embodiments, the relevant stretch is a complete sequence. In some embodiments, the relevant stretch is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more residues.

[0156] *Suffering from*: An individual who is "suffering from" a disease, disorder, and/or condition (*e.g.,* muscular dystrophy or other disease characterized by neuromuscular dysfunction) has been diagnosed with and/or displays one or more symptoms of a disease, disorder, and/or condition.

[0157] *Susceptible to*: An individual who is "susceptible to" a disease, disorder, and/or condition (*e.g.,* Alzheimer's disease (AD), muscular dystrophy or other disease characterized by neurodegeneration or neuromuscular dysfunction) is one who has a higher risk of developing the disease, disorder, and/or condition than does a member of the general public. In some embodiments, an individual who is susceptible to a disease, disorder and/or condition may not have been diagnosed with the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition may exhibit symptoms of the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition may not exhibit symptoms of the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will develop the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will not develop the disease, disorder, and/or condition.

[0158] *Symptoms are reduced:* According to the present invention, "symptoms are reduced" when one or more symptoms of a particular disease, disorder or condition (*e.g.,* Alzheimer's disease (AD), muscular dystrophy or other disease characterized by neurodegeneration or neuromuscular dysfunction) is reduced in magnitude (*e.g.*, intensity,

severity, *etc.*) and/or frequency. For purposes of clarity, a delay in the onset of a particular symptom is considered one form of reducing the frequency of that symptom.

[0159] *Target gene:* A "target gene", as used herein, refers to a gene whose expression is to be modulated, e.g., through modifying splice activity (e.g., by inducing exon-skipping). As used herein, the term "target portion" or "target region" refers to a contiguous portion of the nucleotide sequence of a target gene. In some embodiments, a target portion or target region is one or more exons within the target gene sequence. A target portion may be from about 8-36 nucleotides in length, e.g., about 10-20 or about 15-30 nucleotides in length. A target portion length may have specific value or subrange within the afore-mentioned ranges. For example, in certain embodiments a target portion may be between about 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19- 28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20- 26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length.

[0160] *Therapeutic agent:* As used herein, the phrase "therapeutic agent" refers to any agent that, when administered to a subject, has a therapeutic effect and/or elicits a desired biological and/or pharmacological effect. In some embodiments, a therapeutic agent is any substance that can be used to alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of, and/or reduce incidence of one or more symptoms or features of a disease, disorder, and/or condition (e.g., one or more symptoms or features of Alzheimer's disease (AD), muscular dystrophy or other disease characterized by neurodegeneration or neuromuscular dysfunction).

[0161] *Therapeutically effective amount:* As used herein, the term "therapeutically effective amount" means an amount of a substance (*e.g.,* a therapeutic agent, composition, and/or formulation) that elicits a desired biological response when administered as part of a therapeutic dosing regimen. In some embodiments, a therapeutically effective amount of a substance is an amount that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and/or condition, to treat, diagnose, prevent, and/or delay the onset of the disease, disorder, and/or condition. As will be appreciated by those of

ordinary skill in this art, the effective amount of a substance may vary depending on such factors as the desired biological endpoint, the substance to be delivered, the target cell or tissue, *etc.* It will be appreciated that there will be many ways known in the art to determine the effective amount for a given application. For example, the pharmacological methods for dosage determination may be used in the therapeutic context. In the context of therapeutic or prophylactic applications, the amount of a composition administered to the subject will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. For example, the effective amount of compound in a formulation to treat a disease, disorder, and/or condition is the amount that alleviates, ameliorates, relieves, inhibits, prevents, delays onset of, reduces severity of and/or reduces incidence of one or more symptoms or features of the disease, disorder, and/or condition. As used herein, the terms "effective amount" and "therapeutically-effective amount" include an amount sufficient to prevent or ameliorate a manifestation of disease or medical condition, such as Alzheimer's disease (AD), Parkinson's disease, or another disease characterized by neurodegeneration, reduced mobility, metabolism, and quality of life resulting from muscle wasting in cancer patients, elderly patients, and many others with no history of neuromuscular dysfunction, in addition to muscular dystrophies such as Becker, Congenital, Distal, Duchenne, Emery-Dreifuss, Facioscapulohumeral, Limb-girdle, Myotonic, Oculopharyngeal Muscular Dystrophy. It will be appreciated that there will be many ways known in the art to determine the effective amount for a given application. For example, the pharmacological methods for dosage determination may be used in the therapeutic context. In the context of therapeutic or prophylactic applications, the amount of a composition administered to the subject will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. The compositions can also be administered in combination with one or more additional therapeutic compounds. In some embodiments, a therapeutically effective amount is administered in a single dose; in some embodiments, multiple unit doses are required to deliver a therapeutically effective amount.

[0162] *Treating:* As used herein, the term "treating" refers to providing treatment, i.e., providing any type of medical or surgical management of a subject. The treatment can be provided in order to reverse, alleviate, inhibit the progression of, prevent or reduce the likelihood of a disease, disorder, or condition, or in order to reverse, alleviate, inhibit or prevent the progression of, prevent or reduce the likelihood of one or more symptoms or manifestations of a disease, disorder or condition. Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of the deficit, stabilized (i.e., not worsening) state of a muscular dystrophy, delay or slowing of muscle wasting, and an increased lifespan as compared to that expected in the absence of treatment. Treating can include administering an agent to the subject following the development of one or more symptoms or manifestations indicative of Alzheimer's disease (AD), muscular dystrophy or other disease characterized by neurodegeneration or neuromuscular dysfunction, e.g., in order to reverse, alleviate, reduce the severity of, and/or inhibit or prevent the progression of the condition and/or to reverse, alleviate, reduce the severity of, and/or inhibit or one or more symptoms or manifestations of the condition. A composition of the disclosure can be administered to a subject who has developed Alzheimer's disease, muscular dystrophy or other disease characterized by neurodegeneration, neuromuscular dysfunction or is at increased risk of developing such a disorder relative to a member of the general population. A composition of the disclosure can be administered prophylactically, *i.e.,* before development of any symptom or manifestation of the condition. Typically in this case the subject will be at risk of developing the condition.

[0163] *Variant:* As used herein in the context of molecules, *e.g.,* nucleic acids (*e.g.,* ASOs), proteins, or small molecules, the term "variant" refers to a molecule that shows significant structural identity with a reference molecule but differs structurally from the reference molecule, e.g., in the presence or absence or in the level of one or more chemical moieties as compared to the reference entity. In some embodiments, a variant also differs functionally from its reference molecule. In general, whether a particular molecule is properly considered to be a "variant" of a reference molecule is based on its degree of structural identity with the reference molecule. As will be appreciated by those skilled in the art, any biological or chemical reference molecule has certain characteristic structural elements. A variant, by definition, is a distinct molecule that shares one or more such

characteristic structural elements but differs in at least one aspect from the reference molecule. To give but a few examples, a polypeptide may have a characteristic sequence element comprised of a plurality of amino acids having designated positions relative to one another in linear or three-dimensional space and/or contributing to a particular structural motif and/or biological function; a nucleic acid may have a characteristic sequence element comprised of a plurality of nucleotide residues having designated positions relative to on another in linear or three-dimensional space. In some embodiments, a variant polypeptide or nucleic acid may differ from a reference polypeptide or nucleic acid as a result of one or more differences in amino acid or nucleotide sequence and/or one or more differences in chemical moieties (*e.g.,* carbohydrates, lipids, phosphate groups) that are covalently components of the polypeptide or nucleic acid (*e.g.,* that are attached to the polypeptide or nucleic acid backbone). In some embodiments, a variant polypeptide or nucleic acid shows an overall sequence identity with a reference polypeptide or nucleic acid that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 99%. In some embodiments, a variant polypeptide or nucleic acid does not share at least one characteristic sequence element with a reference polypeptide or nucleic acid. In some embodiments, a reference polypeptide or nucleic acid has one or more biological activities. In some embodiments, a variant polypeptide or nucleic acid shares one or more of the biological activities of the reference polypeptide or nucleic acid. In some embodiments, a variant polypeptide or nucleic acid lacks one or more of the biological activities of the reference polypeptide or nucleic acid. In some embodiments, a variant polypeptide or nucleic acid shows a reduced level of one or more biological activities as compared to the reference polypeptide or nucleic acid. In some embodiments, a polypeptide or nucleic acid of interest is considered to be a "variant" of a reference polypeptide or nucleic acid if it has an amino acid or nucleotide sequence that is identical to that of the reference but for a small number of sequence alterations at particular positions. Typically, fewer than about 20%, about 15%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, or about 2% of the residues in a variant are substituted, inserted, or deleted, as compared to the reference. In some embodiments, a variant polypeptide or nucleic acid comprises about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, or about 1 substituted residues as compared to a reference. Often, a variant polypeptide or nucleic acid comprises a very small number (*e.g.*, fewer than about 5, about 4, about 3, about 2, or about 1) number of

substituted, inserted, or deleted, functional residues (*i.e.*, residues that participate in a particular biological activity) relative to the reference. In some embodiments, a variant polypeptide or nucleic acid comprises not more than about 5, about 4, about 3, about 2, or about 1 addition or deletion, and, in some embodiments, comprises no additions or deletions, as compared to the reference. In some embodiments, a variant polypeptide or nucleic acid comprises fewer than about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 10, about 9, about 8, about 7, about 6, and commonly fewer than about 5, about 4, about 3, or about 2 additions or deletions as compared to the reference. In some embodiments, a reference polypeptide or nucleic acid is one found in nature. In some embodiments, a reference polypeptide or nucleic acid is a human polypeptide or nucleic acid.

[0164] *Vector*: As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "*plasmid*", which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "*expression vectors*". Standard techniques may be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (*e.g.*, electroporation, lipofection). Enzymatic reactions and purification techniques may be performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See *e.g.*, Sambrook et al., Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference for any purpose.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

Neurogenesis

[0165] Neurogenesis occurs in distinct regions of the adult mammalian brain. Neural stem cells (NSCs) are the endogenous source of new neurons and are active throughout life in virtually all mammals, including humans (Eriksson et al., 1998; Ernst et al., 2014; Moreno-Jiménez et al., 2019; Spalding et al., 2013). Extensive work in rodent models shows that neurogenesis supports learning and memory, sensory functions, and mood regulation (Enwere et al., 2004; Gage, 2019; Imayoshi et al., 2008; Zhang et al., 2008b). NSCs reside in two neurogenic niches: the subgranular zone (SGZ) in the dentate gyrus of the hippocampus and the subventricular zone (SVZ) lining the lateral ventricles. NSCs in the SVZ generate astrocytes and oligodendrocytes that support the existing circuitry as well as neurons in the olfactory bulb that are critical for olfactory discrimination. NSCs in the dentate gyrus give rise to granule neurons important for learning and memory. The majority of NSCs in the human brain are located in the hippocampus. Most hippocampal NSCs reside in a state of dormancy, termed quiescence. For neurogenesis to occur, quiescent NSCs must become activated in response to extrinsic or intrinsic cues. Newly born neurons functionally integrate into the local circuitry within the hippocampus and contribute to cognitive functions. The capacity of quiescent NSCs to activate declines during healthy and pathological aging and this loss precedes the decline in cognition (Enwere et al. 2004; Giachino et al. 2014; Capilla-Gonzalez et al. 2014).

[0166] Recent work indicates that endogenous or exogenous NSCs may be a valuable source of new neurons for the millions of individuals suffering from cognitive decline or brain injury. Activation of endogenous NSCs through exercise, re-feeding, or young blood improves age-related cognitive impairments in mice (Brandhorst et al., 2015; van Praag et al., 2005; Villeda et al., 2011, 2014). Accumulation of negative signals that degrade the neurogenic niche may contribute to reduction in newborn neurons in aging and AD. However, it has been difficult to harness the neurogenic potential of NSCs due to the lack of a specific therapeutic target that has the ability to overcome inhibitory signals. The present disclosure appreciates that recent mechanistic studies suggest that BMP signaling may represent a promising pathway to target in the context of AD and other diseases characterized by neurodegeneration. BMPs negatively regulate activation of NSCs (Mira et al., 2010) and

are upregulated in AD and APP transgenic mice (Crews et al., 2010). The present disclosure provides technologies to specifically modulate BMP signaling in the neurogenic niche.

Adult Hippocampal Neurogenesis

[0167] Adult Hippocampal Neurogenesis (AHN) is critical for normal learning and memory. AHN is abundant in healthy aged humans but is reduced from the earliest stages of Alzheimer's Disease (AD). AHN occurs throughout life in humans and is dramatically reduced in AD (Moreno-Jimenez et al., 2019; Steiner et al., 2019). Work in animal models has underscored the role of AHN in improving cognition in the face of AD pathology. Thus, restoring AHN may be an attractive target for an AD therapy. Interventions that promote adult hippocampal neurogenesis could enhance cognitive function and combat neurodegeneration.

[0168] AHN is critical for learning and memory. Newborn dentate granule cells are hyperexcitable and exhibit robust synaptic plasticity. Thus, dysregulation of the quiescent state and/or a failure to integrate into the mature circuitry are thought to contribute to the age-associated decline in neurogenesis and cognitive performance in aging and dementia.

[0169] **AHN in Humans.** Although AHN has been established in rodents and other species for decades, the existence of this process in human has been controversial until quite recently. Reports using BrdU incorporation (Eriksson et al., 1998), ^{14}C dating (Ernst et al., 2014; Spalding et al., 2013) and markers of immature neuron (Boldrini et al., 2018; Moreno-Jiménez et al., 2019; Tobin et al., 2019) have provided independent lines of support from multiple labs supporting human AHN. Mathematical modeling of radiocarbon birth dating data yielded estimates that in humans 35% of hippocampal neurons are replaced by newborn neurons during adulthood at a rate of 1.75% per year (Spalding et al., 2013). On the other hand, another recent report using markers for immature neurons failed to detect significant levels of AHN in adult humans (Sorrells et al., 2018). In depth comparison of these reports have revealed several methodological and sample differences that seem likely to explain the failure to detect adult neurogenesis in the Sorrells et al., paper (Kempermann et al., 2018; Lucassen et al., 2019).

[0170] **AHN and Alzheimer's Disease.** Alzheimer's Disease is a devastating disorder. It is progressive, fatal and has an enormous societal and economic cost. 5.8 million Americans are living with AD. By 2050 this number is projected to rise to 14M. In 2019, AD and other dementias cost the nation $290 billion. By 2050, these costs could rise as high as $1.1 trillion. There are no effective treatments. There have been several recent high profile drug trials. Almost all of these trails have been based upon the 'amyloid hypothesis'. There is an enormous unmet need for innovative and effective therapies for AD. Alzheimer's Disease devastates the hippocampus, a brain region necessary for encoding memories. The hippocampus is one of the two sites of adult neurogenesis in the brain. A large number of animal studies have shown that these adult-born neurons are necessary for learning and memory. A recent crucial study provided convincing evidence for robust neurogenesis in the adult human brain. Importantly, the level of adult neurogenesis in AD brain is greatly diminished compared to age-matched controls. (See E. P. Moreno-Jimenez et al. Nature Med. https://doi. org/10.I038/s41591-019-0375-9; 2019; See also related Editorial in Nature 567:433; 28 March 2019). Thus, promoting adult neurogenesis is emerging as a highly attractive target in treating AD.

[0171] The hippocampus is one of the earliest and most affected brain regions in AD and its atrophy is a hallmark of disease progression (Allison et al., 2019). Moreover, work in both rodents and humans has demonstrated that hippocampal-dependent learning is impaired in the Alzheimer's setting (Crews et al., 2010). Notably, AHN levels in AD patients are only 30% of those observed in age-matched controls (Moreno-Jiménez et al., 2019). Critically, a recent mouse study using genetically diverse AD mouse models showed that the total number of hippocampal neurons (NeuN + cells) correlates with cognition (Neuner Neuron 2019). Finally, a recent study has shown that exercise-mediated rescue of pathology in AD mice requires AHN, and that AHN ablation alone exacerbates cognitive defects in these mice (Choi et al., 2018). Thus, strategies to compensate for the degeneration of hippocampal neurons through enhancing endogenous neurogenesis have the potential to open a new pathway for treating Alzheimer's disease.

[0172] Other diseases associated with impaired AHN include e.g., diseases and disorders associated with progressive memory loss, such as Frontotemporal Dementia (Terreros-Roncal et al., 2019), stroke (Lindvall et al., 2015). Impaired AHN is also

associated with psychiatric disorders such as major depressive disorder (MDD), bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), substance-related and addictive disorders (Yun et al., 2016), and other diseases such as Temporal-Lobe Epilepsy (Cook et al., 1992) , Hippocampal Sclerosis (Tai et al. 2018), Niemann Pick Type C (Hong et al., 2015), and Diabetes-mediated hippocampal neuronal loss (Ho et al, 2013; Gold et al., 2007).

Subventricular Zone Neurogenesis

[0173] In addition to the hippocampus (*i.e.,* the subgranular zone (SGZ) in the dentate gyrus of the hippocampus), NSCs reside in the subventricular zone (SVZ) lining the lateral ventricles. NSCs in the SVZ generate astrocytes and oligodendrocytes that support the existing circuitry as well as neurons in the olfactory bulb that are critical for olfactory discrimination. Recent evidence suggests that SVZ NSCs can give rise to terminally differentiated neurons in the striatum in response to ischemic stroke or neurodegenerative diseases (Arvidsson et al. 2002; Parent et al. 2002; Thored et al. 2006; Ernst et al. 2014).

[0174] The present disclosure recognizes that strategies to compensate for the degeneration of neurons in the SVZ through enhancing endogenous neurogenesis have the potential to open a new pathway for treating diseases specifically associated with striatal neurogenesis such as Parkinson's disease (which could benefit both from increasing AHN and striatal neurogenesis in the SVZ; Pitcher et al. 2012; Sterling et al. 2013) and Huntington's disease (Sassone et al., 2018). Other diseases including addiction (*e.g.,* chronic cocaine use and lifelong cigarette smoking) are also associated with reduced striatal volume (Barrós-Loscertales et al. 2011; Das et al., 2012) and have the potential to be treated through enhancing endogenous neurogenesis in the SVZ.

MuSK and Neurogenesis

[0175] MuSK is a receptor tyrosine kinase comprised extracellularly of three Ig and one CRD/Fz domain and an intracellular tyrosine domain (TK; Fig. 1). The best understood function of MuSK is at the neuromuscular junction (NMJ) where agrin-LRP4 binding to the

Ig1 domain triggers MuSK TK activity and synapse differentiation (Kim et al., 2008; Zhang et al., 2008a).

[0176] **The MuSK-BMP Pathway.** The brain harbors neural stem cells (NSCs) that generate neurons and glial cells throughout life (Moreno-Jiménez et al., 2019; Steiner et al., 2019). BMPs regulate at least two important NSC decision points: 1) quiescence, where proliferating stem cells exit the cell cycle and return to replenish a reserve pool that can supply fresh stem cells; and; 2) differentiation into mature progeny (Mira et al., 2010). The present disclosure contemplates that manipulating the BMP pathway in NSCs is an attractive target for regulating neurogenesis in the adult brain.

[0177] It was recently discovered that MuSK is also a BMP co-receptor that binds BMP and its receptors ALK3 and 6, upregulates BMP signaling and shapes the composition of the transcriptional response in myogenic cells (Yilmaz et al., 2016). This BMP signaling pathway neither regulates nor requires MuSK TK activity nor is it activated by agrin-LRP4. Importantly, the MuSK Ig3 domain is necessary for high affinity BMP binding but is dispensable for agrin-LRP4 TK activation. Moreover, the Ig3 domain is endogenously alternatively spliced, including in the brain (Garcia-Osta et al., 2006; Hesser et al., 1999). Since BMP signaling induces NSC quiescence and can inhibit integration of newborn neurons we have found that restraining BMP drive by reducing MuSK-BMP signaling could increase neurogenesis (Fig. 1).

[0178] Yilmaz et al. 2016 discloses that the 'Ig3' domain of MuSK is required for high affinity binding of BMPs. The major species of MuSK expressed endogenously is full length. This Ig3 domain can be alternatively spliced endogenously, creating an isoform termed "Δg3MuSK". This splicing entails the coordinated removal of exons 6 and 7 from the MuSK pre-mRNA.

[0179] Exemplary amino acid sequences of human and mouse MuSK Ig3 domains (*i.e.,* of MuSK Ig3 domain polypeptides) are as set out below:

MuSK HUMAN_Ig3_Domain:

ARILRAPESHNVTFGSFVTLHCTATGIPVPTITWIENGNAVSSGSIQESVKDRVIDSRLQ LFITKPGLYTCIATNKHGEKFSTAKAAATIS (SEQ ID NO: 116)

MuSK MOUSE Ig3 Domain

ARILRAPESHNVTFGSFVTLRCTAIGIPVPTISWIENGNAVSSGSIQESVKDRVIDSRLQ LFITKPGLYTCIATNKHGEKFSTAKAAATVS (SEQ ID NO: 117)

[0180] Among other things, the present disclosure provides compositions such as MuSK-targeting oligonucleotides that regulate MuSK alternative splicing as a strategy for increasing AHN in AD.

MuSK and Muscle Regeneration and/or Growth

[0181] Satellite cells account for about 5% of muscle nuclei and are distributed along mature, multinucleated myofibers, usually in a state of quiescence. When muscle is injured, satellite cells usually proliferate before either returning to quiescence or differentiating. Upon differentiation, satellite cells become committed myoblasts that fuse into myotubes, eventually forming mature myofibers in a process termed myogenesis. Bone morphogenetic protein (BMP) signaling regulates satellite cell dynamics and muscle regeneration both *in vivo* and *in vitro* by modulating transcriptional outputs. BMP signaling is not detectable in quiescent satellite cells, it is upregulated in proliferating satellite cells, and it is downregulated during differentiation. However, mediators regulating the balance between satellite cell proliferation and differentiation are unknown.

[0182] Muscle-Specific Kinase (MuSK), also known as Muscle-Associated Receptor Tyrosine Kinase, is a transmembrane protein that was first recognized for its essential role in the formation and maintenance of the neuromuscular junction (NMJ). MuSK has three extracellular Immunoglobulin(Ig)-like domains and a cysteine-rich frizzled (CRD /Fz) domain, as well as an intracellular tyrosine kinase (TK) domain. The Ig1, TK and potentially the CRD/Fz domains are required for NMJ formation and maintenance. The Ig1 and TK domains are essential for agrin-LRP4 signaling directing synaptic differentiation. For this reason, global deletion MuSK mice are neo-natal lethal. Two isoforms of MuSK that exist *in vivo* are: full- length (FL) MuSK and a naturally-occurring splice variant that lacks the Ig3

domain (ΔIg3- MuSK). FL MuSK mRNA levels are 10X higher than mRNA of ΔIg3-MuSK but the two are expressed coordinately.

[0183] Among other things, the present disclosure provides compositions such as MuSK-targeting oligonucleotides that regulate MuSK alternative splicing as a strategy for increasing muscle regeneration.

[0184] MuSK is activated by a nerve-derived proteoglycan called agrin. Agrin has been characterized for its role in the development of the neuromuscular junction during embryogenesis. Agrin is named based on its involvement in the aggregation of acetylcholine receptors during synaptogenesis. In humans, this protein is encoded by the *AGRN* gene. The agrin protein has nine domains homologous to protease inhibitors.

[0185] MuSK is expressed in muscle and is upregulated during muscle regeneration. Data suggest that MuSK is implicated in BMP signaling in myogenesis. MuSK can act as a BMP co-receptor that binds BMP2, BMP4, and BMP7 as well as the Type I BMP receptors ALK3 and ALK6. *See,* for example, Yilmaz *et al., Sci. Signal.* 9:ra87, doi: 10.1126/scisignal.aaf0890, 2016, incorporated herein by reference. The Ig3 domain of MuSK is required for high-affinity binding to BMP. MuSK upregulates BMP signaling as measured by BMP4-dependent phosphorylation of SMAD1/5/8. Importantly, MuSK-BMP signaling shapes the magnitude and composition of BMP-induced transcriptome in myoblasts and myotubes and this role is independent of any MuSK tyrosine kinase activity. MuSK is a BMP co-receptor that potentiates BMP signaling and regulates myogenic factors, such as myogenic factor 5 (Myf5), in immortalized myogenic cells.

[0186] Activated satellite cells express MuSK protein and disruption of MuSK-BMP signaling alters satellite cell proliferation in regenerating muscle *in vivo*. Additionally, previous studies have suggested the role of the MuSK-BMP pathway in satellite cells and muscle regeneration and that targeting MuSK-BMP pathway enhances muscle growth (see *e.g.,* PCT Publication No. WO 2021/076883, which is incorporated by reference herein).

MuSK-Targeting Oligonucleotides

[0187] As described herein, a strategy for regulating the MuSK-BMP pathway includes MuSK-targeting oligonucleotides (*e.g.,* MuSK Ig3 targeting oligonucleotides). Specifically, the disclosure provides, among other things, oligonucleotides and compositions thereof that target regions spanning exon 6 and/or exon 7 of MuSK to induce exon-skipping of exon 6 and/or exon 7. Such alternative splicing activity leads to an increased expression of ΔIg3- MuSK.

[0188] The present disclosure also describes regions within the MuSK transcript at or near exon 6 and/or exon 7 that are particularly useful as target sequences for oligonucleotides in inducing exon skipping of exon 6 and/or exon 7, thereby generating and ΔIg3- MuSK transcripts.

[0189] In some embodiments, the present disclosure also provides specific oligonucleotides and combinations thereof that induce alternative splicing activity of MuSK and generate ΔIg3- MuSK transcripts.

[0190] In addition, the present disclosure provides compositions comprising one or more MuSK-targeting oligonucleotides that induce exon skipping of MuSK exons 6 and/or 7, and can be administered to a subject in a therapeutically effective amount to increase neurogenesis and/or muscle regeneration in the subject.

[0191] The disclosure includes compositions and methods related to one or more nucleotide sequences that are, comprise, or encode an oligonucleotide that binds to and inhibits expression of messenger RNA (mRNA) produced by a target gene (*e.g.,* MuSK). Oligonucleotides can be single stranded (*e.g.,* an antisense oligonucleotide) or double stranded nucleic acid. In some embodiments, an oligonucleotide comprises a double stranded RNA duplex such as microRNA (miRNA) or small interfering RNA (siRNA). In some embodiments, an oligonucleotide is an siRNA or miRNA, or a vector comprising a nucleotide sequence encoding an siRNA or miRNA. In some embodiments, an oligonucleotide is an antisense oligonucleotide (ASO), or a vector comprising a nucleotide sequence encoding an ASO.

[0192] In some embodiments, an oligonucleotide is capable of inhibiting expression of the full-length MuSK sequence comprises three extracellular Immunoglobulin (Ig)-like domains (Ig1, Ig2, and Ig3), a cysteine-rich frizzled (CRD /Fz) domain, as well as an intracellular tyrosine kinase (TK) domain.

[0193] As described herein, the oligonucleotides may target the MuSK sequence of human MuSK or one or more non-human species, *e.g.,* a non-human primate MuSK, *e.g., Macaca fascicularis* MuSK (Gene ID 102127677), or *e.g.,* chlorocebus sabaeus (Gene ID: 103219025), or murine MuSK (Gene ID: 18198). In some embodiments, a MuSK-targeting oligonucleotide comprises an antisense strand that is complementary to a target portion that is identical in the human and/or murine MuSK transcripts. In some embodiments, an oligonucleotide comprises a sequence that is complementary to a target portion of a human MuSK transcript that differs by 1, 2, or 3 nucleotides from a sequence in a murine or human MuSK transcript. It will be appreciated that an oligonucleotide that alters splicing of human MuSK may also alter splicing (*i.e.,* induce exon skipping) of non-primate MuSK, *e.g.,* rat or mouse MuSK, particularly if conserved regions of MuSK transcript are targeted.

[0194] The amino acid and nucleotide sequences of human MuSK are known in the art and can be found in publicly available databases, for example, the National Center for Biotechnology Information (NCBI) Reference Sequence (RefSeq) database, where the genomic nucleotide sequence is listed under RefSeq accession numbers NG_016016.2 (SEQ ID NO: 77) and forms of the mRNA/protein sequences are listed under NM_005592.4/NP_005583.1 (muscle, skeletal receptor tyrosine-protein kinase isoform 1), NM_001166280.2/ NP_001159752.1 (muscle, skeletal receptor tyrosine-protein kinase isoform 2), NM_001166281.2/NP_001159753.1 (muscle, skeletal receptor tyrosine-protein kinase isoform 3) and NM_001369398.1/NP_001356327.1 (muscle, skeletal receptor tyrosine-protein kinase isoform 4). See www.ncbi.nlm.nih.gov/gene?Db=gene& Cmd=Details Search&Term=4593, which is incorporated herein by reference.

[0195] In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to a target portion of a MuSK transcript, *e.g.,* MuSK mRNA (*e.g.,* complementary to a nucleotide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a target portion of SEQ ID NO: 77, *e.g.,*

Bld25/hu7-10 (SEQ ID NO: 63), Bld26/hu73 (SEQ ID NO: 64), etc.). In some embodiments, the target portion comprises a region that corresponds to positions 83776-83800 and/or 83854-83878 of SEQ ID No: 77 or a corresponding region of a different version of the genomic sequence MuSK. The target portion may be 15 – 30 nucleotides long, e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides long, although shorter and longer target portions are also contemplated.

[0196] In some embodiments, a target portion of a MuSK transcript, *e.g.,* MuSK mRNA, comprises a sequence of ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATT GACTCAAGAC (region 1, SEQ ID: 126), or a region within or a portion thereof. In some embodiments, a target portion comprises a sequence that is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% identical to region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 10 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 15 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 18 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 19 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 20 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 21 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 22 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 23 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 24 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 25 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to at least 35 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a

target portion comprises a sequence that is identical to at least 15 consecutive bases and no more than 30 consecutive bases of region 1, SEQ ID: 126.

[0197] In some embodiments, a target portion comprises a sequence that is identical to 10 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 11 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 12 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 13 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 14 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 15 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 16 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 17 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 18 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 19 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 20 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 21 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 22 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 23 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 24 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 25 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 26 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 27 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 28 consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 29

consecutive bases of region 1, SEQ ID: 126. In some embodiments, a target portion comprises a sequence that is identical to 30 consecutive bases of region 1, SEQ ID: 126.

[0198] In some embodiments, a target portion of a MuSK transcript, *e.g.*, MuSK mRNA, comprises a sequence of GGGGAGAAGTTCAGTACTGCCAAGGCTGCAGCCACCATCAGCATAGCAGGTAGG ATGCCCCTTCACATTTG (region 2, SEQ ID 211), or a region within or a portion thereof. In some embodiments, a target portion comprises a sequence that is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% identical to region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to at least 10 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to at least 15 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to at least 18 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to at least 19 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to at least 20 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to at least 21 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to at least 22 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to at least 23 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to at least 24 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to at least 25 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to at least 30 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to at least 35 consecutive bases of region 2, SEQ ID: 211.

[0199] In some embodiments, a target portion comprises a sequence that is identical to 10 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 11 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 12 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a

sequence that is identical to 13 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 14 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 15 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 16 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 17 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 18 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 19 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 20 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 21 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 22 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to23 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 24 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 25 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 26 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 27 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 28 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 29 consecutive bases of region 2, SEQ ID: 211. In some embodiments, a target portion comprises a sequence that is identical to 30 consecutive bases of region 2, SEQ ID: 211.

[0200] In some embodiments, the target portion comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of the sequences listed below in Table 1.

Table 1:

Region Description	SEQ ID	5' to 3' Sequence

Exon 6	39	TGCATTTCTAAAAGACCACCCTAGC
Exon 6	40	TCTAAAAGACCACCCTAGCTTGACC
Exon 6	41	ACCCTAGCTTGACCATTTCCTGCAG
Exon 6	42	CTGCAGGAGCGTCACTCACCACTTC
Exon 6	43	CACTCACCACTTCTGTCTTCCTAAC
Exon 6	44	TCTTCCTAACAGTTTTTGCCAGGAT
Exon 6	45	GATCCTGCGGGCTCCTGAATCCCAC
Exon 6	46	GGCTCCTGAATCCCACAATGTCACC
Exon 6	47	ATCCCACAATGTCACCTTTGGCTCC
Exon 6	48	TGTCACCTTTGGCTCCTTTGTGACC
Exon 6	49	TGGCTCCTTTGTGACCCTGCACTGT
Exon 6	50	GTGACCCTGCACTGTACAGCAACAG
Exon 6	51	GTACAGCAACAGGCATTCCTGTCCC
Exon 6	52	GCATTCCTGTCCCCACCATCACCTG
Exon 6	53	CCACCATCACCTGGATTGAAAACGG
Exon 6	54	GAAAACGGAAATGCTGTGAGTGTCA
Exon 6	55	GTGAGTGTCATGTGTGTGGGGACTT
Exon 6	56	TGTGGGGACTTGTCTGGGGAAGACC
Exon 7	57	TTCCCTTCAAATCTACTGACATAGT
Exon 7	58	AATCTACTGACATAGTATAGTGGGA
Exon 7	59	AGTATAGTGGGAAATCCTTGACTGA
Exon 7	60	GGGAAATCCTTGACTGAGTTCTTTT
Exon 7	61	ACTGAGTTCTTTTATTTTCCTTTAC
Exon 7	62	TTATTTTCCTTTACTCTGTCAGGTT
Exon 7	63	ACTCTGTCAGGTTTCTTCTGGGTCC
Exon 7	64	TCTTCTGGGTCCATTCAAGAGAGTG
Exon 7	65	TCAAGAGAGTGTGAAAGACCGAGTG
Exon 7	66	AAAGACCGAGTGATTGACTCAAGAC
Exon 7	67	TGACTCAAGACTGCAGCTGTTTATC
Exon 7	68	AGCTGTTTATCACCAAGCCAGGACT
Exon 7	69	ATCACCAAGCCAGGACTCTACACAT

Exon 7	70	CAGGACTCTACACATGCATAGCTAC
Exon 7	71	ACACATGCATAGCTACCAATAAGCA
Exon 7	72	GCTACCAATAAGCATGGGGAGAAGT
Exon 7	73	GGGGAGAAGTTCAGTACTGCCAAGG
Exon 7	74	CTGCAGCCACCATCAGCATAGCAGG
Exon 7	75	CATCAGCATAGCAGGTAGGATGCCC
Exon 7	76	AGGTAGGATGCCCCTTCACATTTGC
Exon 7	212	TTTCTTCTGGGTCCATTCAA
Exon 7	213	TTCTTCTGGGTCCATTCAAG
Exon 7	214	TCTTCTGGGTCCATTCAAGA
Exon 7	215	CTTCTGGGTCCATTCAAGAG
Exon 7	216	TTCTGGGTCCATTCAAGAGA
Exon 7	217	TCTGGGTCCATTCAAGAGAG
Exon 7	218	CTGGGTCCATTCAAGAGAGT
Exon 7	219	TGGGTCCATTCAAGAGAGTG
Exon 7	220	GGGTCCATTCAAGAGAGTGT
Exon 7	221	GGTCCATTCAAGAGAGTGTG
Exon 7	222	GTCCATTCAAGAGAGTGTGA
Exon 7	223	TCCATTCAAGAGAGTGTGAA
Exon 7	224	CCATTCAAGAGAGTGTGAAA
Exon 7	225	CATTCAAGAGAGTGTGAAAG
Exon 7	226	ATTCAAGAGAGTGTGAAAGA
Exon 7	227	TTCAAGAGAGTGTGAAAGAC
Exon 7	228	CTTTACTCTGTCAGGTTTCTTCTGG
Exon 7	229	TTACTCTGTCAGGTTTCTTCTGGGT
Exon 7	230	TCTGTCAGGTTTCTTCTGGGTCCAT
Exon 7	231	TGTCAGGTTTCTTCTGGGTCCATTC
Exon 7	232	CAGGTTTCTTCTGGGTCCATTCAAG
Exon 7	233	GGTTTCTTCTGGGTCCATTCAAGAG
Exon 7	234	TTTCTTCTGGGTCCATTCAAGAGAG
Exon 7	235	TTCTGGGTCCATTCAAGAGAGTGTG

Exon 7	236	CTGGGTCCATTCAAGAGAGTGTGAA
Exon 7	237	ACTCTGTCAGGTTTCTTCTGGGT
Exon 7	238	ACTCTGTCAGGTTTCTTCTGG
Exon 7	239	TCTGTCAGGTTTCTTCTGGGTCC
Exon 7	240	TCTGTCAGGTTTCTTCTGGGT
Exon 7	241	TGTCAGGTTTCTTCTGGGTCC
Exon 7	242	TCAGGTTTCTTCTGGGTCCATTC
Exon 7	243	TCAGGTTTCTTCTGGGTCCAT
Exon 7	244	AGGTTTCTTCTGGGTCCATTCAA
Exon 7	245	AGGTTTCTTCTGGGTCCATTC
Exon 7	246	GTTTCTTCTGGGTCCATTCAA
Exon 7	247	TTTCTTCTGGGTCCATTCAAGAG
Exon 7	248	TTTCTTCTGGGTCCATTCAAG
Exon 7	249	TCTTCTGGGTCCATTCAAGAGAG
Exon 7	250	TTCTGGGTCCATTCAAGAGAG
Exon 7	251	TCTTCTGGGTCCATTCAAGAG
Exon 7	252	TTCTGGGTCCATTCAAGAGAGTG
Exon 7	253	CTGGGTCCATTCAAGAGAGTG

[0201] Administration of MuSK-targeting oligonucleotide(s) as described herein can reduce the level of full-length MuSK transcript or full-length MuSK protein in a subject or in a biological sample (*e.g.,* a blood, serum or plasma sample, or a sample comprising hepatocytes) compared to a level before the administration of the composition. In some embodiments, the level of full-length MuSK transcript or full-length MuSK protein is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90%, relative to a level before the administration.

[0202] In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to a target portion of a MuSK transcript, *e.g.,* MuSK mRNA. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to a

nucleotide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a target portion of a MuSK transcript, *e.g.,* MuSK mRNA.

[0203] In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATT GACTCAAGAC (region 1, SEQ ID: 126) that includes at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 95% identical to a portion of SEQ ID: 126 that includes at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 10 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 15 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 18 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 19 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 20 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 21 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 22 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 23 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 24 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 25 consecutive bases of region 1, SEQ ID: 126.

In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 26 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 27 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 28 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 29 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes at least 30 consecutive bases of region 1, SEQ ID: 126.

[0204] In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATT GACTCAAGAC (region 1, SEQ ID: 126) that includes 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 95% identical to a portion of SEQ ID: 126 that includes 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 10 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 15 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 18 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 19 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 20 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 21 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence

that is at least 90% identical to a portion of SEQ ID: 126 that includes 22 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 23 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 24 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 25 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 26 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 27 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 28 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 29 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 126 that includes 30 consecutive bases of region 1, SEQ ID: 126.

[0205] In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to a sequence of ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATT GACTCAAGAC (region 1, SEQ ID: 126). In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to a sequence of that is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% identical to region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 10 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 15 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 18 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 19 consecutive bases of region 1, SEQ ID: 126. In

some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 20 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 21 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 22 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 23 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 24 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 25 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 26 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 27 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 28 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 29 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 30 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 35 consecutive bases of region 1, SEQ ID: 126.

[0206] In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 10 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 11 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 12 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 13 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 14 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 15 consecutive bases of region 1, SEQ ID: 126.

In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 16 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 17 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 18 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 19 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 20 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 21 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 22 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 23 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 24 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 25 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 26 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 27 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 28 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 29 consecutive bases of region 1, SEQ ID: 126. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 30 consecutive bases of region 1, SEQ ID: 126.

[0207] In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion sequence GGGGAGAAGTTCAGTACTGCCAAGGCTGCAGCCACCATCAGCATAGCAGGTAGG ATGCCCCTTCACATTTG (region 2, SEQ ID 211) that includes at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a sequence that is at least 95% identical to a

portion of SEQ ID: 211 that includes at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a sequence that is at least 90% identical to a portion of SEQ ID: 211 that includes 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a sequence that is at least 95% identical to a portion of SEQ ID: 211 that includes 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 2, SEQ ID: 211.

[0208] In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to a portion of sequence GGGGAGAAGTTCAGTACTGCCAAGGCTGCAGCCACCATCAGCATAGCAGGTAGG ATGCCCCTTCACATTTG (region 2, SEQ ID 211). In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 10 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 15 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 18 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 19 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 20 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 21 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 22 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 23 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 24 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 25 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 30 consecutive bases of region 2, SEQ ID: 211. In

some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to at least 35 consecutive bases of region 2, SEQ ID: 211.

[0209] In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 10 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 11 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 12 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 13 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 14 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 15 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 16 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 17 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 18 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 19 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 20 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 21 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 22 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 23 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 24 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 25 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 26 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a

nucleic acid strand that is complementary to 27 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 28 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 29 consecutive bases of region 2, SEQ ID: 211. In some embodiments, an oligonucleotide comprises a nucleic acid strand that is complementary to 30 consecutive bases of region 2, SEQ ID: 211.

[0210] In some embodiments, MuSK-targeting oligonucleotides of the disclosure are antisense oligonucleotides comprising a nucleotide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 1-38, 127-142, 159-167, 177-193 in the following Table 2:

Table 2:

SEQ ID	MuSK Targeting Region ID	Oligo ID	5' to 3' Sequence
1	hu6-75	Bld1	GCTAGGGTGGTCTTTTAGAAATGCA
2	hu6-69	Bld2	GGTCAAGCTAGGGTGGTCTTTTAGA
3	hu6-58	Bld3	CTGCAGGAAATGGTCAAGCTAGGGT
4	hu6-39	Bld4	GAAGTGGTGAGTGACGCTCCTGCAG
5	hu6-27	Bld5	GTTAGGAAGACAGAAGTGGTGAGTG
6	hu6-12	Bld6	ATCCTGGCAAAAACTGTTAGGAAGA
7	hu610	Bld7	GTGGGATTCAGGAGCCCGCAGGATC
8	hu619	Bld8	GGTGACATTGTGGGATTCAGGAGCC
9	hu628	Bld9	GGAGCCAAAGGTGACATTGTGGGAT
10	hu637	Bld10	GGTCACAAAGGAGCCAAAGGTGACA
11	hu646	Bld11	ACAGTGCAGGGTCACAAAGGAGCCA
12	hu656	Bld12	CTGTTGCTGTACAGTGCAGGGTCAC
13	hu669	Bld13	GGGACAGGAATGCCTGTTGCTGTAC

14	hu681	Bld14	CAGGTGATGGTGGGGACAGGAATGC
15	hu693	Bld15	CCGTTTTCAATCCAGGTGATGGTGG
16	hu6110	Bld16	TGACACTCACAGCATTTCCGTTTTC
17	hu6125	Bld17	AAGTCCCCACACACATGACACTCAC
18	hu6139	Bld18	GGTCTTCCCCAGACAAGTCCCCACA
19	hu7-75	Bld19	ACTATGTCAGTAGATTTGAAGGGAA
20	hu7-66	Bld20	TCCCACTATACTATGTCAGTAGATT
21	hu7-53	Bld21	TCAGTCAAGGATTTCCCACTATACT
22	hu7-45	Bld22	AAAAGAACTCAGTCAAGGATTTCCC
23	hu7-33	Bld23	GTAAAGGAAAATAAAAGAACTCAGT
24	hu7-22	Bld24	AACCTGACAGAGTAAAGGAAAATAA
25	hu7-10	Bld25	GGACCCAGAAGAAACCTGACAGAGT
26	hu73	Bld26	CACTCTCTTGAATGGACCCAGAAGA
27	hu717	Bld27	CACTCGGTCTTTCACACTCTCTTGA
28	hu730	Bld28	GTCTTGAGTCAATCACTCGGTCTTT
29	hu744	Bld29	GATAAACAGCTGCAGTCTTGAGTCA
30	hu758	Bld30	AGTCCTGGCTTGGTGATAAACAGCT
31	hu766	Bld31	ATGTGTAGAGTCCTGGCTTGGTGAT
32	hu776	Bld32	GTAGCTATGCATGTGTAGAGTCCTG
33	hu785	Bld33	TGCTTATTGGTAGCTATGCATGTGT
34	hu796	Bld34	ACTTCTCCCCATGCTTATTGGTAGC
35	hu7111	Bld35	CCTTGGCAGTACTGAACTTCTCCCC
36	hu7136	Bld36	CCTGCTATGCTGATGGTGGCTGCAG
37	hu7146	Bld37	GGGCATCCTACCTGCTATGCTGATG
38	hu7158	Bld38	GCAAATGTGAAGGGGCATCCTACCT
127		Bld51	TTGAATGGACCCAGAAGAAA
128		Bld52	CTTGAATGGACCCAGAAGAA

129		Bld53	TCTTGAATGGACCCAGAAGA
130		Bld54	CTCTTGAATGGACCCAGAAG
131		Bld55	TCTCTTGAATGGACCCAGAA
132		Bld56	CTCTCTTGAATGGACCCAGA
133		Bld57	ACTCTCTTGAATGGACCCAG
134		Bld58	CACTCTCTTGAATGGACCCA
135		Bld59	ACACTCTCTTGAATGGACCC
136		Bld60	CACACTCTCTTGAATGGACC
137		Bld61	TCACACTCTCTTGAATGGAC
138		Bld62	TTCACACTCTCTTGAATGGA
139		Bld63	TTTCACACTCTCTTGAATGG
140		Bld64	CTTTCACACTCTCTTGAATG
141		Bld65	TCTTTCACACTCTCTTGAAT
142		Bld66	GTCTTTCACACTCTCTTGAA
159		Bld25-1	CCAGAAGAAACCTGACAGAGTAAAG
160		Bld25-2	ACCCAGAAGAAACCTGACAGAGTAA
161		Bld25-3	ATGGACCCAGAAGAAACCTGACAGA
162		Bld25-4	GAATGGACCCAGAAGAAACCTGACA
163		Bld25-5	CTTGAATGGACCCAGAAGAAACCTG
164		Bld26-1	CTCTTGAATGGACCCAGAAGAAACC
165		Bld26-2	CTCTCTTGAATGGACCCAGAAGAAA
166		Bld26-3	CACACTCTCTTGAATGGACCCAGAA
167		Bld26-4	TTCACACTCTCTTGAATGGACCCAG
177		Bld25-A	ACCCAGAAGAAACCTGACAGAGT
178		Bld25-B	CCAGAAGAAACCTGACAGAGT
179		Bld25-C	GGACCCAGAAGAAACCTGACAGA
180		Bld25-D	ACCCAGAAGAAACCTGACAGA

181		Bld25-E	GGACCCAGAAGAAACCTGACA
182		Bld25-5-A	GAATGGACCCAGAAGAAACCTGA
183		Bld25-5-B	ATGGACCCAGAAGAAACCTGA
184		Bld25-5-C	TTGAATGGACCCAGAAGAAACCT
185		Bld25-5-D	GAATGGACCCAGAAGAAACCT
186		Bld25-5-E	TTGAATGGACCCAGAAGAAAC
187		Bld26-2-A	CTCTTGAATGGACCCAGAAGAAA
188		Bld26-2-B	CTTGAATGGACCCAGAAGAAA
189		Bld26-2-C	CTCTCTTGAATGGACCCAGAAGA
190		Bld26-2-D	CTCTCTTGAATGGACCCAGAA
191		Bld26-B	CTCTTGAATGGACCCAGAAGA
192		Bld26-C	CACTCTCTTGAATGGACCCAGAA
193		Bld26-D	CACTCTCTTGAATGGACCCAG

[0211] In some embodiments, an oligonucleotide has a sequence that differs from that explicitly set forth in Table 2, for example by substitution of one or more residues, or types of residues, with an alternative residue or residue type– *e.g.,* an analog or otherwise corresponding residue type. For example, in some embodiments, one or more "T" residues (or all "T" residues) of a sequence presented in Table 2 is a "U" residue or analog thereof.

[0212] In some embodiments, an oligonucleotide comprises mismatch(es) with the target. The base pair may be ranked on the basis of their propensity to promote dissociation or melting (e.g., on the free energy of association or dissociation of a particular pairing, the simplest approach is to examine the pairs on an individual pair basis, though next neighbour or similar analysis can also be used). In terms of promoting dissociation: A:U is preferred over G:C; G:U is preferred over G:C; and I:C is preferred over G:C (I=inosine).

[0213] In some embodiments, an oligonucleotide can include one or more (e.g., 2, 3, 4, or 5) nucleotides on the 3' and/or 5' end that is not complementary to the target sequence.

Chemical Structures of MuSK-Targeting Oligonucleotides

[0214] Synthetic oligonucleotides provide useful molecular tools in a wide variety of applications. For example, oligonucleotides are useful in therapeutic, diagnostic, research, and new nanomaterials applications. The use of naturally occurring nucleic acids (*e.g.,* unmodified DNA or RNA) is limited, for example, by their susceptibility to endo- and exo-nucleases. As such, various synthetic counterparts have been developed to circumvent these shortcomings. These include synthetic oligonucleotides that contain chemical modification, *e.g.,* base modifications, sugar modifications, backbone modifications, etc., which, among other things, render these molecules less susceptible to degradation and improve other properties of oligonucleotides.

[0215] Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages, and patterns thereof), and/or stereochemistry (*e.g.,* stereochemistry of backbone chiral centers (chiral internucleotidic linkages), and/or patterns thereof), can have significant impact on properties, e.g., stability, splicing-altering capabilities, etc. In some embodiments, oligonucleotide properties can be adjusted by optimizing chemical modifications (modifications of base, sugar, and/or internucleotidic linkage) and/or stereochemistry (pattern of backbone chiral centers).

[0216] In some embodiments, the present disclosure demonstrates that oligonucleotide compositions comprising oligonucleotides with controlled structural elements, *e.g.,* controlled chemical modification, provide unexpected properties, including but not limited to those described herein. In some embodiments, provided compositions comprising oligonucleotides having chemical modifications (*e.g.,* base modifications, sugar modification, internucleotidic linkage modifications, etc.) have improved properties, such as improved splicing-altering capabilities, or improved protein binding profile, and/or improved delivery, etc. Particularly, in some embodiments, the present disclosure provides compositions and methods for altering splicing of transcripts (*e.g.,* MuSK transcripts). In some embodiments, the present disclosure provides compositions and methods for improving splicing of transcripts. In some embodiments, altered transcript splicing by provided compositions and methods include production of products having desired and/or improved

biological functions, and/or knockdown of undesired product by, *e.g.,* modifying splicing products so that undesired biological functions can be suppressed or removed.


[0217] In some embodiments, a splicing product is mRNA. In some embodiments, alteration comprises skipping one or more exons. In some embodiments, splicing of a transcript is improved in that exon skipping increases levels of mRNA and proteins that have improved beneficial activities compared with absence of exon skipping.

[0218] In some embodiments, splicing of a transcript is improved in that exon skipping lowers levels of mRNA and proteins that have undesired activities compared with absence of exon skipping. In some embodiments, a target is knocked down through exon skipping which, by skipping one or more exons, causes premature stop codon and/or frameshift mutations.

[0219] In some embodiments, an oligonucleotide of the disclosure includes one or more natural nucleobase and/or one or more modified nucleobases derived from a natural nucleobase. Examples include, but are not limited to, uracil, thymine, adenine, cytosine, and guanine having their respective amino groups protected by acyl protecting groups, 2-fluorouracil, 2-fluorocytosine, 5-bromouracil, 5-iodouracil, 2,6-diaminopurine, azacytosine, pyrimidine analogs such as pseudoisocytosine and pseudouracil and other modified nucleobases such as 8-substituted purines, xanthine, or hypoxanthine (the latter two being the natural degradation products).

[0220] Modified nucleobases also include expanded-size nucleobases in which one or more aryl rings, such as phenyl rings, have been added.

[0221] In some embodiments, modified nucleobases are of any one of the following structures, optionally substituted:



[0222] In some embodiments, a modified nucleobase is unsubstituted. In some embodiments, a modified nucleobase is substituted. In some embodiments, a modified nucleobase is substituted such that it contains, *e.g.*, heteroatoms, alkyl groups, or linking moieties connected to fluorescent moieties, biotin or avidin moieties, or other protein or peptides. In some embodiments, a modified nucleobase is a "universal base" that is not a nucleobase in the most classical sense, but that functions similarly to a nucleobase. One representative example of such a universal base is 3-nitropyrrole.

[0223] In some embodiments, an oligonucleotide described herein includes nucleosides that incorporate modified nucleobases and/or nucleobases covalently bound to modified sugars. Some examples of nucleosides that incorporate modified nucleobases include 4-acetylcytidine; 5-(carboxyhydroxylmethyl)uridine; 2′-*O*-methylcytidine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyluridine; dihydrouridine; 2′-*O*-methylpseudouridine; beta,D-galactosylqueosine; 2′-*O*-methylguanosine; N^6-isopentenyladenosine; 1-methyladenosine; 1-methylpseudouridine; 1-methylguanosine; l-methylinosine; 2,2-dimethylguanosine; 2-methyladenosine; 2-methylguanosine; N^7-methylguanosine; 3-methyl-cytidine; 5-methylcytidine; 5-hydroxymethylcytidine; 5-methylcytosine, 5-formylcytosine; 5-carboxylcytosine; N^6-methyladenosine; 7-methylguanosine; 5-methylaminoethyluridine; 5-methoxyaminomethyl-2-thiouridine; beta,D-mannosylqueosine; 5-methoxycarbonylmethyluridine; 5-methoxyuridine; 2-methylthio-N^6-isopentenyladenosine; *N*-((9-beta,D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine; *N*-((9-beta,D-ribofuranosylpurine-6-yl)-*N*-methylcarbamoyl)threonine; uridine-5-oxyacetic acid methylester; uridine-5-oxyacetic acid

(v); pseudouridine; queosine; 2-thiocytidine; 5-methyl-2-thiouridine; 2-thiouridine; 4-thiouridine; 5-methyluridine; 2′-*O*-methyl-5-methyluridine; and 2′-*O*-methyluridine.


[0224] In some embodiments, nucleosides include 6′-modified bicyclic nucleoside analogs that have either (*R*) or (*S*)-chirality at the 6′-position and include the analogs described in US Patent No. 7,399,845. In other embodiments, nucleosides include 5′-modified bicyclic nucleoside analogs that have either (*R*) or (*S*)-chirality at the 5′-position and include the analogs described in U.S. Publ. No. 20070287831. In some embodiments, a nucleobase or modified nucleobase is 5-bromouracil, 5-iodouracil, or 2,6-diaminopurine. In some embodiments, a nucleobase or modified nucleobase is modified by substitution with a fluorescent moiety.

[0225] In some embodiments, an oligonucleotide described herein includes one or more modified nucleotides wherein a phosphate group or linkage phosphorus in the nucleotides are linked to various positions of a sugar or modified sugar. As non-limiting examples, the phosphate group or linkage phosphorus can be linked to the 2′, 3′, 4′ or 5′ hydroxyl moiety of a sugar or modified sugar. Nucleotides that incorporate modified nucleobases as described herein are also contemplated in this context.

[0226] Other modified sugars can also be incorporated within an oligonucleotide molecule. In some embodiments, a modified sugar contains one or more substituents at the 2′ position including one of the following: –F; $–CF_3$, –CN, $–N_3$, –NO, $–NO_2$, –OR’, –SR’, or –$N(R')_2$, wherein each R’ is independently as defined above and described herein; –O–(C_1–C_{10} alkyl), –S–(C_1–C_{10} alkyl), –NH–(C_1–C_{10} alkyl), or –N(C_1–C_{10} alkyl)$_2$; –O–(C_2–C_{10} alkenyl), –S–(C_2–C_{10} alkenyl), –NH–(C_2–C_{10} alkenyl), or –N(C_2–C_{10} alkenyl)$_2$; –O–(C_2–C_{10} alkynyl), –S–(C_2–C_{10} alkynyl), –NH–(C_2–C_{10} alkynyl), or –N(C_2–C_{10} alkynyl)$_2$; or –O—(C_1–C_{10} alkylene)–O—(C_1–C_{10} alkyl), –O–(C_1–C_{10} alkylene)–NH–(C_1–C_{10} alkyl) or –O–(C_1–C_{10} alkylene)–NH(C_1–C_{10} alkyl)$_2$, –NH–(C_1–C_{10} alkylene)–O–(C_1–C_{10} alkyl), or –N(C_1–C_{10} alkyl)–(C_1–C_{10} alkylene)–O–(C_1–C_{10} alkyl), or salt thereof, wherein the alkyl, alkylene, alkenyl and alkynyl may be substituted or unsubstituted. Examples of substituents include, and are not limited to, $–O(CH_2)_nOCH_3$, and $–O(CH_2)_nNH_2$ or salt thereof, wherein n is from 1 to about 10, $–OCH_2CH_2OMe$ (MOE) or salt thereof, $–OCH_2CH_2N(CH_3)_2$ (DMAOE) or salt thereof, $–OCH_2CH_2OCH_2CH_2N(CH_3)_2$ (DMAEOE) or salt thereof.

[0227] In some embodiments, the 2'-OH of a ribose is replaced with a substituent including one of the following: –H, –F; $–CF_3$, –CN, $–N_3$, –NO, $–NO_2$, –OR', –SR', or $–N(R')_2$, wherein each R' is independently as defined above and described herein; $–O–(C_1–C_{10}$ alkyl), $–S–(C_1–C_{10}$ alkyl), $–NH–(C_1–C_{10}$ alkyl), or $–N(C_1–C_{10}$ alkyl$)_2$; $–O–(C_2–C_{10}$ alkenyl), $–S–(C_2–C_{10}$ alkenyl), $–NH–(C_2–C_{10}$ alkenyl), or $–N(C_2–C_{10}$ alkenyl$)_2$; $–O–(C_2–C_{10}$ alkynyl), $–S–(C_2–C_{10}$ alkynyl), $–NH–(C_2–C_{10}$ alkynyl), or $–N(C_2–C_{10}$ alkynyl$)_2$; or $–O—(C_1–C_{10}$ alkylene$)–O—(C_1–C_{10}$ alkyl), $–O–(C_1–C_{10}$ alkylene$)–NH–(C_1–C_{10}$ alkyl) or $–O–(C_1–C_{10}$ alkylene$)–NH(C_1–C_{10}$ alkyl$)_2$, $–NH–(C_1–C_{10}$ alkylene$)–O–(C_1–C_{10}$ alkyl), or $–N(C_1–C_{10}$ alkyl$)–(C_1–C_{10}$ alkylene$)–O–(C_1–C_{10}$ alkyl), wherein the alkyl, alkylene, alkenyl and alkynyl may be substituted or unsubstituted. In some embodiments, the 2'–OH is replaced with –H (deoxyribose). In some embodiments, the 2'–OH is replaced with –F. In some embodiments, the 2'–OH is replaced with –OR'. In some embodiments, the 2'–OH is replaced with –OMe. In some embodiments, the 2'–OH is replaced with $–OCH_2CH_2OMe$ (MOE).

[0228] Modified sugars also include locked nucleic acids (LNAs). In some embodiments, the locked nucleic acid has the structure indicated below. A locked nucleic acid of the structure below is indicated, wherein Ba represents a nucleobase or modified nucleobase as described herein, and wherein R^{2s} is $–OCH_2C4'–$




[0229] In some embodiments, each sugar of the oligonucleotide is or comprises a modified sugar moiety. In some embodiments, each sugar of the oligonucleotide is or comprises a 2'-MOE modified sugar. In some embodiments, each sugar of the oligonucleotide is or comprises a 2'-OMe modified sugar. In some embodiments, each sugar of the oligonucleotide is or comprises a 2'-OH modified sugar. In some embodiments, each sugar of the oligonucleotide is or comprises a 2'-H modified sugar.

[0230] In some embodiments, the present disclosure provides an oligonucleotide comprising 2'-MOE modified sugar, 2'-OMe modified sugar, 2'-OH modified sugar, 2'-H modified sugar, or combinations thereof. In some embodiments, a provided oligonucleotide

comprises at least one 2'-MOE sugar and at least one 2'-OH sugar (RNA sugar). In some embodiments, a provided oligonucleotide comprises at least one 2'-MOE sugar and at least one 2'-H sugar (DNA sugar).

[0231] In some embodiments, the present invention provides an oligonucleotide comprising one or more modified internucleotidic linkages independently having the structure of formula **I**:



(I)

wherein:

P* is an asymmetric phosphorus atom and is either *R*p or *S*p configuration;

W is O, S or Se;

each of X, Y and Z is independently –O–, –S–, –N(–L–R^1)–, or L;

L is a covalent bond or an optionally substituted, linear or branched C_1–C_{10} alkylene, wherein one or more methylene units of L are optionally and independently replaced by an optionally substituted C_1–C_6 alkylene, C_1–C_6 alkenylene, —C≡C—, –C(R′)$_2$–, –Cy–, –O–, –S–, –S–S–, –N(R′)–, –C(O)–, –C(S)–, –C(NR′)–, –C(O)N(R′)–, –N(R′)C(O)N(R′)-, –N(R′)C(O)–, –N(R′)C(O)O–, –OC(O)N(R′)-, –S(O)–, –S(O)$_2$–, –S(O)$_2$N(R′)–, –N(R′)S(O)$_2$–, –SC(O)–, –C(O)S–, –OC(O)–, or –C(O)O–;

R^1 is halogen, R, or an optionally substituted C_1–C_{50} aliphatic wherein one or more methylene units are optionally and independently replaced by an optionally substituted C_1–C_6 alkylene, C_1–C_6 alkenylene, —C≡C—, –C(R′)$_2$–, –Cy–, –O–, –S–, –S–S–, –N(R′)–, –C(O)–, –C(S)–, –C(NR′)–, –C(O)N(R′)–, –N(R′)C(O)N(R′)-, –N(R′)C(O)–, –N(R′)C(O)O–, –OC(O)N(R′)-, –S(O)–, –S(O)$_2$–, –S(O)$_2$N(R′)–, –N(R′)S(O)$_2$–, –SC(O)–, –C(O)S–, –OC(O)–, or –C(O)O–;

each R′ is independently –R, -C(O)R, -CO_2R, or –SO_2R, or:

two R′ on the same nitrogen are taken together with their intervening atoms to form an optionally substituted heterocyclic or heteroaryl ring, or


two R′ on the same carbon are taken together with their intervening atoms to form an optionally substituted aryl, carbocyclic, heterocyclic, or heteroaryl ring;

–Cy– is an optionally substituted bivalent ring selected from phenylene, carbocyclylene, arylene, heteroarylene, or heterocyclylene;


each R is independently hydrogen, or an optionally substituted group selected from C_1–C_6 aliphatic, phenyl, carbocyclyl, aryl, heteroaryl, or heterocyclyl; and

each $-\!\!\sim\!\!-$ independently represents a connection to a nucleoside.

[0232] In some embodiments, the internucleotidic linkage having the structure of formula **I** is



[0233] In some embodiments, an oligonucleotide comprises both non-natural internucleotidic linkage as described herein and natural phosphate linkage. In some embodiments, each internucleotidic linkages of the oligonucleotide is a non-natural internucleotidic linkage. In some embodiments, each internucleotidic linkages of the oligonucleotide is a chiral internucleotidic linkage. In some embodiments, each internucleotidic linkages of the oligonucleotide is a phosphorothioate linkage


( ).

[0234] In some embodiments, each internucleotidic linkages of an oligonucleotide is a natural phosphate linkage. In some embodiments, an oligonucleotide comprises at least one natural phosphate linkage and at least one phosphodithioate linkage. In some embodiments, at least 50% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 60% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 70% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 80% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 90% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 94% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages. In some embodiments, at least 95% internucleotidic linkages of an oligonucleotide are phosphodithioate linkages.

[0235] In some embodiments, at least 50% internucleotidic linkages of an oligonucleotide are natural phosphate linkages. In some embodiments, at least 60% internucleotidic linkages of an oligonucleotide are natural phosphate linkages. In some embodiments, at least 70% internucleotidic linkages of an oligonucleotide are natural phosphate linkages. In some embodiments, at least 80% internucleotidic linkages of an oligonucleotide are natural phosphate linkages. In some embodiments, at least 90% internucleotidic linkages of an oligonucleotide are natural phosphate linkages. In some embodiments, at least 94% internucleotidic linkages of an oligonucleotide are natural phosphate linkages. In some embodiments, at least 95% internucleotidic linkages of an oligonucleotide are natural phosphate linkages.

[0236] Among other things, the present disclosure provides oligonucleotides of various designs, which may comprises various nucleobases and patterns thereof, sugars and patterns thereof, internucleotidic linkages and patterns thereof, and/or additional chemical moieties and patterns thereof as described in the present disclosure. In some embodiments, provided oligonucleotides can downregulate the MuSK Ig3 domain protein expression, the MuSK Ig3 domain gene expression, and/or the MuSK Ig3 activation of BMP signaling level,

thereby increasing adult hippocampal neurogenesis (AHN) and improving cognition in AD. In some embodiments, provided oligonucleotides can downregulate the MuSK Ig3 domain protein expression, the MuSK Ig3 domain gene expression, and/or the MuSK Ig3 activation of BMP signaling level, thereby increasing muscle regeneration. In some embodiments, provided oligonucleotides can direct a decrease in the expression, level and/or activity of MuSK Ig3 domain and/or one or more of its products in a cell of a subject or patient. In some embodiments, provided oligonucleotides can direct a decrease in the expression, level and/or activity of MuSK Ig3 domain and/or one or more of its products in a cell of a subject or patient, while the expression, level, and/or activity of all forms of MuSK remains substantially the same. In some embodiments, a cell normally expresses or produces protein encoded by MuSK Ig3 domain. In some embodiments, provided MuSK-targeting oligonucleotides can direct a decrease in the expression, level and/or activity of MuSK Ig3 domain gene or a gene product and have a base sequence which consists of, comprises, or comprises a portion (e.g., a span of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more contiguous bases) of the base sequence of a oligonucleotide disclosed herein, wherein each T can be independently substituted with U and vice versa, and the oligonucleotide comprises at least one non-naturally-occurring modification of a base, sugar and/or internucleotidic linkage.

[0237] As described herein, the naturally highly abundant full length MuSK harbors the BMP-binding Ig3 domain and potentiates BMP signaling and thus restrains neurogenesis. In contrast, ΔIg3-MuSK has lower BMP signaling and promotes AHN and improves cognition. In some embodiments, the present disclosure provides exon-skipping MuSK-targeting oligonucleotides that switch MuSK from the AHN restraining full length MuSK to AHN permissive ΔIg3-MuSK splice form.

[0238] As described herein, the highly abundant full length MuSK harbors the BMP-binding Ig3 domain and potentiates BMP signaling and affects muscle regeneration. In contrast, ΔIg3-MuSK has lower BMP signaling and promotes muscle regeneration and/or prevents muscle fibrosis. In some embodiments, the present disclosure provides exon-skipping MuSK-targeting oligonucleotides that switch MuSK from the full length MuSK to the muscle-promoting ΔIg3-MuSK splice form.

[0239] In some embodiments, one or more skipped exons are selected from exon 6 and/or 7 of the MuSK gene. In some embodiments, exon 6 of MuSK is skipped. In some embodiments, exon 7 of MuSK is skipped. In some embodiments, both exons 6 and 7 of MuSK are skipped.

[0240] In some embodiments, a MuSK-targeting oligonucleotide described herein can provide exon-skipping of exon 6 and/or 7, but does not provide exon-skipping of exon 3 and/or 4.

[0241] In some embodiments, a MuSK-targeting oligonucleotide described herein can provide exon-skipping of exon 6 and/or 7 at a greater level than it provides exon-skipping of exon 3 and/or 4.

[0242] In some embodiments, a MuSK-targeting oligonucleotide described herein provides exon-skipping such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0243] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0244] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 70% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0245] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 80% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0246] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 90% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

[0247] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 30%.

[0248] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 20%.

[0249] In some embodiments, a MuSK-targeting oligonucleotide alters the splicing of MuSK transcripts such that the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 10%.

[0250] In various embodiments, an active compound is an oligonucleotide that directs skipping of one or more exons in a MuSK gene. In various embodiments, an active compound is an oligonucleotide that directs skipping of multiple exons in a MuSK gene. In some embodiments, an active compound is an oligonucleotide that directs skipping of exon 6, exon 7, or both in a MuSK gene. In some embodiments, an active compound is an oligonucleotide that directs skipping of exon 6 in a MuSK gene. In some embodiments, an active compound is an oligonucleotide that directs skipping of exon 7 in a MuSK gene. In some embodiments, an active compound is an oligonucleotide that directs skipping of exons 6 and 7 in a MuSK gene. In some embodiments, a plurality of oligonucleotides may be used together. In some such embodiments, two or more different exon skipping oligonucleotides (e.g., at least one that directs skipping of exon 6 and one that directs skipping of exon 7) may be used in combination. Alternatively or additionally, in some embodiments, at least one exon skipping oligonucleotide may be used in combination with at least one degrading oligonucleotide (*e.g.,* that targets a transcript for RNase H degradation) which, for example, may target MuSK transcript(s) that include a functional Ig3 domain, or portion thereof.

[0251] In some embodiments, oligonucleotides are provided and/or utilized in salt forms. In some embodiments, oligonucleotides are provided as salts comprising negatively-charged internucleotidic linkages (*e.g.,* phosphorothioate internucleotidic linkages, natural phosphate linkages, etc.) existing as their salt forms. In some embodiments, oligonucleotides are provided as pharmaceutically acceptable salts. In some embodiments, oligonucleotides are provided as metal salts. In some embodiments, oligonucleotides are provided as sodium salts. In some embodiments, oligonucleotides are provided as metal salts, *e.g.,* sodium salts, wherein each negatively-charged internucleotidic linkage is independently in a salt form (*e.g.,* for sodium salts, −O−P(O)(SNa)−O− for a phosphorothioate internucleotidic linkage, −O−P(O)(ONa)−O− for a natural phosphate linkage, etc.).

[0252] In some embodiments, individual oligonucleotides within a composition may be considered to be of the same constitution and/or structure even though, within such composition (*e.g.,* a liquid composition), particular such oligonucleotides might be in different salt form(s) (and may be dissolved and the oligonucleotide chain may exist as an anion form when, e.g., in a liquid composition) at a particular moment in time. For example, those skilled in the art will appreciate that, at a given pH, individual internucleotidic linkages

along an oligonucleotide chain may be in an acid (H) form, or in one of a plurality of possible salt forms (*e.g.*, a sodium salt, or a salt of a different cation, depending on which ions might be present in the preparation or composition), and will understand that, so long as their acid forms (*e.g.*, replacing all cations, if any, with H+) are of the same constitution and/or structure, such individual oligonucleotides may properly be considered to be of the same constitution and/or structure.

[0253] In some embodiments, an oligonucleotide composition comprises two or more oligonucleotides. In some embodiments, an oligonucleotide composition comprises two or more pluralities of oligonucleotides, wherein each plurality is independently a plurality of oligonucleotides as described herein. For example, in some embodiments, each plurality independently shares a same base sequence and the same internucleotidic linkages. In some embodiments, at least two pluralities or each plurality independently targets the same exon(s) of the same transcript (*e.g.*, exons 6 and/or 7 of MuSK). In some embodiments, at least two pluralities or each plurality independently targets different exons of the same transcript (*e.g.*, exons 3, 4, 6, and/or 7 of MuSK). In some embodiments, at least two pluralities or each plurality independently targets a different transcript of the same or different nucleic acids. In some embodiments, at least two pluralities or each plurality independently targets transcripts of a different gene. In some embodiments, at least two pluralities or each plurality independently targets different regions on the MuSK transcript. Among other things, such compositions may be utilized to target two or more targets, in some embodiments, simultaneously and in the same system.

Characterization of MuSK-targeting Oligonucleotides

[0254] MuSK-targeting oligonucleotides provided herein may be identified, assessed and/or characterized for one or more their physical/chemical properties and/or biological activities. Those skilled in the art will be aware of a variety of approaches, including particular assays, that may be utilized for such identification, assessment, and/or characterization.

[0255] In some embodiments, a MuSK-targeting oligonucleotide as described herein is characterized in that, for example, the MuSK-targeting oligonucleotide, when contacted

with a cell expressing MuSK, will increase the level or activity of MuSK ΔIg3 mRNA and/or protein, e.g., relative to another MuSK form or other appropriate reference. In some embodiments, achieving such increase may be considered to represent "agonizing" MuSK ΔIg3.

[0256] In some embodiments, a MuSK-targeting oligonucleotide is characterized by its ability to alter splicing activity of MuSK pre-mRNA in a cell. For example, a cell may be transfected with a MuSK-targeting oligonucleotide, and after a period of incubation, expression of an alternative form of processed form of a MuSK RNA transcript (e.g., where exons 6 and 7 have been skipped), can be measured by RT-PCR. For example, the efficiency of MuSK exon skipping in cultured cells greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 95%.

[0257] In some aspects, a MuSK-targeting oligonucleotide increases of MuSK ΔIg3 mRNA. In some aspects, a MuSK-targeting oligonucleotide alters splicing of MuSK pre-mRNA. In some aspects, a MuSK-targeting oligonucleotide promotes the skipping of exon 6 and/or exon 7.

[0258] Modulation of expression of MuSK ΔIg3 can be measured in a bodily fluid of a subject treated with MuSK MR-targeting oligonucleotide, which may or may not contain cells; tissue; or organ of the animal. Methods of obtaining samples for analysis, such as body fluids (e.g., sputum, serum, CSF), tissues (e.g., biopsy), or organs, and methods of preparation of the samples to allow for analysis are well known to those skilled in the art. The effects of treatment on a subject can be assessed by measuring biomarkers associated with the target gene expression in one or more biological fluids, tissues or organs, collected from an animal contacted with one or more compositions described in this application.

[0259] In some embodiments, an increase in MuSK ΔIg3 mRNA means that the intracellular level of MuSK ΔIg3 mRNA is higher than a reference level, such as the level of MuSK ΔIg3 mRNA in a control (for example in a subject that is not being administered an MuSK-targeting oligonucleotide). An increase in intracellular MuSK ΔIg3 mRNA can be measured as an increase in the level of MuSK ΔIg3 protein and/or mRNA produced. In some embodiments, an increase in MuSK ΔIg3 mRNA can be determined by e.g., methods as described below in the examples, and/or by assay techniques such as RNA solution

hybridization, nuclease protection, Northern hybridization, reverse transcription, gene expression monitoring with a microarray, antibody binding, enzyme linked immunosorbent assay (ELISA), nucleic acid sequencing, Western blotting, radioimmunoassay (RIA), other immunoassays, fluorescence activated cell analysis (FACS), or any other technique or combination of techniques that can detect the presence of MuSK ΔIg3 mRNA or protein (e.g., in a subject or a sample obtained from a subject).

[0260] In some embodiments, by comparing the level of MuSK ΔIg3 mRNA in a sample obtained from a subject receiving a MuSK-targeting oligonucleotide treatment to a level of MuSK ΔIg3 mRNA in a subject not treated with a MuSK-targeting oligonucleotide, the extent to which the MuSK-targeting oligonucleotide treatment increased MuSK ΔIg3 mRNA can be determined. In some embodiments, the reference level of MuSK ΔIg3 mRNA is obtained from the same subject prior to receiving MuSK-targeting oligonucleotide treatment. In some embodiments, the reference level of MuSK ΔIg3 mRNA is a range determined by a population of subjects not receiving MuSK-targeting oligonucleotide treatment. In some embodiments, the level of full-length MuSK mRNA is compared to the level of MuSK ΔIg3 mRNA. In some embodiments, the ratio of the MuSK ΔIg3 mRNA to a full length MuSK mRNA (e.g., MuSK mRNA without exons 6 and 7) in a subject receiving a MuSK-targeting oligonucleotide treatment, for example, greater than 1 fold, 1.5-5 fold, 5-10 fold, 10-50 fold, 50-100 fold, about 1.1-, 1.2-, 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 30-, 40-, 50-, 60-, 70-, 80- , 90-, l00-fold or more higher than a reference ratio.

[0261] In some embodiments, an increased level of MuSK ΔIg3 mRNA is, for example, greater than 1 fold, 1.5-5 fold, 5-10 fold, 10-50 fold, 50-100 fold, about 1.1-, 1.2-, 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-fold or more higher than a reference value.

[0262] In some embodiments, the increase of MuSK ΔIg3 mRNA in a subject can be indicated by the increase of MuSK ΔIg3 protein as compared to a reference level. In some embodiments, the reference level of MuSK ΔIg3 protein is the MuSK ΔIg3 protein level obtained from a subject having or at risk of having *e.g.,* AD or a disease characterized by neurodegeneration. In some embodiments, the reference level of MuSK ΔIg3 protein is the MuSK ΔIg3 protein level obtained from a subject having or at risk of having *e.g.,*

neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder (e.g., myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting prior to treatment. Methods whereby bodily fluids, organs or tissues are contacted with an effective amount of one or more compositions described herein are also contemplated. Bodily fluids, organs or tissues can be contacted with one or more compositions comprising MuSK-targeting oligonucleotides, resulting in expression of MuSK ΔIg3 and modulation of MuSK expression in the cells of bodily fluids, organs or tissues. An effective amount of can be determined by monitoring the effect on functional MuSK ΔIg3 protein expression of MuSK-targeting oligonucleotides that are administered to a subject or contacted to a cell.

[0263] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells, (*e.g.,* comprising NSCs and/or neural progenitor cells (MPCs)), increases the number of cells that are in an activated state (e.g., active proliferation). Cells within a population can be assessed for whether they are in an activated state by known methods in the art, including e.g., an EdU assay, where EdU+ cycling cells are compared with total cell counts. In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells comprising NSCs, decreases the number of quiescent NSCs in the population and/or increases the number of activated NSCs.

[0264] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells, (*e.g.,* comprising satellite cells (SCs), myoblasts, myogenic progenitor cells (MPCs)), increases the number of cells that are in an activated state (*e.g.,* active proliferation). Cells within a population can be assessed for whether they are in an activated state by known methods in the art, including *e.g.,* an EdU assay, where EdU+ cycling cells are compared with total cell counts. In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells comprising satellite cells, decreases the number of quiescent satellite cells in the population and/or increases the number of activated satellite cells.

[0265] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells comprising NSCs and/or NPCs, increases the number of cells expressing genes associated with early neurons (*e.g.,*

Dex) and/or decreases the number of cells expressing genes associated with mature neurons (*e.g.,* Map2), astrocytes (*e.g.,* GFAP and S100b), and/or oligodendrocytes (*e.g.,* CNPase and O4). In some embodiments, a MuSK-targeting oligonucleotide, when administered to a population of cells comprising NSCs and/or NPCs, increases the level of expression of genes associated with early neurons (*e.g.,* Dex) and/or decreases the level of expression of genes associated with mature neurons (*e.g.,* Map2), astrocytes (*e.g.,* GFAP and S100b), and/or oligodendrocytes (*e.g.,* CNPase and O4) in the population of cells.

[0266] In some embodiments, a population of cells comprises NSCs that have been induced to be NSCs (*e.g.,* from stem cells such as embryonic stems cells or pluripotent stem cells).

[0267] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells comprising SCs, MPCs, and/or myoblasts, increases the number of cells expressing genes or myogenic factors (e.g., Pax7, MyoD, myogenin, and MERGE) and/or decreases the number of cells expressing genes associated with the MuSK-BMP signaling pathway (e.g., RGS4, Msx2, Myf5, Ptx3, Id1). In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a population of cells comprising satellite cells and/or myoblasts, increases the level of expression of genes associated with myogenic factors (e.g., Pax7, MyoD, myogenin, and MERGE) and/or decreases the level of expression of genes associated the MuSK-BMP signaling pathway (e.g., RGS4, Msx2, Myf5, Ptx3, Id1) in the population of cells.

[0268] In some embodiments, a population of cells comprises satellite cells and/or myoblasts that have been induced to be satellite cells and/or myoblasts (e.g., from stem cells such as embryonic stems cells or pluripotent stem cells).

[0269] In some embodiments, a population of cells is obtained from a healthy subject. In some embodiments, a population of cells is obtained from a subject having or at risk of having *e.g.,* AD or a disease characterized by neurodegeneration or a subject suffering from a disease or disorder such as a neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder (e.g., myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting.

[0270] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when contacted with a population of cells from a subject, increases neurogenesis in a subject. In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same is contacted with the population of cells in vivo, for example, by injection into a subject. In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same is contacted with the population of cells *ex vivo* by obtaining a population of cells from a subject, and neurogenesis is increased when the treated cells are re-introduced into the subject.

[0271] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when contacted with a population of cells from a subject, increases muscle regeneration and/or growth in a subject. In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same is contacted with the population of cells in vivo, for example, by injection into a subject. In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same is contacted with the population of cells ex vivo by obtaining a population of cells from a subject, and muscle regeneration is increased when the treated cells are re-introduced into the subject.

[0272] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a subject, will increase neurogenesis and/or growth, and/or improve cognition. Examples of methods to assess these biological effects are detailed, *e.g.,* in the below examples.

[0273] In some embodiments, a MuSK-targeting oligonucleotide or composition comprising the same, when administered to a subject, will increase muscle regeneration and/or growth, and/or neuromuscular function, and/or myogenesis. Examples of methods to assess these biological effects are detailed, *e.g.,* in the below examples.

Production of MuSK-Targeting Oliogonucleotides

[0274] A MuSK-targeting oligonucleotide described herein can be synthesized by standard methods known in the art, e.g., by use of an automated synthesizer. Following chemical synthesis (e.g., solid-phase synthesis using phosphoramidite method), oligonucleotide molecules can be deprotected, annealed to ds molecules, and purified (e.g.,

by gel electrophoresis or HPLC). Protocols for preparation of MuSK-targeting oligonucleotide oligonucleotides are known in the art.

[0275] In some embodiments, the present disclosure provides technologies for preparing chirally controlled oligonucleotides and compositions thereof. In some embodiments, the present disclosure provides technologies for preparing stereopure oligonucleotides and compositions thereof. In some embodiments, provided oligonucleotides and compositions thereof are of high purity. In some embodiments, oligonucleotides of the present disclosure are at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% stereochemically pure at linkage phosphorus of chiral internucleotidic linkages. In some embodiments, oligonucleotides of the present disclosure are prepared stereoselectively and are substantially free of stereoisomers. In some embodiments, in provided compositions comprising a plurality of oligonucleotides which share the same base sequence of the same pattern of chiral linkage phosphorus stereochemistry (*e.g.,* comprising one or more of Rp and/or Sp, wherein each chiral linkage phosphorus is independently Rp or Sp), at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% of all oligonucleotides in the composition that share the same base sequence as oligonucleotides of the plurality share the same pattern of chiral linkage phosphorus stereochemistry or are oligonucleotides of the plurality. In some embodiments, in provided compositions comprising a plurality of oligonucleotides which share the same base sequence of the same pattern of chiral linkage phosphorus stereochemistry, at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% of all oligonucleotides in the composition that share the same constitution as oligonucleotides of the plurality share the same pattern of chiral linkage phosphorus stereochemistry or are oligonucleotides of the plurality.

[0276] MuSK-targeting oligonucleotides can also be formed within a cell by transcription of RNA from an expression construct introduced into the cell (see, *e.g.,* Yu et al., Proc. Natl. Acad. Sci. USA 2002; 99:6047-6052). An expression construct for in vivo production of oligonucleotide molecules can include one or more antisense encoding sequences operably linked to elements necessary for the proper transcription of the antisense encoding sequence(s), including, *e.g.,* promoter elements and transcription termination signals. Preferred promoters for use in such expression constructs include the polymerase-III HI-RNA promoter (see, *e.g.,* Brummelkamp et al., Science 2002; 296:550-553) and the U6

polymerase-III promoter (see, *e.g.,* Sui et al., Proc. Natl. Acad. Sci. USA 2002; Paul et al., Nature Biotechnol. 2002; 20:505-508; and Yu et al., Proc. Natl. Acad. Sci. USA 2002; 99:6047-6052). A MuSK-targeting oligonucleotide expression construct can further comprise one or more vector sequences that facilitate the cloning of the expression construct. Standard vectors that can be used include, *e.g.,* pSilencer 2.0-U6 vector (Ambion Inc., Austin, Tex.).

Pharmaceutical Compositions

[0277] The present disclosure provides pharmaceutical compositions that comprise and/or deliver MuSK-targeting oligonucleotides as described herein. The present disclosure also provides pharmaceutical compositions that are or comprise cell populations that have been exposed to MuSK-targeting oligonucleotides as described herein.

[0278] For example, in some embodiments, a provided pharmaceutical composition may comprise and/or deliver MuSK-targeting oligonucleotides that, when administered, achieves an increase in level and/or activity of a MuSK polypeptide (*e.g.,* a MuSK ΔIg3 polypeptide, or another MuSK variant polypeptide with disrupted Ig3) that lacks an Ig3 domain functional for interaction with BMP. Alternatively or additionally, in some embodiments, a provided pharmaceutical composition may comprise and/or deliver a population of cells that has been exposed to a MuSK-targeting oligonucleotide, so that neuronal cell number and/or activity is increased in the population.

[0279] In many embodiments, a pharmaceutical composition will be or comprise an active agent (*e.g.,* a MuSK-targeting oligonucleotide as described herein or a precursor thereof) in combination with one or more pharmaceutically acceptable excipients. Those skilled in the art will appreciate that components of a particular pharmaceutical composition may be influenced by route of administration of the pharmaceutical composition.

[0280] The compositions of the disclosure can be formulated for a variety of modes of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in Remington, The Science and Practice of Pharmacy, (20th ed. 2000).

[0281] Compositions of the present invention can be prepared and administered in a wide variety of oral, parenteral, and topical dosage forms. Thus, the compositions of the present invention can be administered by injection (*e.g.* intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally). Also, the compositions described herein can be administered by inhalation, for example, intranasally. Additionally, the composition of the present invention can be administered transdermally. It is also envisioned that multiple routes of administration (*e.g.,* intramuscular, oral, transdermal) can be used to administer the compositions of the invention.

[0282] In some embodiments, a pharmaceutical composition as described herein may be formulated for delivery by a route selected from intravenous injection, intrathecal administration, oral administration, buccal administration, inhalation, nasal administration, topical administration, ophthalmic administration or otic administration. In some embodiments, a pharmaceutical composition may be formulated for delivery by intrathecal administration. In some embodiments, a pharmaceutical composition may be formulated for delivery by intravenous administration. In some embodiments, a pharmaceutical composition may be formulated for delivery by oral administration.

[0283] In certain embodiments, oligonucleotides and compositions are delivered to the CNS. In certain embodiments, oligonucleotides and compositions are delivered to the cerebrospinal fluid. In certain embodiments, oligonucleotides and compositions are administered to the brain parenchyma. In certain embodiments, oligonucleotides and compositions are delivered to an animal/subject by intrathecal administration, or intracerebroventricular administration. Broad distribution of oligonucleotides and compositions, described herein, within the central nervous system may be achieved with intraparenchymal administration, intrathecal administration, or intracerebroventricular administration.

[0284] In certain embodiments, parenteral administration is by injection, by, *e.g.,* a syringe, a pump, etc. In certain embodiments, the injection is a bolus injection. In certain embodiments, the injection is administered directly to a tissue, such as striatum, caudate, cortex, hippocampus and cerebellum.

[0285] In certain embodiments, methods of specifically localizing a pharmaceutical agent, such as by bolus injection, decreases median effective concentration (EC50) by a factor of 20, 25, 30, 35, 40, 45 or 50. In certain embodiments, the pharmaceutical agent in an antisense compound as further described herein. In certain embodiments, the targeted tissue is brain tissue. In certain embodiments the targeted tissue is hippocampus tissue. In certain embodiments, decreasing EC50 is desirable because it reduces the dose required to achieve a pharmacological result in a patient in need thereof.

[0286] In certain embodiments, an antisense oligonucleotide is delivered by injection or infusion once every month, every two months, every 90 days, every 3 months, every 6 months, twice a year or once a year.

[0287] In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of an active compound into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.

[0288] Pharmaceutical preparations for oral use can be obtained by combining an active compound with solid excipients, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethyl-cellulose (CMC), and/or polyvinylpyrrolidone (PVP: povidone). If desired, disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[0289] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol (PEG), and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dye-stuffs or pigments

may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0290] Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin, and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, an active compound may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols (PEGs). In addition, stabilizers may be added.

[0291] In some embodiments, the pharmaceutical composition is a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop or an ear drop.

[0292] Depending on the specific conditions being treated, pharmaceutical composition of the present disclosure may be formulated into liquid or solid dosage forms and administered systemically or locally. The pharmaceutical composition may be delivered, for example, in a timed- or sustained- low release form as is known to those skilled in the art. Techniques for formulation and administration may be found in Remington, The Science and Practice of Pharmacy (20th ed. 2000). Suitable routes may include oral, buccal, by inhalation spray, sublingual, rectal, transdermal, vaginal, transmucosal, nasal or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intra-articullar, intra-sternal, intra-synovial, intra-hepatic, intralesional, intracranial, intraperitoneal, intranasal, or intraocular injections or other modes of delivery.

[0293] For injection, the pharmaceutical composition of the disclosure may be formulated and diluted in aqueous solutions, such as in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For such transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0294] Use of pharmaceutically acceptable inert carriers to formulate the compositions herein disclosed for the practice of the disclosure into dosages suitable for systemic administration is within the scope of the disclosure. With proper choice of carrier and suitable manufacturing practice, the compositions of the present disclosure, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection.

[0295] In some embodiments, compositions as described herein can be formulated using pharmaceutically acceptable carriers available in the art into dosages suitable for oral administration. Such carriers enable the compounds of the disclosure to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject (*e.g.,* patient) to be treated.

[0296] For nasal or inhalation delivery, one or more solubilizing, diluting, or dispersing substances such as, saline, preservatives, such as benzyl alcohol, absorption promoters, and fluorocarbons, may be employed.

[0297] In some embodiments, a provided composition may comprise and/or deliver a precursor of an active agent, wherein the precursor becomes or releases active therapeutic agent upon administration. In some embodiments, for example, a precursor may be or comprise a prodrug of a small molecule agonizing agent, or a nucleic acid that encodes a protein agonizing agent, etc.

[0298] In some particular embodiments, a provided pharmaceutical composition comprises or delivers a therapeutically effective amount (*e.g.,* an amount that is effective when administered according to an established protocol) of a provided oligonucleotide (which may, as described herein, be provided in a pharmaceutically acceptable salt form, *e.g.,* as a sodium salt, ammonium salt, etc.); in some embodiments, such a provided pharmaceutical composition includes a relevant oligonucleotide and at least one pharmaceutically acceptable inactive ingredient selected from pharmaceutically acceptable diluents, pharmaceutically acceptable excipients, and pharmaceutically acceptable carriers. In some embodiments, a salt form of a provided oligonucleotide comprises two or more cations, for example, in some embodiments, up to the number of negatively charged acidic groups (*e.g.*, phosphate, phosphorothioate, etc.) in an oligonucleotide.

[0299] Pharmaceutically acceptable salts are generally well known to those of ordinary skill in the art, and may include, by way of example but not limitation, acetate, benzenesulfonate, besylate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, carnsylate, carbonate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, or teoclate. Other pharmaceutically acceptable salts may be found in, for example, Remington, The Science and Practice of Pharmacy (20th ed. 2000). Preferred pharmaceutically acceptable salts include, for example, acetate, benzoate, bromide, carbonate, citrate, gluconate, hydrobromide, hydrochloride, maleate, mesylate, napsylate, pamoate (embonate), phosphate, salicylate, succinate, sulfate, or tartrate.

[0300] As appreciated by a person having ordinary skill in the art, oligonucleotides may be formulated as a number of salts for, *e.g.*, pharmaceutical uses. In some embodiments, a salt is a metal cation salt and/or ammonium salt. In some embodiments, a salt is a metal cation salt of an oligonucleotide. In some embodiments, a salt is an ammonium salt of an oligonucleotide. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. In some embodiments, a salt is a sodium salt of an oligonucleotide. In some embodiments, pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed with counterions such as hydroxide, carboxylate, sulfate, phosphate, nitrate, sulfonate, phosphorothioate, *etc.* that may be within provided oligonucleotides. As appreciated by a person having ordinary skill in the art, a salt of an oligonucleotide may contain more than one cations, *e.g.*, sodium ions, as there may be more than one anions within an oligonucleotide.

[0301] In some embodiments, provided oligonucleotides, and compositions thereof, may be effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.01 to about 1000 mg, from about 0.5 to about 100 mg, from about 1 to about 50 mg per day, and from about 5 to about 100 mg per day are examples of dosages that may be used. The exact dosage will depend upon the route of administration, the form in

which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.

[0302] In some embodiments, the present disclosure provides technologies (*e.g.*, compositions, methods, *etc.*) for combination therapy, for example, with other therapeutic agents and/or medical procedures. In some embodiments, provided oligonucleotides and/or compositions may be used together with one or more other therapeutic agents. In some embodiments, provided compositions comprise provided oligonucleotides, and one or more other therapeutic agents. In some embodiments, the one or more other therapeutic agents may have one or more different targets, and/or one or more different mechanisms toward targets, when compared to provided oligonucleotides in the composition. In some embodiments, a therapeutic agent is an oligonucleotide. In some embodiments, a therapeutic agent is a small molecule drug. In some embodiments, a therapeutic agent is a protein. In some embodiments, a therapeutic agent is an antibody. A number of a therapeutic agent may be utilized in accordance with the present disclosure. In some embodiments, provided oligonucleotides or compositions thereof are administered prior to, concurrently with, or subsequent to one or more other therapeutic agents and/or medical procedures. In some embodiments, provided oligonucleotides or compositions thereof are administered concurrently with one or more other therapeutic agents and/or medical procedures. In some embodiments, provided oligonucleotides or compositions thereof are administered prior to one or more other therapeutic agents and/or medical procedures. In some embodiments, provided oligonucleotides or compositions thereof are administered subsequent to one or more other therapeutic agents and/or medical procedures. In some embodiments, provide compositions comprise one or more other therapeutic agents.

Production of Pharmaceutical Compositions

[0303] For preparing pharmaceutical compositions from the compositions of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substance that may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

[0304] In powders, the carrier is a finely divided solid in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

[0305] The powders and tablets preferably contain from 5% to 70% of the therapeutic agent. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active therapeutic agent with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

[0306] For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

[0307] Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

[0308] When parenteral application is needed or desired, particularly suitable admixtures for compositions of the invention are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories. In particular, carriers for parenteral administration include aqueous solutions of dextrose, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-block polymers, and the like. Ampoules are convenient unit dosages. The compositions of the invention can also be incorporated into liposomes or administered via transdermal pumps or patches. Pharmaceutical admixtures suitable for use in the present invention include those described, for example, in Pharmaceutical Sciences (17th Ed., Mack Pub. Co., Easton, PA) and WO 96/05309, which is herein incorporated by reference.

[0309] Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

[0310] Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

[0311] The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

[0312] The quantity of active component in a unit dose preparation may be varied or adjusted according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

Patient populations

[0313] In some embodiments, an appropriate patient or population is one suffering from and/or susceptible to a disease, disorder or a condition associated with neurodegeneration (*e.g.,* AD) or that otherwise would benefit from increased neurogenesis. In some embodiments, an appropriate patient or population is one suffering from and/or susceptible to a disease, disorder such as neuromuscular dysfunction, a cardiac disorder (*e.g.,* myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting or that otherwise would benefit from increased muscle regeneration).

[0314] In some embodiments, such neurodegenerative disease, disorder, or condition is one or more of Alzheimer's Disease (AD), Parkinson's disease, dementia (*e.g.*, Frontotemporal dementia), stroke, Major Depressive Disorder (MDD), bipolar disorder, Schizophrenia, Post-Traumatic Stress Disorder (PTSD), substance-related and addictive disorders (e.g., chronic cocaine use and lifelong cigarette smoking), Temporal-Lobe Epilepsy, Hippocampal Sclerosis, Niemann Pick Type C, Diabetes-mediated hippocampal neuronal loss, brain injury (*e.g.*, traumatic and/or anoxic brain injury), and Huntington's disease.

[0315] In some embodiments, population may additionally or alternatively be suffering from and/or susceptible to a disease or disorder of the lung. In some embodiments, such a disease or disorder is one or more of idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), pneumonia, and lung complications due to viral infections.

[0316] In some embodiments, an appropriate patient or population is model organisms. In some embodiments, an appropriate patient or population is humans. In some embodiments, a human has an age in a range of from about 0 months to about 6 months old, from about 6 to about 12 months old, from about 6 to about 18 months old, from about 18 to about 36 months old, from about 1 to about 5 years old, from about 5 to about 10 years old, from about 10 to about 15 years old, from about 15 to about 20 years old, from about 20 to about 25 years old, from about 25 to about 30 years old, from about 30 to about 35 years old, from about 35 to about 40 years old, from about 40 to about 45 years old, from about 45 to about 50 years old, from about 50 to about 55 years old, from about 55 to about 60 years old, from about 60 to about 65 years old, from about 65 to about 70 years old, from about 70 to about 75 years old, from about 75 to about 80 years old, from about 80 to about 85 years old, from about 85 to about 90 years old, from about 90 to about 95 years old or from about 95 to about 100 years old.

[0317] In some embodiments, a human is a human infant. In some embodiments, a human is a human toddler. In some embodiments, a human is a human child. In some embodiments, a human is a human adult. In yet other embodiments, a human is an elderly human.

[0318] In some embodiments, an appropriate patient or population may be characterized by one or more criterion such as age group, gender, genetic background, preexisting clinical conditions, prior exposure to therapy.

[0319] In some embodiments, an appropriate patient or population is one suffering from e.g., neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder (*e.g.,* myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting. In some embodiments, an appropriate patient or population is one suffering that has received surgery or experienced injury, trauma and/or prolonged immobilization (*e.g.,* from bed-rest or casting). In some embodiments, an appropriate patient or population is one suffering from sarcopenia. In some embodiments, an appropriate patient or population is one suffering from or at risk of muscle fibrosis resulting from a disease or condition including, but not limited to, trauma, heritable disease, muscle disorder, and aging. Trauma can result from, for example, radiation treatment, crush injury, laceration, and amputation. In some embodiments, an appropriate patient or population is one suffering from or at risk of heritable disease associated with muscle fibrosis such as Congenital Muscular Dystrophy, Duchenne Muscular Dystrophy, Becker's Muscular Dystrophy, Amyotrophic Lateral Sclerosis (ALS), age-associated sarcopenia, Distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral muscular dystrophy, Limb-girdle muscular dystrophy, Myotonic muscular dystrophy, and Oculo-pharyngeal muscular dystrophy.

[0320] In some embodiments, an appropriate patient or population maybe defined by those in accordance with the screening tools for diseases or disorders associated with Alzheimer's disease. In some embodiments, an appropriate patient or population maybe defined by those in accordance with the screening tools for other diseases characterized by neurodegeneration, *e.g.,* Parkinson's disease, dementia (*e.g.,* Frontotemporal dementia), stroke, Major Depressive Disorder (MDD), bipolar disorder, Schizophrenia, Post-Traumatic Stress Disorder (PTSD), substance-related and addictive disorders (*e.g.,* chronic cocaine use and lifelong cigarette smoking), Temporal-Lobe Epilepsy, Hippocampal Sclerosis, Niemann Pick Type C, Diabetes-mediated hippocampal neuronal loss, brain injury (*e.g.,* traumatic and/or anoxic brain injury), and Huntington's disease.

[0321] In some embodiments, an appropriate patient or population maybe defined by those in accordance with the screening tools for diseases or disorders associated with muscle fibrosis and/or muscle wasting. In some embodiments, an appropriate patient or population maybe defined by those in accordance with the screening tools and methods for diagnosing a disease associated with muscle fibrosis and/or muscle wasting.

[0322] In some embodiments, an appropriate patient or population may be defined according to the results obtained in structural imaging (*e.g.*, magnetic resonance imaging (MRI), computed tomography (CT), ultrasound etc.). In some embodiments, an appropriate patient or population may be defined according to the results of cognitive tests. In some embodiments, an appropriate patient or population may be defined according to the results of neurological tests. In some embodiments, the cognitive tests involve one or more tests of Motor Screening Task (MOT), Reaction Time (RTI), Paired Associates Learning (PAL), Spatial Working Memory (SWM), Pattern Recognition Memory (PRM), Delayed Matching to Sample (DMS), Rapid Visual Information Processing (RVP). Rapid Visual Information Processing (RVP), Delayed Matching to Sample (DMS), Match to Sample Visual Search (MTS). In some embodiments, an appropriate patient or population may be defined according to the results of assessments such as measuring muscle enzymes, EMG, muscle biopsy, genetic testing, heart testing (e.g., ECG), assessments of strength and respiratory function.

Administration

[0323] Those skilled in the art will appreciate that, in some embodiments, dosage administered to a subject, particularly a human, may vary, for example depending on the particular therapeutic and/or formulation employed, the method of administration, the dosing regimen, one or more characteristics of the particular subject being treated, etc.. In some embodiments, a clinician skilled in the art will determine the therapeutically effective amount of a therapeutic to be administered to a human or other subject in order to treat or prevent a particular medical condition. The precise amount of the therapeutic required to be therapeutically effective will depend upon numerous factors, *e.g.*, such as the specific activity of the therapeutic, and the route of administration, in addition to many subject-specific considerations, which are within those of skill in the art.

[0324] In some embodiments, administration may be ocular, oral, buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, etc), enteral, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (*e.g.,* intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (*e.g.,* by intratracheal instillation), vaginal, vitreal, etc.

[0325] Those skilled in the art, reading the present disclosure will appreciate that, in some embodiments, it may be desirable to achieve delivery of a MuSK-targeting oligonucleotide composition to muscle. Alternatively or additionally, in some embodiments, it may be desirable to achieve delivery of a MuSK-targeting oligonucleotide composition to the CNS (*e.g.,* the brain, such as the hippocampus and/or the subventricular region) and/or to the lung.

[0326] In some embodiments, a MuSK-targeting oligonucleotide composition is delivered via systemic delivery and/or local delivery to muscle (*e.g.,* via intramuscular injection).

[0327] In some embodiments, a MuSK-targeting oligonucleotide composition is administered using a viral vector to effectively deliver a MuSK-targeting oligonucleotide composition in the form of a nucleic acid payload. In some embodiments, a viral vector targets certain cell types (*e.g.,* myoblasts, myocytes, myotubes, satellite cells and myofibers). AAV1, AAV6, and AAV9 vectors have been used to target different muscle cell types (*See,* for example, Arnett et al., *Mol Ther Methods Clin Dev.* 1. pii: 14038, 2014 and Riaz et al., *Skeletal Muscle* 5 (37) 2015).

[0328] Those skilled in the art, reading the present disclosure will appreciate that, in some embodiments, it may be desirable to achieve delivery of a MuSK-targeting oligonucleotide composition to the CNS, and, in some embodiments to the brain.

[0329] In some embodiments systemic administration achieves delivery to CNS (*e.g.,* brain *e.g.,* hippocampus and/or subventricular zone). In some embodiments, an agent (*e.g.,* an agonizing agent or MuSK-targeting oligonucleotide) is delivered to the central nervous system (CNS), via intracerebroventricular administration.

[0330] Additionally, certain viral vectors are known to selectively target neurons, and to effectively deliver genetic payloads to the brain. For example, AAV2/1 vectors have been established to effectively deliver nucleic acid payloads (e.g., gene therapy, encoded RNAs, etc) to neuronal cells in the hippocampus. *See,* for example, Hammond et al *PLoS One* 12:e0188830, 2017; Guggenhuber et al *PLoS One* 5:e15707, 2010; Lawlor et al *Mol. Neurodeg.* 2:11, 2007). Analogously, certain AAV vectors (e.g., AAV2/1 and/or AAV4 vectors) have been established to target and effectively deliver nucleic acid payloads to certain cells in the subventricular zone cells. *See,* for example, Liu et al *Gene Thep* 12:1503, 2005; Bockstael *et al Hum Gene Therap* 23:doi.org/10.1089/hum.2011.216, 2012*).*

[0331] For subjects suffering from or susceptible to a disease, disorder or condition associated with neurodegeneration, administration that achieves delivery to the CNS, *e.g.,* to the brain (*e.g.,* to the hippocampus and/or the subventricular region) may be desirable.

[0332] In some embodiments, effective delivery may be achieved by systemic administration of a composition as described herein. Alternatively or additionally, in some embodiments, effective delivery may be achieved by local administration to the CNS and/or to the brain, for example by intrathecal and/or intracavitary (*e.g.,* intracerebroventricular) delivery.

[0333] Technologies for local administration to the CNS and/or to the brain have been developed and demonstrated to be effective, for example, for various protein therapeutics (see, for example Calias et al., *Pharmacol. & Therap.* 144:122, 2014), for small molecules (see, for example, Dodou *Pharm. J.* 289:501, 2012), for cell compositions (see, for example, Eftekharzadeh et al., *Iran J Basic Med Sci* 18:520, 2015); and nucleic acid therapeutics (see, for example, Otsuka et al, *J. Neurotrauma* 28:1063, 2011; see also prescribing information for onasemnogene abeparvovec-xioi [sold under the brand name Zolgensma™] and that for nusinersen [sold under the brand name Spinraza™]).

[0334] Those skilled in the art will be aware that intrathecal delivery may be particularly effective to achieve delivery to the hippocampus, including for cellular, protein, and nucleic acid therapeutics.

[0335] Systemic administration technologies (including, *e.g.*, oral, parenteral, mucosal, etc) are well established for a wide variety of agents. Systemic administration that achieves CNS and/or brain delivery, in some embodiments, may depend on ability to cross the blood brain barrier (BBB).

[0336] Certain active agents and/or delivery systems are known to cross the BBB. Recent technologies have been shown to achieve CNS and/or brain delivery even of agents, such as oligonucleotides, that had historically been considered to be particularly challenging in that regard. To give but one example, Min et al. *Angew Chem Int Ed Engl* doi: 10.1002/anie.201914751, 2020, incorporated herein by reference, describes glucose-coated polymeric nanocarriers that transport oligonucleotides across the BBB.

[0337] It has also been reported that incorporation of certain particular chemistries into oligonucleotide therapeutics can facilitate their travel across the BBB. For example, Khorkova et al (*Nature Biotech* 35:249, 2017, incorporated herein by reference) have described that:

> "2′-modified phosphorothioate oligonucleotides . . . may be particularly adaptable for CNS disorders, given their long half-life, with effects in the brain lasting up to 6 months following a single injection. In another type of sugar moiety modification, locked nucleic acids (LNAs), a bridge is introduced that connects the 2′ oxygen and 4′ carbon. This modification substantially elevates the melting temperature of the LNA–DNA and LNA–RNA hybrids, thus allowing the creation of shorter ODN-based compounds with increased bioavailability and reduced manufacturing costs. A recently proposed tricyclo-DNA, a conformationally constrained oligonucleotide analog, has three additional C-atoms between C(5′) and C(3′) of the sugar (Fig. 2). This modification increases stability, hydrophobicity and RNA affinity, and improves tissue uptake and BBB permeability".

(citations omitted).

[0338] For subjects suffering from or susceptible to a disease or disorder such as idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), pneumonia,

and lung complications due to viral infections, administration that achieves delivery to the lungs may be desirable.

[0339] In some embodiments, oligonucleotides (*e.g.,* antisense oligonucleotides) are developed to enhance their delivery to target site(s). As described in the art, oligonucleotide is covalently or non-covalently bound to additional chemical moieties (*e.g.,* a carrier or ligand) to enhance the delivery. *See* Thomas C. Roberts et al. Nature Reviews Drug Discovery volume 19, pages 673–694 (2020), the entirety of which is incorporated herein by reference).

[0340] As appreciated by those skilled in the art, various technologies of bioconjugation can be utilized to enhance the delivery oligonucleotides to target site(s). For example, oligonucleotides can be covalently conjugated to lipids (*e.g.,* cholesterol that facilitates interactions with lipoprotein particles in the circulation), peptides (for cell targeting and/or cell penetration), aptamers, antibodies and sugars (e.g., N-acetyl galactosamine to enhance safer delivery to the target site (*See* Verma, *Ann Indian Acad Neurol.* 2018 21(1): 3–8. doi: 10.4103/aian.AIAN_298_17), N-acetylgalactosamine (GalNAc)).

[0341] As appreciated by those skilled in the art, lipid conjugates include, *e.g.,* oligonucleotides bound to Cholesterol, α-tocopherol (vitamin E), long-chain (>C18) fatty acids, lipoprotein particles (for example, HDL and LDL), etc.

[0342] As appreciated by those skilled in the art, conjugation of N-acetylgalactosamine (GalNAc) can enhance the uptake of oligonucleotides into target sites (*e.g.,* hepatocytes).

[0343] As appreciated by those skilled in the art, antibody and aptamer conjugates can be used to enhance oligonucleotide delivery. Various receptors have been successfully targeted for oligonucleotide delivery, including, e.g., the HIV gp160 protein, HER2, CD7 (T cell marker), CD71 (transferrin receptor, highly expressed in cardiac and skeletal muscle) and TMEFF2. Similarly, oligonucleotides have also been conjugated with antibodies against CD44 (a neural stem cell marker), EPHA2 and EGFR193. Additionally, aptamers can be conjugated to oligonucleotide to enhance its delivery.

[0344] As appreciated by those skilled in the art, various nanocarriers can be used to enhance oligonucleotide delivery. For example, oligonucleotide can form non-covalent complex with cationic polymers (for example, polyethylenimine), dendrimers, CPPs (for example, MPG-8, PepFect6, RVG-9R228, and Xentry-KALA229) and inorganic methods (for example, calcium phosphate nanoparticles).

[0345] As appreciated by those skilled in the art, various lipoplexes and liposomes (*e.g.,* lipid nano-particles (LNPs)) can be used to enhance oligonucleotide delivery.

[0346] In some embodiments, a MuSK-targeting oligonucleotide is modified to form a bioconjugate (*e.g.,* conjugated with sugar, peptide, antibody, aptamer, lipid, etc.) to enhance its delivery to target site(s). In some embodiments, a MuSK-targeting oligonucleotide is formulated as lipoplexes and liposomes (*e.g.,* lipid nano-particles (LNPs)) to enhance its delivery to target site(s).

[0347] Certain technologies have been developed to improve the efficiency of cellular delivery of ASOs to target site, e.g., muscle. For example, aminoglycosides (AGs) are shown to improve the delivery of antisense phosphorodiamidate morpholino oligomer (PMO) both in vitro and in vivo (*See* Wang, et al., *Mol Ther Nucleic Acids,* 2019; 16: 663–674, doi: 10.1016/j. omtn.2019.04.023). Short cell-penetrating peptides (CPPs) that can be either directly attached to oligonucleotides through covalent linkages or through the formation of noncovalent nanoparticle complexes can facilitate cellular uptake (*See* McClorey et al.; *Biomedicines* 2018, 6(2), 51). ASO fatty acid conjugates are also reported to enhance the functional uptake of antisense oligonucleotide (ASO) in the muscle (*See* Prakash et al.; *Nucleic Acids Research*, 47, 2019, 6029–6044).

[0348] Those skilled in the art will be familiar with eteplirsen (ExonDys 51), an approved treatment for Duchenne muscular dystrophy (DMD), which is a third-generation phosphorodiamidate morpholino ASO.

[0349] Eteplirsen, sold under the brand name Exondys 51™, (Sarepta Therapeutics') causes exon 51 to be spliced out in pre-mRNA, restoring the reading frame in the 13% of patients with amenable frame-shifting mutations (*See* Crudele et al. *Human Molecular Genetics*, Volume 28, Issue R1, pp. R102–R107, 2019).

[0350] Eteplirsen is administered via intravenous infusion over 35 to 60 minutes. In particular, its recommended dosage is 30mg/kg body weight weekly. In a single-dose vial, the pharmaceutical composition is formulated as a 100mg/2mL or 500mg/mL (50mg/mL) solution.

[0351] Those skilled in the art will further be familiar with other delivery systems used with oligonucleotide therapeutics. For example, the first approved RNAi oligonucleotide therapeutic, Patisiran (Onpattro), which is developed by Alnylam Pharma for treatment for TTR (hereditary transthyretin amyloidosis, polyneuropathy), utilizes a nanoparticle delivery system (*i.e.*, lipid nano-particles, LNP formulation); it also includes co-treatment with steroids and antihistamines.

[0352] Patisiran is administered via intravenous infusion. In particular, for patients weighing less than 100 kg, its recommended dosage is 0.3 mg/kg once every 3 weeks. For patients weighing 100 kg or more, the recommended dosage is 30 mg once every 3 weeks.

[0353] Other approved oligonucleotide therapeutics are typically administered via intravenous infusion to various organs, e.g., eyes, liver, skeletal muscle, spinal cord, etc..

[0354] In some embodiments, an oligonucleotide therapeutic as described herein may be administered intravenously. In some such embodiments, such oligonucleotide therapeutic may be administered according to a regimen reasonably comparable to that used for eteplirsen [sold under the brand name Exondys 51™]. In some such embodiments, such oligonucleotide therapeutic may be administered according to a regimen reasonably comparable to that used for Patisiran [sold under the brand name Onpattro].

[0355] In some embodiments a lower dose of an MuSK-targeting oligonucleotide oligonucleotide as described herein is 12 mg. In some embodiments, a total of 5 mg to 60 mg per dose of MuSK-targeting oligonucleotide is administered to a subject. In some embodiments, a total of 12 mg to 48 mg per dose of MuSK-targeting oligonucleotide is administered to a subject. In some aspects, a total of 12 mg to 36 mg per dose of MuSK-targeting oligonucleotide is administered to a subject. In some aspects, a total of 12 mg per dose of MuSK-targeting oligonucleotide is administered to a subject.

[0356] Those skilled in the art will be familiar with nusinersen [sold under the brand name Spinraza™], an antisense oligonucleotide therapeutic that targets the survival motor neuron-2 (SMN2)-directed gene transcript and is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. Spinraza is administered intrathecally. In particular, its recommended dosage is 12 mg/5 mL (2.4 mg/mL) in a single-dose vial per administration, according to a regiment that involves four loading doses; the first three of which are administered at 14-day intervals, and the fourth of which is administered 30 days after the 3rd dose; a maintenance dose is administered once every 4 months thereafter. It is recommended that platelet count, coagulation laboratory testing, and quantitative spot urine protein testing is done at baseline, and prior to each dose.

[0357] In some embodiments, an oligonucleotide therapeutic as described herein may be administered intrathecally. In some such embodiments, such oligonucleotide therapeutic may be administered according to a regimen reasonably comparable to that used for nusinersen [sold under the brand name Spinraza™].

[0358] In some embodiments, an oligonucleotide therapeutic as described herein may be administered intrathecally. In some such embodiments, such oligonucleotide therapeutic may be administered according to a regimen reasonably comparable to that used for nusinersen [sold under the brand name Spinraza™].

[0359] An oligonucleotide therapeutic as described herein may be administered according to any of the dosing regimens described herein.

Cell Therapy

[0360] In light of the ability of MuSK-targeting oligonucleotide compositions, as described herein, to promote neurogenesis (e.g., in cell populations that are or comprise neural progenitor cells), those skilled in the art reading the present disclosure will appreciate that, among other things, the present disclosure provides technologies for enhancing level of neural cells present in a cell population. That is, contacting an original cell population with a MuSK-targeting oligonucleotide composition as described herein can generate a resulting population with an increased level and/or percentage of neural cells as compared with that in

the original population; administration of such MuSK-targeting oligonucleotide composition as described herein can achieve such increase.

[0361] Additionally, MuSK-targeting oligonucleotide compositions, as described herein, promote muscle regeneration (e.g., in cell populations that are or comprise SCs, MPCs, and/or myoblasts), and those skilled in the art reading the present disclosure will appreciate that, among other things, the present disclosure provides technologies for enhancing level of SCs, MPCs, and/or myoblasts present in a cell population. That is, contacting an original cell population with a MuSK-targeting oligonucleotide composition as described herein can generate a resulting population with an increased level and/or percentage of SCs, MPCs, and/or myoblasts as compared with that in the original population; administration of such MuSK-targeting oligonucleotide composition as described herein can achieve such increase.

[0362] In some embodiments, an original cell population may be or comprise NSCs and/or NPCs. In some embodiments, an original cell population may be or comprise SCs, MPCs, and/or myoblasts. In some embodiments, an original cell population is or comprises embryonic stems cells and/or pluripotent stem cells. In some embodiments, embryonic stems cells and/or pluripotent stem cells are or have been differentiated into neural or neural precursor cells, for example using techniques known in the art (*see e.g.,* U.S. Pat. 9,631,175). In some embodiments, embryonic stems cells and/or pluripotent stem cells are or have been differentiated into myogenic progenitor cells, for example using techniques known in the art (*See e.g.,* Miyagoe-Suzuki et al.., *Stem Cells Int.* 7824614 2017).

[0363] In some embodiments, as discussed above, administration to a cell population delivers the MuSK-targeting oligonucleotide composition such that it is exposed to (*i.e.,* contacts) a relevant original cell population *in vivo* (*e.g.,* in a human, and in particular in an adult human, for example into in the brain – e.g., the hippocampus and/or subventricular region of the brain, of such human).

[0364] In some embodiments, as discussed above, administration delivers the MuSK-targeting oligonucleotide composition such that it is exposed to (*i.e.,* contacts) a relevant original cell population *in vivo* (e.g., in a human, and in particular in an adult human, for example into muscle tissue, of such human).

[0365] In some embodiments, administration in accordance with the present disclosure contacts a MuSK-targeting oligonucleotide composition with a population of cells (*e.g.,* an original population of cells), that for example, may be or comprise neural progenitor cells, SCs, MPCs, and/or myoblasts, *ex vivo.* For example, in some embodiments, a MuSK-targeting oligonucleotide composition is administered *ex vivo* (*e.g., in vitro*) to a population of cells from a subject. In some embodiments, a population of cells obtained from a subject.

[0366] Oligonucleotides that direct exon skipping of MuSK transcript(s) to favor forms that lack functional Ig3, and/or that direct degradation (and/or block translation) of forms that include functional Ig3, may be utilized.

[0367] In some embodiments, a population of cells is contacted with a MuSK-targeting oligonucleotide composition and simultaneously or subsequently stimulated and/or expanded. Alternatively or additionally, a population of cells is enriched and/or selected for cells exhibiting characteristics of activated NSCs (e.g., expression of Dex) or satellite cells or for expression of myogenic factors (*e.g.,* Pax7, MyoD, myogenin, and MERGE) or for decreased/lack of expression of genes associated with the MuSK-BMP signaling pathway (*e.g.,* RGS4, Msx2, Myf5, Ptx3, Id1).

[0368] In some embodiments, a resulting population of cells, achieved by contacting an original population of cells with a MuSK-targeting oligonucleotide composition *ex vivo* is then administered to a subject. In some embodiments, a resulting population of cells is administered to a subject suffering from or susceptible to a disease or disorder such as a neuromuscular dysfunction, a neurodegenerative disorder (*e.g.,* AD), a cardiac disorder (*e.g.,* myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting. In some embodiments, a resulting population of cells is administered to the subject from whom the original population of cells was obtained. In some embodiments, a resulting population of cells is administered to a different subject than the one from which the original population of cells was obtained; in some such embodiments, the original population was obtained from a healthy subject and the resulting population is administered to a subject suffering from or susceptible to a disease or disorder such as a neurodegenerative disorder (*e.g.,* AD), a neuromuscular dysfunction, a cardiac disorder (e.g., myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting.

[0369] In some embodiments, administering a population of cells, contacted with a MuSK-targeting oligonucleotide composition effectively treats a disease or disorder such as a neuromuscular dysfunction, a neurodegenerative disorder (*e.g.,* AD), a cardiac disorder (*e.g.,* myocardial infarction, cardiomyopathy), or genetic diseases characterized by muscle wasting in the subject.

[0370] In some embodiments, a population of stimulated and/or expanded NSCs, SCs, MPCs, and/or myoblasts described herein can be formulated into a cellular therapeutic. In some embodiments, a cellular therapeutic includes a pharmaceutically acceptable carrier, diluent, and/or excipient. Pharmaceutically acceptable carriers described herein, for example, vehicles, adjuvants, excipients, and diluents, are well known and readily available to those skilled in the art. Preferably, the pharmaceutically acceptable carrier is chemically inert to the active agent(s), *e.g.*, a cellular therapeutic, and does not elicit any detrimental side effects or toxicity under the conditions of use.

[0371] In some embodiments, a cellular therapeutic can be formulated for administration by any suitable route, such as, for example, intravenous, intratumoral, intraarterial, intramuscular, intraperitoneal, intrathecal, epidural, and/or subcutaneous administration routes. Preferably, the cellular therapeutic is formulated for a parenteral route of administration. In some embodiments, a cellular therapeutic is administered to a subject via an infusion.

[0372] In some embodiments, a cellular therapeutic suitable for parenteral administration can be an aqueous or non-aqueous, isotonic sterile injection solution, which can contain anti-oxidants, buffers, bacteriostats, and solutes, for example, that render the composition isotonic with the blood of the intended recipient. An aqueous or nonaqueous sterile suspension can contain one or more suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.

[0373] In some embodiments, a single therapeutic cell described herein is capable of expanding and providing a therapeutic benefit. In some embodiments, 10^2 or more, *e.g.*, 10^3 or more, 10^4 or more, 10^5 or more, or 10^8 or more, therapeutic cells are administered as a cellular therapeutic. Alternatively, or additionally 10^{12} or less, *e.g.*, 10^{11} or less, 10^9 or less, 10^7 or less, or 10^5 or less, therapeutic cells described herein are administered to a subject as a

cellular therapeutic. In some embodiments, 10^2-10^5, 10^4-10^7, 10^3-10^9, or 10^5-10^{10} therapeutic cells described herein are administered as a cellular therapeutic.

[0374] A dose of a cellular therapeutic described herein can be administered to a subject at one time or in a series of subdoses administered over a suitable period of time, *e.g.*, on a daily, semi-weekly, weekly, bi-weekly, semi-monthly, bi-monthly, semi-annual, or annual basis, as needed. A dosage unit comprising an effective amount of a cellular therapeutic may be administered in a single daily dose, or the total daily dosage may be administered in two, three, four, or more divided doses administered daily, as needed. In some embodiments, a cellular therapeutic is administered in combination with another therapy.

Combination Therapy

[0375] In some embodiments, a MuSK-targeting oligonucleotide therapy as described herein is administered in combination with another therapy – *e.g.,* so that a subject is simultaneously or sequentially exposed to both therapies.

[0376] The dosage of the MuSK-targeting oligonucleotide therapy as described herein and the dosage of another therapy administered in combination, as well as the dosing schedule can depend on various parameters, including, but not limited to, the disease being treated (*e.g.,* a neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder, or a genetic disease characterized by muscle wasting), the subject's general health, and the administering physician's discretion.

[0377] MuSK-targeting oligonucleotide therapy can be administered prior to (*e.g.,* 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concurrently with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of the other therapy, to a subject in need thereof. In various embodiments MuSK-targeting oligonucleotide therapy and the other therapy are administered 1 minute apart, 10 minutes apart, 30 minutes apart, less than 1 hour apart, 1

hour apart, 1 hour to 2 hours apart, 2 hours to 3 hours apart, 3 hours to 4 hours apart, 4 hours to 5 hours apart, 5 hours to 6 hours apart, 6 hours to 7 hours apart, 7 hours to 8 hours apart, 8 hours to 9 hours apart, 9 hours to 10 hours apart, 10 hours to 11 hours apart, 11 hours to 12 hours apart, no more than 24 hours apart or no more than 48 hours apart. In one embodiment, MuSK-targeting oligonucleotide therapy and the other therapy are administered within 3 hours. In another embodiment, MuSK-targeting oligonucleotide therapy and the other therapy are administered at 1 minute to 24 hours apart.

[0378] A synergistic combination of MuSK-targeting oligonucleotide therapy and the other therapy, might allow the use of lower dosages of one or both of these agents and/or less frequent administration of the therapies to a subject suffering from neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder, or genetic diseases characterized by muscle wasting. A synergistic effect might result in the improved efficacy of these agents and/or the reduction of any adverse or unwanted side effects associated with the use of either agent alone.

[0379] In some embodiments, MuSK-targeting oligonucleotide therapy is administered in combination with a standard of care treatment for a relevant disease, disorder, or condition (*e.g.,* a neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder, or genetic diseases characterized by muscle wasting).

[0380] Therapies for DMD include deflazacort (Emflaza; PTC Therapeutics) eteplirsen (Exondys 51; Sarepta Therapeutics), Ataluren (Translarna; PTC Therapeutics), and glucocorticoids such as prednisone. In some embodiments, MuSK-targeting oligonucleotide therapy is administered in combination with one or more therapies for DMD.

[0381] Approved therapies for ALS include Radicava, Rilutek, Tiglutik, and Nuedexta. In some embodiments, MuSK-targeting oligonucleotide therapy is administered in combination with one or more therapies for ALS.

[0382] Approved therapies for cardiomyopathy include but are not limited to angiotensin II-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and spironolactone. In some embodiments, MuSK-targeting oligonucleotide therapy is administered in combination with one or more therapies for cardiomyopathy.

[0383] In some embodiments, MuSK-targeting oligonucleotide therapy is administered in combination with one or more therapies that relieves a symptom or characteristic of a relevant disease, disorder or condition, or of a therapy therefor. In some embodiments, MuSK-targeting oligonucleotide therapy is administered in combination with one or more other therapies that relieves a symptom or characteristic so that the side effects associated with said other therapies are relieved. In some embodiments, the side effect associated with therapy is characterized by one or more of nausea, vomiting, loss of appetite, muscle cramps and spasms, increased frequency of bowel movements, headache, confusion and dizziness, constipation, fatigue, excessive saliva and phlegm, pain, depression, sleep problems, and uncontrolled outbursts of laughing or crying.

[0384] Any therapy which is known to be useful, or which has been used, will be used or is currently being used for the treatment or prevention of neuromuscular dysfunction, a neurodegenerative disorder, a cardiac disorder, or genetic diseases characterized by muscle wasting, can be used in combination with the MuSK-targeting oligonucleotide therapy in accordance with the invention described herein.

EXEMPLIFICATION

Example 1: Design and Screening of MuSK-targeting Oligonucleotides

[0385] In this Example, human MuSK-targeting oligonucleotides were designed and tested for their ability to induce exon skipping of the MuSK exon 6 and/or exon 7.

Methods

A. Cell types

[0386] The choice of cell type was based on the expression of MuSK and the relevance of the cell type for the study. Two cell types were retained and tested:

[0387] 1. HEK293 (*ATCC*, CRL-1573) is a cell line commonly used in neuroscience studies because of its ability to differentiate to neurogenic lineage (Shaw et al., 2002).

[0388] 2. LHCN-M2 (*Evercyte*, CkHT-040-231-2) is a cell line that was shown to highly express MuSK (19.8NX according to ProteinAtlas). In HEK293, MuSK expression was variable, and sometimes not high enough to be detected with qPCR. In LHCN-M2, MuSK expression was more consistent and detectable. Therefore, LHCN-M2 was chosen.

B. Cell Culture

[0389] LHCN-M2 were obtained from *Evercyte* (CkHT-040-231-2) and were cultured according to their protocol.

[0390] The cell vessels were pre-coated with 80 µl/cm² of 0.1% porcine gelatin (*Sigma-Aldrich*, Cat# G1890) in water for at least 4h in 37°C and up to one week. Before plating the cells, excess gelatin was removed.

[0391] For detachment, cells were rinsed twice with PBS (*Thermofisher*, 14190144) and were incubated with Trypsin-EDTA solution (*Sigma*, T3924-100ML) (room-temperature; 20 µl/cm²) for 2 minutes.

[0392] Once the cells are detached, about 160 µl/cm² of growth medium was added to the trypsin. Cells were detached by pipetting and diluted at the appropriate density (between 1/2 to 1/6). Final volume of growth medium was 240 µl/cm².

[0393] LHCN-M2 cells were grown in MyoUp medium at 37°C in a humidified atmosphere with 5 % CO2. Cells were passaged twice a week when having reached about 30 - 40 % confluence.

[0394] MyoUp medium:

DMEM (*Thermofisher* Cat # 10566016) / M199 (*Gibco*, Cat# 31150022) (4+1)
15 % Fetal bovine serum (FBS) (*Hyclone*, SH30071.03)
20 mM Hepes (*Sigma Aldrich*, Cat# H0887)
3 µg/ml Zinc sulfate (*Sigma*, Cat# Z0251)
1.4 µg/ml Vitamin B12 (*Sigma*, Cat# V2876)
0.055 µg/ml Dexamethasone (*Sigma Aldrich*, Cat# D4902)
2.5 ng/ml HGF (*Merck Millipore*, Cat# GF116)
10 ng/ml bFGF (*Peprotech*, Cat# 100-18C)

C. ASO Transfection

[0395] ASOs were diluted in cell culture grade water to reach a concentration of 100 µM and were preserved at -20°C.

[0396] LHCN-M2 cells were plated in gelatin-coated 6 well plates at 35,000 cells/well in 2.25mL. After 2 days, cells reached 60% confluency and were ready to be transfected with the ASOs and lipofectamine RNAiMAX (*Invitrogen*, 13778150) according to the manufacturer's protocol:

		Volume (µL)	
		Oligos	
		50 nM final	100 nM final
1- Dilution of Lipofectamine in Opti-MEM	Opti-MEM Lipofectamine	400 24	
2- Dilution of siRNA in OptiMEM	Opti-MEM siRNA	400 8 of 50µM	400 8 of 100µM
3- Add siRNA/Opti-MEM in lipo-OptiMEM	siRNA/Opti-MEM Lipo/Opti-MEM	400 400	
4- Incubate 5min at RT			
5- Add siRNA-lipo to cells	mix siRNA/Lipo/Opti-MEM	250 µL per well	

[0397] 24 hours after transfection, cells were rinsed with PBS and the RNA was extracted.

D. RNA extraction

[0398] To obtain the best RNA extraction ratio, two kits were tested: Zymo Research *Quick*-RNA™ Miniprep Kit (cat# 50444597) and Qiagen RNeasy Plus Mini Kit (cat# 74136).

[0399] Cells were seeded in 6-well plates at a density of 45 000 cells/well. The RNA was extracted 2 days after seeding. The RNA concentration was measured using a nanodrop (Thermofisher, NanoDrop ™ 8000 Spectrophotometer) and the results are given in Table 3.

Table 3

ZYMO			QIAGEN		
	Total (ug)	**A260/A280**		**Total (ug)**	**A260/A280**
Control1	4.14	1.99	Control1	2.56	2.08
Control2	3.51	1.98	Control2	2.86	1.98
Control3	3.81	2.00	Control3	3.27	1.9

Table 3: Yield of RNA extraction from LHCN-M2 cells with ZYMO or QIAGEN extraction kits.

[0400] With the Zymo kit, a yield of RNA extraction of 3.82 µg/well was obtained, while 2.9 µg/well was obtained with the Qiagen kit. Therefore, the Zymo kit was chosen for the study.

[0401] The Zymo Research *Quick*-RNA™ Miniprep Kit is used for RNA extraction (cat# 50444597).

Zymo Kit Protocol:
All steps at room temperature and centrifugation at 13,000 x g for 30 seconds, unless specified.

1. Cells are lysed in 400 µL of RNA Lysis buffer using a cell scraper.
2. Lysates are vortexed for 20s to be homogenized and centrifuged for 30s at 13,000 x g to remove the cell debris.
3. The supernatants are transferred into a Spin-Away™ Filter (yellow) in a Collection Tube and centrifuged to remove the majority of genomic DNA.
4. 0.5 volume of ethanol (95-100%) is added to the flow-through and well mixed. The samples are transferred into a Zymo-Spin™ IIICG Column (green) in a Collection Tube and centrifuged.

5. The RNA, attached to the column, is DNase treated.
   (D1) Wash the column with 400 µl RNA Wash Buffer and centrifuge. Discard the flow-through.
   (D2) In a nuclease-free tube, 5 µl DNase I (1 U/µl) is added to 75 µl DNA Digestion Buffer
   and mix. Mixture is directly added into the column matrix.
   (D3) The column incubates at room temperature (20-30°C) for 15 minutes.
6. 400 µl of RNA Prep Buffer is added to the column and centrifuged. The flow-through is discarded.
7. 700 µl of RNA Wash Buffer is added to the column and centrifuged. The flow-through is discarded.
8. 400 µl of RNA Wash Buffer is added to the column and centrifuged for 1 min to ensure complete removal of the wash buffer. Then, the column is transferred into a 1.5 mL nuclease-free tube.
9. 100 µl of DNase/RNase-Free Water is added directly to the column matrix and centrifuged.
10. Extracted RNA is usually immediately transcripted to cDNA, or stored at -80°C if necessary.

cDNA transcription:

The reverse transcriptase SuperScript™ IV VILO™ Master Mix from *Thermofisher* (11756050) is used. 4 uL of the enzyme is added to 16 uL of RNA (corresponding to ~550-650 ng).

According to the manufacturer's protocol, the reverse transcription is obtained by the following steps:

- 10 min at 25°C to anneal the primers
- 10 min at 50°C to perform the reverse transcription
- 5 min at 85°C to inactivate the enzyme

The cDNA is then diluted by 2 in DNase RNase free water and conserved at -20°C until the qPCR is done.

For MuSK analyses, the cDNA was used at this concentration.

For housekeeping gene analyses, the cDNA was further diluted by 5.

E. qPCR

[0402] Two qPCR technologies were tested, TaqMan and SYBR Green.

[0403] Relative MuSK expression was measured by qPCR using Taqman or SYBR green technology in LHCN-M2 cells. Both gave similar results regarding MuSK inhibition by siRNA (Thermofisher, 4392420) (FIG. 3). However, the Cq, related to the level of detection, was lower with SYBR green than for Taqman - around 22 and 27 respectively for the controls, indicating better detection with SYBR green technology. Since the level of detection is important to discriminate the level of MuSK inhibition between conditions, SYBR Green technology was chosen for the study.

[0404] SYBR Green qPCR Protocol:

[0405] To analyze the gene expression, SYBR Green technology was used. Results were normalized to two housekeeping genes (GAPDH and YWHAZ). qPCR was performed in 384-well plates. cDNA was used at 1/2 to analyze MuSK expression and at 1/10 to analyze HKG expressions. Measures were performed in duplicates or triplicates.

[0406] The primer sequences are shown below in Table 4:

Table 4

Gene	Forward	Reverse
MuSK 34 (spanning the exon/exon junction 3-4)	CCTGCAAGTGAAGATGAAACCTAAA (SEQ ID NO: 118)	ATGAATCCTCAAGCTCCCAGA (SEQ ID NO: 119)
MuSK 67 (spanning the exon/exon junction 6-7)	GGCTCCTGAATCCCACAATG (SEQ ID NO: 120)	GAATGGACCCAGAAGAAACAGCA (SEQ ID NO: 121)
GAPDH (HKG)	CCTCAACGACCACTTTGTCA(SEQ ID NO: 122)	TTACTCCTTGGAGGCCATGT (SEQ ID NO: 123)
YWHAZ (HKG)	CGAAGCTGAAGCAGGAGAAG (SEQ ID NO: 124)	TTTGTGGGACAGCATGGATG (SEQ ID NO: 125)

[0407] In each well, 9 µL of the premix [3.5 µL RNAse/DNAse free water, 5 µL SYBR Green (*Biorad*, 1725120), 0.5 µL primer at 10 µM] is deposited and 1 µL of the cDNA at the appropriate dilution was added. After being sealed, the plate was centrifuged, briefly vortexed and centrifuged a second time. The Thermocycler QuantStudio 6 or 7 Pro (*Thermofisher*) was used to perform the qPCR. The steps are:

- 30 s at 95°C
- PCR (X40 cycles):
    - 3 s at 95°C
    - 30 s at 60°C
- Melting curve (step and hold, 4s):
    - 20 s at 65°C
    - 15s at 95°C

Design and Screen of Human ASOs

[0408] A first batch of 38 human antisense oligonucleotides (ASOs) were designed and then subsequently produced by Microsynth (Switzerland). The ASO sequences are shown below in Table 5.

Table 5:

Oligo ID	SEQ ID	5' to 3' Sequence
Bld1	1	GCTAGGGTGGTCTTTTAGAAATGCA
Bld2	2	GGTCAAGCTAGGGTGGTCTTTTAGA
Bld3	3	CTGCAGGAAATGGTCAAGCTAGGGT
Bld4	4	GAAGTGGTGAGTGACGCTCCTGCAG
Bld5	5	GTTAGGAAGACAGAAGTGGTGAGTG
Bld6	6	ATCCTGGCAAAAACTGTTAGGAAGA
Bld7	7	GTGGGATTCAGGAGCCCGCAGGATC
Bld8	8	GGTGACATTGTGGGATTCAGGAGCC
Bld9	9	GGAGCCAAAGGTGACATTGTGGGAT
Bld10	10	GGTCACAAAGGAGCCAAAGGTGACA
Bld11	11	ACAGTGCAGGGTCACAAAGGAGCCA

Bld12	12	CTGTTGCTGTACAGTGCAGGGTCAC
Bld13	13	GGGACAGGAATGCCTGTTGCTGTAC
Bld14	14	CAGGTGATGGTGGGGACAGGAATGC
Bld15	15	CCGTTTTCAATCCAGGTGATGGTGG
Bld16	16	TGACACTCACAGCATTTCCGTTTTC
Bld17	17	AAGTCCCCACACACATGACACTCAC
Bld18	18	GGTCTTCCCCAGACAAGTCCCCACA
Bld19	19	ACTATGTCAGTAGATTTGAAGGGAA
Bld20	20	TCCCACTATACTATGTCAGTAGATT
Bld21	21	TCAGTCAAGGATTTCCCACTATACT
Bld22	22	AAAAGAACTCAGTCAAGGATTTCCC
Bld23	23	GTAAAGGAAAATAAAAGAACTCAGT
Bld24	24	AACCTGACAGAGTAAAGGAAAATAA
Bld25	25	GGACCCAGAAGAAACCTGACAGAGT
Bld26	26	CACTCTCTTGAATGGACCCAGAAGA
Bld27	27	CACTCGGTCTTTCACACTCTCTTGA
Bld28	28	GTCTTGAGTCAATCACTCGGTCTTT
Bld29	29	GATAAACAGCTGCAGTCTTGAGTCA
Bld30	30	AGTCCTGGCTTGGTGATAAACAGCT
Bld31	31	ATGTGTAGAGTCCTGGCTTGGTGAT
Bld32	32	GTAGCTATGCATGTGTAGAGTCCTG
Bld33	33	TGCTTATTGGTAGCTATGCATGTGT
Bld34	34	ACTTCTCCCCATGCTTATTGGTAGC
Bld35	35	CCTTGGCAGTACTGAACTTCTCCCC
Bld36	36	CCTGCTATGCTGATGGTGGCTGCAG
Bld37	37	GGGCATCCTACCTGCTATGCTGATG
Bld38	38	GCAAATGTGAAGGGGCATCCTACCT

[0409] All ASOs Bld1-Bld38 were designed to include 2'-MOE modification on each sugar and where there is a phosphorothioate internucleotidic linkage between each nucleotide. Sequences were designed so that they would avoid activation of RNase H. All

ASOs were 25 nucleotides in length. Alignment of ASOs Bld1-Bld38 to the MuSK genomic sequence along regions including exons 6 and 7 is shown in **FIG. 4**.

Antisense oligonucleotides targeting Exon6

i. Alignment to the genetic sequence

[0410] The ASOs were designed to be complementary to regions of the MuSK Exon6 genetic sequence, presented in **FIG. 5**.

ii. Cell observations

[0411] Cells were plated at 30,000 cells/well in gelatin pre-coated 6-well plates and were transfected 48h after seeding with ASO at 50 nM and 100 nM. 24 h after transfection, cells were observed (FIG. 4) and the RNA was extracted and analyzed. **FIG. 6** shows microscopic acquisitions of LHCN-M2 cells 24 h after being transfected with the ASO at 100 nM (Scale = 100nm). The data of Bld5, Bld8, Bld10, and Bld18 are not shown.

[0412] Some ASOs induced a visible effect to the cells after 24 h: Bld8 (data not shown), Bld5 (data not shown), Bld10 (data not shown), Bld126 and Bld14 appeared to have a negative effect on the cell health. Other ASOs induced small differences. For example, cells transfected with the ASOs Bld11, Bld13, and Bld15 were shorter. Otherwise, cells in the other treatment groups were healthy and similar to the control, including Bld18, the data of which are not shown in **FIG. 6** and and Bld9.

iii. MuSK expression analyses

[0413] 24 h after transfection, RNA was extracted and MuSK expression was measured by qPCR. The primers were designed to span either the 3-4 exon/exon junction (named MuSK34) or the 6-7 exon/exon junction (named MuSK67). The MuSK34 primer therefor detects all forms of the MuSK transcript (both the long form (i.e., containing the Ig3 domain and the short form (i.e., MuSKΔIg3)) while the MuSK67 primer detects only the long form of MuSK and not MuSKΔIg3. The primer design rationale is shown in **FIG. 2**. Results were normalized to two housekeeping genes, YWHAZ and GAPDH, whose stabilities were assessed using the software BestKeeper and are shown in **FIG. 7**.

[0414] The qPCR results show that the ASOs Bld7, Bld8, Bld9, Bld11, Bld13, Bld16, Bld15, and Bld18 induced a decrease in the expression of MuSK34 (>75%) and of MuSK67 (>90%). The ASOs Bld13, Bld4, Bld5, Bld6, Bld12 and Bld14 and Bld17 induced a decrease of MuSK34 (between 50-75%) and a higher decrease of MuSK67 (70-85%). The ASOs Bld3 and Bld17 induced slighter effects on MuSK34 and MuSK67 expression (20-50%). Finally, the two ASOs Bld1 and Bld18 induced an increase in the expression of MuSK34 and 67.

[0415] The goal of the screen of ASOs was to identify an ASO that would induce a moderate/important decrease of MuSK67 with no effect on MuSK34 (*i.e.*, would induce an increase in MuSKΔIg3). The results shown in FIG. 7 indicate that the ASOs tested targeting Exon 6 may not be targeting the appropriate region to obtain a good skipping of Exons 6 and 7.

[0416] The results were correlated with the ASO alignment (**FIG. 8**) in order to identify key regions on the sequence important for MuSK expression. In **FIG. 8**, Green indicates a slight decrease or an increase in MuSK expression (between 90-300% of the control). Orange indicates a moderate decrease in MuSK expression (MuSK34 between 40 and 70% of the control, MuSK67 < 45% of the control). Red indicates high decrease in MuSK expression (MuSK34 <40 % of the control, MuSK67 < 20% of the control). Red areas indicate key regions for the expression of MuSK where ASOs induced a decrease of MuSK34 by >60% and MuSK67 by >80%.

[0417] The relative expression of MuSK 67 for each of the ASOs Bld1-Bld18 at 50nM are shown in Table 6 below:

Table 6:

Oligo ID	**SEQ ID NO:**	**Sequence - (5' to 3')[a]**	**Relative MuSK 67 expression[b]**
ASOs targeting exon 6			
Bld1	78	G*C*T *A*G*G *G*T*G *G*T*C *T*T*T *T*A*G *A*A*A *T*G*C *A	1.0449
Bld2	79	G*G*T *C*A*A *G*C*T *A*G*G *G*T*G *G*T*C *T*T*T *T*A*G *A	0.4366
Bld3	80	C*T*G *C*A*G *G*A*A *A*T*G *G*T*C *A*A*G *C*T*A *G*G*G *T	0.5139

Bld4	81	G*A*A *G*T*G *G*T*G *A*G*T *G*A*C *G*C*T *C*C*T *G*C*A *G	0.1545
Bld5	82	G*T*T *A*G*G *A*A*G *A*C*A *G*A*A *G*T*G *G*T*G *A*G*T *G	0.2419
Bld6	83	A*T*C *C*T*G *G*C*A *A*A*A *A*C*T *G*T*T *A*G*G *A*A*G *A	0.3612
Bld7	84	G*T*G *G*G*A *T*T*C *A*G*G *A*G*C *C*C*G *C*A*G *G*A*T *C	0.0180
Bld8	85	G*G*T *G*A*C *A*T*T *G*T*G *G*G*A *T*T*C *A*G*G *A*G*C *C	0.0098
Bld9	86	G*G*A *G*C*C *A*A*A *G*G*T *G*A*C *A*T*T *G*T*G *G*G*A *T	0.0091
Bld10	87	G*G*T *C*A*C *A*A*A *G*G*A *G*C*C *A*A*A *G*G*T *G*A*C *A	0.0099
Bld11	88	A*C*A *G*T*G *C*A*G *G*G*T *C*A*C *A*A*A *G*G*A *G*C*C *A	0.0103
Bld12	89	C*T*G *T*T*G *C*T*G *T*A*C *A*G*T *G*C*A *G*G*G *T*C*A *C	0.0053
Bld13	90	G*G*G *A*C*A *G*G*A *A*T*G *C*C*T *G*T*T *G*C*T *G*T*A *C	0.0088
Bld14	91	C*A*G *G*T*G *A*T*G *G*T*G *G*G*G *A*C*A *G*G*A *A*T*G *C	0.0911
Bld15	92	C*C*G *T*T*T *T*C*A *A*T*C *C*A*G *G*T*G *A*T*G *G*T*G *G	0.0222
Bld16	93	T*G*A *C*A*C *T*C*A *C*A*G *C*A*T *T*T*C *C*G*T *T*T*T *C	0.0558
Bld17	94	A*A*G *T*C*C *C*C*A *C*A*C *A*C*A *T*G*A *C*A*C *T*C*A *C	0.6501
Bld18	95	G*G*T *C*T*T *C*C*C *C*A*G *A*C*A *A*G*T *C*C*C *C*A*C *A	1.6763

a) * represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar.

b) a value of 1.0 represents the level of MuSK67 expression for untreated cells.

Antisense oligonucleotides targeting Exon7

i. Alignment to the genetic sequence

[0418] The alignment of the ASOs Bld19-Bld38 on the genetic sequence of Exon7 of MuSK is presented in **FIG. 9**.

ii. Cell observations

[0419] Cells were plated at 30,000 cells/well in gelatin pre-coated 6-well plates and were transfected 48h after seeding with ASO at 50 nM and 100 nM. 24 h after transfection, cells were observed (**FIG. 10**) and the RNA was extracted and analyzed. **FIG. 10** shows microscopic acquisitions of LHCN-M2 cells 24 h after being transfected with the ASO at 100 nM (Scale = 100nm).

[0420] After 24 h of transfection, cells looked healthy in all conditions. Cells transfected with the ASOs Bld19 and Bld30 were shorter than the control, while cells transfected with the ASOs Bld32 and Bld34 were more elongated. Cell transfected with the ASOs Bld23, Bld24, Bld25, Bld26, Bld27, Bld28, Bld35, Bld36, Bld37, Bld38 did not present any significant differences compared to the control (data not shown).

iii. MuSK expression analyses

[0421] 24 h after transfection, RNA was extracted, and MuSK gene expression was analyzed in qPCR (**FIG. 11**).Methods described for screen of ASOs to Exon6 were used.

[0422] Relative expression of each ASO at 50nM is shown in **Table 7** below.

Table 7:

Oligo ID	**SEQ ID NO:**	**Sequence - (5' to 3')[a]**	**Relative MuSK 67 expression [b]**
ASOs targeting exon 7			
Bld19	96	A*C*T *A*T*G *T*C*A *G*T*A *G*A*T *T*T*G *A*A*G *G*G*A *A	1.1548
Bld20	97	T*C*C *C*A*C *T*A*T *A*C*T *A*T*G *T*C*A *G*T*A *G*A*T *T	1.7641
Bld21	98	T*C*A *G*T*C *A*A*G *G*A*T *T*T*C *C*C*A *C*T*A *T*A*C *T	0.4483
Bld22	99	A*A*A *A*G*A *A*C*T *C*A*G *T*C*A *A*G*G *A*T*T *T*C*C *C	1.0207
Bld23	100	G*T*A *A*A*G *G*A*A *A*A*T *A*A*A *A*G*A *A*C*T *C*A*G *T	1.8924
Bld24	101	A*A*C *C*T*G *A*C*A *G*A*G *T*A*A *A*G*G *A*A*A *A*T*A *A	1.1254
Bld25	102	G*G*A *C*C*C *A*G*A *A*G*A *A*A*C *C*T*G *A*C*A *G*A*G *T	0.1010
Bld26	103	C*A*C *T*C*T *C*T*T *G*A*A *T*G*G *A*C*C *C*A*G *A*A*G *A	0.1450

Bld27	104	C*A*C *T*C*G *G*T*C *T*T*T *C*A*C *A*C*T *C*T*C *T*T*G *A	0.1570
Bld28	105	G*T*C *T*T*G *A*G*T *C*A*A *T*C*A *C*T*C *G*G*T *C*T*T *T	0.1024
Bld29	106	G*A*T *A*A*A *C*A*G *C*T*G *C*A*G *T*C*T *T*G*A *G*T*C *A	0.0555
Bld30	107	A*G*T *C*C*T *G*G*C *T*T*G *G*T*G *A*T*A *A*A*C *A*G*C *T	0.1978
Bld31	108	A*T*G *T*G*T *A*G*A *G*T*C *C*T*G *G*C*T *T*G*G *T*G*A *T	0.0871
Bld32	109	G*T*A *G*C*T *A*T*G *C*A*T *G*T*G *T*A*G *A*G*T *C*C*T *G	0.3343
Bld33	110	T*G*C *T*T*A *T*T*G *G*T*A *G*C*T *A*T*G *C*A*T *G*T*G *T	1.0718
Bld34	111	A*C*T *T*C*T *C*C*C *C*A*T *G*C*T *T*A*T *T*G*G *T*A*G *C	0.3860
Bld35	112	C*C*T *T*G*G *C*A*G *T*A*C *T*G*A *A*C*T *T*C*T *C*C*C *C	0.3559
Bld36	113	C*C*T *G*C*T *A*T*G *C*T*G *A*T*G *G*T*G *G*C*T *G*C*A *G	0.3926
Bld37	114	G*G*G *C*A*T *C*C*T *A*C*C *T*G*C *T*A*T *G*C*T *G*A*T *G	0.4601
Bld38	115	G*C*A *A*A*T *G*T*G *A*A*G *G*G*G *C*A*T *C*C*T *A*C*C *T	0.3908

a) * represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar.

b) a value of 1.0 represents the level of MuSK67 expression for untreated cells.

[0423] ASOs Bld29 and Bld31 induced a decrease in the expression of MuSK34 (>75%) and of MuSK67 (>90%). ASOs Bld30, Bld32and Bld34 induced a decrease of MuSK34 (between 40-60%) and a higher decrease of MuSK67 (55-85%). ASO Bld19 induced slighter effects on MuSK34 and MuSK67 expression (<20%). ASOs Bld19, Bld20, Bld24, Bld23 and Bld33 induced an increase in expression of MuSK34 and 67.

[0424] ASOs Bld25, Bld26, Bld27, Bld28, Bld35 and Bld38 induced a decrease of MuSK67 > 60% at 50nM and a decrease of MuSK34 < 40% for both concentrations. Therefore, these ASOs were considered good candidates to be tested at additional doses.

[0425] The alignment of these results to the genetic sequences indicated that one region is key region to regulate the splicing of the exons 6 and 7 without affecting the transcription of the other exons (indicated in purple in **FIG. 12**).

[0426] The alignment of these results to the MuSK exon7 genetic sequence indicated that some regions may be key regions to regulate the splicing of the exons 6 and 7 without affecting the transcription of the other exons (indicated in purple in **FIG. 12**). In **FIG. 12**, green indicates a slight decrease or an increase in MuSK expression (between 90-300% of the control). Orange indicates a moderate decrease in MuSK expression (MuSK34 between 40 and 70% of the control, MuSK67 < 45% of the control). Red indicates high decrease in MuSK expression. MuSK34 <40 % of the control, MuSK67 < 20% of the control Purple and grey areas indicate regions that may be targeted to obtain an efficient skipping of exons 6/7 with lower effect on other exons based on the results shown in **FIG. 11** (i.e., the regions targeted by ASOs hu7-10, hu73, hu717, hu730, hu711 and hu7158). These regions "region 1" and "region 2" are shown in **FIG. 4**.

Dose Response of Exemplary ASO candidates

[0427] The first ASO screen at 50 and 100 nM indicated that Bld25, Bld26, Bld27, Bld28, Bld35 and Bld38 were potential candidates that could induce efficient skipping of exons 6/7 to generate MuSKΔIg3 transcript expression. These ASOs were tested at different concentrations: 2.5, 5, 25, 125 and 400 nM to examine the dose response. Results are shown in **FIG. 13** (panels A-F).

[0428] Specifically, **FIG. 13** shows relative MuSK expression in response to various doses of the 6 candidate ASOs (Bld25(A), Bld26 (B), Bld27 (C), Bld28 (D), Bld35 (E), Bld38 (F)). MuSK34 (in blue) and MuSK67 (in red) expression was measured by qPCR and each was normalized to the housekeeping genes and to the values obtained for untreated cells. The estimated IC is indicated on each graph. The 5 tested doses were 2.5, 5, 25, 125, 400 nM.

[0429] The results from the dose response study indicated that ASO Bld35 induced both a decrease of MuSK34 and of MuSK67 of 20-40% and 50-70%, respectively. Therefore, the difference between the expression of MuSK34 and MuSK67 is too low to obtain a high ratio of ΔIg3 MuSK without affecting the transcription of the other exons.

[0430] For the ASOs that Bld25, Bld26, Bld27, Bld28 and Bld38, MuSK34 expression was between 75 and 85% of the control level while MuSK67 was at 50% of the control level, making them potential candidates.

[0431] For ASO Bld38, the inhibition of MuSK67 was limited at 60% of the control level, even at high concentrations (400 nM).

[0432] For ASOs Bld27 and Bld28, a concentration higher than 125 nM induced a decrease in MuSK34 expression > 75%.

[0433] For ASOs Bld25 and Bld26, MuSK34 expression reached a plateau of 60% of the control level when the ASO concentration was between 25 and 400 nM, while MuSK67 expression decreased to 10% of the control. These results indicate that ASOs Bld25 and Bld26 result in a targeted decrease in expression of MuSK67, with less of an effect on MuSK34 expression, making them the 2 best candidates of this study. The estimated IC50 values were 11.5 nM and 11.4 nM for Bld25 and Bld26, respectively.

[0434] A more targeted dose response was performed in this area to refine these results (**FIG. 14**). These additional data indicated that the IC50 is actually between 5 and 7.5 nM for both Bld25 and Bld26. With ASO Bld26, MuSK34 expression dropped at the same ASO concentration as MuSK67 (7.5 nM). With ASO Bld25, at a concentration of 7.5nM, MuSK67 expression decreased by 70% while MuSK34 expression was at 94% of the control. Therefore, Bld25 may be a better candidate than Bld26 to obtain a selective skipping of exons 6 and 7.

[0435] An additional test was done by combining both Bld25 and Bld26 at a final concentration of 12.5 nM. Results are shown in **FIG. 15**. Specifically, FIG. 19 shows MuSK34 expression in green and MuSK67 expression in red measured by qPCR and normalized to housekeeping genes and to the controls.

[0436] The Bld25/Bld26 mix resulted in MuSK34 expression at a level of 72% of the control level, while MuSK67 expression was at a level of 6% of the control level. Of note, MuSK67 expression was at 8% when inhibited by siRNA (Thermofisher, cat# 4392420, Assay Id s224071) against MuSK at 10nM (data not shown). These results suggest that

combining several oligos (e.g., Bld25 and Bld26) may be a good strategy to obtain a selective skipping of exons 6 and 7.

Confirmation of Exon skipping by Gel Migration

[0437] To verify the ASO-induced splicing of the RNA, we amplified the genetic sequence from exon 3 to exon 9 by PCR and the size of the PCR product was measured by migrating it on gel electrophoresis.

[0438] Several forms of MuSK RNA exist naturally in human. 3 variants were identified in the literature (**FIG. 26**):

Variant 1, NM_005592.4 (full length: 972 bp and ΔIg3: 687 bp)

Variant 2, NM_001166280.2 (full length: 783 bp and ΔIg3: 453 bp)

Variant 3, NM_001166281.2 (full length: 708 bp and ΔIg3: 423 bp)

[0439] Full length and ΔIg3 indicate the lengths of the full-length sequence and ΔIg3 (6,7) sequence amplified by PCR from exon 3 to exon 9. Compared to variant 1, the exon 8 is missing in variant 2 and variant 3. In addition, a small exon of 30 bases is present only in variant 2. Therefore, skipping exons 6 and 7 would produce 3 additional MuSK RNA forms.

[0440] The sequence of exon3-9 of the cDNA from the dose response presented in FIG. 10 was amplified by PCR in the conditions without or with hu7-10 (Bld25) and hu73 (Bld26) at 5 and 25 nM. Results from the gel electrophoresis are shown in **FIG. 16**. In **FIG. 16**, "Long" (with exon6-7) and "Short" (without exon 6-7, i.e., ΔIg3) designed synthetic sequences were based on variant 1.

[0441] As shown in **FIG. 16**, several bands were detected. In the control conditions, major bands were visible at approximately 1kb, 970b (red arrow), and a double band at 700-750b (green arrows) (see **FIG. 16**, **panel B**). In conditions where splicing of the exons 6/7 occured (confirmed previously by qPCR), major bands were observed at approximately 690b (yellow arrow) and 450b (blue arrow) (**FIG. 16**, **panel B'**), and a lighter band at 970b. An additional double band was detected at 600b (orange arrow).

[0442] Based on the sequences presented in **FIG. 16** it appears that:

[0443] The red arrow indicated the cDNA of variant 1 full-length (972 bases), while the double bands highlighted by the green arrow correspond to the variant 2 and 3 full-length (738 and 708 bases respectively). This would explain why we observed a small fraction of the red band in the Bld25 at 25 nM condition (see **FIG. 16 B'**) and the fraction of the green band was too light to be detected.

[0444] For the ASO hu7-10 (Bld25) at 25 nM, the yellow band corresponded to Δ6,7 variant 1 (687 bases) and the blue band corresponded to Δ5+,6,7 variant 2 and Δ6,7 variant 3 (453 bases).

[0445] Next the bands were sequenced to confirm these bands correspond to the indicated variants.

Conclusions

[0446] This study aimed to find ASOs that would induce the skipping of the exons 6 and 7 in MuSK protein without affecting the other exons. 38 ASOs were designed and manufactured to be tested. LHCN-M2 cell line was chosen for its qPCR detectable MuSK expression.

[0447] In the first screening, we tested each of the 38 ASOs at concentrations of 50 and 100 nM. From this screen, the 6 best candidates in a key region near/on the exon 7 were selected or further testing. These 6 candidates were further tested at different doses: 2.5, 5, 25, 125 and 400 nM. The results indicated that a dose below 25 nM would be enough to obtain the desired splicing without affecting the transcription of the other exons, and that 2 ASOs, Bld25 and Bld26, were better to obtain the desired splicing, while maintaining stability of the expression of the other exons at higher doses. These 2 candidates were tested at additional doses, 5, 7.5, 12.5 and 25 nM. These results indicated that the IC50 would be between 5 and 7.5 nM for both ASOs. Additionally, Bld25 was considered the best candidate since there is a dose (7.5 nM) where we obtained an efficient skipping of exons 6/7 (by 70%) with little effect on the other exons (expression was 94% of the control level).

[0448] Additionally, a combination of these 2 candidates (Bld25 and Bld26) at 12.5 nM was also shown to be efficient in reducing the level of expression of full-length MuSK transcripts by 94% (indicated by MuSK67 in **FIG. 15**), where the total MuSK expression (indicated by MuSK34 in **FIG. 15**) was only reduced by 28%. Migration on gel electrophoresis and further sequence confirmed this was due to exon skipping.

Example 2: *In vivo* evaluation of exon-skipping induced by MuSK-Targeting Oligonucleotides

[0449] Preliminary confirmation of activities for oligonucleotides provided herein have been confirmed by testing corresponding murine oligonucleotide sequences in an established mouse model. See, e.g., Renault et al., 2009, the entirety of which is incorporated herein by reference.

[0450] In this experiment, the corresponding murine oligonucleotides are further evaluated *in vivo* in wild-type mice at ages where AHN has declined. Further evaluations such as pharmacodynamic and safety studies are conducted to establish optimal conditions for ASO-mediated MuSK exon skipping in aging wild type mice.

Experiment #1: Tolerability, exon skipping and PK

[0451] ASOs are delivered by intracerebroventricular (ICV) stereotactic injection in 4 doses ranging from 5 - 100µg, n=6/group. A scrambled ASO (with the same number of bases) will serve as a control.

[0452] Mice are monitored for potential immediate safety signals (*e.g.* seizures, hindlimb weakness, prolonged lethargy) and animals where these issues do not resolve within the first hours after dosing are euthanized.

[0453] Mice receiving doses that do not show tolerability signals are monitored daily.

[0454] Unfixed brains are harvested at 4 weeks. One-half of the brains are sectioned and analyzed by histology for signs of inflammation or other toxicity by a board-certified veterinary pathologist.

[0455] The hippocampus and cortex from the other half are dissected and further divided for RNA isolation and PK analysis. The level of MuSK alternative splicing (*i.e.*, skipping of exons 6-7) are assessed by TaqMan assays and gel-based PCR as described in Examples 1-2. For the latter, gel bands are excised and sequenced to confirm correct skipping. The remaining portion for of cortex are used for HPLC quantification of the ASO (PK).

Experiment #2. Neurogenesis (fixed brains)

[0456] **Neurogenesis Group size:** To determine the number of animals required to assess increased neurogenesis, a power analysis using G*Power version 3.1 was performed (Faul et al., 2007). To allow for possible loss of animals during the experiment 6 animals/group are allocated. Analyses is performed using either GraphPad Prism or R.

[0457] In this experiment, ASOs are delivered to a second set of animals with at least three non-toxic doses (as determined in Experiment 1).

[0458] For these animals EdU is delivered from 3 to 4 weeks post-injection. Animals are perfused, fixed and immunohistochemistry is performed against EdU and DCX to assess the numbers of new neurons (EdU+/DCX+ cells).

[0459] Maturation of the newborn cells is assessed by performing a 30-day chase after administration of the EdU and measuring Edu+/NeuN+ cells.

Experiment #3. Cognition

[0460] **Cognition group size**: An analysis using G*Power 3.1.9.4. (Faul et al., 2007) was performed to determine the group size of cognition experiment. Based on the prior studies, 18 animals per group is sufficient to observe an effect size (d) of 1 (a=.05; power = .80).

[0461] Aged wild-type mice are dosed by ICV at 11 months of age and are assessed for cognition at 12 months of age. A single dose is performed to promote AHN as determined from Experiment #2 (18 animals per group).

[0462] The mice are evaluated using tests including Novel Object Location task, a hippocampal-dependent spatial learning task, and a Conditioned Fear and a Y-maze to

measure spatial working memory (Gotz and Ittner, 2008), two tasks commonly used to test cognition.

[0463] Pairwise comparisons will be analyzed by using the Student's t test. Experiments with more than two groups will be analyzed using a Bonferroni correction for multiple comparisons.

[0464] **Female mice.** Efficacy of ASO treatment on promoting neurogenesis using the optimal dose determined above in female mice is also assessed.

[0465] **Discussion.** Experiments 1-3 are designed such that they will relate the dose delivered to safety, PK, level of MuSK splicing, degree of AHN promotion and cognitive improvement.

[0466] A 4 week period of exposure was utilized since this is the time course over which NSCs are born and mature (Babcock et al., 2021). However, additionally studies with longer exposures, with and without repeat dosing will also be performed.

[0467] In addition to the HPLC measurement of ASO in the brain hybridization-based method will also be utilized.

Example 3: *In vivo* evaluation of exon-skipping induced by MuSK-Targeting Oligonucleotides in FAD model

[0468] In this experiment, the corresponding murine oligonucleotides from Example 2 are evaluated in Familial Alzheimer's Disease (FAD) mouse model where plaque burden is well established and tangles are present. This experiments aims to determine whether corresponding murine oligonucleotides and the exon-skipping approach is effective in the hostile, inflammatory milieu along with a high plaque burden and neurofibrillary tangles that characterize the AD brain, and whether corresponding oligonucleotides promote AHN in an FAD mouse model.

[0469] **FAD Mouse Model.** 3xTg is used in this experiment, which harbors transgenes for Tau, PSEN1 and APP FAD alleles (Oakley et al., 2006; Kimura and Ohno, 2009; Belfiore et al., 2019). This model has been characterized and develops both amyloid

plaques at 6 months and neurofibrillary tangles by 12 months. AHN is decreased as early as 3 months of age and is essentially undetectable by 12 months. We have confirmed a reduction AHN at 6 months in these mice. This decrease in AHN is strongly correlated with the increase in amyloid burden (Rodríguez et al., 2008). Animals are dosed with ASO at 11 months and analyzed at 12 months of age, when AHN and cognitive phenotypes are evident. Female 3xTg mice are used since they show an earlier and more consistent pathological profile (Belfiore et al., 2019).

[0470] **Experimental Approach.** The dosing strategy (level, duration) is based on the results from Example 3. Three groups are dosed: scrambled ASO, and two doses of MuSK exon-skipping ASOs. Group sizes will be n=18 in order to assess both AHN and cognition. 6 animals from each group are also treated with EdU once a day for 7 days for neurogenesis analysis. In order to control for potential effects of handling, the remaining animals are injected with saline. Neurogenesis and cognition analyses are performed as described in Example 3. The effects of ASO treatment on AD histopathology is also assessed.

Example 4: Formulation and Administration of MuSK-Targeting Oligonucleotides

A. Formulation

[0471] In this Example, human MuSK-targeting oligonucleotides as described herein are formulated into suitable forms to enhance the delivery to target site(s) and are administered to human subject via various means.

[0472] In some embodiments, human MuSK-targeting oligonucleotides are formulated into lipid complex, as a homogeneous solution in a single-dose vial. In some embodiments, single-dose vial is 10 mg/5 mL (2 mg/mL).

B. Administration

1. Indication

[0473] MuSK-targeting oligonucleotides are indicated for the treatment of the AD in adults.

2. Dosage and Administration

2.1 Dosing Information

[0474] MuSK-targeting oligonucleotides are administered by a healthcare professional.

[0475] MuSK-targeting oligonucleotides are administered via intravenous (IV) infusion. Dosing is based on actual body weight. For patients weighing less than 100 kg, the recommended dosage is 0.3 mg/kg once every 3 weeks. For patients weighing 100 kg or more, the recommended dosage is 30 mg once every 3 weeks.

[0476] Missed Dose: If a dose is missed, administer MuSK-targeting oligonucleotides as soon as possible. If MuSK-targeting oligonucleotides are administered within 3 days of the missed dose, continue dosing according to the patient's original schedule. If MuSK-targeting oligonucleotides are administered more than 3 days after the missed dose, continue dosing every 3 weeks thereafter.

2.2 Preparation

[0477] MuSK-targeting oligonucleotides are filtered and diluted prior to intravenous infusion. The diluted solution for infusion is prepared by a healthcare professional using aseptic technique as follows:

1. Remove MuSK-targeting oligonucleotides vial from the refrigerator and allow to warm to room temperature. Do not shake or vortex.
2. Inspect visually for particulate matter and discoloration. Do not use if discoloration or foreign particles are present.
3. Calculate the required dose of MuSK-targeting oligonucleotides based on the recommended weight-based dosage [see Dosage and Administration (2.1)].
4. Withdraw the entire contents of one or more vials into a single sterile syringe.
5. Filter MuSK-targeting oligonucleotides through a sterile 0.45 micron polyethersulfone (PES) syringe filter into a sterile container.

6. Withdraw the required volume of filtered MuSK-targeting oligonucleotides from the sterile container using a sterile syringe.

7. Dilute the required volume of filtered MuSK-targeting oligonucleotides into an infusion bag containing 0.9% Sodium Chloride Injection, USP for a total volume of 200 mL. Use infusion bags that are di(2-ethylhexyl)phthalate-free (DEHPfree).

8. Gently invert the bag to mix the solution. Do not shake. Do not mix or dilute with other drugs.

9. Discard any unused portion of MuSK-targeting oligonucleotides.

10. The diluted solution should be administered immediately after preparation. If not used immediately, store in the infusion bag at room temperature (up to 30°C [86°F]) for up to 16 hours (including infusion time). Do not freeze.

2.3 Infusion

[0478] MuSK-targeting oligonucleotides are infused as follows:

1. Use a dedicated line with an infusion set containing a 1.2 micron polyethersulfone (PES) in-line infusion filter. Use infusion sets and lines that are DEHP-free. •

2. Infuse the diluted solution of MuSK-targeting oligonucleotides intravenously, via an ambulatory infusion pump, over approximately 80 minutes, at an initial infusion rate of approximately 1 mL/min for the first 15 minutes, then increase to approximately 3 mL/min for the remainder of the infusion.

3. Administer only through a free-flowing venous access line. Monitor the infusion site for possible infiltration during drug administration. Suspected extravasation should be managed according to local standard practice for non-vesicants. •

4. Observe the patient during the infusion.

5. After completion of the infusion, flush the intravenous administration set with 0.9% Sodium Chloride Injection, USP to ensure that all ONPATTRO has been administered.

References

Shaw, G., Morse, S., Ararat, M., & Graham, F. L. (2002). Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. *The FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology*, *16*(8), 869–871

Example 5: Design and Screening of 20-mer MuSK-targeting Oligonucleotides

[0479] In this Example, additional human MuSK-targeting oligonucleotides were designed based on the lead candidates from Example 1 targeting exon 7 of MuSK. The screen in Example 1 identified 6 lead ASOs that targeted two regions within the MuSK exon 7. Upon further dose response experiments and analysis of the resulting MuSK transcripts, one of these regions was identified as a key region to modulate the splicing of Ig3 domain. This region, or "region 1" corresponds to the core sequence SEQ ID NO: 126 (ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATTGACTCAAGAC) which is located at positions 83841-83905 of the MuSK transcript (SEQ ID NO: 77) (or corresponding regions within other MuSKvariant sequences). In this Example, additional ASOs are designed to target the region corresponding to SEQ ID NO: 126 ("region 1") of exon 7 and specifically to include different portions of the sequences of ASOs Bld25 and Bld26. These ASOs were designed to test whether shorter ASOs of 20 nucleotides, rather then 25 nucleotides (as tested in Example 1) would have increased activity.

[0480] The additional oligonucleotides were tested for their ability to induce exon skipping of the MuSK exon 6 and/or exon 7.

Design of Human ASOs

[0481] Human antisense oligonucleotides (ASOs) were designed as described above and as shown in **FIG. 17**, and produced by Microsynth (Switzerland). The ASO sequences are shown below in **Table 8**.

Table 8:

Oligo ID	SEQ ID	5' to 3' Sequence
Bld51	127	TTGAATGGACCCAGAAGAAA
Bld52	128	CTTGAATGGACCCAGAAGAA
Bld53	129	TCTTGAATGGACCCAGAAGA
Bld54	130	CTCTTGAATGGACCCAGAAG
Bld55	131	TCTCTTGAATGGACCCAGAA
Bld56	132	CTCTCTTGAATGGACCCAGA
Bld57	133	ACTCTCTTGAATGGACCCAG
Bld58	134	CACTCTCTTGAATGGACCCA
Bld59	135	ACACTCTCTTGAATGGACCC
Bld60	136	CACACTCTCTTGAATGGACC
Bld61	137	TCACACTCTCTTGAATGGAC
Bld62	138	TTCACACTCTCTTGAATGGA
Bld63	139	TTTCACACTCTCTTGAATGG
Bld64	140	CTTTCACACTCTCTTGAATG
Bld65	141	TCTTTCACACTCTCTTGAAT
Bld66	142	GTCTTTCACACTCTCTTGAA

[0482] All ASOs in **Table 8** were designed to include 2'-MOE modification on each sugar and where there is a phosphorothioate internucleotidic linkage between each nucleotide. All ASOs in **Table 8** were 20 nucleotides in length.

Screen of Shorter Antisense oligonucleotides targeting Exon7 Region 1

[0483] ASO transfection and cell culture, RNA extraction, cDNA transcription, qPCR were performed according to the methods described in Example 1, unless indicated otherwise.

i. Alignment to the genetic sequence

[0484] The alignment of the ASOs in **Table 8** on the genetic sequence of Exon7 of MuSK is presented in **FIG. 17**.

ii. Cell observations

[0485] LHCN-M2 cells were plated at 30,000 cells/well in gelatin pre-coated 6-well plates and were transfected 48h after seeding with ASO at 12.5 nM and 100 nM. 24 h after transfection, cells were observed (data not shown) and the RNA was extracted and analyzed.

[0486] After 24 h of transfection, cells looked healthy in all conditions except for cells treated with ASOs Bld54, Bld55, and Bld56 at the 100nM dose (data not shown).

iii. MuSK expression analyses

[0487] 24 h after transfection, RNA was extracted, and MuSK gene expression was analyzed in qPCR. Relative gene expression of total MuSK (MuSK34) and MuSKIg3 domain (MuSK67) is shown in **FIG. 18**. Methods described for screening of ASOs in Example 1 were used.

[0488] ASOs with the modifications used in this Example are shown in **Table 9** below.

Table 9:

Oligo ID	SEQ ID NO:	Sequence - (5' to 3')[a]
Bld51	143	T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A
Bld52	144	C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A
Bld53	145	T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A

Bld54	146	C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G
Bld55	147	T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A
Bld56	148	C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A
Bld57	149	A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G
Bld58	150	C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A
Bld59	151	A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C
Bld60	152	C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C
Bld61	153	T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C
Bld62	154	T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A
Bld63	155	T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G
Bld64	156	C*T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G
Bld65	157	T*C*T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T
Bld66	158	G*T*C*T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A

a) * represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar.

b) a value of 1.0 represents the level of MuSK67 expression for untreated cells.

[0489] Results from the screen showed that these shorter ASOs (20-mers) targeting region 1 of Exon 7 resulted in less potent activity than the ASOs Bld25 and Bld26 (25mers) and had either little/no effect on MuSKdelIg3 level or inhibited levels of total MuSK.

Example 6: Design and Screening of Additional MuSK-targeting Oligonucleotides targeting Region 1 of Exon 7

[0490] In this Example, additional human MuSK-targeting oligonucleotides were designed based on the lead candidates from Example 1 targeting region 1 of exon 7 of MuSK SEQ ID NO: 126 (CTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATTGACTCAAGAC), which is located at positions 83841-83905 of the MuSK transcript (SEQ ID NO: 77) (or corresponding regions within other MuSK variant sequences).

[0491] Sequences were desined to specifically to include different portions of the sequences of ASOs Bld25 and Bld26. Because shortening the length of the ASOs targeting this region was showed less activity, ASOs designed in this Example were produced to be 25 nucleotides in length.

[0492] The additional oligonucleotides were tested for their ability to induce exon skipping of the MuSK exon 6 and/or exon 7.

Design of Human ASOs

[0493] Human antisense oligonucleotides (ASOs) were designed as described above and are shown in **Fig. 19**. These ASOs were produced by Microsynth (Switzerland). The ASO sequences are shown below in **Table 10**.

Table 10:

Oligo ID	SEQ ID	5' to 3' Sequence
Bld25-1	159	CCAGAAGAAACCTGACAGAGTAAAG
Bld25-2	160	ACCCAGAAGAAACCTGACAGAGTAA
Bld25-3	161	ATGGACCCAGAAGAAACCTGACAGA
Bld25-4	162	GAATGGACCCAGAAGAAACCTGACA
Bld25-5	163	CTTGAATGGACCCAGAAGAAACCTG
Bld26-1	164	CTCTTGAATGGACCCAGAAGAAACC
Bld26-2	165	CTCTCTTGAATGGACCCAGAAGAAA
Bld26-3	166	CACACTCTCTTGAATGGACCCAGAA
Bld26-4	167	TTCACACTCTCTTGAATGGACCCAG

[0494] All ASOs in **Table 10** were designed to include 2'-MOE modification on each sugar and where there is a phosphorothioate internucleotidic linkage between each nucleotide. All ASOs in **Table 10** were 25 nucleotides in length.

Screen of Antisense oligonucleotides targeting Exon7 Region 1

[0495] ASO transfection and cell culture, RNA extraction, cDNA transcription, qPCR were performed according to the methods described in Example 1, except as where indicated otherwise.

i. Alignment to the genetic sequence

[0496] The alignment of the ASOs in **Table 10** on the genetic sequence of Exon7 of MuSK is presented in **FIG. 19**.

ii. Cell observations

[0497] LHCN-M2 cells were plated at 35,000 cells/well in gelatin pre-coated 6-well plates and were transfected 48h after seeding with ASO at 5nM, 12.5 nM, 25nM, 50nM, and 125 nM. Each of the ASOs in **Table 10** were tested with Bld25, Bld26, Bld27, Bld28, Bld35 and Bld38 (leads identified in Example 1). 24 h after transfection, cells were observed (data not shown) and the RNA was extracted and analyzed.

[0498] After 24 h of transfection, cells looked healthy in all conditions except for cells treated with ASOs Bld25-3 and Bld25-4 at the 140nM dose (data not shown).

iii. MuSK expression analyses

[0499] 24 h after transfection, RNA was extracted, and MuSK gene expression was analyzed in qPCR (**FIG. 20**). **Panel A** shows relative gene expression of MuSK67 and **Panel B** shows relative gene expression of total MuSK (MuSK34). The new sequences were compared to Bld25 and Bld26 from Example 1. **FIG. 21** shows the same data from only the ASOs which showed relative expression of MuSK67 of less than 50% and total MuSK (MuSK34) of greater than 60% compared to the untreated control.

[0500] **FIG. 22** shows a comparison of Bld25-5 to Bld25 after transfection with ASO for 24hours (**Panels A** and **B**) and 48 hours (**Panels C** and **D**). Methods described for screen of ASOs in Example 1 were used.

[0501] ASOs with the modifications used in this Example are shown in **Table 11** below.

Table 11:

Oligo ID	SEQ ID NO:	Sequence - (5' to 3')[a]
Bld25-1	168	C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T*A*A*A*G*
Bld25-2	169	A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T*A*A*
Bld25-3	170	A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*
Bld25-4	171	G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*
Bld25-5	172	C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*
Bld26-1	173	C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*
Bld26-2	174	C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*
Bld26-3	175	C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*
Bld26-4	176	T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*

a) * represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar.

Table 12: Potency

	MuSK 67 (IC in nM)	
	IC50	IC75
Bld25-5	15.6	30.2
Bld25	16.5	30.4
Bld26	17.0	20.8
Bld25-4	18.0	n/a
Bld25-3	20.8	34.4
Bld26-2	22.8	n/a
Bld26-4	28.8	n/a

Table 13: Selectivity

	MuSK 34 (IC in nM)	
	IC10	IC25
Bld26-2	n/a	n/a
Bld25-4	49.7	52.4
Bld26	23.7	24.5
Bld26-4	19.2	69.5
Bld25	13.3	n/a
Bld25-5	8.4	30.4
Bld25-3	0.9	15.0

[0502] **Table 12** shows the concentration at which there is either 50% (IC50) or 75% (IC75) inhibition in total MuSK67 expression. **Table 13** shows the IC10 and IC25 values of MuSK34 (nM) of each ASO, and represents concentration in which there is either 10% (IC10) or 25% (IC25) inhibition in total MuSK expression (MuSK34). ASOs performing exon skipping of exon 6 and/or 7, are expected to show lower IC50/IC75 values of MuSK67 and higher IC10/25 values of MuSK34.

[0503] Results from this screen showed that ASOs Bld25, Bld25-5, Bld26-2, and Bld26 showed the best potency and selectivity (see **Tables 12** and **13**).

Confirmation of Exon skipping by Gel Migration

[0504] To verify the ASO-induced splicing of the RNA, the genetic sequence from exon 3 to exon 9 was amplified by PCR and the size of the PCR product was measured by migrating it on gel electrophoresis.

[0505] Several forms of MuSK RNA exist naturally in human. 3 variants were identified in the literature (**FIG. 26**):

Variant 1, NM_005592.4 (full length: 972 bp and ΔIg3: 687 bp)

Variant 2, NM_001166280.2 (full length: 783 bp and ΔIg3: 453 bp)

Variant 3, NM_001166281.2 (full length: 708 bp and ΔIg3: 423 bp)

[0506] Full length and ΔIg3 indicate the lengths of the full-length sequence and ΔIg3 (6,7) sequence amplified by PCR from exon 3 to exon 9. Compared to variant 1, the exon 8 is missing in variant 2 and variant 3. In addition, a small exon of 30 bases is present only in variant 2. Therefore, skipping exons 6 and 7 would produce 3 additional MuSK RNA forms.

[0507] The sequence of exon3-9 of the cDNA from the dose response presented in this Example was amplified by PCR in the conditions without or with Bld25 and Bld25-5 at 50 nM. Results from the gel electrophoresis are shown in **FIG. 27**. In **FIG. 27**, "4/5/6/7/EWS/8/9" indicates full length variant 1, "4/5/5+/6/7/EWS/9" indicates full length variant 2, and "4/5/6/7/EWS/9" indicates full length variant 3. Similarly, "4/5/EWS/8/9" indicates ΔIg3 (6,7) in variant 1, "4/5/9" indicates Δ5+/Ig3 (6,7) of variant 2, and indicates the ΔIg3 (6,7) of variant 3.

[0508] As shown in **FIG. 27**, several bands were detected. In the control conditions, major bands were visible where the full length variants would be expected. In conditions where splicing of the exons 6/7 occured (confirmed previously by qPCR), major bands were observed at for the spliced versions of the variants.

[0509] Intensity of the bands was also examined. Intensity of bands from Bld25 and Bld25-5 products are also shown above the gel images in **FIG. 27**. These results show that amount of MuSK PCR product with ASO is about 80-90% of the amount of MuSK PCR product in untreated conditions (controls). Therefore, total MuSK is decreased by only a small amount.

[0510] Next, the bands of pcr products from cells treated with ASO 25-5 were sequenced to confirm these bands correspond to the indicated variants. **FIG. 28** shows that the sequence of the band lower band positioned where Δ6,7 variant 1 (687 bases) was indeed the sequence of this splice variant.

Example 7: Design and Screening of Shortened MuSK-targeting Oligonucleotides targeting Region 1 of Exon 7

[0511] In this Example, additional human MuSK-targeting oligonucleotides were designed by reducing the size of the lead ASOs identified in Example 1 and Example 6

(Bld25, Bld25-5, Bld26, and Bld26-2). These ASOs target region 1 of exon 7 of MuSK SEQ ID NO: 126 (ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATTGACTCAAGAC) which is located at positions 83841-83905 of the MuSK transcript (SEQ ID NO: 77) (or a corresponding regions within other MuSK variant sequences).

[0512] Sequences were designed by shortening the sequences of ASOs Bld25, Bld25-5, Bld26- and Bld26-2 by different amounts. ASOs designed in this Example were produced to be 21 and 23 nucleotides in length.

[0513] These ASOs were then tested for their ability to induce exon skipping of the MuSK exon 6 and/or exon 7.

Design of Human ASOs

[0514] Human antisense oligonucleotides (ASOs) were designed as described above and as shown in **FIG. 23**. The ASOs were produced by Microsynth (Switzerland). The ASO sequences are shown below in **Table 14**.

Table 14:

Oligo ID	SEQ ID	5' to 3' Sequence
Bld25-A	177	ACCCAGAAGAAACCTGACAGAGT
Bld25-B	178	CCAGAAGAAACCTGACAGAGT
Bld25-C	179	GGACCCAGAAGAAACCTGACAGA
Bld25-D	180	ACCCAGAAGAAACCTGACAGA
Bld25-E	181	GGACCCAGAAGAAACCTGACA
Bld25-5-A	182	GAATGGACCCAGAAGAAACCTGA
Bld25-5-B	183	ATGGACCCAGAAGAAACCTGA
Bld25-5-C	184	TTGAATGGACCCAGAAGAAACCT
Bld25-5-D	185	GAATGGACCCAGAAGAAACCT
Bld25-5-E	186	TTGAATGGACCCAGAAGAAAC
Bld26-2-A	187	CTCTTGAATGGACCCAGAAGAAA
Bld26-2-B	188	CTTGAATGGACCCAGAAGAAA

Bld26-2-C	189	CTCTCTTGAATGGACCCAGAAGA
Bld26-2-D	190	CTCTCTTGAATGGACCCAGAA
Bld26-B	191	CTCTTGAATGGACCCAGAAGA
Bld26-C	192	CACTCTCTTGAATGGACCCAGAA
Bld26-D	193	CACTCTCTTGAATGGACCCAG

[0515] All ASOs in **Table 14** were designed to include 2'-MOE modification on each sugar and where there is a phosphorothioate internucleotidic linkage between each nucleotide. All ASOs in **Table 14** were 21 or 23 nucleotides in length.

Screen of 21-mer and 23-mer Antisense oligonucleotides targeting Exon7 Region 1

[0516] ASO transfection and cell culture, RNA extraction, cDNA transcription, qPCR were performed according to the methods described in Example 1, except as where indicated otherwise.

i. Alignment to the genetic sequence

[0517] The alignment of the ASOs in Table 14 on the genetic sequence of Exon7 of MuSK is presented in **FIGs. 23**.

ii. Cell observations

[0518] LHCN-M2 cells were plated at 35,000 cells/well in gelatin pre-coated 6-well plates and were transfected 48h after seeding with ASO at 5nM, 12.5 nM, 25nM, 50nM, and 125 nM. Each of the ASOs in Table 14 were tested in addition to Bld25, Bld25-5, Bld26, and Bld26-2 (leads identified in Examples 1 and 6). 24 h after transfection, cells were observed (data not shown) and the RNA was extracted and analyzed.

[0519] After 24 h of transfection, cells looked healthy in all conditions (data not shown).

iii. MuSK expression analyses

[0520] 24 h after transfection, RNA was extracted, and MuSK gene expression was analyzed in qPCR (**FIGs. 24-25**).

[0521] ASOs with the modifications used in this Example are shown in **Table 15** below.

Table 15:

Oligo ID	SEQ ID NO:	Sequence - (5' to 3')[a]
Bld25-A	194	A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T
Bld25-B	195	C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T
Bld25-C	196	G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A
Bld25-D	197	A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A
Bld25-E	198	G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A
Bld25-5-A	199	G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A
Bld25-5-B	200	A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A
Bld25-5-C	201	T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T
Bld25-5-D	202	G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T
Bld25-5-E	203	T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C
Bld26-2-A	204	C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A
Bld26-2-B	205	C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A
Bld26-2-C	206	C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A
Bld26-2-D	207	C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A
Bld26-B	208	C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A
Bld26-C	209	C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A
Bld26-D	210	C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G

a) * represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar.

[0522] Results from this screen showed that ASOs Bld25-E and Bld25-5-A showed the best activity (see **FIG. 24** and **FIG. 25**). Bld25-E showed MuSK67 maximum correction of 80%, with less of an effect on total MuSK (MuSK34), and an IC50 of MuSK67 of about 21nM. Bld25-5-A showed MuSK67 maximum correction of 80%, with less of an effect on total MuSK (MuSK34) and an IC50 of MuSK67 about 35nM. These results indicate that ASOs Bld25-E and Bld25-5-A are additional candidates to effectuate exon6-7 skipping in MuSK and have shorter lengths (21-mer and 23-mer) than the lead ASOs idenfitied from Examples 1 and 6.

Example 8: Analysis of MuSK Protein

[0523] This Example aims to examine the resulting MuSK protein after treatments with the ASOs described herein.

Timing of Effect on MuSK Protein

[0524] In order to examine resulting MuSK protein produced from ASO-treated cells, it is important to understand the relative timing of the effect of targeting MuSK with RNA.

[0525] Length of time from RNA treatment was examined to determine how long after treatment will there be an effect on MuSK protein (*i.e.*, production of MuSKΔIg3).

[0526] In this experiment, LHCN-M2 cells were treated for 48h with 10nM of siRNA (Thermofisher, 4392420, assay ID s224071) against MuSK and were then stained for MuSK protein on days 2, 3, 4, and 5 (with MuSK antibodies isolated from patients with a disease involving the natural production of MuSK antibodies followed by goat anti-human (A-2133)) following siRNA treatment. Results for each timepoint in treated and untreated cells are shown in **FIG. 29**. Results show that in the untreated wells, MuSK protein amount increases while cells start to be confluent. In wells treated with siRNA, MuSK protein amount decreases, especially 5 days after the transfection. Overall, these results show that MuSK protein amount can be modulated, and the best timing to observe an effect is 5 days after modulating the RNA.

[0527] **FIG. 29** shows the cells at Day 5 magnified and stained for MuSK (red) (with MuSK antibodies isolated from patients with a disease involving the natural production of MuSK antibodies followed by goat anti-human (A-2133)) and actin phalloidin (green) (ab ab176743 at 1:1000). These results confirm that (i) the MuSK antibody used to stain for MuSK protein works in immunofluorescence, (ii) MuSK protein level increases over time, probably along with cell differentiation, and (iii) MuSK siRNA ("Si-MuSK") induces a reduction of MuSK protein, especially after 5 days of exposure.

Measuring Removal of Ig3 domain of MuSK

[0528] Since ASOs as described herein are targeting the Ig3 domain and inducing exon skipping (6,7) to produce MuSKΔIg3, there needs to be a way to detect MuSKΔIg3 protein. Timing of the effects of the ASOs/RNA on MuSK protein has been established. An assessment (*e.g.,* Western blot analysis) will be performed. Such an assessment includes assessment of MuSKΔIg3 protein produced from cells treated with ASOs described herein. A MuSK antibody that targets the MuSK cytoplasmic domain will be utilized for identification of MuSKΔIg3 protein. Antibodies are produced and tested using the recombinant MuSK cytoplasmic domain.

[0529] Since human and murine MuSK protein sequences vary, human MuSK controls should be used for assessment (e.g., by Western Blot). Positive controls (*i.e.,* MuSKΔIg3 protein and human FL MuSK protein) are used to confirm the forms of MuSK that are present. Plasmids coding for the different WT and D3 (Ig3) isoforms of MuSK protein are obtained. Cells are transfected with the plasmids and positive control isoforms are expressed and obtained.

[0530] Human MuSK antibodies targeting the cytoplasmic domain of MuSK and human MuSK positive controls (*i.e.,* MuSKΔIg3 protein and human FL MuSK protein) are obtained, and such reagents are used in a assessment (*e.g.,* Western Blot) to characterize the MuSK protein produced from cells treated with ASOs described herein.

LISTING OF SEQUENCES

Oligonucleotide (SEQ ID NO: 1)
GCTAGGGTGGTCTTTTAGAAATGCA

Oligonucleotide (SEQ ID NO: 2)
GGTCAAGCTAGGGTGGTCTTTTAGA

Oligonucleotide (SEQ ID NO: 3)
CTGCAGGAAATGGTCAAGCTAGGGT

Oligonucleotide (SEQ ID NO: 4)
GAAGTGGTGAGTGACGCTCCTGCAG

Oligonucleotide (SEQ ID NO: 5)
GTTAGGAAGACAGAAGTGGTGAGTG

Oligonucleotide (SEQ ID NO: 6)
ATCCTGGCAAAAACTGTTAGGAAGA

Oligonucleotide (SEQ ID NO: 7)
GTGGGATTCAGGAGCCCGCAGGATC

Oligonucleotide (SEQ ID NO: 8)
GGTGACATTGTGGGATTCAGGAGCC

Oligonucleotide (SEQ ID NO: 9)
GGAGCCAAAGGTGACATTGTGGGAT

Oligonucleotide (SEQ ID NO: 10)
GGTCACAAAGGAGCCAAAGGTGACA

Oligonucleotide (SEQ ID NO: 11)
ACAGTGCAGGGTCACAAAGGAGCCA

Oligonucleotide (SEQ ID NO: 12)
CTGTTGCTGTACAGTGCAGGGTCAC

Oligonucleotide (SEQ ID NO: 13)

GGGACAGGAATGCCTGTTGCTGTAC

Oligonucleotide (SEQ ID NO: 14)
CAGGTGATGGTGGGGACAGGAATGC

Oligonucleotide (SEQ ID NO: 15)
CCGTTTTCAATCCAGGTGATGGTGG

Oligonucleotide (SEQ ID NO: 16)
TGACACTCACAGCATTTCCGTTTTC

Oligonucleotide (SEQ ID NO: 17)
AAGTCCCCACACACATGACACTCAC

Oligonucleotide (SEQ ID NO: 18)
GGTCTTCCCCAGACAAGTCCCCACA

Oligonucleotide (SEQ ID NO: 19)
ACTATGTCAGTAGATTTGAAGGGAA

Oligonucleotide (SEQ ID NO: 20)
TCCCACTATACTATGTCAGTAGATT

Oligonucleotide (SEQ ID NO: 21)
TCAGTCAAGGATTTCCCACTATACT

Oligonucleotide (SEQ ID NO: 22)
AAAAGAACTCAGTCAAGGATTTCCC

Oligonucleotide (SEQ ID NO: 23)
GTAAAGGAAAATAAAAGAACTCAGT

Oligonucleotide (SEQ ID NO: 24)
AACCTGACAGAGTAAAGGAAAATAA

Oligonucleotide (SEQ ID NO: 25)
GGACCCAGAAGAAACCTGACAGAGT

Oligonucleotide (SEQ ID NO: 26)

CACTCTCTTGAATGGACCCAGAAGA

Oligonucleotide (SEQ ID NO: 27)
CACTCGGTCTTTCACACTCTCTTGA

Oligonucleotide (SEQ ID NO: 28)
GTCTTGAGTCAATCACTCGGTCTTT

Oligonucleotide (SEQ ID NO: 29)
GATAAACAGCTGCAGTCTTGAGTCA

Oligonucleotide (SEQ ID NO: 30)
AGTCCTGGCTTGGTGATAAACAGCT

Oligonucleotide (SEQ ID NO: 31)
ATGTGTAGAGTCCTGGCTTGGTGAT

Oligonucleotide (SEQ ID NO: 32)
GTAGCTATGCATGTGTAGAGTCCTG

Oligonucleotide (SEQ ID NO: 33)
TGCTTATTGGTAGCTATGCATGTGT

Oligonucleotide (SEQ ID NO: 34)
ACTTCTCCCCATGCTTATTGGTAGC

Oligonucleotide (SEQ ID NO: 35)
CCTTGGCAGTACTGAACTTCTCCCC

Oligonucleotide (SEQ ID NO: 36)
CCTGCTATGCTGATGGTGGCTGCAG

Oligonucleotide (SEQ ID NO: 37)
GGGCATCCTACCTGCTATGCTGATG

Oligonucleotide (SEQ ID NO: 38)
GCAAATGTGAAGGGGCATCCTACCT

hu6-75; SEQ ID NO: 39

TGCATTTCTAAAAGACCACCCTAGC

hu6-69; SEQ ID NO: 40
TCTAAAAGACCACCCTAGCTTGACC

hu6-58; SEQ ID NO: 41
ACCCTAGCTTGACCATTTCCTGCAG

hu6-39; SEQ ID NO: 42
CTGCAGGAGCGTCACTCACCACTTC

hu6-27; SEQ ID NO: 43
CACTCACCACTTCTGTCTTCCTAAC

hu6-12; SEQ ID NO: 44
TCTTCCTAACAGTTTTTGCCAGGAT

hu610; SEQ ID NO: 45
GATCCTGCGGGCTCCTGAATCCCAC

hu619; SEQ ID NO: 46
GGCTCCTGAATCCCACAATGTCACC

hu628; SEQ ID NO: 47
ATCCCACAATGTCACCTTTGGCTCC

hu637; SEQ ID NO: 48
TGTCACCTTTGGCTCCTTTGTGACC

hu646; SEQ ID NO: 49
TGGCTCCTTTGTGACCCTGCACTGT

hu656; SEQ ID NO: 50
GTGACCCTGCACTGTACAGCAACAG

hu669; SEQ ID NO: 51
GTACAGCAACAGGCATTCCTGTCCC

hu681; SEQ ID NO: 52

GCATTCCTGTCCCCACCATCACCTG

hu693; SEQ ID NO: 53
CCACCATCACCTGGATTGAAAACGG

hu6110; SEQ ID NO: 54
GAAAACGGAAATGCTGTGAGTGTCA

hu6125; SEQ ID NO: 55
GTGAGTGTCATGTGTGTGGGGACTT

hu6139; SEQ ID NO: 56
TGTGGGGACTTGTCTGGGGAAGACC

hu7-75; SEQ ID NO: 57
TTCCCTTCAAATCTACTGACATAGT

hu7-66; SEQ ID NO: 58
AATCTACTGACATAGTATAGTGGGA

hu7-53; SEQ ID NO: 59
AGTATAGTGGGAAATCCTTGACTGA

hu7-45; SEQ ID NO: 60
GGGAAATCCTTGACTGAGTTCTTTT

hu7-33; SEQ ID NO: 61
ACTGAGTTCTTTTATTTTCCTTTAC

hu7-22; SEQ ID NO: 62
TTATTTTCCTTTACTCTGTCAGGTT

hu7-10; SEQ ID NO: 63
ACTCTGTCAGGTTTCTTCTGGGTCC

hu73; SEQ ID NO: 64
TCTTCTGGGTCCATTCAAGAGAGTG

hu717; SEQ ID NO: 65

TCAAGAGAGTGTGAAAGACCGAGTG

hu730; SEQ ID NO: 66
AAAGACCGAGTGATTGACTCAAGAC

hu744; SEQ ID NO: 67
TGACTCAAGACTGCAGCTGTTTATC

hu758; SEQ ID NO: 68
AGCTGTTTATCACCAAGCCAGGACT

hu766; SEQ ID NO: 69
ATCACCAAGCCAGGACTCTACACAT

hu776; SEQ ID NO: 70
CAGGACTCTACACATGCATAGCTAC

hu785; SEQ ID NO: 71
ACACATGCATAGCTACCAATAAGCA

hu796; SEQ ID NO: 72
GCTACCAATAAGCATGGGGAGAAGT

hu7111; SEQ ID NO: 73
GGGGAGAAGTTCAGTACTGCCAAGG

hu7136; SEQ ID NO: 74
CTGCAGCCACCATCAGCATAGCAGG

hu7146; SEQ ID NO: 75
CATCAGCATAGCAGGTAGGATGCCC

hu7158; SEQ ID NO: 76
AGGTAGGATGCCCCTTCACATTTGC

MuSK Genomic Sequence (SEQ ID NO: 77)

```
        1 tatacagtca tttatcactt aacatcaggg atatgttctg agaaatgcat ccatagttca
       61 ttttgttatt gtgtgaacat catagagtat acttacagaa accttgatgg tatagcccac
      121 tgcacaccta ggctgtatgg atagcctatt gcccgtaggc tacaaacctg tcagcatgtt
```

181 actacactga atactgtagg caattgtagc acaatggtac gtatttgtgt atctaaacat
241 agaaaacata cagtaaaaat acagtataaa agataaaaat ggtacacctg cattgggcac
301 ttaccatgaa cgaagatttc agcactgaag tttgctctgg gtaagtcagt gagtgagtga
361 tgtgtgaatg tgaaggccta ggacattact gtacactgct gtaaacttta taaatactgt
421 acacttagac tacgctaaat ttatttttaa aatatttttc tttctttaat aataaattaa
481 ccttagctta ccacaactat tttattttat aaacttttaa aatttgtaat ctttttgact
541 cttttgtaat aatactctgt ttgaaacaca aatatattgt acagttatac aaaaatagtt
601 tttcttcata tccttaagct cttttctatc ttaaaatttt atttttattt tttacttttct
661 aaacttttttt tgttaaacac taagacaaaa acacacaata gccttggcct acacagggtc
721 aggatcaaaa catcactgcc tttcaacagc ttgtcctact ggaaggtcct caggggcaat
781 aacacacatg gagctgccat ctcctatggt aacaatgtat tcttctagaa tacctgcctg
841 aggctgtttt acaatcaatt ttttatttat ttttatttttt tatgttttta aataagtaca
901 gggtatacac agtaaaataa taataaaaat atagtacatt aaaaaaacca gcaacatggt
961 catttattat cattatcaac tattatgtac tctacataat tgtatgtgct tttttattca
1021 aaaagaaaat cattaagaac acagcaatat taatatttat tctttttttt agaagaacct
1081 gatttattta tttaattttt ttattatact ttaagttctg ggatacatgt gcaaaacgtg
1141 taggtttgtt acacaggtat acatgtgcca tggtggtttg ctgtatccat caacccatca
1201 tctacattag gcatttctcc taatgctatc cctcccctag ccccccaccc cttgacaggc
1261 cccagtatgt gattctcccc tccctgtgtc catgtgttct cattgttagc tcccacttat
1321 gagtgagaac atgtggtgtt tggttttctg ttcctgtatt agtttgctga gaatgatggt
1381 ttccagcttc atccatgtcc ctgcaaagga tataaactca ttgtttttta tggctgcata
1441 gtattccgta gtgtatatgt gccacatttt ctttatctag tctatcattg attggcattt
1501 gggttggttc caagtctttg ccattgtgaa tagtgctgaa ataaacatat atgtgcatgt
1561 gtctttatag tagaatgatt tatagtcctt tgggtatata cccagtaatg agattgctgg
1621 gtcaaatggt atttctggtt ctaatccttg aagaattgcc acactgtctc ccacaatggt
1681 tgaactaatt tacactccca caaacagtgt aaaagcattc ctatttttcc acattctctc
1741 cagcatcggt tgcttcctga ctttttaatg attgccactc taacaggcat gagatggtat
1801 ctcattgtgg ttttgatttg catttctcta atgaccaata atgatgagct ttatttcata
1861 tgtttgttgg ctgcataaat gtcttatttt gagaagtgtc tgttcatatc cttcgcccac
1921 tttttgatgg ggttgtttgt ttttttcttg taaatttgtt taagttcttt gtagattctg
1981 gatattagcc ctttgtcaga tggatagatt gcaaaaattt tctcccactc tgtaggttgc
2041 ctgctcactc taatgatagt tccttttgct gagcagatgg tctttagttt aattaggtcc
2101 catttgtcaa ttttgacttt tgttgccatt gcttttgggg ttttagtcat gaagtctttg
2161 cccatgccta tgtcctgaat ggtattgcct aggttttctt ctagggtttt tatggtttta
2221 ggttttacat ttaagtattt aatccatctt gagttaattt ttgtatgaga tataaggaag
2281 gggtccagtt ccagttttcc gcatatggct agccagtttt cccaacacca tttattaaat
2341 agggaatcct ttccctactg cttgtttttg tcaggtttgt caaagatcag atggttgtag
2401 atgtgtggca ttatttctta ggcctctgtt ctgttccatt ggtctatata tctgttttgg
2461 taccagtacc atgctgtttt ggcaaaccag gaagaagctg aatccctgaa tataccaata

2521 agaagttctg aaattgaggc agtaattaat agcctaccga gcaaaaaaaa aaaaaaaaaa
2581 aaaaaaatcc aggaccagac ggattcacag ccgaattcta ccagaggtac aaagaggagc
2641 tggtaccatt ccttctgaaa ctattccaat caatagaaaa agagggaatc ctctctaact
2701 aattttatga gtccagcatc atcctgatac caaaacctgg cagaggcaca accaaaaaca
2761 gaaaatttca ggccaatatc cctgatgaat attgatgtga aaattctcaa taaaatactg
2821 gcaaactgaa tccaacagca catcaaaaag cttacccacc acgatcaagt tggcttcatc
2881 cctgggatgc aaggctggtt aaacatatgc aaatcaataa atgtaatcca tcacataaac
2941 agaaccagtg acaaaaacca catgattatc tcaatagatg cagaaaaggc tttcaataaa
3001 atttaacacc cctttatgct aaaaactctc aataaactag gtattgatgg aacccatcga
3061 aaaaaaatga gctatttatg acaaacccac agccaatgtc acactgaatg agaaaaagct
3121 ggaagtattc cctttgaaaa ctggcacgag acaaggatgc cctctctcac cactcgtatt
3181 caacctacta ttggaagttc tggccagggc aatcaggcaa gagaaagaaa taaagcgtat
3241 tcaaatagga agagagaaag tcaaattgtc tctgtttgca gatgacatga ttgtatattt
3301 agaaaacccc atcatctcag ccccaaatct ccttaagctg ataagcaact tcagcaaagt
3361 cccaggatac aaaatcaatg tgcaaagatc acaagattcc tatataccaa taacagacaa
3421 acagagagcc aaatcatgag tgaactccca ttcacaattg ctacaaagag aataaaatac
3481 ctaggaatcc aacttacaag ggatatgaag gacctcttca aggagaacta caaaccactg
3541 ctcaagggaa taaaagagga cacaaataaa tggaaaaaca ttccatgctc atgataggaa
3601 gaatcaatat tgtgaaaatg gctgtactgc ccaaggtaat ttatagattc aatgctatcc
3661 ccatcaagct accattgact ttcttcacag aattagaaaa aactacttta aatttcatat
3721 ggaaccaaaa aagagcccat atagccaagg caatcctaag caaaaagaac aaagctggcg
3781 gcatcacact acctgactct aaagttctat aaatgaactc acgaggccaa agaatgaaga
3841 agacaccaac acaaagggga aaaaatcaaa acaatatggt cattgcaatg gtagagatat
3901 gcacagtata ttatggaaac ccagagaaga caaacgtaac acagctttgg gaagatatgg
3961 aatttttctc ccaggaggag aggatgatca agctgagaga tgtgtgaact gagtggaaag
4021 gaggggagta gtattccaag agaagcaaac agtatgagca attcatggag gtaggaaagc
4081 tgtatacagg gaaccatcag caggttgttg aataaaggaa gctgaatgag gctgggcaca
4141 gtagctcacg cctgcattcc cagcactttg agaggccgag gtggaatcat catttgaggc
4201 cagcagtttg agaccagcct gggtaacata gcctgaccac atctctccaa aaaataaaaa
4261 taaattagcc tgctgtagtg gcagtgcctg tagtcctagc tactctgaaa ggatcacttg
4321 agtccaggag gctgaggttg cagtgagcta tgattacccc attgcactcc agcctgggca
4381 acagagcaag accctgactc tgaaaaaaaa aaaaaacaaa aaacaaaaac aggatcgtaa
4441 aagacaatac taacatacaa caaagcatgc agattccagt aaagcctgtc atattaggca
4501 gattaggcag gtttaaatat atttttatgt gatgatgagc ccctaaaggc ttttgagcag
4561 gagggactat ctgaaaaaag atatagaatg gttaagaccc aagacagaga gaaggtacaa
4621 ggactatttg gttgataaaa tctgtaggaa ttggaatggg ctgaatgtgg gagtgggggt
4681 ggggtgagag atggggagga ctgaagactg aatagaccca gatttctggt ttgagtccgg
4741 gagaggtggg gtgctgaatt cgaaggtcag gacacctata cctctgggaa tacagcgatg
4801 gttgcaaaag gcatctggta ttgtccttct gccactgtct taaaagggat tctaaaggga

4861 ttttcttgcc cttgttcctc agccctaca cttgcattac tggcctacgt ggatgctcac
4921 cagctggctg tgtccatcat tgcagccaag tctgagaatt cctgattata cttagagcct
4981 gtggagctgc tgacacaaac agtcattagc agacaaccct tttgcaacaa agtatgcttt
5041 aaaatgtaaa ctgtggagcc attttccttg cgttgtccag aaggaacttc gtcctgcgtg
5101 agcctggatt aatcatgaga gagctcgtca acattccact ggtacatatt cttactctgg
5161 ttgccttcag cggaactgag aaacttccaa aaggttggtt tgagcaatcg tgtcttcttg
5221 ttgtcttgtc atggttgtaa agtgtgtgta tatgagatat gaccaagact gatttatagt
5281 atggtgggct tgggttttac ttgaagaagt aagggtgaaa tgtatgatga gggaggaaat
5341 tatatacata agcaattggt tgatggtctc tctaccaata ttttactccg aagttctgca
5401 ataaaaggct tagccacata gtgcatgcag agctctgact tctagggcaa aacataagca
5461 tgtacactgc aagttatcaa ggtctatttt gtttatgcga atgtcaaatt tcagggtggt
5521 ctaagtggat gatgacaacc ttttcgcatc aggtttgcca ggaatagaat caaccccatt
5581 ctcagacatc cagagcattt gcttctgaat aaaaatcact tttattttca gttttagctt
5641 tgccaaactc ttaataaata ttttagttgc taaaaattgg aaatacagaa agacgtacac
5701 aatttgcctg tgtaacaaac ccggaagaca atggatttta aataactttg aggctggagt
5761 catgatttgg cttggcaaga gactgcaaaa gtttttttca gagcctttgg aatgtaccgg
5821 aaataacacc acctcagggg aaaggaaagc aacttaagaa actgacaaac acctgttgca
5881 gtagcaagaa tgtccagtga tatagtttct ggccagtgta ttatgaaact gggactagcg
5941 tatttgaaat cagaaagact ggaaagtctg tgatttgcaa agtgactaag ggtatcactg
6001 aaatcttttt ttaaaaagac atgagaaagc agatcgagtg gtatcaatac aagagttttc
6061 aaatttaatg ttataccata gagtaaaaag agatttttgc ttcaggacat gttcaaatta
6121 atcattttcc ctttatatta atcaaagcac tgaaacagtt tgtattgtgt agataaatga
6181 aggtggtatc tgtatataga tgcaaaatgt atctttagat tttctggttc actaaaaatt
6241 ctggagccat aaggtcaaag ttcacatgca aataagatgc gggtttcttc acaaacaatc
6301 tgatttcaca gatttttttg tttcattttg ttgcttctct ttttccattt tacttgagta
6361 taatggtatc ttcaaatgta tttaaacatt taatttctaa tgaatacttt aaggcatcta
6421 cagataaaag agactctaga tcttttcaaa cagctaataa tagtcagaaa gacttaacat
6481 tggcttcaga ttattttaat acttcctgat caaacaacgg atgtccggta aggccccacc
6541 tggatgtttg aacgtatggg ttgtcttaag tattatttgt atatttctaa accacgcagt
6601 tacataaaaa tgatagggtt aaatactaaa atacagtctt ataaagagca ggacaattga
6661 ttttgatgat tcaaataagg atttgttgta cacacacaca aaacccccaa aatctctcta
6721 tctgaataag tcttaattta tattctagaa agaattgatt ttcatttcca aactttacaa
6781 ataaagccct taattcaaat gcacactatc tctattttga aaatattgaa atatagtggc
6841 atagagataa caaagccaaa caccctgact tttaaataaa ctaaccagat cattcaccca
6901 atttcatttc ttataattta tttactacta gaattaggtt ttaaaatcaa aaaatttaag
6961 caatttttttc tcagtctatt gtactgtaaa atctaaatta gtatgagttt aacatcactc
7021 ttagccaaaa taccatgtct aggagaacaa acatttattt actacataca gcagttctga
7081 gaataactaa tatcatgaaa gcataatcct taaaatttta aatgttgaag ggtgaggaat
7141 acattggtag aaaagaacca caataaaatt ttattatttt cattattatt attattattt

7201 gagacagagt ctcgttctgt tgccaggctg cagtgcagtg gtgtgatctc agctcactgc
7261 aacctcctcc tcccaggttc aagctatact cctgcctcag actcgcaaat acctgggact
7321 acaggtgcaa gccaccacac tcggctaatt tttatatttt tagtagagac agggtttcac
7381 catgttggcc aagatggtct ccatctcttg acctcgtgat ctgcctgcct cggcctccca
7441 aagtgctggg attacaggca tgagccactg cgccagccat tatactactg aaactaataa
7501 aaatggccca cccaaactat ttctactatt tctagaaaac tactgttttc cctattcttg
7561 gcagacggta ataacaaaaa gagtttttta gataatatac ttcttcctaa gtcctttatc
7621 atgaatgcat aaaggaaatt gtacaatatg tattagctaa taaattgaca tatttaaaat
7681 aacacaaaag tattcagtgg attattttct gactttctgc acatcatttt ttgataaaaa
7741 ttaatatcca actttgtaga attaattgtt catagttttc attttagttt aattaaggct
7801 actaatgccc aatgataagg ggaagaatca ttgtctttct gaatcatttc aactagtgat
7861 attttcaatg atgaattcag tgccataacc caagtagtag aatttcacaa actgtcattt
7921 atgaaagtag ccaatgttcc actggataat tggcttaact acatacatca ataacattta
7981 atgctttatt agggagtatt aaatgtatgg tgcaatgtta gattctgcag gagcataaga
8041 gttcatgtaa gcagctctgg atttgcttaa tatgcacaaa gaactatcaa aagtctcact
8101 ttcaaaacac ccgacttact acaatacgtt gaagtgtttg agcgtacgtg attttatctt
8161 tagatagatt tgaataacct cctcttttaa attgtatgta tataaggata ggattcacag
8221 atttgacata tgactaagtc atgactgaca cagctgtcat tgaaatccag gacacacagt
8281 cctggatgaa tattttatat tgacatgcat tgaaagagtt actcattgca tgtttgagta
8341 aacagagttg cttcaaatat tattgacctt aaagaaaaga aggaaggagc agaaatttca
8401 agatctcttt aaactctacc ttatttccaa aggtaaatga agtaggcagc ttctcagtga
8461 aataaaacct gatgtcgttg aaggagagta acaagtgagg ggtggaaaga gggcctgaaa
8521 ggagtggctc tattcaggaa gatgagagga tcacatgggc catgctgaag acccagctgg
8581 ggctaggaac tgcagctttc tttatagtgc ccctgacctg aacatttact gcactatacc
8641 cagcagtgct atgtgaacat agggtaggga ggacagatgg ctggattaat tcaggattgg
8701 cactttccag ggtcagtaca gctaaagaac tagagagtaa aggagttgga gttatatggc
8761 agcgtaccat gagatacaga ttggatcagg aagaaagtaa aacaaggata tttaatgctt
8821 ggaagagaag gttaaaaagt ttaaaccaac cccaaagtgt tttgttgtac taaaaaaaaa
8881 atactgcatt cataatgtta gagaaacatg aatattttcc aagtcagagc cctaatttta
8941 ctaaaataga aaggagcaaa tacaccttgt ttctttatgt acccaatcat tgggtcatgt
9001 caatccaaaa ataatcaatc aaaagttggt aagtcaatag tcatatgcga gagcccataa
9061 aatacaaagg aaaggtaatg tcatgtcctt ctcatcaagc agttgatatc caagtcaagc
9121 ttttcttcgg gtccagaaaa ggattgtgtt cattttcatg tatttgttat tcatgtagtc
9181 cttggattga gagaagaaat agtgccctag tttaaacgag ctctggctga gatgaaagct
9241 ggatagtaga atgaaagtaa acaagagaca gtgtgctgag tcaacaaata tcattaaata
9301 caactgatcc atgtgattgt gtcagtgaaa accggaaagc agatttggat aactggaaat
9361 atggacaatg tggacttggc attctgtgtg tagaaactga tattgatgta catcttctct
9421 tatccatctg tgcataatca gtatgatctt gaagatgcag tatgtcttag agaaaggaag
9481 tataaaccaa ctttaaccct gaagttcagc tagttcagct ctatcacttc ctatttttgt

9541 gatatgtaga caagttgtgc aaccattttt agtccccatt tctggtctgc aagtggaaat
9601 attaatagta tctacctttt ttgtgttaaa taaaaagata atgaataaaa agtataatgc
9661 atggcacata ccagattctt aatcactttt agatgctaat attagtaaaa acagtcaaac
9721 ttcacacaag actgttatgt cactgaatct tatgggaagg tgttaactta ataaagttct
9781 tagtaacacc ttccatattt ctccatgtct attttccaag acattctaag actcacttct
9841 ttgatcttaa ctgatctcaa cagttcatgt gacatctcca gtgtgtcacc tcattggaaa
9901 gataacatta atagtaagtc tattacctct gccacttctg catctgtgta ttgagtgaaa
9961 ataacactag tgcataaagt ttctctctta taaaagtagc acatggtatt taagattgat
10021 tttgaaaatg caaaatacat aaagtttaag acagaagaag tcatccatac ttccaggact
10081 attaacacat tggcatattt tcttccattt ttttctacat atttttaaag tccttattaa
10141 cattgtgctg cctgctattt ttacttagca ctaaagcatg agcatattct atattattag
10201 taatcttcca aacgtcatgt gtggtgacta aataatattc tgtttagata acagtgtgct
10261 agtatatgtt taatattcac ctcactgaga aaaaaaaaga cgtggatttg ttgctcttgt
10321 ttatttctgc agtaaaatac tctatagtaa aaaactctat tgtgtctgtg gccagtctca
10381 agctactatc aaataatgag cactgagttg ggaaatagca tgtgtagtag catccttcat
10441 atattatttc taccacacag acacattaca gataacctca agaacttata taataataaa
10501 atgtagttaa atcattggga atttcaagta ttaatacttt gtttttaata tatttgatta
10561 taaatgtata caacttagtt tttaataatg attgtatata acaatcacct ctcaaaattc
10621 ctaaaaaatt accaagtggc tcttgcaaac ctgcggaaga caaaacttgt gtgcctcaat
10681 cttctcccac ttgactacga ttaatagaat ttagtacaat tgatctgttt tctgcagtaa
10741 aagtcaccta tatgcctttc tatatgtgag attatttcct taggatagat tcccagagat
10801 gatgatgatg atgatgatga tattattatt attttagaga tagagtcttg ctctgtcaca
10861 caggctggag tacagaggtg caatcacagc tcactgaaac tttgaactcc taggctcagt
10921 tgatcctccc acctcagctt cttcccaagt agctgggatt acaaagtgtg tgccaccatg
10981 ccggctaatt tttaaatttt ttgtagagat gtggtttctc tgtgctgccc agcctggtct
11041 caaactccta ggctcaagtg atcctcccac ctcggcctca aaagtgctgg gattacagac
11101 atgagccacc aaccacaccc agcctgagat aaaatattaa cggtataata catttgaatg
11161 taataaagac aaggaaaaca atcaaacagc ctgggtttct ttttctaaat tatagaatca
11221 agtaacattt gcacagtgct ccatgtggac caaggacaat tttaaatggt ttccatttat
11281 ttattccttg tgacaagtta tgtggaggct atacattatc tccgtctata gctgagacac
11341 tgaggttaag tgtggttaag tgacttgcag agtcggtaag tgatggagct gggatgtgaa
11401 ttcaagtcct gtgccacatt gcctcttttt ttttttttt ttttttttg agacagagtc
11461 ttgcactgtc gcccaggctg gagtgcagtg tcgcgatctc agctcattac aagctccgcc
11521 tccctggttc acgccattct cctgcctcag cctcccgagt tgctgggact acaggcaccc
11581 gccaccacgc ccggctaatt ttttgtattt ttagtagaga tggggtttca ccctgttagc
11641 caggatggtc tcgatctcct gacctcgtga tccgcccgcc tcggcctctc aaagtgctag
11701 gattacaggc gtgagccacc gtgcctggcc gctacattgc ctcttaatgt gtagttgctc
11761 aatagtcttc cctttttttt ttttttttt ttttttgggg actgagtctc actctgttgc
11821 ccaggctgga gtgcagcggt gcggtctcgg ctcactgcaa tctccacctc ctgggttcaa

11881 gtgattctcc tgcctcagcc tcccgagtag ctgggattac aggcctgcac caccacaccc
11941 agctaatttt tgtattttta gtagagatgg gatttcacca tgttggccag gaatctcttg
12001 aactcgtggt cctccccgcc tcggcctccc aaagtgctcg gattacaggc gtgagccacc
12061 gcacctggcc tagtctttct ttttaaacag taaaagcatt caacatcatc aattaacctt
12121 tgggctcatt gttaaccaca ctccacaagc ttaataaaat attgtttttg ttctttatct
12181 ctcaatatct agatgattat actattaatt gcttatttca ttcattcgtt gtttagaaaa
12241 taacttttta ttgagattga ctttctcaaa ctttatgaat tataagtttg cctccattgc
12301 attttgaaaa ttaacacttc tttggcattc tatctgctac aatttttttc tattatgaaa
12361 gcaatatgta ttcatttttt taaaaaatcc tgtaagatac agaaaaacaa aaatataaaa
12421 ttacacataa tgctcatagc aagggataag tgctcttagc attttgctat tcattctttc
12481 agtctctttc tctcatatat gtgtgtgtgt atatgtaagt gtatatatgt tgtatatata
12541 cacatacaca cacatatatt atatattata tattatatat gtgtgtgtat gtgtatgtaa
12601 ttttatttg taaattttaa gttccggggt acaagtgcag gatgtgcagt tttgttacat
12661 aggtaaacgt gtgccatggt ggtttgctgc acctgtcacc catcacctaa ataactgggc
12721 tcagcatgta ttagctattt ttcataatgc tctccctccc ccaatcccac ctgctgacag
12781 gccccagtgt gtgttgttcc cttccctgtg tccatgtgtt ctcattgttc agttcccact
12841 tataagtgaa aacgtggtgt ttgcttttct gttcctgcat tagtttgctg aagagaatgg
12901 cttccagctc tatccatgtc cctgcaaagg acataatctc attccttttt atggctgcat
12961 agtattccat ggtgtatatg tatcacattt tctttatcca gtctatcatt gatggtcact
13021 tgggttgctt ccatgtcttt gctattgtga atagtgctgc agtgaacata ggtgtgcatg
13081 tatctttaca aatttcagag gctgttattt cattgaggaa agagaagcat ttaaataaga
13141 agctctctct tcagctgcct accagcaaag gggaaaaacc tacctctctg catccatctt
13201 gtcctccttc tccctcactg tgctttaaga ggactttctc ttcctatccg tggttaaccc
13261 gtctttcttc ctctgagccc cacataaatc tgctttctca gggacctatt tccctcaatt
13321 atctcctgtc tttctccaat gtcctacatt tttgcttcta ctaggtgctt ccagtcagca
13381 tttaaaccca ctcttgtcac catactcacc tccagcacca tgcagcccct ttcttccctt
13441 ttattgttaa actctgctgc aaaaagatgt cttccctctc ctcttagttt ccacttcctt
13501 atcacaacct aacccccacc actgcaatct ggcttccgcc aaatctgcaa gcaccaaaat
13561 caacatgacc tcctcatcag gaaactcagt gggcactttt aggtccttat ttaacttaac
13621 gtctcggcag catttgattc tccctctttt gtgaaacgtg tgctactctt gggctctgcc
13681 aatagcctcc actggctttg cttacaactc tgatttcttc ctctcagtct cttttctaaa
13741 ctcttcattc tcccacccat cttttataaa tgtttgtgtt ttcttctaat tggcttaggg
13801 caccagcctc cctccgtctt caggctttca cgggtaccgt ttcctctgcc tggaacactc
13861 ttctctctcc actgcaccaa gccaaatttg aatcatcctg tgaatgtgtg tgaatgtatt
13921 gtgtagtttt tttttattcc tagttttatc aagttcagtg gttgagaaac attatttatc
13981 atgttaaaga aatactatta tattccgact ctactaatgg ttttcaagta gggaatggat
14041 agttaactct gttactgcct ttttgactgt gataggtatc ttttaaacta tgactatagt
14101 aaatcctgtt taaaggactt ttctattaaa ttatccttat atttttgcaa ggatttttt
14161 tctgcctaaa tgcatagtaa taattttgaa atttatgatt taatttaatt tgctttttaa

14221 aattttactt tagggcttta catcctgctt gacttacatt agcattgttt tattccaaag
14281 attgatttga gaagctttct atactttata ttccctatag cttttgtttg tttgtttttg
14341 agacaaggtc tttctctgtc acccaggctg gagtgcagtg gtgcaatcac agctcactgc
14401 agccttgacc tcctgggctc aagtgatcct cctgcctcag gctcccaagt agctgggact
14461 acagatgtgt gccacctgta cccggctaat ttttttattt ttgtattttt tgtagagatg
14521 cagtcttgcc atgttgccca ggctggtctc aaaacacctg gatccttcag tggatccttc
14581 tgggctcaat ggatcatcct gcctcagcct cccaaagtgt tgagattaca ggtatgagcc
14641 actgcacctg gctccttgta gcttttatgt aactggagac ttaattcttt cttaagagtt
14701 ttttaaaact tatctgaaaa actttggggc attatatttt tttcagaagt gttctttgct
14761 aatctaatct ttttcttctg tgagtattgt tgatgatttt accccaccct ttactacatg
14821 tgaacaattt tgtttttaaa attcttaatt ctttagattt tcatctttaa atattcatta
14881 ctgtttagct ctgttgaatt gtggtccaag aatgtgacat ataatctgtt tttaaaattt
14941 atttaagctt taattttcat gggcatttga aaatatgtgt catctatcag ggcttacagt
15001 tgatgtgcat atctgtttaa ttaattttac taattctgct attctgtttt actacatata
15061 taattatatt tttgtctttt gatctataaa caggattggg atttttgtt tttttgctat
15121 ctttttattg tctatttctt acagatttta ttatggttag aaaatataga ctatataaaa
15181 tcaattcttt gagctgggtt aaaatctcct atgtagcttg gtatattttc tttatgtttg
15241 aatgtttcat ctatgcatca tttacaaaat gtattctgta attgtttcat tgttttataa
15301 atgtacatta tatctagtgt taattttgat gtttatatct tctatatctt tactgtagtt
15361 ctgtttgata tattagtgtc tgaaggagat ctcttaaagg gttacactat gttaaaacat
15421 ttctccatgt actcttgtga taattttact tttgggtttg agtccatatt tttaaataat
15481 taagtttcat gattgtcata tctttttagg gcttgttcct tttatcatta agcaatgttt
15541 ctttttttct tataaatgca tatgccccta tattacattt ttcttatatt actattgcta
15601 tgtcactttc tttgggatat cgtttgcttt atacatattt tccctcccct ttatttttaa
15661 catttctgtt ttattttatt taagtgtgtc ttttgtgttt gatagcatct gtcatttcat
15721 aggtcagctt ataccattgg cacttactgt gatttctggt atatttggac ttgtttcttc
15781 catattattt tatgtcttct gttaaccatg ctttttcttg gcttatttat tcctcctctt
15841 cttcctgttt gtttttgctt ttgtttttga ttgataaagc ctttctggta cctctttttt
15901 tctctgttgt tttggaattt ttgaatttta tttatttttt agtagtaacc attaataagg
15961 ttttaacata atcatttaac catagatgct tctttctgtt tgaagttatt caatatttct
16021 gtcctcttgt ttatggcaaa gagcttagca ttttttaatt acttagcatt ttaaacttct
16081 ttcctgaact ttgatcttat agttgtttgt ctagaattta attccactct ttttaaacac
16141 aaaaatttgt gatttttaa tattccatag tgtgttaaaa ttgcaatggt atttcaccac
16201 catttatgct attgtttttt ataactcacc cctttctttc tggtataaat tattccttag
16261 tgagtttatt tactctagta actatttcag agaaagtctg tgagtggtaa acactctcaa
16321 tatttgttta taagtgttct gagtttaaaa ttattaccta agctagctgt gtaattctaa
16381 gctaacagtt atttttacgc agtcatgtaa aggtattagc ctattgcctt ttggtatcaa
16441 ttgttgttgc tgaataatct caggttaccc aaaattggca ttcctattaa ggaattaaac
16501 tttttctttc tggtagagtt taagatttta tttatcttta atttttacag ttttaattca

16561 atgtgtccaa gtatgaattt ctttcttttt ttctttttt ttttttcttc tgagacagag
16621 tctccctcta tcactcaggc tggagtgcag tggtgcgatc tcagctcact gcagcctcca
16681 cctcctgggt tcaagcgatt atagtacttc agcctcccac atagctggga ctacaggtgt
16741 gcaccaccat gtccagctaa atttttttgta tttttagtag agacagggtt tcaccatgtt
16801 agccaggctg gtcttgaact cctgagctca agtgatctgc cctcctcggc ctcccaaagt
16861 gctgggatga caggtgtgag ccaccatgcc cagctgtatt tctttttttaa atctgtcttg
16921 tcatttggtg ggtactttcg accttaatat tccagggttt gtttttcagt tttgaaaaat
16981 tatcagccat ttatctcttt atatattgct tctaggctgc tcccctcttt tatttttctc
17041 aaactcctat cagaggtgta ttagtgcctg tcactgtata ctttatatct cctaactatt
17101 ctttaatagt gtccatgtct gtatttcttt gtattatgtt ctgtatatta taatgatcct
17161 tatgatatat atatcatata tatgatatat ataatgatcc ttataatata ttatattata
17221 tataatatat attatatatt atatattata taatatatat tatatattat atatataata
17281 ttatatatat tatataatat atattatata atatatatta tatataatat atattatata
17341 tattataagg atcgttataa tatatattat aaaaattatt ataatatata ttataacaat
17401 ccttataata tatattataa tgattattct gttgaaaagc tgggaagaaa gtggccctga
17461 tgactgtgta taagatgtca ttttacataa aaattctgct ttcttatttc aactactatg
17521 tttcaacttt tttatttact ccttttgtga aggccttata aatacagttt tgttcattta
17581 aacagtacat cagtcactgt gctcaccctg ggaattaaat gatgtctaaa acatgatccc
17641 tgacctaaag ctcaaggttt taataattga gtgtgggtca aagacgtaaa cagatcattt
17701 taatagtatc tgtgtgacaa gtggcattat aagaatgaca tttcaggata acataaggtt
17761 aaggaaagag gcatttgggt ctgcctagca tgtcagggga agtggaagga gatggatgct
17821 taaactgaat cgtaaaagac aaaataacat tagcaaggga gatatggggc aagtaaaacg
17881 ctcccactca ccatttttt tcactctcag cagatgagct tgcctttgac tttaccaaaa
17941 aataataata ataataaggt ttattcagaa agtggatgta tcttttatgg ccaaacaacg
18001 tgccagtctg ttctagatgc tctataagtc tgtcactgac tatttcactt ctaaatgtca
18061 atcatactac ttatttggct ttgatgtata ccttgccctt taactgaagg gaccatataa
18121 tttactgtat aaatgcaggt agccctcatt tcacagagga gtgagaaaaa agaaaggacg
18181 atgtctatag cctttcctcc tgttgtctta aaaaaaataa aatagaacaa aacagctttg
18241 agatctaatt cacataccgt gcgctttacc cattaaagtg tacaattcac aaagtggtgt
18301 ctcttcattt tctagttgta tgcccaagtg aattctctat gaatctgatg aagcttaagc
18361 ttcagattct ctcatttgca ggagcccttt ctaagaccct cagtgggctt tagcaatgtg
18421 cttttatgag tgtctatttt tataaaatta ggggaaaatt gttcttaaaa aacaattttt
18481 taaattatta tccttttcca ccctgacttc ccttcagact cacttccctt tatgctgatg
18541 atattggggt ggacacagaa attttgtatt cataatttta tatttttttct ttaaaaagta
18601 caaattgcac aaacttgggc cccataaaac ttggatctgc ctctcctcgt atatcataaa
18661 ctctaagccc tgctctcctg agagacttct cttttgattt tcaaatgcct agtttggaag
18721 tagaaacaac attctttaca taagctcttc ctttcttttg gcaaatttct actctgggga
18781 aacagaattc tcattcaggt atgtaatggc ttctgactgc ttaaggaagg gttagtaaac
18841 aaaattctag aatgttctct tttgatttct cctttccttt cagctcctgt catcaccact

18901 cctcttgaaa cagtggatgc cttagttgaa gaagtggcta ctttcatgtg tgcagtggaa
18961 tcctaccccc agcctgagat ttcctggact agaaataaaa ttctcattaa gtaagtattc
19021 cacattttaa ttttttaaa tttttgtggg tatatagtag gtgtatatat atgtatatat
19081 ttatgaagta gatgagatgt tttgatacag gcatgcaatg taaaataagt acctcatgga
19141 gaatggggta tccatcccct caagcattaa tcatttgaat tacaaacaat ccaattacac
19201 actttaagtt attttaaaat gtacaactaa gttattgttg actatagtca ctctgttgtc
19261 ttatcaaata gtaggacttt ttcattcttt ctatttttt tgcacccact aaacatcccc
19321 tactcccccc gatccctgta ctacccttc cagcctctgg taaccatcct tttacgctcc
19381 atgtccatga gttcaattgt tttgatgttt agatcccaca aataagtgag aacatgcaat
19441 gtttgtcttt ctgtgcctgg ctaatttcat ttaacataat gatctccagt tccatccatg
19501 tctttgcaaa tgactggatc tcattctttt tatggctgaa tagtactcca ttgtgtatat
19561 gtaccacatt ttctttatcc attcatctgt taatgaacac ataggttgct ttcaaatctt
19621 agttactgaa aacagtgctg caacaaacat aggagtatag atatctcttt gatatactga
19681 tttcctttca tttgcttata tatgcagcag tggggttgct ggatcatatg gtagctcaat
19741 ttttagtttt ttgaggaaac ttcaaactat tctccatagt ggttgtacca atttacattc
19801 ccacatcaac agtgtacaag gattccctta tctacacatc cttgcgagca tttgttattg
19861 cctgtctttt ggctctaagc cattttcact gaggtgagat gatatcttat tgtagttttt
19921 atttgcattt ctctgatgat cagtgatgtt gagcactttt tcatatgcct gtttgccatc
19981 tgcatgtctt ctttcgagaa attgttcaaa ctttttttgcc tatttttgat tggattaata
20041 tatttttttac tatagagttg tttgagctcc atatatattc tggttattaa tcctttgtca
20101 gatgggtagt ttgcaaatat ttcctcccat tctatttgtt gtctcttcac tttgtttatt
20161 gtatcctttg ctgtgcagaa ggccttttaa cttgatgtga tcccatttgt ccatttttgt
20221 tttggttgcc tatgcctgtg ggtatctctc aagaaatttt tccccagacc aatgtcctgg
20281 agagtttccc caatgttttc ttggagtagt ttcatagatt gaagtcttag atttaaatct
20341 ttaatccatt ttgatttgat ttttgtatat ggagagagat aggggtctag ttttattctt
20401 ctgtacatgg atatccagtt ttccacacat catttactga agagactgtc ttttttcccag
20461 tgtatgttct tggtacctct gtcaaaaatg aaatgagttc actgcaggtg catgaattta
20521 tttctgggtt ctctgttttt tcccattggt ctatgtgtct cttttgatga aagtactgtg
20581 ctgttttggt tactctagct ctgtagtatg atttgaagta aggcaatgtg attcctccag
20641 tttttttctt ttttcttttg gctattctgg gcctttcgtg gtttcacata aattttagga
20701 tttttttttt ctatttctgt gaagaatgtc atcggtattt tgataggaat tgcatggaat
20761 ctatagactg cttttggtag tatgaacatt ttaataatat tgattcttcc aatccattaa
20821 tatggaatat ttttccattt ttttggtgtc ctcatgaatt tctttcattg atgtcttaca
20881 gttttcatta tagagatctt tcacttcttt gattaattcc tagctattta attttatgtg
20941 tggctattgt aaataggatt atttttaaat ttatttttca tattgttcat tgttggtata
21001 tacaaatgtt actgattttt gtacattgat tttgtatcct gcaacttcat tgaatttatc
21061 agttctaata gttttctgtg gagtatttaa gtttttccaa atataagagc atatcatttg
21121 taaacaaaga taattcttcc cttccaattt ggatggccct taatatcttt ctcttgtctg
21181 attgctctag gtaggacttc caggactgtg ttgaattaac agtggtgaca gtgagcatcc

21241 ttgttgcatt ccagactaga ggaaaggctt tcagtttttc cccattcagt atgatactac
21301 tagctgtggg tctgtcatat atggctttta ttattttgag gcattttcca tctatttttt
21361 gagggttttt atcacaaagg gatgctgaat ttttatcaaa tgctttttca gcatatattg
21421 aaataatcgt atgtttctta cccttcatct gttgatatga tgtatcacat tgattgattt
21481 gcatatgttg aactatcctt gtatcccagg gataagtttc acttggtgat gatatatgat
21541 ctttctaatg tattgttgaa tttggtttgc tagtattttg tgcagtctgg ataggccaat
21601 aatcccaaat catcaagtcc tggttccttt tttgcttagc agtttttccc acttatcttt
21661 tcctcttgaa ttttactata accagaaaaa agaaatgagg ccgcagcttc gacacatttc
21721 ttagaaattt cctcagctaa atatctgagt tcatcattca caagctttgt tttccacata
21781 actgcaggac accattcagc taagttctct gtcctgcata acaaggatcc ccctttcttc
21841 ttttcccagt agcatgctcc tcatttccac tcaagtcctc accagtagtg ctttgaacat
21901 acatatttct acgaatagtc tgttcatgat aatttaggta ttctttaaga tgatgtagat
21961 tttctctacc atggaactct cttccttcca attcctcagg agcagaatca ttaacacacg
22021 tatttctatt aacagtctct ttgaggaaat acaggctttt tctagcatgc ttttcaaatt
22081 tttttcggtt ctaactattc atcaattgca aagccacatc cacatgttta ggtatttgtt
22141 gcagcagcac cacacttcca ggtaccaaaa cctgtattta tttattatcc ttgctgtaac
22201 aaattaccac aaacttagtg gcctaaaaca acataaacgt actatgttac agttctggag
22261 ttcacacgta tgaaataaat ctctctgggc taaaatcaaa gtgttggcag ggctgagttc
22321 cttctggagg ctctagggaa gaatctgatt tcttgccttt cctagcttct agaggccacc
22381 tgcgttcctt ggcccccctac tccacttata agtctagcaa tggcactact ctgacctctg
22441 cctccattgt catacctccc tttatcaatc tgcctctctc ttccatcttt taaggatact
22501 tattatcaca cagggaccat tcgaatagtc cagaacactc cattttaaga ttcttaacat
22561 ctgcaaaata aggtaacata ttgacagatt ttggtgatta aaacaagaac ctctgtggga
22621 gtgttattct gcttaccaca cgcatttggc ataaaaaaac tcttatttgg ttaaaagaaa
22681 ctctctttta tattgctgct tctcttccta tttctttcta ctgccctaat tcccttctca
22741 acaaatggtt tgcatataat taaataggta atatatgtaa agcatatatt tttatagttg
22801 gaaattgttt tcctccctta tgtatcccaa gtaactagaa gtgtgcctgg cacttgttag
22861 caatcagtaa gtaattgttt aatgaaagaa taaatattca actaatcatt agttacttct
22921 ataagtaatt aacccttttct gttcatcgta tttatacata tgcatgttct ttatctatta
22981 atagctgcta cttcccagaa cttattggga gaagacacct atgtcttggt tttatatgct
23041 tttctgaata aagtaaactt tacattttgt cttatcagtg ggcatcaccc tttgaaagca
23101 tttttgaagg actatggtac tttgactatt ggagcctaag aaagatgaga atataatgtt
23161 agctttatat tatcaagtaa ggttattcta ttattcagaa gtcactcaag tttcctctca
23221 cctttattct acttcctcat taacaagtca tcggtttgat acattaatca tggcaaaaaa
23281 atcacagagg aagcactaat ctgtcatttt tttctgtgac ctgcagactc tttgacaccc
23341 ggtacagcat ccgggagaat gggcagctcc tcaccatcct gagtgtggaa gacagtgatg
23401 atggcattta ctgctgcacg gccaacaatg gtgtgggagg agctgtggag agttgtggag
23461 ccctgcaagt gaagatgagt gagtgggaaa cagattcgtc tattgatttg aaagttgact
23521 tggtacactt agttttgtat ttatttttta catttttttt ttgagacaga gtctcactct

23581 gttgctcagg ctggagtgca gtggcatgat ctcggttcac tgcaacctcc acctcctggg
23641 ttcaagtgat tctcctgcct caggctcctg agtagctggg actacaggtg cgtgccacca
23701 agctcagcta atttttctat tttcagaata tacagggttt cactatgttg gacaggctgg
23761 tctcgaactc ctgacctctg gtgatccgcc caccttggca tcctgaagtg ctggaattac
23821 aggcgtgagc cactgtgccc ccgctgactt ggtacacttt aaaacagtca gtaaatagag
23881 attttctcag gcctggtgat tcagcactga gacaagttca agttcaagca caaccctgag
23941 gccaattaat cccacacctc ttatgcctgc tatcaaccac taccctaagg caagcctctc
24001 aattctctat cctctcccat tttcttacct tcactcatct cctgacttct tccaccctga
24061 attctttcac caggaaaact tcctctgaaa catttaccct acacctgtga aacacaacca
24121 aacacacttt ttatttctaa cctctttgca gacacttttg ccttatttca aatttgatat
24181 tcttctgagt gattttctgc ttcagtggaa gctgttctat tttctccact tcatgtctac
24241 aagactgcca aacactagta ggtaatctcc cagccctcag tgttgctttt aaaccattct
24301 attttgtatt cctatacaaa atctttcctc tgatgagggc ttatgccatt ctgacctatc
24361 ttttctctaa ctgtattcat catgtcatct gctcttctag gcacttcccc atatttatta
24421 aaaactttga ttccaggctt actatctttc tatccatctc tactcctgca attaccctaa
24481 gaaattttaa cagccatgaa atagaaccac tagccactta attctcataa ttccttgacc
24541 tgcagaaatc cagtgatgtt tgtctttttt tttcaatttt aaggctcata cttttaatct
24601 ctatgtacac acgtatgtag tcgttaaggt aagtctgcca ctgtgaggaa aggtagtttc
24661 attttatttt tttaactttc attttgagtt caggggtaca tctgcagaat gtgcagttgt
24721 tttacatagg taaacatgtg ccatggtggt atactgcaca gatcatccca tcacctaggt
24781 attaagccta gcatccattc tattcttctt gatgttctcc ctccccacac caacaccccc
24841 gacaggcccc gtgtgtgctg tttcccccca tgtgttcatg tgttcccatc gttagctccc
24901 acttctaagt gagaacatgc agtgtttggt tatctgttcc tgcattagtt tactgaggat
24961 aatggcttcc aactccatcc atgtccctgc aaaggacatg atttcattcc attttatggc
25021 tctgtagtat tccatggtgt ttaggtacca cattttcttt atccagtcca tcattaatgg
25081 gcatttaggt tgtttgtgtt aactgtttta ttgtttttt gttatatata tttatatata
25141 aatatatgta aacatatatt taaatataaa tacatacata tatttaaata tatacaaata
25201 tatacttaaa tatataaaaa catatttaaa tataaatacg tataactata tatttaaata
25261 tataaatata tagctatagt tatatatagt tatatattta catttaaata tatagtttta
25321 taatttattt atataaacta cataaataaa ctatatattt atataaaata taaataaact
25381 atatatttat ataaatatat catatatata ttcatatttt atataatata taatatataa
25441 atatataaat atataaacta tatatttata tattgtatag ttatatttat atataaatat
25501 atagctatat atttatattt aaatatatat taaatatata tttaaatata aatatataaa
25561 tatatataaa tacatattta tatatatgta aaaaatataa aaatatgtga aaaatacata
25621 tttatatata atatatgtaa aaaatattaa aatatgtaaa aaatacatat ttatatatat
25681 gtaaaaaata taaaaatatg taaaaaatac atatttatat ataaatatat acaactatat
25741 ataaatatat agttatatat atttatatat tatatatatt tatatatttt ttactacata
25801 atatataaca tattatatat tttagtatat atattatata ttagtatata ttagtaatat
25861 accatataat atacatagta tattatatat aactatatat agttatatat aaatatataa

25921 ctatatatgt tatatatagt ttatatataa tattatatat tatatataaa ctatatatat
25981 cacatatagt ttatatattt tttaatatat aatatataac tatatattta aatatataaa
26041 tatgtaacta tatatttata tataactata tatttaaata taaatatata tttaaatata
26101 aattatataa atatacataa aaatacatat ttaaatataa tatataaata tatatttaaa
26161 tataaatata tatttatata ttatattata aatattataa ttatatatta tatattataa
26221 atatataata tatattatat attaatataa gtataaatat ataaatatat attatgtaag
26281 tataaatata taaatatata ttatataagt ataaatatag aaatatatat tatataagta
26341 taaatataga aatatatatt taagtataaa tatataaata tataaatata tatttaagta
26401 tatataaata tatataaata tatatttaag tataaatata tatttaagta tatataaata
26461 tatataaata tatatttaag tacaaatata taaatatata taaatatata tttaagtata
26521 aatatagaaa tatatattta aatataagta tatatatatt taaatataag tatatacata
26581 aatatatata tttaaatata agtatataca taaatatata tatttaaata taaatatata
26641 tttcaatata agtatatata aatatatatt taaatataag tatatatata aatatatatt
26701 taaatataag tatatatata aatatatatt taaatataag tatatatata aatatatatt
26761 taaatataag tatatatata aatatatata tttaaatata agtatatata taaatatata
26821 tatttaaata taagtatata tataaatata tatatttaaa tataagtata tatataaata
26881 tatatattta aatataagta tatatataaa tatatatatt taaatataag tatatatata
26941 aatatatata tttaaatata agtatatata taaatatata tatttaaata taagtatata
27001 tataaatata tatatttaaa tataagtata tatataaata tatataaata taagtatata
27061 tataaatata tatatttaaa taaatatata tatatttttt gagacggagt ctcgctcagg
27121 ctggagtgca gtggcatgat catggctcac tgcaacctct gcctcctgag ttcaagcaat
27181 tctcctgcct cagcctccca agtagctgag attacaggca tgtgccaccg gaccctgcta
27241 atttttgtat ttttggtaga gtcagagttt cgccaagttg gccaggccag tctcaaactc
27301 ctaaccttga gtaatctgcc cactttggcc tcccaaagtt ctgggattac aggcatgagc
27361 ctgtttgtgt taactcttta tcagcgtagc caatcgatga ctcactcttg gccttgtcac
27421 ccactggaag tagtctgcat ttaaaatctt cagcttcagt atgtcactct catcatggac
27481 atttttttggt acagccttgt cagatgagca aaacagtttc ccatactcat gatttgcctc
27541 caagtagagt ttgtgggcac aaacttccat tgtctccttc tcagctaaca acagtgtctc
27601 agtctctctc attctcctac tcttgctata caacctcaac atcaccagca tcatcatgtt
27661 ctcttacctt gattcgtctc tgttctcctt tccattgatt ccccaatggg gcttttattt
27721 ccttccatac ttagttcttt cttctacctg gtgatgtatc atcaaacact gccttaccag
27781 catctttaaa tctcatggcc tcctgtcctg taagcatctg ctacttgcaa actgtcaatc
27841 ttacaatgat gtaaccttca tcttctcttc tctgacatgc ttataaccat acatacgggc
27901 accacacaaa ttagaggaat ttaggtctac ttgggacatt tatttttagt ttttgtgttg
27961 ttgtctttcc tcattatttc ttatcttttg ttattttgct ggaggaaatc attaggtact
28021 tttttcagag tgtgaagatg taaaatattt cctgaatttg tgcacgattg gaagtcttca
28081 ttttgctcgc attgttggat aataattttg ctgcatgcag aatgagagtt ttaaaatccc
28141 ttttctttag ttttagtaga tatcctctgt tgcagatgag aagtcttttt cttatttctt
28201 tacaagtaaa tctgatgtct ctcttaaaaa gtttaggatt tttctttttt ttctagagtt

28261 cataaatttc acaaattgac aagaatatat taggtgtatt tttaagaatt attgctactc
28321 agttttaggt gggccttgtt tttttgtttg tttggttggt tggtttttgt tttgttttgg
28381 tttttttgag acaagatctc actctgtaac tcaggctgta gtgcagttgt gtgaccatgg
28441 ctcactgcag ccttgactgc ttgggctaaa gcaatcctcc tgcttcagcc tcccaagtag
28501 ctaggactac aggcatgagc caccatacca ggctactttt atttatttat ttacttttt
28561 ttggtagaga taagttctca gtgtgttgca catactgagt cttgaagtcc tgtgctcaag
28621 tgatcctccc accttggcct tccaaagtat cgagattata ggagtgagcc actgcaccca
28681 gcctaggtgg gccttttga tctaaagacc aaagcttttt agaaaggtac attttctcta
28741 tttttttct tttttctttc tctatgactt caaatttttc ttctcatatt ttctgcatgt
28801 cttaatattc tactctcttg aagattcctt ttacttttc ttcatattat gaatgtggtc
28861 tccagtatga ctattctgtc attctgagtg ttttggtctt aaaaactata tttttaattt
28921 ctaagaattt ccttgatgtc tctgttgtca taacaaactc acttgtatga tacaatattc
28981 acttaagctt ctaaggatat cactagtgca tcttttaaaa agacattttc ttttttcccc
29041 tgcattactt ttatttcctt cagaaaaaaa aaaattgatt ttgtttgggt tccatccttt
29101 tatgtttaca atttttctca aattgatctt ttatttttg atcataataa atatacatgg
29161 agtgttcagt taattaggat aaaaagctgg tgggaatagc atgactttat ggaatactga
29221 tttggtactt actgtgagta agtaggtggg gatctgccta tatgcaggct tcccttcagt
29281 atgcagagaa gtaagaaatc aaataaggaa gttggaatgc tctcatttgc taaataatga
29341 agacttcatt ctgaggatga aacacattca agtatttcct tactttgtga cactaccttt
29401 cttttgaata tttttgcata ttctctctgg cccaattgtt cttgatttgg gttctatact
29461 aaatcccctt ttcttttctt gccttctttt ttccaacctc tcctttggag atctcatcca
29521 ttcatgtgga tatacaccgg tgtggccatt ccaattgcta aaattttgga atgcttccat
29581 acttcttgga aagatccgtt ttataaggct cccgagatcc cccaacccct atcactactc
29641 cagctctctt aagccctccc ccaagagctc cctcccctaa attcctaatg gtccatcagc
29701 taaagtctca atgctggcac agcgggatac ttccagcatc ctgctttaag gtgaccagtt
29761 ctgattggtc agtacttatg actccaccct gaatcatgtt cccttacagt ggggatccat
29821 ggctatgcgt caatacccta gtcattccta gttgacttta cattcaattt cccaaaaggg
29881 aattcctcac ccctcaccta acagatgacc aagacatcaa gtcactgaga agataggaga
29941 tttttgcttt aagcaaaggt ctttacctaa gacattatct gtgcctcagc tttaccatag
30001 agatcttgtt cagggaacct atggaaggca tagataacac tttatttgac tgtcatagga
30061 atatcaagtg ctcagctaag tttttcccag caactgtatg acaatacaac tcacaattga
30121 ggaacctggc cagtactgta tttacatgta ggtatttaca gtttattaga aggagagttg
30181 tatgctatag atagcaggca aagtaataaa gttgttattt tcctatattt taaagccttt
30241 cttgtatttt tgctataaca cagggccgca ggaactctaa atgacagtga atgcttagat
30301 taaaaaccaa caggtctcac gcctgtaatc ccggcacttt gggaggccga ggcgggcaga
30361 acacgaggtc aggagatcaa gatcatcctg acaacagggt gaaaccccgt ctccactaaa
30421 aatacaaaaa aaaaaaaaaa aaaaaattag ccgggtgtgg tggtgggcgc ctgtagtccc
30481 agctactcgg gaagctgagg caggacaatg gcatgaaccc gggaggcgga acttgcagtg
30541 ggccgagatc gcgccactgc actccagcct gggcgacaga gcgagactcc gtctcaaaaa

30601 aaaaaaaaaa aaaaaacaaa aaaacaaaac ccaacaggtc atgaaggctt tgcaagtatc
30661 tcttaccacc aacaacacca aagcccccat tcctctccct cacattgaag tagaagaaaa
30721 caaagtccat atttcatgcg ttccctttgtc aaaataacaa attggttacg gcacatgtcc
30781 tgcaagaaat aaaatgtgtc cattgctcag tagtctctct tgcgaagtcc ccctctgtat
30841 ctgtaacgta aaattcctaa ggacataaat gtagttttaa ctattttacg aatagtacta
30901 aaataactgg catcctgaac ttatcaattc ttttgtatat tagatttaat aactttcttt
30961 gaaagtttca tatttgagaa taaaaattaa ctggcataaa ctatttcttc tgaaagatta
31021 aaagtgtttg aacagtaaat tacatgtttg agtcccccca aattgtatga cagaatttct
31081 tctgattgtt aatataataa tatctggttt actttctaga gaatgaatgt atttaattaa
31141 taatcataaa atttaatagt caaattaaga tggaagctaa agggaaaata ggtcataatt
31201 tctaactagg taagaatata gttatatcaa aatttttctt tcaaatgttt tatgtctatc
31261 agtatgaatt aaataatgtt gaattgctat ggtgacagtc tatgttaatc agcttttatt
31321 aactatcttt taaaatgaag aatgctatgg taacttcaca ctgttaatat ttttcataaa
31381 tttgtgtttt gctagtaaga ttctaataaa gcagagacaa ccaagtgttt ctaaactgat
31441 ttctgtttga gatctactga ggaaaactgt ctttgcattt ggtgaatttt gtaatgtaac
31501 atgcctcaaa tgattctcaa aacagatgtt tagaattaaa ttgaaagtta gaaactctag
31561 gtttaataaa gccatattgc cttatttatt ttgaattttc atttcttttt agaacctaaa
31621 ataactcgtc ctcccataaa tgtgaaaata atagagggat taaaagcagt cctaccatgt
31681 actacaatgg gtaatcccaa accatcagtg tcttggataa agggagacag ccctctcagg
31741 gtaagtggtt atgatgttaa aacacatata taaaatgtat tttaaaatat aacatttctt
31801 tacacactca gttacacact tacaaacttc tagtataaag tagtttccat gtacatttta
31861 accaaatgta aatatttctg tttgcatata tgcaaactgc atggcatttc atttgggtct
31921 ggctagggaa aaaagagatg ggaaccaata atgttaaaga tagaaaagga ggcaatgaaa
31981 aagcaaacct ggaatccttt gtatttgttg gctggctaaa tcatttattt ttttttaatg
32041 ttgaatctga gacttagggg atgaaaaaga aaaactaaaa cccaggcttt agaactgaca
32101 gtttctggaa ggagggaggg agacaaggtt cggaagaaaa gaaatgagat ctctggagag
32161 aagttaggcg aaaagactca agactcatac acaaatacct tggcaaatcc ctcctgagtc
32221 atgaagagta gtcacgcctg taattccagc acttcaggat gccaaggcct gaggtcagaa
32281 gttcaagacc agcctggcca acatggcgaa atcctgtctc tactaaaaat acaaaaatta
32341 gctgggtgtg gtggtgtgtg cctataatcc cagctactca ggaggctgag gcaggagaat
32401 aacttgaacc cgagaggcag aggttgcaag tgagccaaga tctcaccact gcactccagc
32461 ctgggcaaca gaatgagact ccatctcaaa aaaaaaaaaa gttattatcc atatgcttat
32521 tttgtactgc ctctgtatct tatccccaca tttattgata aattattatg aggcatcatt
32581 attgtctttc catctttata tcacctaaaa gattacagac tatgtttttc atttaacaat
32641 gcatagtata ttttaagagg aatacaaagg tgtcacttta tgtcaattaa ctgaactaag
32701 gtataaaatt gctcagcttt gctttattta aaataaaata aatattgcta atttttaatg
32761 attaattatc tggctttcct cttgttataa atcttggtgc atttcctaca atgacaaaca
32821 agggtggttg tacttatgtt actgaattta gggttcaaaa cagaaaagac agatgtaata
32881 tttaaactcc aaagagtaat tttaatatta tgtgtgaaat tttctagtat ttcaaaggac

32941 atgtactctt ctaaagatac catctagggt gcaaggtaaa cctgatagtt aaaagcaatg
33001 tgtttattta ttcatatttc aatagctttt ggggtactag tggtttttgg ttgcaaggat
33061 gaactgtata gtggccaagt ctgagatttt agcgtgccta ttacctgagt gctgtacatt
33121 atacccagta tatagttttg tatgtctcac caccccactc tgcaacattt ccccttctta
33181 aaagcaatgc ttttaatcag atttagctgt gactttgggg aagcaaaata agcccatata
33241 catatatata ttatacatat acatattata tatataatat atatatacac acactcatgg
33301 gatgaaagaa aataaaaata aactatacct cataggaccc tggtgaagat taatttaggt
33361 actcttgcac tatttcattt aatattgtat gttttacata ataagtggcc aataaaggtc
33421 aaagcgatat ctttgatgat gataatagtg atgacaataa gttgatgata tttggcaaat
33481 gtatccttga tagacccata aacatttttg aattcacgtc cctatctctg gcaggaaaat
33541 tcccgaattg cagttcttga atctgggagc ttgaggattc ataacgtaca aaaggaagat
33601 gcaggacagt atcgatgtgt ggcaaaaaac agcctcggga cagcatattc caaagtggtg
33661 aagctggaag ttgagggtaa ggagctgcat ttcttcccct gactgtgtga ccaggggcct
33721 cactgtctac tgtgaaggct gcacctgggc ttgggagaga agagatgtgg gcagcccact
33781 tccctcagtt gttccagata ttaggccata agttcaagcg tatgataaca gaaaaggaaa
33841 actgaaaaaa gaaagaaatt ttcactagta taaaaggtca tattccattg attactcaca
33901 atcactggta atttttacca aaacagacta aatttactgt aacagtaaaa taatagaaac
33961 ccattttaga atgccttcct ggtttggaca attcttccct catttaaaga cttgggcata
34021 ataattttaa tctttttaat catacagaac aactttaaaa agatgtgata aggaggaaaa
34081 agtagctatt ttcagatagt gttctatcac aaagcttgaa aaaaaaaaca ttaactcaaa
34141 tcgtaaagcc aaaaataatc ccagttctgt gagttatgtt atcaaaatcg tttttctttt
34201 ctttctgaaa atatttttta atcagctaat tcaataactt ggtgtgaaag gtcttcactg
34261 agaaatcaga atccaaatag gtctaggtgt tctatttgct tgttagtcgg gtccttcttg
34321 acctaaaatt gcaccacatt ttgcttaaaa agaactatca gcacacctct attaggcgaa
34381 taaactgagt acaaaccctt cctagctctt cctgttgtat gccagagaat taacattttt
34441 ggctcctagc tttctcacct gttaagtggg gtttgctcta tttaatgaag ttaggtgttg
34501 atagtgttta gcagagcatc tggtcctttg tgcaccctca ataaatgttg gctataagaa
34561 ttatcatcta tttttctgct tttctcttat ctgattgata agtgttagag tatcacatac
34621 tggcacaaat tacagttcaa tcaggaaaag acttgaagag ttctccatat tttactttga
34681 ttctgtccta ctttccttag gccaaaatct atcttttttct gcatatttcc ttctcattca
34741 tatagttttc tattaactcc tttaagatta tttttatttc cttgatggac attcctgtca
34801 cagctttaat gatctcgttt cccacgtttg cctccaattg aggtaacatc tttattatgt
34861 cattgtacca attgctcata aaattttcat taattcctca tggaaaataa tgaggttggt
34921 gggaatagtg gctgtcagaa tataaaaata cattttcatc aagttgctgt aatttaatat
34981 cttctaaata atcagtgcta tttgaagctc cgtattcaac aaccagttga tatgatttat
35041 tcagtaaaaa ctaaataaac ctacaaaccc acccagacac acattcagac tcactgaata
35101 tctgtctgcc tagatccagt gttttcttgt tctgtctaag gaatgatgca gaattaatgc
35161 tatccatttg tataaaatat cacaaagagt ttttctcttt aagatattaa aaataagctt
35221 tctgtattat aatatttaat actgatcatt taggtcacta gcttcataga tattaaaaca

35281 acttgcttta cctttgacct agagaaaatt atcaccgaac tccattagtt ggagttatta
35341 tacagtttgg ttttgtgtta ccatttaatt ttgtatcatg cctgtcagta acattgaata
35401 ctgcctcttt tctcgtaacc tttaaatggt catgcttagt gctttaaaag ttaatatatg
35461 ctagagatag tattaaattt gctagaactg agagctcata atatcattta aagttattct
35521 aactgtaggt aagatgattt tcgcacacat ttagcacaca tgcctatttc taccctcatc
35581 ttagtcccta ttaaaatagc caaaatatgt gacatgctta gcacaattgc tggtacataa
35641 taagcattta ataaatggaa tctactatac ttattatgat taaaacataa aattgtaaca
35701 aatttgcttt ggctctggaa gctctgaaag gttgacttcc acttgaataa atagttgagg
35761 tattttcata agatataatg tagacgtgac ctatttagag gtaaggctaa ctcaacctac
35821 aactcagaac aagtttttt ttaaaaaaaa gcaactgaga aatgactgga aaaacctcaa
35881 aagtacatgc agatgcctgc tagtttggca atgatgagga ctgaagatga tgaggcaggg
35941 ccatcgtcag ttggggcaga cgagcatatg tatgtatcaa gtcgtaactc tgcaaattag
36001 ttatgcagtg actatatcga atcagaactc tatggtgcca tttgatgctg ggctacatgt
36061 aacacagatg ggcatacagg aaaagataga gttttgtcat tgatagcctc taataaagat
36121 aaacatgcca ggccatggat tgggtaccat gtgttaacta aatctttgtt gttacaactg
36181 tgaaagaaac accctaccac acagaagtaa agctcccttt ccagattgcc attctcagac
36241 tgctggacct ctgcaatgga aatgtaaagg tatcctatac tttggtcttg ccttaaaatg
36301 ttcaaacggt gacatacata attattgatg gaaccatcta actcaagcgt ggtgcagcat
36361 ggatgtcttt ctgaaaggat gtccaatggg aaggctaaca ttttaaaaag ttccattgag
36421 gctaaatgtt ttatgtggat tatcttgttt aattctcact aaaagtctgt aacaagggcc
36481 ctatattctg ccattttagg aaacagagga atagagagga tagctaactt acacaaggct
36541 gcacagatag ctgtgtctaa gaatttgagt caggctgaat actgtctgtt ctattaaaga
36601 atgagatagt cctgtgtgac attgtcaaga gaagtatcta gatgaaaatg aggggaaaac
36661 cagaattctg caaatgaagg agaggatggg agctgaaaaa aaatagacag gaggtattga
36721 caaatttttt gataaatttt tcagagaaaa gggaggagtc aaaaaaggaa gcagtagctg
36781 gagctatgtt tggtgtgtag atcacgttgc attgcaagat ttctcttcga aaaatattga
36841 aatgtaaaaa aatttaaatg ttaaaatatt aatgacactg agctcagaga gaagaaaaat
36901 ttgaacatac ataagagaac aaaatactca atgaaatgtg gtgctggata atgcacaagg
36961 gttgtatttg ggggccaagt agaatgataa actgtataca gagggtgacc acatgttctg
37021 gttttcccag gacagttctg gtttacacct gttgtcctgg aatcattatt aatagagtct
37081 ctcttttact ttcagaagta tccaagcttc cacgataaat tatatggtta ctctccttag
37141 acaggaagac agaatgtcct tgtaatagga agaaaagaga agagggaagt tttcagtata
37201 aatcagttca taagtatgat ggatggaatt tgagaaaatt ctgttcttat ggtctctatt
37261 tcctctagga aggagaaatt agggttatct tttgaaaaca cttttgttaa agggtcaggg
37321 aaggggggtga ggatgaagtg agttctaaaa tagctgtgga atgggagaga tgactcacaa
37381 agtaaaccag gattgtaggg cagcattaaa gttttagtag agagcaggac cgtgaatatg
37441 gagtagcatc aatccacatg gttgcagggt ttttccctcc agtgttgctc tgctgtacag
37501 gtgtaagttc agaaaatagc agaaagctaa attcaaaggc aagacataaa tgttggagtt
37561 ttgtcaggaa ggaaaatagg gcaaaggatt tgagactatt gcaaaagaga gattgaagca

37621 tgaatcatgg aatctttagg taccaaatac acctataatt tctctttctt ttcttttctt
37681 tctttccgtc tttcttgttt gtttgttttg ttttgtgaca aagtctcact ctgttgctca
37741 ggctggagtg caatggcaca atcatagctt actatagcct caaactccta ggcttaagtg
37801 attctcccac ctcagcttct tgattagctg gggctacagg tgtgcactac tgtgctcagc
37861 tatttatttt atttatttta ttttatttt tttactttac tttattttat tttattttat
37921 tttattttat tttattttat tttattttat tttattttat tttattttat tttattttat
37981 tttattttat tttattttat tttattttat tttattttat tttattttat tttattttat
38041 tttattttat tttattttat tttattttat tttattttat tttattttat tttattttat
38101 tttattttat tttattttat tttattttat tttatttcat agagacaggg tcttgctatg
38161 ttgcccaggc tggtctcaaa ctcctcaagc aatcctccag ccttgacctc ccaaaatgtt
38221 gggattatag gcatgagcta ccatgcccag ccatacctat gatttaatat ccaaatatga
38281 aatatcctcg gatatgagcc taggattaaa cactatagct ccagcaatat aacagacaag
38341 ataatatgaa aatcttccaa ctagcccgga aatgctgggc tagttgtata actgataaga
38401 ataaaatata aatctctgga agctcaaaat ggacaggaac tgcaaaaacc ataagctcaa
38461 tgagctggtt tcttattgtt ctaaaggtaa tgggacaggt gctcatctcc ataacctagg
38521 agattggttt taagaccctt aaaggggcag gagacagggt cttggcccat gtgaaatgga
38581 ggttagcatt caaaaccttg tataaagctg agaaccacaa aagtagaaag atgggccaga
38641 aattccatct tcaggcacaa aaacacaaca caatggcttg tctgtcttta gtcgtgaggg
38701 agaaaaaacc aggtcatctt aggagtgaat attcaacact caggactata gcttccatag
38761 gcttgatatt gacttaatac catcagcaca gtctgggaat tctcagctgg aaaaatgaac
38821 atacaaactg gtttcaggct gggcacagtg gctcacccct gtaatcccag cacattggga
38881 ggctgatggc ttgagcactg gagaccaacc tgggcgacat ggcaaaactc catctctaca
38941 aaaaatataa aaattagcca ggtgtggtgg tacatgcctc tagtctcaac tatttgggag
39001 cctgaagtgg gaggatggct tgaacctggg aggtggaggc tgcagtaagc caagattgtg
39061 ccactgcact tcagcctggg caacagagtg agaccctgtc tcaaaataaa aaaataataa
39121 taaaaaacct acatacacat aaaacattgg ttccaggcca aaaaacccac acacacacaa
39181 aacattggtt ccaggccaaa aatttaacaa gaaaaaaaag ctaaaagaag aagcacttta
39241 cccaagttac ataggctttt catggatata cctacactga ggatgagttc acaatgcaaa
39301 attgtcacac ctacagaaaa caacctacct tgagtgagtg ttgtccaaca taatatacaa
39361 agaaaattca gttaaccaca taacatcata gaaattataa aataagtatg cttaaagtaa
39421 ttaaaaatgc aaaaggagga ataaggaaaa caaaaataca ttagggccag gcacagtgac
39481 tcacgcctgt aatcccagaa ctttgggagg ccaaggcagg cagattactt gaggtcagga
39541 gttcaagacc agcctggcca acattgtgaa accctgtctc tatacaaaaa ttagccgggc
39601 gtggtggtgc acgcctgtag ttccagctac tcagaaggct gagacaaaag gatctcttaa
39661 acccaggagg cagaggttgc agtgagccaa gattgcacca ctacactcca gcctgggcaa
39721 cagagtgaga ctttgtctaa aaaaaaaaat taaataaata aataaattag gaagacaggc
39781 ggttttgata aataattaaa cacaatttta acacataaaa atataattaa aattaaaatt
39841 caatggatga gtaatagtat attagagata aagagataat tcagccatta gaaatcagct
39901 cttcagaatt tagaattcag tgcagaaaga ttttgaaagc atagaaaaga tgaaattgaa

39961 tttaagaaat gataaaagat acattacaga aagagaaaat acagaaaata tgagaggcaa
40021 tactcaaaaa catgatgact aagaactttc cagcattgat gaaagactta aatcttcaag
40081 tacgtgaagc ataccaagtc ccaatcggta aaaatgaaga gcagagaaat aagcatttca
40141 cacccagtca aatcataagg aaacatcaaa gacaaagaga ttatcttaaa atattgaaga
40201 cagattattt ataagggaca acaattagga taacaataga gtgtggggaa actatcactt
40261 tcatctatcc ttacaatttg gtatagccgc atgaaggttt atgaaaaata aaaatcaaac
40321 tttaaaatgt atatagattt gtctcagcaa tttaacttct gacaatttat ctaaaagaat
40381 atttgcacaa gtgtatgttc aagattattt gttacaaagt tacttagtaa aaagttgtaa
40441 agaacttaaa tttgcttcaa taggacacca tctaaatatg tgatgtaatt ccatgcagcc
40501 attaaaaaga atgagatgga tttatataca ttaacttcta aaattatcta ccgtatatgt
40561 gacttgggtc tgctttccat ctctgagcct cagcttcctc ttctctaaaa tagagataaa
40621 agcagaacct acctcttagg atgcttgatt attagttatt atagacacat agtgtgtact
40681 atataattat ttgctgtttt attatttatt tcatgtattt aataagtact tgtatagtgc
40741 ttaccatgtg caaggtactg ttctaagtgc tttagaatat taattcatta tcaatataat
40801 atgttcataa gtgaaaaagt aagtaaagaa cagtatatct tattattata tattagagta
40861 catgtatatc gaactcttaa gtcatcatct ctgcatagag aattatatgg ggggtcccgg
40921 cacgatggct cacgcctata atcccagcac tttgggaggc cgaggtgggc gaatcacgag
40981 gttaggagtt tgagaccagc ctggccaaca tggtgaaacc ccatctctac taaaaataca
41041 aaaaattatc tgggcatggt ggcaggcacc tgaaattcta gctactcagg aggctgaggc
41101 aggaaaatca cttgaaccca ggaggcagag gttgcagtga gcagagattg tgccactgca
41161 ctccagccca ggcaacagtg caagattcca tctcaaaaaa aaaaaaaaga aagaaagaaa
41221 attatatggg gggtaacttc tattttatac tttatgtagg cctatacttt ttgcatcttt
41281 ataaagagaa ctttataatt aggaagaatt aatacatgta tttatgcttt ggaaaaaaaa
41341 cacttcttcc aaatattata ctatttttga taaagtaaca tgaatctttc tgttcattag
41401 tttgatattt ttgcagttct gttgctccat tgatctccaa gacaaactca gggatgggaa
41461 aagttttgtc aaaggtaatt gattcctatg ttgcttaggt tttcacaact cttggatatt
41521 ggctgaagaa ttttgaaggt ggaggttctg atgaacagga catagaacat gccatttctt
41581 tagggaagga atcaatccat aaagctgcta agcttgagac ctacaagagg aagctggcag
41641 agtcacctag atggaggaag tgaagggggt cagagaacag cagctgctgc tgaagtctcc
41701 actcatctga ctcttctttt ctatgtatag atggaaatct gaaatttatg attttatagt
41761 ctggaatagt ttgcaggatc cagcacaaaa gttttgttag ggttctgatt tctcagtgaa
41821 cattttccac actttgttgg gtgttactga cttacagcat aaagggaaaa gtaaaacaaa
41881 gggaagttcc tataggaaag ggaagcaccg ctaggtaaga actatttagg tatactgatt
41941 tgacattgac agggaagcct cagtcatctg ggaggcagaa gaaagttttc agtctcacaa
42001 ctgtggaggc tcttctggaa aggttaagcc ctgtctcagg cccccatgtg ccaaagggct
42061 ctaggagagg attcacggca ggatgtgacc agggaacatc ttattgtctg atgtcaccag
42121 agaaatctac atatcatatt tcatacattc taagatgctc attatttcat attttggcat
42181 atctgggtta catctcatca ttaatccctt acaatcacaa ttgaataaat tttagtttct
42241 ttgttgcaca ttttaatatc tctgaaattg agatttttct tacaggtgct aaaggcattc

42301 acacccagtt tgtggcttct gccctccagc taagatcgtt ccttagctgt ccccaaatat
42361 gagaatgaat atacaatgat aaaacaaaaa taaatcaacc atattggctc ataaagcttt
42421 ctttatttt aactagaaat tttccttctg cttgagatca tttcatttgt tcctcacaga
42481 aatgaaagca ttattttcag tgagatgatg ccacctagcc tttttccctc aaaacctttt
42541 atttgctgcc tattcatttt attaggttga aatagagact aagtggcttt tcagggccat
42601 atagaggaaa ttatctttta agagacaatt ttgtctgctt ctctaatcca cttcacattc
42661 tactttaggt atggtgtgta gccaaagagt gatctatgtt gtttttctta tatatctgaa
42721 accattttct cctgagtacc tctaaaggac aggaagacag atactcaggg gcagagggat
42781 atggcagtgg aacatgctga tttgaatggc agggctggaa ttttcagtga gggtttgcta
42841 tcatgattgc ttgggacaac ttttgaaatt ctgattttat ttccctgttt tgaccagtgg
42901 catatgcccc ctttaaaacg ctagaccaga gggccaacca tagtggctca cacctgtcat
42961 ctcggcactt tgggaggtcg aggcaggcgg atcacttgag gtcaggagtt agagaccagc
43021 ctgggcaaca tggtgaagcc acgtctctac taaaaataca aaaattagcc gggcatggtg
43081 gtgcacacct gtaatcccag ctactcagga ggctgaggca ggagaactgc ttgagcctgg
43141 gaggtggagg ttgcagtgag ctgagatgga gccactgaac tccagcctgg gcaacagatt
43201 gagaccctgt ctcaaaaaaa tagagagaga gagagagaaa caaataaaga gagagagaga
43261 gagagaatta actcctctga ccagtgcagg ggctcatgcc tgtaatccca atacattgga
43321 aggccaaggt aggtgaacct cttgaatcca ggagttcgag acaagcctgg gtgacatggc
43381 aaaaacctca tctctacact gaagtaaaat aaagtaaaat aaaaataaaa taccagacca
43441 tacaaatcaa atcttttaag gtgataacat aattactgtt ttttatagct ggggggtgtc
43501 tttgttataa gatttttaa acattgcaaa agactcattt aaaatttata aatatctaat
43561 tttctttttt cccctcacat tctctgcctt aactaagatt ttttaaaatg cacttattta
43621 tttgaggctg aatgtggctc ttactacatt ctgtgaatat cacattcaga tgaatactgc
43681 tttgtatata gaaactggct gaatgtagtg tacttgagac ccaaattaaa atagatggat
43741 gctggagtgt atcaagctct tgttaattgc attttctatt attatcttgt ttacccttga
43801 agctttaagc cattaaggaa aatattgggc agaagctgga atcaagagag ggctgtcagt
43861 cagcaattgc tggtgggaag aggtgtcttg gcaccaatac aaaactgcaa ataagagcca
43921 gggagggtct agaagcagaa caaaaagaag agagtccttc tgggtacagg gttattgtag
43981 ggctccttca tgtttaaaca actccttatt tcctcagggc tttgaaaagc agcctcttgt
44041 caaaacgtgg agaggcattt tggggagtag caagggaagg caagtcatat ggagaattta
44101 agtggcttca gtgcatgagt ctccatcact tgtcaggaca cctgcgtgct gccagcccag
44161 tttctttgca atctgaaagg ctgcactatc tacccttaag gccaacaaat ctattcagaa
44221 acttttatc tgaagatatt tttgcagaca tatgaaatag gtaagacaag tagaattcca
44281 aaagatgaaa ataaataatt cctatctatc tatctatcta tctatctatc tatctatcta
44341 tctatctatc atgtcacaga agcagatgtc aatagacata actataaaag atcagcattg
44401 tcttcaaaat tttagacttc tggctgcctt ctttcctaga gatcaaattt acttgttgca
44461 tctacaaaag tggaagcaat catgtaatgt ttataccaca tttgatttgc tttttccttt
44521 gtttatgctg cagctcttaa tatcacaaat gccacagaga gaggtattta aaaccccacc
44581 gtgtgctgtg ctctcagtga ttgcagtttt aataaaattt gcagtggtcc tgttcccggc

44641 atcagtccta attgtttgat gccactaaca ggtttgattt gctgtcatga gtacattgtg
44701 catttgaaaa ccaaacaaag aaaaaaatca caaacctctg atatccctgg aggctatcat
44761 tgggaaaatt aaatctgcat gatttaatag gatgcatgtt ctaaaagagg agcttgaccc
44821 attgattttg actttagggg atattatggt atattatggt atggtttcat ctaaaaagtt
44881 ctataaggct ttcagagaag aatggtaaag tggtccttta gttgaacagt tgtcactgca
44941 tttctctaag aaaaagtcac ttgtataata atgatagcac tgaatagata atacataatg
45001 cttcaagtca acacatagtt aggccctctt aaagtgcagt gttaaagaaa atgtacttta
45061 aagtaattaa attgtttagt ataatgttga cattatatta tttgaaatga aaagttatcg
45121 tgacctgaaa tacatatact ctaattggag tgagttttta atatcagttt tcagatatta
45181 aaatgagatg cataagttca agcatacata cacagtaaag gaaaattgct ttctattcaa
45241 tgcattagtt catccaacaa agacacactg agcaatgttc caggtgcgac atgagacaga
45301 gaaggccatg cctccactgg gcttaatttc aaaatgtgac tattttgatt catgcaaaga
45361 tatcatggaa agctattaga attctatggc aagaaggagt tcaagtaatt ttatattcag
45421 ttattttctt cagatatcaa atacatgact ctgagactgt aattgttata tttatttccg
45481 tgaacaacaa actatacaag gcattatttt tggagaggac ttaatatagt ggttaataac
45541 atgggtggta ggatctcaag aaaactgcat gggctctaga gtctcaggta aacttcttga
45601 gtccaaatcc tggttctacc acctatcaca tgtgtaactt ccagtaggtt acttatctct
45661 ttgtgcttca gtttccctac ttgtaaaatt aggttaataa tactatctac ttcataaatt
45721 gaagaatgta gaagtagatg atatatttat agctcttaca agagtgactg acacagagta
45781 aacactcaaa tagaaattat caatgttagt tctagggcta atataacttc tgtgcaacag
45841 aagcagtgat ttacgcactt gtgcagacaa ttatagctcc cttttccatg tgtcatcttt
45901 atctctgagg tacaagcaat aaagtccaat ggcaaaaact aaatttttat ttttaatagt
45961 ttatttgtat taattttggt tctagcaaaa gaataataac caactttaaa tctgcaagga
46021 gaccccaaag tcatatagtt caattcctta gtttgtagat aaagaaattt gagactaggg
46081 gcagtggctc acgcctgtaa tcccagccct ttgggaggct gaggcaggag gattgcttga
46141 ggccaggagt tcgaggccag cctgggaaac atagtgagac ccccctctct aaaaaaagta
46201 tttatttaaa aatatttaaa aaaaataaat ttgagaccgg aaacatcttt tattttatag
46261 ataaagacac ttgagaccaa acaaattgtg actttgccca ggttggcaaa ggaacttgag
46321 tgtcttattc ctagtctagg acatgttcca ctacctattc cgattctttc ctcttttaa
46381 tatttatgtt gtgtagataa tactctgcag agttcacatg ctttagtatc agacagacct
46441 gggtgttaat cctgactgtg ctgcttacca gttatgtgag gtaggataat ttacttgacc
46501 tctgcaagtc tatttcctca tttgtgaaat ggggggtaat attatctaga acacagagtt
46561 cttaaaatgg actcagatag catattcaca gtgtctatgc agtagctctt tgataagtat
46621 ttgctgttgt tggtattgtt gtctgttgtt tacattgtta taaagctgga tgacatctat
46681 ccagagaata ccactagtca agcttcttga atttcataaa tagaatgtca acattaacaa
46741 ctgctcatct ggtctccaaa gaacataaat ctactttcaa tcagcaatgc tttgtacctg
46801 cattcttgtt acttgttaga gattataact ttggtgtggc ttcaccgtga caagtgataa
46861 agggaagctt atctaagaag ctgtgtaaag aggtgccttt aatggctaac aggagagagg
46921 ctatttggag tcaacctgtt aaaaaaaaaa atagtacaac aacataaaag tgaaggcggc

46981 cttcgtgtgt atcctgagct tatatcatat tttattcact atagaaatag atatttgcca
47041 aaaatcttgt tgaaaatact gatccattct agcactcact gctcccaagt aaatcccaag
47101 tgagaaatca ctttaaaaat ttagtgccat aaaaaatgat gagttcatgt cctttgtagg
47161 gacatagatg aagctggaaa ccatcattct cagcaaacta ttgcaaggac aaaaaaccaa
47221 acaccgcatg ttctcactca taggtgggaa ttgaacaatg agaacacttg gacacaggaa
47281 gggggacatc acacaccgga gcctgttgtg gggtcggggg agaggggagg gatagatagc
47341 attaggagat atacctaatg taaatgatga gttaatgggt gcagcacacc aacatggcac
47401 atgtatacat atgtaacaaa cctgcacgtt gtgcacaggt accctagaac ttaaagtata
47461 ataataataa aaaaaattta gtgcctggct gaagctctgt gaacaatggc tgcagaggag
47521 cttcctgcca gcctggggaa gccatagcct gcacatgatc tgtccctttt agtgaactaa
47581 ggttgacttg atggagccaa tgctggcaaa ggtctctgag gaaaactgac ctggatttat
47641 acaaggtcca gccttgcagg ttgtaaggga ggtcactttc atggcaggcc aagatccttg
47701 agatgttttg aaaatttgaa ggagaaagga attaggccaa aatgaataga tactgcagac
47761 gaaatcttat ggagaaattt ccttggactt acatccttag cctcagcaca gcaaattaat
47821 agaagcttgc agaagaccaa gctgagattt cttatagaga cctccagtgg aacaaactta
47881 aagaaggccc atatggttaa cgttcttgat gcccatatgg ttaacattgt tgatgcacct
47941 gtgtaaagaa ccaggctaaa tctaataagg ccatactcac tttgtcgtca agaatctttg
48001 agattctttt taatcaaaag tggggagact ataaggaaca atttgtgctt aaatggaaaa
48061 ttgtgtgttg tcattctaga gcacacctgt gttgtgtgat tccaattctg tgggagctgt
48121 tttaaagctt tataaattgt agataactgg cagcaatgct aaatcgttct cctccataga
48181 cttgcaaatg aattctgtcc agtggaaaag caaccaaaaa acccaatctg gctctgtttg
48241 cacagtcatt ttaatattcc tgatctataa atgggtctgt ccttgggatt ctcttttcac
48301 ctggttgcaa cacttcactg gtttccttgt gaatgagtta aataaaacct ttaactcatg
48361 tttattctga aaaaaaaaaa aaaaatcagt gcctgggttg gggagaaggg tctctgctga
48421 gaaactgaca ttttatccat tcctatagta agtactgtgt actttatttt cttttacttt
48481 atttttgct cggcctggca tgtatcttag aatccaattt gaagcttagt catagtatct
48541 gttacaccaa accatccaga ggttttctcc ctgatcctaa tatattgtta ttcatttaat
48601 ttatggccat atcaatatac cttccttaag atctctatgg aaagagaaag aaataactaa
48661 gttgacggat tcatggaact tctcctccaa gtggttctca aatgccagtg cacatcagaa
48721 gcatctggag atcttactaa atgacacagc ttcaggatgc attccccagt tattcatatt
48781 tgataggttt atgttagtgc tttttaacaa caccccaaag gatccttaat gcagtgaccc
48841 atgaaccaca ctttgaaaaa cactgacttc aggttttcta cttagaggga ctttattcca
48901 gatgaatcta aacaattcaa ggagaaagct tatctgcaaa tagtaagata tcaatgttag
48961 gatagcttca aattcatcca tttgtggaat gcctactatg ttctatgcaa tgaggtaatt
49021 cttaaggata cagacgaaag agagatgtgg ttcatttctt gaaaagtgtt caaattcagt
49081 gaggaagatg gatatgcaaa caagtaaaat gcaatatatt tacaatgata gaagtttgtg
49141 tagggttata tacacaggac agaggagata gggaaaggtc agggaaatct tcagagaggt
49201 gaaggccaac agggctttga ttgatgaaga gtgaggagct cttggtgagg atcatatcac
49261 attgagggag gaaaaagaaa atagaggaaa aaattcagat ttaccatgca agcacagcct

49321 gacactgact cataaccagg gagtaaaaga aggattagag agtttgggac agtatctatt
49381 agtggtgcta taaaaacaga ataaaccatg atttgactca caggctaaca tggagatcat
49441 cttcttggta tcttctcttg gacctttttt tctttttttt ttttttgag acagagtctc
49501 tctctgtcat tcaggctgaa gtgcagtggt gcaatctctg ctcactgcaa cctccgcctc
49561 ccaggttcaa gcgattctta tgcttcagcc tcctgagtag ctaggattac aggcatgtgc
49621 caccatgccc agctaattct tgtattttta gtggagatgg ggcttcacca tgttggccag
49681 tctgctctca agctcctggc ctcaagtgat ccacctgcct cagtcttcca aagtgctagg
49741 attacaggtg tgagccacca tgcctagccc tctcttagac ataattttaa acgggtagat
49801 acctaacatc ctgacaatgt gggaacctat ggtttggagg catatggcct tatctggcat
49861 ccagaattcc atctaaaagg ttacagaaat gttcccaacc caagccactt taggcaactg
49921 ggatactgtg gtatgattta agattaagtt tatggcttct atttatttt ccaactaaaa
49981 tttccggttg gctaaaacaa aaatcttatt cttaatagac ctcagctcgt ttaacgcatg
50041 tcagagtgca ggcatcttcc agagcttaga tcaaaaaagt tatttaaaag taaactaaga
50101 ttttgataaa cgtaccatgg ttatacagga tgctaacatt aggggaagtt gggtgaacag
50161 tacatggaaa ccttctatac tatctttgca actcttatgt aaatctaaaa ttatttcaaa
50221 ataaaaatgt tttaaaaagg taaactaaga aatacttctt tgtcctggta attaagcagt
50281 ttagcatctc ctcccatcaa aaacagaaaa tgaactttct ttaagaagaa aaaagtgaat
50341 caggaatgaa gtcacatatt ttattggctg atgattaaac ttctaatata ttttcagaac
50401 cagtttaaca aaagtgcggt tgctttatat acacctaaga ctgaaacaaa aacaagtaaa
50461 ctttgtgtag ctcttgtctg atttacatgg taaacatttc ttgctcgtac ccactattca
50521 ccatccatat ttacaagtga gaaaaacgtt accatctcaa aggccacaga aatgttccca
50581 acccaagcca tgggagggaa tcccacatca ttgaggcagg cagcccttat tttgtcctgg
50641 agaagagagt cactgtattt gaggatgatg tgtatgtttt ctaaaggagc ttgccttctg
50701 actccttcag agttggagcc acagtgggta aacctcttca ggcattgccc tgcttcaaag
50761 cagacagaaa cgtaaacagt ggcagtacac caggatcggg tttctttgct ttagctacca
50821 agagtcagga aagagaaacc aggtatttat ttaggtttgt cattattgct aggttttctt
50881 ttaatgataa gggtttgaga aaagaagtat ctgttcagaa acaaagtatc acagagcctc
50941 aataggatta ctttttcaac cacccagggc cacgtgtttt ttaagtcaaa tataaaaaca
51001 atttaaccca ttttgttctt tgtagtcctt gccttctaac aggcatctcc aactcagtta
51061 ttcttaaaat atgatgctag atgagacaaa tagtctattt aagagcagat tcaaataatc
51121 tgtatagatg agcatctatg ttttaataac agggtcgaaa gaatttctct ctctacagag
51181 tgatttctct gtctcaaata attcagttta tgaaaggagt taaggatatg ctttttaaca
51241 ccggaaaagg gtacttaaca tgatcaatat ctaggataca gccagctaaa gcagattgac
51301 gttacaaaat aaaataaagc cttctccctt tgaagtccgc taaaggaaca gctttcatga
51361 ctcagaaaga tatcctagag atcaaaaaag ctctggagaa agaaaaagaa ctagaagacc
51421 tggcttcaaa atttacctct agtacttccc agttatgagt tagctgctat attaattaat
51481 tgctttatat aaatcatgtc atttaatctt ctccacaatt ctatgagttg aaagttaata
51541 actacgtttt ctggataaaa aacctgaagt tcagagaagt tgaacagcaa ctcagaaaaa
51601 acagctagtg agagtgaagt gaggatccaa ttctaccacc tggattgctg ttagggtatt

51661 gtacatgagt gtaaggaaag tatcctacta ctaagatttt gacttcccaa cctctgagtt
51721 tgtcctttga aaaagccctg caatggtgtt cttatttacc aaatggtcag agattttctc
51781 aagatattga ctataaggaa aatgataaac aacttaatga aatggcacta tgaaaataaa
51841 ataatctagg aacaaatatt attttatttt catagtgcca tttcattaaa ttgcagcact
51901 attcacaata gcaaagactt ggaaccaacc taaaagccca tcaatgatag actggataaa
51961 gaaaatgtgg tacatatatg ccatggaata ctatgcagcc ataaaaagga aagagatcat
52021 gccctttgaa gggacataga tggagctgga agccattatc ctcagcaaac taacacagga
52081 acacaaaacc aaacaccaca tgttgtcact tataagtggg agctgaacga tgagaacaca
52141 tggacacatg gggggaacaa tacacactgg ggcctgttgg aggctgggag tgggaggaag
52201 gagagcttca ggaagagtag ctaacggatg ctaggcttat tacctaagtg atgggctgat
52261 ctgtgcagca aaccaccgtg gcacacgttt acctatgtaa caaacctgca catcctgcac
52321 ttgtacccct gaacttaaaa tagaagttgg gggaaaaaaa agaaaaaaga aaatattagc
52381 ttggtgcaaa agaaataatg gcaaaaactg caattacttt ttttgcacta acctaataaa
52441 gtgatcttca gaaaacagtc tacttttta aaaggcaaaa aacagagtgg tttatataat
52501 tggaataatt tttacatctc tttttgatac acacttctta ttttctaaaa ttttcacaaa
52561 tcatcttaaa cattaatgct gtcaccaaat aaattctcac aaagtaatag aaagctcagg
52621 aaattaatat ttgagaagta aatttagagg caaggataac ttaaactgag aagcatttat
52681 aattttccat tttgagaaat actctgtagc atttataaac attatatttt aattttctat
52741 ttcaataaat taatattgta ccagaatacc aaactgcatt tggaatcata ggcaactgtt
52801 atgtttgtcc tttcttgata tttgaaaaaa atgaccttcc ttttgaatgc tgccctcata
52861 atttaaaatt ggccttctcc ttcacagggg acattcacga taaactctca ataggcttta
52921 atttggagaa ttttagtttt gccttagcag cttttcttat atcttctctt aattctataa
52981 gtttaggctt tatatgtttt gaaattatat tgttaagtgc atacacatta attattgttg
53041 taattcctcc tctgcagatt gcatttttaa cctttggatg atgttcctct tcatcccttt
53101 tttataatac cttttagcat aattctgtat tgtttgatat taatatcatt accacatttt
53161 tcctttgttt tgtgttttcc tgtgctcttt gtttggtatt cttctatccc tttcttccaa
53221 cctccccaca atcttgtaag cagaatatag ataaatactt ttgtaattca atccaaaaga
53281 ctttattttt agtagataag tgtaggtctt tgtatttatt ctgaaaattt atttctatta
53341 ttctttagac gatttctatc atgtattatg ctgtttcttt tctctgcttc ttttttaat
53401 tccttttctg ttttctggta gatcattata tatttttta attctccact ttaacccaca
53461 ccacaaccac tttgctgatt ttgaaattgt ggatcacaat gttatatttc agtgattact
53521 tttacatttt aatatacata tatgatgcta taattctaac agtttaagat catgtaggat
53581 cttctccagt ctctttaact aaagcaagca tcttatcatt ctttaaaatc ttatctaaca
53641 gcaccttccc tcatcctctg tcactttcct tggcattatc caaaatttta tttatcttaa
53701 aacactgaat tattttatgg tccataaata gttctatcaa tatatgccac caattgctgt
53761 gttcatcatt caattttcat gtgccttttt tcttctgttt ccaatttctt atttctgaaa
53821 catattattc attagttcat tcaattagat ctgtgagcag atatctttgt ctttgtcttt
53881 gtatgtttga aaatgccact attttaccct gatcattcag gtgaacattg aaatctaagt
53941 tgacagatat tttccctcag tgttgtccta tgtcttctta catcaattga tgagaagtgt

54001 tctgtcattg taactataat tctttggtag gtaacagagt tcttctatct ggtcttttta
54061 cctttgatta ccagtacttt taccataatt tgtcatagaa tctgtattag ttatctgttt
54121 ctctgtaacg aattacacag aaactcaatg ttttaaaaca ataaacgatt atcacttcat
54181 agtttctata actcaggaag tacagagtga ctttcccagg ccaatgtatg gattatgttt
54241 gcagtaaaga tgttggccac ttctgcagtc atctgaaagc ttgaatgggc tgaaggatct
54301 aattcaaatg tggttgactc ataagttggt ataaattgat gctggccagt gcagagcctc
54361 cctttgtccc catgtgggtc tctcctcagg ctgcttgagt gtccccacac tatggtgcct
54421 tccttcccta agagtagatg atctaataga gaacaaggag gagttagtaa tgtttttcat
54481 ggtctagctt caaaagccac acacagtcac ttctgccaca tcctatttgt tagaagtgag
54541 tctaagtcca gcctacttcc aaggagagca gaggaactat actctacttt tccaagggag
54601 aatttgtgga caggttttaa aactacaata gtgtcaatgc aaaatgcacc agaaagtctc
54661 agtaacagaa tcacacaagc agaagaaaga acttcagagc ttgaagacaa ggcttgaact
54721 aaccaaatcc atcaaagaca aagaaaaaat aatttttaaa aatggacaaa gcctccaaga
54781 agtttaggac tatgttaaaa gtcaaaacct aagaatagtt ggaaggaaga agagaaagaa
54841 gataaatcta aaagtctgga aaacatattt gaggaaataa tcaaggaaaa cttccctggc
54901 ctcgctagag atctagacat ccgaatacaa gaagctcaaa gaacacctgg gaaattcatt
54961 gcaaaaaaat cattgcctag acacatagtt atcaggttat ctagaatcaa gacaaagaaa
55021 agaatcttga gagctgtgag gcaaaagcat caggcatctt ataaaggaaa atctatcaga
55081 gtaacagcag atttctcagc agaaacccta caagctagaa gaaattgggg tcctatttt
55141 agcctcctaa aacaaagcaa ttatcagcca agaattttgt atccagtaaa actaagcttc
55201 ataaatgaag gaaagataca gtctttccag acaaatgctg aattagccac cacaaagcca
55261 gcactacaat ctcaaatgaa ctctaaatct tgaaacagat tctggaaata caccaaaata
55321 gaacctcttt aaagtttaca tctcacagga cctatataac agtaacacaa tgaaaacaac
55381 aacaacaaca acaacaaggt attcaggcaa caaatagcac aatgaataga atagtacctc
55441 tcatctcaat actaacgtgg aatgtaaatg gcctaagtgc tccacttaaa agatacagaa
55501 tagcagaatg gataagaatt tcaccaacca agtttctact gtcttcaaga gactcaccta
55561 acacataagg actaacataa acttaaggta aaggggtaga aaaacatatt ccatacaaac
55621 agacaccaaa agcgagcagg agtcgctatt cttatatcag acaaaacaaa ctatagagca
55681 atagcagtta agaaagacaa agagggagat tatataatga taaaaacact agttcaacag
55741 gaaaatatca caatcctaaa tatatataca ccttaacact ggagctccca aatttataaa
55801 acaattatta ctagacctta aaaataagat agatggcaac acactaacag tgagggactt
55861 taatactaca ctgatagcac tagacagatc atcaggacag aaagtcaaca aataaacaat
55921 ggaattaaac tataccctac aacaaatgga cctaacagat atttacagaa cattctaccc
55981 aacaaatgca gaatatacat tgtaatcatc agcacatgga acattctcca agacagacca
56041 tatgataggc cacaaaacaa gtctcagtga atttgagaaa atagaaatta tatcaaatat
56101 tctctcacac cacagtgaaa taaaactgga aatcaactcc aaaaggaacc ctcaaaacca
56161 tgaaaataca tggaaattaa atgacctgct cctgaatgat tgttgggtca acaatgaagt
56221 caagatggaa atttaaaaat tatttggact gaacgataat agtaacaaat agtgagacaa
56281 cctatcaaaa cctctgggat acagcaaaaa cggtactaag aggaaaattc atagcattat

56341 ctgaaaaagc acatatagac aatccaaggc cacacctcca attctccatg caattggtga
56401 aacaagaaca atctaaacac aaatgcagaa gaagaaaaga aatataaaag atgagagcag
56461 aactaaatga aattgaaatg gaaaaaaata caaaagataa atgaaacaaa aagctggttc
56521 tttgaaaaga taaataaaat cgatagacca ttagctagat taaccaagaa aagaagacag
56581 aaaattcaaa taagctttat tagaaatgaa atggaaggta ttacaactga tatcacagaa
56641 atatgaaaca ttattcaagg ctaatatgaa caccttttatg gacataaact agaaaaccta
56701 gaggagatgg ataaactcct ggaagtatac aaccctccta gattaaacca ggaagatgta
56761 gaaactctga gcagaccaat aacaagcaga aagattgaaa tggtaatttt aaaattgcca
56821 agaaaaagca gtccaggacc agacagattc atagctgaat tgtatcagac attcaaagaa
56881 gaattggtac caatcctatt gacactattc cacaagatag acaaagaggg aatcctccct
56941 aaattattct atgaaggcag tatcacccta atactaaacc aggaaagagc ataaccaaaa
57001 aagaaaacta cagaccaata cacctgatga acacagatgc aaaaattctc aacaaagtac
57061 tagtgaactg aatccaacaa cataccaaaa atataatcta ccatgatcaa gtgggtttca
57121 taccagggat gcagggatgg tttaacatat gtaactcaat aaatgtgata caccacataa
57181 acagaatcaa aaacaaaaat cacgatcatc tcagtagaca cagaaaaagc atttgacaaa
57241 attaagcatc ccattatgat taaaaccctc agcaaaatca gcatagaaaa gacatacctt
57301 aaggtaataa aagccatcta tgacaaaccc acagccaacg ttatactgaa tggggaaaag
57361 ctgaaagtgt taccctgag aactgaaaca agacaaggat gcccactttc accacttcta
57421 ttcaacatag tactggaagt cctagccaga gcaatcagac aagagaaaga aataaagggc
57481 atccaaatca gtaaagagga agtcagaatg tcactgtttg ctgatgatat aatcttatac
57541 ctagaaaacc ctaaagactc atccaaaaaa ctcttagaac tggtagatga attcagcaaa
57601 gtttcaggat acaaaattaa tgtacacaaa tcagtagttc tcctatacag caacagtgac
57661 caagctgaaa atcaaatcaa gaactcaact gcttttacaa tagctacaaa aataaaataa
57721 aatacttaag aatatatcta accaaggagg tgaaagacct ctacaaggaa aactacaaaa
57781 tactgctgaa agaaatcata gatggcacaa agaaatggaa acacatcccg tgctcataga
57841 taggtagaat caatattgtg aaaatgacca tactgcctaa agcaatctat aattcaatgc
57901 aattcccatg gaaataccac gattactctt tacagaacta gaaaaagcaa tcctaaaatt
57961 catatggaac ctaaaaagag cccacatggc caaagcaaga ctaagcaaaa agaacaaatc
58021 tggatgcatt accttaccca acttcaaacc atactacaac gccacagaca ccaaaacagc
58081 atggtactgg tataaaaatg ggcacagaga tcagtggaac tgaattgtga acccagaaat
58141 gaagccaaat acttacagtt aaccgatctt tgacaaagca aacaaaagta taaagtgggg
58201 aaaggacacc ctattcaata aatggtgctg ggataattgg caagccacat gtagaagaat
58261 gaaactggat cctcacctct caccttttac aaaaatcaac tcaagataga tcaaggactt
58321 aaattgaaga cctggaacca taaaaattct agaagataac atcagaaaaa ctcttctaga
58381 cattggctta ggcaaagact tcataaccaa gaactaaaag caaatgcaac aaaaacaaag
58441 aaaaatagat gggacttggc cgggtgcatt ggctcatgcc tgtaatccct gcactttggg
58501 aggccaaggc tggcagatca cttaaggtca ggagttgaag accagcctgg ccaatatggt
58561 gaaaccccat ctctactaaa aatacaaaaa ttagctgggt gtggtggtac gtgcctgtag
58621 tctcagctgc cctggaggct gaggcagagg aatcacttga aactgggagg tggaggttgc

58681 agtgatccta gatagtgcaa ctgcactcca gcctgggcaa cagagcgaga caccatcatg
58741 ggaagaaaaa aaaaaacatg ggacttaatt aaactaaaaa gcttctgtac agcaaaagaa
58801 ataatcagca gagttaacag acaacccccа gagtgggaga aaattttgca aataatggat
58861 ctgaccaagg agtaatattc agaatctaca aagaactgaa acagcaagaa aaaaaaaatc
58921 ccatcaaaaa gtgggctaag gacatgaaca gacaatctca aaagaagata tacaaatggc
58981 caacaagcat ggaaaaatgc tccacatcac taattatcag ggaaatgcaa atcaaaacca
59041 caacgtgata tcaccttact cctgcaagaa tggctataat aaaaaataat agatgttggc
59101 atgggatgtg gtgaaaaggg aacactttta tattgttgtt gggaacgtaa actagtacaa
59161 ccactatgga aaacagtgtg gtgattcttt aaagaactaa aagtagatct accatttgat
59221 ccagcaatcc cactactagg catgtaccca gaggaaaaga agtgattata caaaaaagat
59281 acctgcacat gcatgttcat agcagcacaa tttgcaattg caaaaatata gaaccagccc
59341 aaatgctcat caatcaacca gtggataaag aaaatgtgag acatataaat acacacacat
59401 acatacatat acacacacac catggaatac tactacatat acatacacac acacacacac
59461 acacacacac acatacatac catggaatac tacttatcca taaaaaggaa tgaaataatg
59521 gcattcacag caacctggtt ggaattggag atcattattc taagtgaagt aactcaggaa
59581 tggaaaacca aacattgtat gttttcatgc ataagtggga gctaagataa tgaggatgca
59641 aaggcataag aacgacacat tagactttgg ggactcaggg gaaaagagtg gaagggggat
59701 gagggataaa agactatata ttacgtacag tttaccctgc tcaggtgatg ggtgcaccaa
59761 aatctcagaa atgaaaaaat tttaaaaact acaacaatgt caaattgttt gtattaatcc
59821 tcctatgcaa tcccagtgcc acttgaaagg cagtcttcaa gtacttctga aaaatactca
59881 tccccaaaac acaggcaaaa aattttgatt cagtaaccta aattgtgtgt ctggcattta
59941 attgtttgtt tgtttgcttg cttaaacttc ataagtgatt caatgaattt cgagttttaa
60001 aagccaccac tttaactgat ctggggtttc atgtattgct tcaagcctag aaaatctcca
60061 ccactatgtc ttcaaatata acctctctgc tcttccttct cttctctact gctcacactc
60121 ctgtaagcat atattagagc tctaaatctg ttcttcccat cttttagtta atctttcaca
60181 tttctgtcca tctttctctc tggcctcagg gctgtatgat ggcttaagtg ccatcttctg
60241 attcattaat tcttcacttg accttgtcca agcttgagtt tatcatatct tttgtgtctc
60301 tgcttgttat tatcaatttc tagcatttct actattatat gtatttcaat tttgcctgtt
60361 tgttttataa tttatttta tacatatact attatttaag gttcttaaac tccttttgaa
60421 cttctttgtt ttcttccaga gtaaattaat cccccagtta ctgaattcat taagttgaaa
60481 gtcaatttat tattgcttag caattgtttt cctaatgtgc tttgaaatta tgatttgcca
60541 ctgtaaatct tatcatcatc tctctgaaat gatttattcc ttttccagta attttggggg
60601 ttgccctcta cttccttcat tcatataaga tatttcaggg agcaatttta ggactctatt
60661 ctgtaatgtt ttgacattca atccagaccc agtcactaaa ccgtcaaaag cataacacat
60721 gttctgacta cgatactatg actgctttgg tttcaagcag cgagcctcca atcccccatc
60781 tcatatagta cacttctaga gaaatcaaac ttcaagcccc tttctctgtt tatagaattg
60841 gaactcagca gtgactactt atctgttgtg ttttgtctac tttcttatac actgagatat
60901 tcatcttgtt ttttaatatg gctttgtctt tttaggtagc aaaaaattat atcttcatta
60961 ttgctatgta cttatattct acctagatga ctgaattgta atatcataac accaacttga

61021 gtagtactct ttgtgctata attattatat atcatcatat aaattctatc cagctgaata
61081 tataaaaata aaaatttata ttattgtttg aaagaggtca aaagtattga tgtttaaaag
61141 tgatattttt atccatctag aaaacacaag agtatcaact ccaaagctac tttaactaat
61201 atgataatta atcctattta caaataaaat gcacttatgt acacatatat taacagtttt
61261 cctatatagc agaaataacg cattagaaat taattgaaat aatggcattc acagcaacct
61321 ggttggaatt ggagatcatt attctaagtg aagtaactca ggaatggaaa accaaacatt
61381 gtatgttttc atgcataagt gggagctaag ataatgagga tgcaaaggca taagaatgac
61441 acattagact ttggggactc aggggaaaag agtggaaggg ggatgaggga taaaagacta
61501 catattacgt acagtttcat tcttgttagg tggatagaag tgggaaaagg gtcttataga
61561 tagtaagtat aaagagattg gttttggttt gattttgatt tacagatatt ctctctcctt
61621 tacaacacag ttgatcaaaa tggattgcta ctatggtact gagtttctca taaataaaac
61681 ttttcaagaa aattatggat tactatttac cttggatgtt gaagtgaagt gaataaatta
61741 tatctcagat tagtccaata agagcagtca ttgattattc taaataccct attggacagt
61801 tccaacaaaa taggatgaaa atgccccact aatgcaactg gcaaataact tgtttaacaa
61861 taaatgtgtt cttctttcta caagagactg tgctggactt tagaggaaaa taaagcagca
61921 acaaaagtct gatactaatc ccagtttaat tctagcccta acctccctaa agaagattac
61981 aaatcaattt ggaagacaag aacaatgcat tacatataaa gcagttaaat aaaaatttag
62041 taattaaatg ggaataaaga ctatgaagca gaatatttta aaaatgataa gtggtaaaac
62101 aataagttca gaagtcaaga gtgatcctag taggctaggc gagcaggata tgtggaaaaa
62161 ctaggactac tgtttgagct cgaaatgacc aaaaaagtca tacagcgaat aactatacct
62221 gagcttaaat aggcctatag acttttcttg cataattttc tctaatttaa agtaacctca
62281 attgtgtgtg catgcatgta aatgtgtgta tgttaatgca taaacatata taaatttgta
62341 tctataaaga ggtataatat atttgcatta gaaagaaatt ttgatagtct ataactgaaa
62401 ctataatttc tggtagaact tctaagcttc ctcccaggaa aatgacaaat cttagacatt
62461 ctttcatgtc ttgagttcat ccactgttta cttacagtgg atgaaatagg tgtattcttt
62521 caaaattttg cactgcttcc aatcccaaat aaggcaaaat gaacaatagt agcaacaata
62581 acatcaaact gaaaaatttc aaaggaaaat taatattatc taaaattgag cctacgctca
62641 aagtagagtt caagtatagt cctgtataga tcatggagtg aaactgaaac gagactcaga
62701 attgacctgc agttgccctt gaaccctgac aaagaacact ctaagagaag aaaatgacaa
62761 gtgaatataa ttctcaaaat ttactaatgg aaaaagttta ctgatactct ttaactttag
62821 tggaataaag ttttggagat accacagttg cagaataaag acacttaata tccctataaa
62881 aacaccatgg ccatcccaac cactctaagt tacttggctg ataaaggaaa tagaaaaaga
62941 gagagaggga gagagttttt gttttgtttt gttttgtttg tttgtttttc caaacttaga
63001 aacaaacaca ttgttctggg gctctagaaa gatgtgtcca gcccgaaggc attcaaatgc
63061 aatttttcaa gtctaatctg gcccagtcat ggaccttctt tcatttctcc tgattgaggt
63121 atgtgataca gacagggaat ctgcagtttc ctaatgtcca gatgaccagt tttaaatatg
63181 aaagaaacta atatttatcc aatacctatg ctttaccagg aaccgttacg aatattgtaa
63241 aaaaaagatt tcttcatttg aaggtacatt tgacagacga cctctaaatc tccttttaac
63301 gataaatata ttcaattcag aagttttaaa tagtttttga acttgatgct tataaacaaa

63361 aaccaagaat gtaccactga gttgatggag gtagggaaag ttcagacagt agaatctaaa
63421 tgaggaatca caaattcact taaatgtaag gggattgggt gttaagtgta aatatgagac
63481 cttctcattg ggaagactca atgtctgaaa agggggttga atttctggct ctgcacctgc
63541 agcaaatctc caagacttag atcctttgtc cggaaaatgg gctaattttg gcggggagga
63601 agtgaagggt ttcactattt atttatgaca aatattcaac actcacaatt ctctccaatc
63661 agaagttctt tgagatgctg ttggtcttga ccagtcagag aatggagtca tctgactcac
63721 ccattctgag aatggtccta cagacactat aggttttaaa ttggccatta aacctgccta
63781 taaccttgtc aaccttggct aagttcatct ggatggatgc atggtccttg gcacccatga
63841 tgcggttgct ggcggaacat ttccactgca tgttcaggtc cacaaactca ggctggataa
63901 tatcaattat gttcaattac agagacatgg ggagagtcaa atgagatcga gtaaaaaatg
63961 tgcatgaaaa tatccacaat ctgtgaaaga ctatgcaagt gtattattgt cattgaatgt
64021 tgttagcaat agcatggcca ttttttactt acaaataaat attgcagttg acatattact
64081 aactctaaga aaggttcaaa tttacatgaa caaataaaac ttcaggaaag aaaactagag
64141 ttccacttgg ggactacgtc tgacatggtt atattaaaca ttttggaaca attaatttgg
64201 ttttgttgtc tctcttctag gatttttaaa catttataaa ttctcaattc tttctattca
64261 atctaaacat tttacaatat cctgtggacc ttacttcctt agtagattcc cagaaggtaa
64321 tgatttgctc ctttctgctc tccaagcagc ttctgtgttg gtgcagagtt gcagatctct
64381 gttggtggta ggttctattc tgcagaaacc ccctaatcct ctgtttacca caacatgagt
64441 ctattgccat agaaatgata gctgagatcc cagattgaac accactgact tcacagcagg
64501 gcctggtaag aggagactct aagctacaag gggggaacgc aatgtatgag aatagtaggc
64561 actctgtagc cttgaaagaa agggtaactg tcaacattag aataaaaatt catgaaagag
64621 ctacattgtt aggtatgctg tagtttattt tctgtataat actgcctggc taaaagtaat
64681 cattctgaaa tcttatgtca tttaacagtt tgctttcaaa aggtctgcag ttttccttga
64741 ttgcatttgt ttcttattga aataagaaac aagcagcttc taattaatct tgttgcacaa
64801 ctgatgtttc tgtggtcaaa gatttccctt ttcatgatgt gttgttttgt ttgcgtgttt
64861 attgtgtgtg tttgttttgt cttgttttta ttaacagaag aaagtgaacc cgaacaagat
64921 actaaaggta ttttttttte tttctgcatg gcttcttttt aattgtgtag ctcttttcaa
64981 ttgtttattt ttgttgacct tataaacagc tctaagtgcc atttttaaag aaataacaaa
65041 caatgtatgg ggaatattaa gtcacagcac ttaacggtgt tattagatag gcttctttat
65101 tatataatat gcttactgac catttgcatt tcttaagcaa gattgagtta aaagtaatgt
65161 ttaaatttgg tgtctctgga aatacaaaca aaatgaaatg aaataaatca gcatgagagt
65221 ataaatccca catagattgg aaaagaaaga tacccctttga ctaaaagact tttggtgggg
65281 gttgggggge tttacagtct ttggataaat gttaggatgt caaggtgcca atttggtttt
65341 tattgtgatg atttcaacaa gatcaggagt attatgcaat tgctccaaat caataaaaat
65401 taagttattt taattgcaca gagacatatg tttgtagtgg aatatgttta gaggaaaata
65461 gctggaaatt aaatttgtat gggaaaaatt ctacttttte cccaacagtt ttctgtcaac
65521 agtttctgtt ttctgtaaaa aaaaaaaaaa aaaagaaaaa agaaaaaaaa aaaaggtacc
65581 ttgcattctg attaagcccc aaactttgtg ctcttctaac ctaaaatttg atatttgggg
65641 gatgaaattt gtgagttctc atgtaataga gttgactgta ggaattaatc tcaaactggt

65701 attatttaaa acagtacctc cttatcttag tatctcatat aaagtacaga taatgttttc
65761 ttatttttaa ataccaggtt gcttacaatt aaatacaggt aaaaaagcat tttacctggt
65821 cctatgtgaa tttttttttct taatttattc ctatcagtca ttgctggttt gaatcatgta
65881 acctaaaaac ccttttcaaa ggaagctaga aaataacaaa agaggaaggg aaaataaaat
65941 ccatgggagc tccttgtgtc ctttgaaata actgctcaga aatagaaatt gataagagac
66001 ttaagtattc ctctggcact gctcccttac caagaaaaga gaggtagttc atctccagcc
66061 aaaccactca tttatttcag gacttaacat ggatgccctg tcccttgggc tttttattac
66121 actccagtgc aatttcagag tgaattatgc ctttatcttt ttactatacc ttactcctta
66181 agatgacaat caataataaa actgattaca tatctgaaag tgctttgaaa taaggagaga
66241 gagagaatat aatgtgggta tgttataaaa gattttagaa ttgctggctt cttgagccca
66301 attttgaata taggattctc cacttgcagt tagcctgcaa gtctgctcaa gagacattaa
66361 agccccaaac tcatgaatag atcccatgag agaaaaccca gagttaaata tattaccttg
66421 gtctattttc catgttgcag atgcacttgc ttacccacag gaaaccaagt ggtttagggc
66481 tcacagtgaa ttggagaagg atggataaga ctatgtacag aaagaggggt ttgatgattt
66541 ttttgtttaa aaatccatat caaaacagtt ataaatgctt tccaacttac taagtaattt
66601 aatgttcctt ctattaagtg gtttaattgt ttatgtaaca aaaacacttt tatattcttt
66661 tatgcagata aaacacaaaa tagggatatt ctatgcccat tttatttaat aagaaacatg
66721 tcatataact ttttaaattg atgacctaga atgcattttc agattgtgac taccactgaa
66781 ataatgggat ttactgttga cttgtgtcca agtttgttat tgccggtgta ttattattca
66841 tggaggttaa tctggcattt atttttaatt gcaactgact ttattgttta caatgcttga
66901 aaaacatgtc aaaatttccc tcatcacctt tttacctttc atatttgaaa aatggtaaat
66961 ttgagtatta tgcaattgct cagatagagt tgggtaaaaa catatcagct ttattgctga
67021 taaggctgga atgaaaaata aagatttcta ttccatgtga ggattagact aacataactt
67081 atgtttcctc atcctcttcc tccccacccc actctttccc cttgactctt agttgtagga
67141 tgaagaagcc ctgacctggt aaacttactt acacacatca accctatatc cttcttagat
67201 gcaagagagc tgggagactg atagctcaga ataggattga gatacacata acatatccaa
67261 gtcccttccc ccaaccttac cagagaagtc atcatgttcg ttcatttatt tattcgttca
67321 ctcagcaaat attcattgag tgcctaccat atatatatac catgcagggt tctagaaata
67381 gagacagata tgtagataga tatatagatt gtatcagtca gctcatgtta aaaagcaaag
67441 caaaccttgc ccttgtgatg cttacattct agagaggaga gactgacaaa aaacaaacaa
67501 gcaaacaaat aaatcagtaa ttaccaaatg attcagatag tggtgatatg atacaatata
67561 aacaagggta aggggaatgg ggatgagaaa gtactatgat aaggaaacat ttgagtagaa
67621 acccagaaga catctgctat ctcctttgag aagggaggaa gactgggagg aagggtggaa
67681 actaactttc aatactgaaa aaaggggttt gagtttctat tttatcattt agagagcatg
67741 tgagagtgca ggagaaagca gcttcccttt aatccctggc cttattgtcc tcttaaccta
67801 atccactgca cttaatgaaa cccatggtca gccatagcct atctgccccc ttcagggaga
67861 agtttatcag cagtctcata ttcatgaagc tacctataat gtcagcagta ctcctgtacc
67921 tgcctgtgcc acactggagc ccccagaaag ttcccatgga gggcagagta ttacattagt
67981 taaattaatt ccaaagtcac gttgaattga ctctgtttta tttaccatac cacactatgc

68041 ttagttgtgt tgtgcaatgt ggataatcag aggtttcaca ataagcccaa atgatattcc
68101 aaatataata acagccaaaa gaaaaaaaac tgctataaat taggacaaaa taaaaccttt
68161 ccaagaagaa tttaaagtcc ccaaattaaa actcttggct tcataaatta aagcagcaaa
68221 acataatcga aattacatta ttctccaatt ttttattctg ctcatcttca gccagaaggc
68281 tttcattcaa aaggcgtttt tgattcaaaa agttcaaggg tatagtcaat gttactagaa
68341 cagttttcta gcacatgtga ggttgaaatg tgctagattt tccaaatctc tcaaagatcc
68401 tgcttgtttc agattctcgg gcagtgggat ccatagatgg tcatgcagta gtcccacact
68461 caaaaaattt aggaaacaca agcatagccc caacccctac aagagttatt ttagccagat
68521 gatgcacatg gactctaagt ctccattatt gtaaccagaa aacattagaa gagtacctgg
68581 acgcaccctc actacgatgc ctgtcagtgt tagttgtcaa gagtctgtaa cgtgtgaatt
68641 tagattaagt tgggagaata agaatccaag cagaggcaca cattgcattt gggtgatatg
68701 tctcttaagt ctcttttaat ctataatgga tcactctttc ttttttaccc cctaatgcta
68761 atgattttcc ctgttaaata tctgggtttg attgaattgc atctccatag tgttctttga
68821 aatgttcctc aacccttaa tttttgtaga ttgttaattg gaccccagga cttacttaaa
68881 atcaggctca attttgcttc tgggggacag attcagcttc attttaaaca tttgatagca
68941 ttctttgtta ttttttaata atctcttttt gccttgaaga cagcaccttc cttgcatttc
69001 ttttctcctg gttttgggac ccacatttct atatctaaaa tatcaatatc aaaagatagg
69061 aagtcaaatt aatttaaatc tgcaaaaagc ccccaatagt caaacaaatc aaatgttcct
69121 taatctcttt aaattatgca atgcttttta agaggtactc aacaatgaga ccaactggaa
69181 acactactct ggacctgttc tatcattgtc ctgcgtatct ccttatgtag cacatgtggt
69241 ctcccatact ttagtttaga atccaatatt cacaaatttc aatttaacta gaattaagtt
69301 tcaaagcatt gtgctaattg gggcttcata ctctaatatt atattctgtg cttaagtcct
69361 agaaatcaaa aagtaggagc ataaaatata cttacagtat aataggccat ccaaaagatt
69421 ccgtaatagt ttaaacaaac actgaatttg aagtcagaag acttgagtcc aggtttctca
69481 ctcatcattc ttgttacctt gggaaaccaa cttacttaaa ttaacaaaga tttggttttc
69541 actgctataa gataagaaca ggaatctagc caatctctgg agtctcttcc aagtttaatg
69601 attctgtgaa tctaagtacc ctccaatttg taatgcattg tgagcctcaa tcccactgtt
69661 tagttaaagg taaaatttct tcctacatca aaataacctc ctcttactta atcagtgggg
69721 attcagggtc agaaaggaat agaaattact cattctgctg cctacacttt atctaaaata
69781 tccttttttt tttttgccca atatatcatc tgaaaagttt gacacaattt gtctgccctc
69841 ccactatgat acagttgagg gtgtaaagtg taattatttg attaattcaa taaaatacta
69901 tcctgtgctt gctctggtca ggaactctgc ctgaaacaat acagcagtca acgaaaggca
69961 aggcttttgg cttcaaacaa tctaatggga aaggggaata atagacaagt aaaaaataaa
70021 taaggtaatt tcagatagtt gtaaggtctg taaagacaat aatgtaggct gatgaaaagt
70081 gaatgggggg aggattacac ttgatgttgt gtgagtaaga aggacctttc tgagaaaatg
70141 tcacttaaac agagacttga atgattcaag gaacctacta cttgaggatc tgggggatga
70201 gtggtctagg cagaggaaga acaagggcaa gtttccatgt taagaacaag ctcagtgtgt
70261 ccttgagtgg tgagaaatat agggttataa cataaagggc ttggaggctc ggccatggca
70321 tgtggtatta tccttaaaac agagcaaaca ctgaagaact gcacacaggg gaacatggtc

70381 taatttgcat ttctaaaaga ccaccctagc ttgaccattt cctgcaggag cgtcactcac
70441 cacttctgtc ttcctaacag tttttgccag gatcctgcgg gctcctgaat cccacaatgt
70501 caccttttggc tcctttgtga ccctgcactg tacagcaaca ggcattcctg tccccaccat
70561 cacctggatt gaaaacggaa atgctgtgag tgtcatgtgt gtggggactt gtctggggaa
70621 gacccattgg tggtgaactt caggatagac catatagttg tagttaccca gatctctgtc
70681 attggtctca cctacaccac ttttcaaagc ctcccaatat ctttgtccta gaagccattg
70741 ccatagaaat caaactccaa gagtttgctt ccttccatgt atcatgagga atactagaaa
70801 accaatttct ttctttgtgc ctttgtgtaa atgggaagtg gtaataatat cttcccatat
70861 aagtaaaata attttcatta aactcatcac cgaaagatta gttccctgct agaggctact
70921 ttgatggaaa gtaatccgga gttagaatca gtgtcagttc agcattcttt tcttcatttt
70981 caatagtggt aataataact gatgtatatt aagtagttat tttcagccag gctctattcc
71041 aagcacttta cctacataca tttatttatt tatttattca ttctacaaat atgtattgag
71101 cttctgaaca tcaaacacta ttctaggccc tgtggataca ggagtaaaca aaacaggcaa
71161 agttctctgc cctcaaagag cttaccttct catggggaaa tacgggaaaa tatatgttgt
71221 atgtgtatgg tgtcaaatgc catgcagaaa aataaatcag gaaaaggaga cagaaagttc
71281 aaccttagga gaaatcagaa ctctcctaca ctgttcatgg gaatgggaat tactacagtc
71341 actatggaaa acagtatggc ggttactcaa aaagctaaaa atggaattgc catatgatcc
71401 accaatccac tactgggtat acagtcaaaa gaaagaaaat cagtatatct aagaggtatc
71461 tgcactccca tgtttattgc ggcactattc acaataacca agatatagaa tcaaactaag
71521 tatccatcaa tggatgaatg gatacagaaa atgtggtaca tatacacaat gaaagaaata
71581 ttactaatcc ataagaagaa taaaatcctg ttatttgcaa caacatggat ggaaccgcag
71641 gacattatgt taagtgaaat aaaccagaca cagcaagaaa agtatttcat gttctctttc
71701 ataactaaaa aaattgatct catggagata gagagtagaa tgatggatat cagaggctgg
71761 gaaaggtagt ggggaaggga ggataaagag gggttcgttc atgggtacat aagttagaag
71821 gaacaatatt gagtgcttag tagctttatt agtcagttct cgcatcgcga taaagaaata
71881 cctgagactg ggtaatttat aaagaaaaga ggtttaattg gctcatggtt ctgcaggcta
71941 ttcaggaagc ataatggctt ctgcttctgg ggaggcctcc agaaacttac aatcatggca
72001 gaaagcaaag tgggagcaag acatctcaca tggccagagc aggaaggaga ggaaaggtgc
72061 cacacacgtt taaacaacca gatctcacaa ttcactcact cactatcatg agaacagcac
72121 tgaggggatg gtgttaaccc attcatgaga cttctgtccc catgatccaa tcaccccacg
72181 ccaggcccaa ctccaacact gggaattaca attcgacttg agatttggtg gggacacaga
72241 tctaaaccat agcaatagca caacaggaca actatacata gttcacgata ttgaactaca
72301 tagcacaata caatatttaa gtatttcaaa atatcaagaa gagtggaatt ggaatgttcc
72361 tagcacaaaa aaatgacaaa ttacttaggt gatggatatc ccaattatcc taatttgatc
72421 attacacatt gtatgcttat atcaaaattt cacatgtacc ccataaatat gtacaactat
72481 tatatatcca taaaatttta aattaagaaa cattttaaac agaaagttag acctcaggag
72541 gaagattata tttttaaaag aatgatcagt gaaggctcat ttggacaaag acatttgaac
72601 aaagatctga aggagttgaa gggtgaagtt acatagataa ctgggggaac ataactagac
72661 aaagtctctg agataatggt atacatggca tgtcagaaaa acagcaagga gaccaatgtg

72721 gttagtgggg agtaagcaaa gggtcaagag atgagaggca ggcattgtgg atcctatagg
72781 ccgtgtggtc atttagacaa ctttgctttt atttgagtga gatgaggtgc cactgtaggt
72841 ctgtttctgt tgtctgtttt cccactgatt cttgttcatt ttgtgttgtt tccttgtgtg
72901 cctagctatc tttgattacc tgctgtgcat tgttttgtat aaaaatatca ggaactattt
72961 tgaggtctag atgaaggtat tttcctccaa agagaatttt gcttgtttct gccagggaca
73021 agaggttact gctaatcttg taccaccttc aactaagctc aaggtatgaa gctccttggg
73081 catcccagat aattataaca tgaccagtaa ttcattatgt ggactattta acttgtagtt
73141 cacactgata gctccctgat atctagttct tttatatctt aatttattat atctcttatt
73201 agactcttaa gggcatgaag ttttgattta tctcctgact ccctaaggcc atccaaagga
73261 aagttcaaat tttctgggtt tggaaaactc tctaagggta aataagattt tcttagtttg
73321 ttacatctgt taaaaatttt tttttcaaaa ttttaatttt ctcactgtgt agctttgtct
73381 gaataaccta acatcaacat ctgagacaga aacctaccat ggatttttat tgtcattata
73441 tagactttaa ccactttggt ttgcaccgag tctttagttt ctgatactct ttatgaggtt
73501 aagaaaatgt atttttattc ttaatttgat aattattttt aatataaata tattttaaaa
73561 tcaataaaac acttcatcat caattacatc ctctttttga tgtcattttt cactttaaat
73621 tgcaaagttt cccttatatt gaaccattct ttcatttctg aatacattgc ttttttgttt
73681 aatttttaa ttgtgttgtt tcaattttct gtatttcttt caggattatt tgcatctatt
73741 ttcaataaca gaaatggttt tgtcttttag taggctatca tgatcaggct ttgttaatat
73801 ttttccaatc ttatagaata gactgccaag tttacatagt ttcctttgat acagagcttg
73861 aggtgagaaa gttgagatgc aagtctttct tatactccaa gacattttcc tctactatac
73921 caataattac tgcttctctc ttctccacat cctttctatg tagactccat tgaaatgaat
73981 ttctttcaaa acttcaatct ttctcttctt tatgctctgc atatgtttgt ggaggaaata
74041 gggggcccta ttttatctgt caggttattc tcaagctcta gtgtccacca tgattgtcaa
74101 ctataggaac ccacaacaga aaatctcatt cgcaatctct atctcacagg tagatgcctc
74161 agcctggtgc catatgcata cattatagct cccagagttc ttcaattact ttgctgactt
74221 tcttaaagtt ggctcctgct tacagcccct gctatctgaa gtttgaaatt ttccatgact
74281 ttgtagggaa aatgtatcca ttctcctctc agtaaacctc ttcttttgtg ctaggtttca
74341 gctacttagt tgatgttaat ttttctatct atcaaatcac ctctttttat cttccagaat
74401 ttgctggaaa tatctgatcc tttgattata ataccatctt tctatatatt tacttttctt
74461 aattttgtat ttatctttta ggatttcagg tccataaaca agggttaaac atgtgagcta
74521 agattattat tactgtaact ctgatgttaa tgaacatgac ttgcatagag cactatctta
74581 ttattttctt tgtcatttaa aaatattcag cagagcaagt tcttttgcta ctatctaagc
74641 ctaccttaag caggctctgt gatttttctg gttactatta gatgatttga aatcattaac
74701 attatcccaa cttagtcatt taagtgtcta gtcctaagta ataaccaaag catccaatgg
74761 cattcacagt tcctcccttc tcagggatat ttcagcttaa ctttcatata agaaaaaatt
74821 gcagttggct tcttacctca tgctcactca ttcttccccc atttcctagc tgctctttat
74881 gaccccagaa ggggtgggtg ggaggtaggg aggagcaata actggtgcaa gagagctcta
74941 attcaactga tgcacttgta agttggcttt ataccttctg tgcctgccag atatttaaaa
75001 ctgactctta ccctcataga cctattcatg attcttcaga aatcagggaa cattaagatg

75061 ataccagtga tgcattttcc tcaggctatc catctttggc cacattagca agtccccaat
75121 ttgttagttg atggaaagtc tctttgtgtt ggggtctaat cagtccccca aaaagtcatc
75181 ttgggaggac tgaaaatgac tcccaatcag atcttctata aaacctttтt attgacaaac
75241 tctggaagcc cagaccattg gactctgtct tctttgttcc ttccattgga gctgccagac
75301 atcctttaga ttttacaggt gggaattaca tacttgtcta atgtgtctcc aaattgcaag
75361 tgtgttagag tccccaagat cacattcatg tctgatgatt catgagaagg actcacagat
75421 tttagataag ctgttatgat tatggcttat tgcaggaaaa ggatatagat taaaatcatc
75481 aaagaggcat cagttttcct cttctagtga agttgcatgg acagcacttc attctcccag
75541 caacaatgtg tgacagcatg catgaagtat tgtcaaccaa ggaggctcac cctaaccttg
75601 gtgtccagag tttttactgg agctcagtta catagatgtg gagtgctcac ataactagtc
75661 ttagctagtt tccagcccct ccaaaggtca aactaataca acgtggccta ggattccaag
75721 tattcactat cattcacatt attatcataa accatccagc attgcccaaa atctcagata
75781 tataaagata ttcttattac acaggatatt ccaaggggca gaggtcatct ctcaggagcc
75841 aaaggccaga cctttctttg gaatgtgtag ggtttgagca cctcgagccc attgagttag
75901 cccttcaact ttttactgca cagcagtaaa acacatttat aactctccgg gtggtcccat
75961 ggaggatact tttatccctt aaggagatgg gtgcatgtcc aacccagtcc tttgggtgga
76021 ttgagaatgg ctttcaatat ggctgaacaa cccaaacctt tataactcat ctaactggtg
76081 gctattttca gttttcattt cctccaggac aggctgtcca acttttggt atcttggctg
76141 tagtgaacat atattatcat attacaatat attaatggta ccatttggag atcaaagaag
76201 tgtcccaaat cgggacactt taatatccac atcatcccaa attgtgttta atgcaagcat
76261 cacaacaaga aaatggggga cttcttttta aggaaggcaa aaccttatgg tataattcaa
76321 atgatattaa gtataatttc tacccaatcc aaggcacatt ccttcatgga cttgaactat
76381 ttcatgtctt catgactttc tcttctccag gattacatta gtatttaggg ctgccataat
76441 agaataccac agatagggtg tcttaaaaaa cagaattttt tttcctacag ttctaaaagc
76501 tggaagtcca aggtcaaggt gctatcaggg ttggtttctg gtaaggcctc tcttcctggc
76561 ttgcagatgg cttcacatgg ttatctccct gtattctcac agggctttct ctccttgtgt
76621 gtgcacttct ggtgtctgtg cctacaatga tgagcgccaa aaatcccaga gtgtttttтc
76681 ataacacagt tctcattcca aaatagtttt tattcctctc ttttatagac cattataagg
76741 tttcttcctc taaattaaat aacagtgact aaaactaagg caaatactct ggagcaaaat
76801 aaaaactaaa aaacagatag ccttaaagca ggaagttacc ctgtcactag ggcttggcat
76861 actgtaggct ttagaagcat ttcgcggcat gaaagaatgg taaccctgag gcatctccat
76921 gtaataagtt aatttgtata ctgcttttaa ataaagttaa acaacttaca gtttcagaaa
76981 gatagaaggg aagagcattc ggaagactgg gagtgaagtt tcccgggcct gaacccttat
77041 tcaaaggcgt ctcgacatgg ataacctcga gaacattatg ctaagtgaaa taagccagat
77101 acagaaaggc aaataccaaa tgatctcact tatatgtgga atctaagagt tgaactcata
77161 gaagcacaga atagaatagt ggctgtcagg gatgggagga tggggagatg atcatcaaag
77221 ggtacaaagt ttcagtcatg caagatgaat taagtactgt agatgtaatg tacaatatgg
77281 tgactacagc taacaacact gtattgcgca cttgaaattt gctaagaggg tagatcctaa
77341 gtgttctcaa aacacacaca caaaggtaac catgtgagat gatacttcac tagcttgatt

77401 gcagtaatca tttcataata tacatatata tctcaaaaca tcaccttgtt caccttaaat
77461 atatacaatt tctatttgtg agttatacca ccaataagct aaaaaaaatt aaaagtctaa
77521 atttttttaa aggagtttca aaaactaatg ctttgctcta tacttgtacc tggccccacc
77581 cttgtctctc taaagcaggg tgccctagga agactgattg gctgtagccc caaaaggtga
77641 gaactaggac ataagataag aaagggaaga agggaaaggg agagaaggaa gtggggaaca
77701 aagtgcgtca atgtgtgaaa ttttagttgg atgttgtaaa acaggaaaaa aaatgccaaa
77761 ttctatggct accccaataa caaagaatgt cttatggcaa tggcaccctc caagtcatat
77821 aattcattta ttattgtcac tttcactatt gttttcgctg aagtcttttt tctgttactt
77881 gaacaaaatc atttttttcg taatttgtta ataaaattgt ttcattttat ctgtctatcc
77941 tacatccctt caaatacagt acacaaacaa atgaacgtgc ttttccagct tgtaacttga
78001 ggcatggtag aatgagaatt agatggggag ttggaagact gaggttgtaa atgcccctct
78061 ttagttaatg tgattttggg gtccgtttac aactcagaca ctgattttct catatctatc
78121 tacactaaca cagacgtcag gtggctgtca aagatgatct ctaatggtat aattagagac
78181 atcagggcta atgttctcta attttgtcca gttatgataa agtaacttgg agtgcctgtt
78241 ctttacctct ctaagaacgt ttcaagtgtc atttaaaatt tgattcttat ttgtcaatgt
78301 gttttttggc tcctctgtgg aaactgttat agtcttaagc ctgtcaaggg agtataaaga
78361 catcctaaga aaatttggag actgggccgg gtgcggtgac tcactcctgt aatcccagca
78421 cttttggagg ccaaggtggg aggattatga ggtcaggatg gagaccatcc tggctaacac
78481 ggtgaaaacc tcgtatctac taaaaataca aaaaatttag tcaggcgtgg tggcacatgt
78541 ctgtagtccc agctacttgg gaggctgagg cagaagaatc acttgaatcc aggaggtgga
78601 ggttacagtg agccaagatt gcgccactgc actccagtct gggcaacaga gagaaactcc
78661 atctcaaaaa ataaacaaaa taaaattggg agactgacaa tataacttca ctaatttgtc
78721 tatgtaaaaa tagtaataaa gaaaatggaa aggtatatac tttttaaatt tctagtattt
78781 tcaaaagatt catatgaggt tataaatgga agataaatga ttattctctg tcgaagttta
78841 ggaataacaa gagtaggata gtttaagata gttgaggcct tattgagacc ccaacttatt
78901 cattcaacat gtgactcaca aaaagtgaaa ggcaaaatag atttatcacc tcagattcta
78961 aaacaggaat aaaacaaaca aagtgacttt catccaggaa gaaagcaaaa gtacatccgc
79021 agttcttacg gtcagagagt gtgtgctgct cttagagcca agtttagttc ttggtaattc
79081 tacccaagtc tgaaaggaaa tcaagatgac tgtccacatt gacgcaaatc acaggacatg
79141 gaggcaatgt caggcattta atgttgtaaa agttgcaaac cagaaatccc atggaggaga
79201 acacagagaa tcctatagtc ctgatatcat ttttggtgga atgaacaaag acgaacgcag
79261 agctgggaga tatttggcac agaatgaaac agagtttgaa ctgtggctct tcactcacta
79321 cgagttagta aactaatgcc atagcacgct gctcagtaca atgggtactc tgaaagaagt
79381 gagtgctccc tttctcccct gctgtgaacc tgccagtgaa ccaaaaccct taacagttag
79441 agccaaagag caggagaaag tccagcaacg tgtcccaaag tgattagaaa ctatcttgct
79501 ttcctcctat ggaaatacca agcatttttt gtggaaatct gaattcacag atgaagttca
79561 gagtgaatag taacattcct tttgttttac aatcttggaa atagtagttt ggcatggaaa
79621 gagcagagct tacttttaa aaagaaaatt atttgtattt ttataaccag atttatttat
79681 agttatacca gtaatatctc tgttattttg gcatgcaact aaaaaatata gaaaaatttc

79741 atgtccctct tgctttgtcc aataaatata atttctaaaa tattgtagaa gttgaataat
79801 tttaacttgt tagaagaatt ttataaaata aacagccaaa tcacctaggt tgaaggttgt
79861 cttttagaat tttcttaaag ggaggcatat ctatatttag acatattttt aagaggcagt
79921 agttttgctt taaaatatat gacctgtgaa gtccttttat cttactagct gtgtaaacca
79981 aaataattac atgtaacaag tcttatgtgg aataattcag cagccagttt gaaagaggct
80041 aattaatatt tgtggctaca ttaatcagaa aaactatgga aatgtctctt ggtttattat
80101 ccctttttct atgattcata aacagacatt attacaactg cataaacatg aaccctactg
80161 ggcaacatcc ttttttttt ttttattttt ttccccaaga tggagtcttg ctctgtcatg
80221 aggctggagt gcagtggcgc gatctcagct cactgcaacc tccacctcct gggttcaagc
80281 aatgctcctg cctcagcctc tggagtagct gggactacag gtgggtgcca tcaagcccag
80341 ctaacttttt gtattcttag tagagacagg gtttcaccat gtgagccagg atggtcttga
80401 tctcctaacc tcgtgatctg cctgccttgg tcttccaaag cgctgggatt acaggcatga
80461 gccactgcac ccggccctgg gccatattct aacagttcca caggatattt ccagccagct
80521 ggaactatct gcaagacagg gccattgagg ccagaatacc tttcagaggt cttccctagc
80581 taaggtcaaa tcataaaatt atcggattat ccatagctgg gggtggattc tctcaagacc
80641 gcattagtaa tgtattaatg atacattaag aagtactcca caggtctata actgctcaat
80701 caccttcaaa gagtttttac acacattatg tcaggcatga attattatgc ctatttaata
80761 gagcttccta tcctactgcc tctttttaga aaaaaaagtt ttattgtgat ctttattgta
80821 tacatttaag gtacaaaaca tgatgtttag ataaacatat acagtgaaat gattactata
80881 gtcaagcaaa ttaacaagtc catctcctca catagttaca gctaacttag aaagacagaa
80941 catcacaccc agagcaggga gctgtgtctc cagctccctc aggtccatat acctgagtga
81001 cttggagaaa atcatgcatt tcctgtaact accagacgta gtcacctcaa ttaagtaatc
81061 tgttttgctt aggcatacct tggtaaaagc tcacagtact aatctggacc cacccctttg
81121 atctttgaaa cctgaggtgc gaaaaaatat caaaatggag ggcagaggga tttgttttta
81181 ttttcagatc atcaaaaata ctaaactgtt gatcagaacc atccatgaag aaagaaaaac
81241 aaattcaaac tatgactaat ggggcctgct gtgcgtgagt cacaaactga atcaagcaag
81301 gcctctggaa gcaggggggaa aagcattcag gagtcacttt gtactcaagc atgaacctcc
81361 taaagtgttg gtctctttgc tgaactattt caacacctgg atgaagtcca ggagaagaga
81421 cgtcaggcag tttaaaaatt gcttctcttt cctactaagg atgttttcag tgaccttgag
81481 gaggtgttta agaatgactt tcttaggtgt gaacatgaaa acagtgggac ttagggcaac
81541 atttggggag attccttgct tcaaagttgt ctctaaggca ttgcacattc ctacttcttg
81601 caggagggaa ctgtctttcc aaaggatttt gcaaactgtt ctgcttttgc ttatctaaac
81661 tggaaagaga tatataaaca aaatataaaa tacaaaataa cataaagtct gttgattgag
81721 catagaggct tggggtcttt agctttttt cttattgttg ctttgtatta aaattcaagg
81781 gagtccaaat attttcagtc cccttgatct aactgggata ctcatacaat gagacattgc
81841 acttctgata aatatgataa tgatgagttt agtttgaatt cccaactgag tgcatgtctc
81901 ttaaaaacat ttttctcttc actttgtaaa tttcttatag agtctaggtt gctcatctgg
81961 ggaaaatgcc acaatacttg atctgacctg gaaagattcc cagtgaaggt aaattgatac
82021 tcacataagc cagtttttat cataagaatt gagactagta ctgaaggtaa agaataaaaa

82081 gctagttgga caaacgttca ctgcatgatt gctacacagt gcttggtgcc agggatagcc
82141 agccacctgg cagctaggaa gaaagctggc cttacctcag agctttcttc ttcctggcta
82201 gtcaaactgt gaaaatcctt tctcatgcaa cacaataaaa taattggctc caaaatgtct
82261 cattctcagc ctcattccct aatactggac acaggaatct ctttcagcca agcagccaag
82321 ctcaggccaa catgggacgt acctccactc ctttaagata aagtcaaagc ataacaccag
82381 ctgattcctt aactgtcatt tcactccagt ttccctcaat tggcatcatg tttccctgat
82441 ataagcagcg ttaattaaag attagttatt gaaaaggtgg tattgtgctc aagaaaacag
82501 tgaaaaaaga accaccattt aaaaaaaatg ccaccacctt aacaatgaca tttgtcagat
82561 atgtattttg ttcatggttg gttgatttgt taaggtagtt gttactcttg ttttctaatg
82621 actgctcatt tgttctctct tctaggacta gggaaggcac tgtaacataa tgattaaaag
82681 cataggcttt ggtgtcagac acgctaggat gcaaattcta actatgcaac cttgtaaaat
82741 gtgctgggca gctatctttc ctacagagtt ggagtaatgt tgactaatat atatgcattt
82801 gtataaatta agctgttaat tgtgtgtcaa tattgcattg atatcttggc tctttaagga
82861 catttgattt tctggtttaa gtagtacctc ctgcatgaac ttcctgacgt gttgaactat
82921 ttcaacacct ggatgaagtc caggagaaga gaggtcaggc agtttaaaaa ctgcttctgt
82981 ttcctactaa ggatgttttc ggtgaccttg aggtattatg tatgtattat gtatgtcatg
83041 cctcagagac agacttggct tcacaaccat ttttcctgac aaccatccac ctatctgaca
83101 tgcatttatg gggaactgaa caggagttat gaaaataagt ccttaagtct gcaacctctc
83161 atacttaact gtcatctgta ggacactgaa gacatatatc agaggatcca caccgtatat
83221 aattcatgcc ttgtattggt tatctatggt tgtatcacaa atcagcccaa agcttagtga
83281 cttaaaccaa taactattag tgctcacaag tctgtggttc aactgggtgg ttttgctgat
83341 ttggttttgc tgctgggcag gactgcctga tcttggctgg tcaagttcct gtgatcggca
83401 gattgaaaag gtggtagttg gttcagaata gccttatgcg taccttggat ggttgttgtt
83461 ggttcccacc tggggcagag gggataaacg ggccaggtgt gtttcatctt ctaccatgct
83521 ggctcttgct tgtttatagg cagtcccagg ttccataaac aagaaagcaa gccacaatgt
83581 gcaagaacgt tagtttctgc tcattcattc caaaacacat cacaaggcta atctagattc
83641 aaattatgga ggaaaatgct acttcttgag ggaagagcta caaagtcaca ttgcaagggc
83701 atggacacag ggagggaaaa tcttttggct atgtttgcag tgtaccacat gcacttgatt
83761 ataatcttaa tgcttttccc ttcaaatcta ctgacatagt atagtgggaa atccttgact
83821 gagttctttt attttccttt actctgtcag gtttcttctg ggtccattca agagagtgtg
83881 aaagaccgag tgattgactc aagactgcag ctgtttatca ccaagccagg actctacaca
83941 tgcatagcta ccaataagca tggggagaag ttcagtactg ccaaggctgc agccaccatc
84001 agcatagcag gtaggatgcc ccttcacatt tgcgttgttc caggagaggg gagagttgat
84061 actattctac aatatcgagc attggagaaa atctcccttt tcttttatct cttatttcag
84121 ttgcatttgg gctatttcct cccccatggg gatactccgg aggtgaccta gatatggatt
84181 ttggcagatt tgctgcctgg aaaactaaat cctcaatacc tacccaagtg gtaggtaaca
84241 gcttccagga actcacttct tccttccttc ttgtttttct tatctttttt ccttttctcc
84301 atttctcttt cctccctccc tccttccctc cctcgctccc ttttttcctt ccttctttcc
84361 ttccttccct tattccctcc ttcattcctc cctccttccc tccctccctc ttcccttccc

84421 tccctccctc ttttcctttt ctttaatttc ctttcctttt ccccactcct cgttctctct
84481 tttggttgat caaactttcc aagtctctca tggagaaagt tggcagacat tcaacatggt
84541 catgccaatt tctgcatggc tatttcttgc gggcattttt acctgtgagc atgatccctg
84601 tggtctttcc cttccctgct tcagcaagcc acagcaggtc ttacaggtgt tttcaagaaa
84661 aaggctgaca cacggatttc taggatgttt gtgttgagtt ctaaaggttt atttttaaaa
84721 tgtaaatgtc ccaaaggctt ctgagaacat ttatagaatt cctagagatg gaaataatcc
84781 ctgtatcagg aaatgccagg catattagat tcatagcgtg cctagggctc aagggtcagg
84841 agagaggtgc ttggcctgac atgtaaggca agcacggata gagcttgtgc ctagggccaa
84901 ctccccacag cctgctgttt cttattacag tgccacctct ttgatcttcc ctgatgggga
84961 actttccagt aatgtctgtg atttgtaata tgaggtgaat aaaaaccaca gataaatgat
85021 aaggagcact ggacaaggct ggccctctgg gactgcctat gaaggaaaag gaagacttca
85081 aaattaaggt tccctctcct ttctcccccc agtgatatct ctgcctacca tgtcttcaga
85141 caccatatca gttattctag catttccaca ggtgggaaat tatttctccc agaaaatgaa
85201 aagtcttcta aaagtaaatt caactcaatt taacaaataa taataatatc acataataag
85261 taatagtata atcatataat ataaatagta ataagaatta ctatttacat agcactttgc
85321 tgtttataaa gcacttttac atgcatttat caaatactct agatgacgcc cattgtgttg
85381 ggtagagtaa gagatgaaaa gttaatttaa aaatgggtcc tgccttccag ggactctgca
85441 tctagaagga agtcagtcag tcacgtatat tatggcactg gctgtattct attgcagaag
85501 catacacaaa atacaacagc agaacaagag aggcaggatg tcagggaatc cttggaaaag
85561 aggtatcatt ggagcagaag atgtggatat gagatgacta ggttgaagtc aaacctttca
85621 aacctgttca aaaaacagca aatcagtggt caaggctaga ccacgagaga gacagcaggg
85681 aggtggaaag tggaaacaaa agttgaaaca tgggctctag ccaggttatg aagagcctgc
85741 ataggtttag tatattattt cattgatgag aagtcattta atgatttaga agaaataagt
85801 gcaatagata tatcctctag caaattaaca gatgctgagg tgttaggagg ttgagaagtg
85861 cggcaagctg tcaggaggct cttccaggtg tctcaaaaag tcatgaaggt ctgaacagca
85921 gcagcagcat tggttcaaag ggaagaggag agatgcacag gacaaatcag gatagaaata
85981 aggtttgcaa atgcttgaaa atggcagtgg gctagaagga tgagttcaga tgtgtctgat
86041 tttgaaaggt gcccaggaca agcaataata tataaacaca aagcatatga acaggagaag
86101 gtccaggaga taatagaata ctcaaaaatg ttgatgcctt tgaattacct ggaattattc
86161 tggtctcact gtctttgtat tatttgacat ttgatcaaga cctactgtta aataaacata
86221 tatttataaa aatctatcaa tatatattta tataacatat atgtatgtat gtgtgtttat
86281 atacacacac atggagagag agagagaatc acatttaaat atgaatactc catccaagaa
86341 aataaactga tctactttaa tttaacctgc actttcactg gcagaagaaa aatactaatg
86401 ttactaatct taggagagtc tcatttcagg tcattattca gtcactcaaa gatacccgtg
86461 ccagagctct ttctcccttt tcttccttct ttctctttcc ctagatggca aaggagaaga
86521 ggatttgtat ttaggcagtg gtgtcttctg gacacccccc acaccactgc taacccccgg
86581 atctctagtg aagtctgcag ctgaacttgt gattttatct cttggcttgg ttagggccca
86641 ggggacctcc ctggctggct tagcctgttt gagacatctt ttggagcagc acagccctct
86701 gcatctcagc caaatccttc atcatgccat tgtctacact ctgctctgca acctcagaag

86761 ctaggtctcc ctgtctgtcc ctactgtggc cctgtggctg gcctgctgaa ttccaactca
86821 gctccttcag tactcctcac agggcctgaa gcaacttcta gatcactttc aaggcataca
86881 gaattcagga gagatttggg cttgctaact cagttctgct gtctgcccaa ccttgtcatg
86941 ctaccatttt cacattaatg ttgccatcca tgttggagta agggatccct gtggggtgtt
87001 ttacttatag catcctaaat aagaagttag aaaaactcca tctgcttttg gctttttcct
87061 taattgatca atacacctct attctaggat ttgcattcag aaaagggatc tataaaatct
87121 ataaaatatc caaattttta atctccctac cttcctcctt ttcacagcat atgaagctgg
87181 aagagcaggt ggtcaggaat ctcccccaac cttcagtgca gtaatcttta gagcctactc
87241 atcataagta caaaggtggt tgtgaaggca gtgctataac cactgagggg aacctaataa
87301 aatgggtata tctactccac acaagggaag attcatccca tggacacaat ctttaagatg
87361 ccgagaggac tacagggcat gattgccacc atactatatg cagcaacatc atgacttcat
87421 tcctgtccta gcccagatga gaacctgatc caactccata aacggaacac caacagggaa
87481 atctgtaacc ttaaaaaaac ggcatcttcc agtggtagaa agagcctaaa ggtctgagac
87541 aggcagtata ggaaggccat gtcctagggt gtagggagag gtcatcttag atatcagtgt
87601 tgagaaagac cagaatgagg atggggacaa tcagcaatgg ccacccagga aaaataacag
87661 tggaatttgc atgggggaag ggatggtggg agcaatgcaa agattggcat gtggcagcag
87721 agagcaactt gcaatctgct gcagcagcag aggtgagtgc ctatgaagag cagttatctc
87781 tgtaggaata atggttgtgt agactagaac cagctatgac ttttcatgag cttgacaatg
87841 gcagtgcgat ggaggtcagc tttagagtgg ggagaagttg gggaccctgg aagtgaggct
87901 tgaagccact ctggacaggg gtatgtttac agtagctacc caaggaactt gggtagaggt
87961 agagaaggca gcataaggag agggttaacc tataactggg acctgggact ttgctcttct
88021 gaaccacaaa ggcaacaatt aaatctgacc atatacagaa tcatagtgct gcacgatgtt
88081 cggagtcaag taaagaaatg agagttgtta ctcgaaaact gaaaaatgga aaagactaaa
88141 aaggtctaga gtggatatga taaatgagaa acatgcctat taattaaaaa attgctacac
88201 atctagtgtt attccctgga ataagaccct tttgtccaac ccctgatttg tttgtctggt
88261 tgattctcac tgattattag gggacttgac actcctcgac ttttcccaaa atttcccgag
88321 gcagacctaa taagggtgtg tcatgagtgt gattgaataa gacttctgaa ctcccatgag
88381 acaacttcca ttttctcttc ctctttgacc tgctcttgtg agttagacct gctagaagcc
88441 ccatgaaggt ccctctggaa tcactgagga aactacctcc caacactggg gtgctccgtg
88501 gactgatatt ttagggaaat gaggctactt cgatgaaaaa gggatccttg gagcctcttt
88561 cattcagggt catttgaaag aagcatggcc ttatgctccc cagatctccc agaactcaag
88621 tatggtatct gctttctcca tttctgcttt tggcccctct ctcggcatcc gatgaggctg
88681 gccagaagtc cagaacttca agtcagacat ggcgcctctt ttgccattct ggcaatgctt
88741 ccttaatgcc aaactctgct gtctcattta accatctcca tcctccccta tgtgactagt
88801 acccctagta gtcaacagcc ccctctgtca tgttcctcgt gtttcccttt gaaatttcta
88861 ctccatctgt ttatttgctc ttcccagcag gaaaactgga aatggaaaaa gctgatctta
88921 tgcttatgct taggattatg tctaatgata tttctagtgt ttgaaggaca acaaaaaata
88981 aagatcaggc ttcatttttc caaaaccctt ccatgtgtct gcccaaatcc ttatgcattg
89041 ttttagaaat gtgatatatt tctttctgac tcatttacat ttactgttag tcatcaaaag

89101 gagtcagaaa aacttttgga acctctccct atgaaccagg aagttgcatt tcccctccag
89161 tcacaacccc ataaagcctc aagttgcaaa gtaaacttgc caggatgctg ggcatttggc
89221 aagatgcttc tctttgtcat cagaaccctc agccctgtgg aagaaagcaa gacagcctat
89281 gataccaata gtgagcatag tcctaaaaca gccggagacc atgaaaatgg acacagggat
89341 tcagaagaga aaaatacagg ccgggtgtgg tgactcacac ctgtaacccc aacactttgg
89401 gagtccgagg tgggcagatc acctgaagtc aggagttcga gaccagcttg ggcaacatgg
89461 tgaaactcca tctctactaa aaaatacaaa aattagccag gtatggtgac gcatgcctgt
89521 aatcccagct acttgggagg ccgaggcatg agagtcactt gcacctggga gatggaggct
89581 gcaatgagct gaaattgcac cactgcacca cggcactcca gcctgagcaa tagagtgaga
89641 cttcatctca aaaaggaaaa aaaaaaaaaa gagagagaga gagagagaga aataaaatac
89701 atatttgtat ttcccattct caatggcacc aacaggtcct tcatcagaga gtgcagtcca
89761 tggttctatc catgtttatc cagtctcaga gtacagggac gagcctatgg tcacacaccc
89821 ctctaatgta agccgctccc cattctacca acaaccccca ctttctatat tgccccttct
89881 ttgaatcgac ctcagggtct aagccttttg gtcactaaat ttaaaagtca catgaataca
89941 agtagtatca aaactgagca ggagggaaaa atctgatgtg gtaatactgg agtctcccaa
90001 actccccaga tgaaccacat ggttttattt ttcttatttc aaaagaggtg atgtttcaca
90061 ctactacaga aaaaaaaaat ggaactttga acactatttc ataatcagta tagctgattg
90121 aatgtactga catgtttcat gctctttctc atgtctgata gccacactcc tgtttcctcc
90181 caatgttgga gataattctt gagacttggt aacagagcag tagcacgtaa tttgctttac
90241 cactcagtgc ttcaaccatc ataggtaaag agtgttctta tcaacaaaac agacaccatc
90301 cctggcattc catgctggct ttctctggtt ttaaattaat taaagtcatt ttgtttttgt
90361 tcttaataaa agggaaaagg ataaatgagt aacagccagt agccacatta aattgctacc
90421 agatgttctg cagttaggca taaaaggtaa gcatcctttt acaatcaggc agctttctta
90481 tattagaaca gttctgtttc agaagagagc caatgttttt gctgacttct agataatttt
90541 aaagatacta taatattggt ggatatttta agaattttta aatactacaa atattggtgg
90601 gatattttga gaatttttta aaattgaatt ctgagcttaa agcactttat agttgcaagg
90661 ttcttggacc ccttcctcat ctcctagcca tacaccccca caaaaataaa agaaaatgca
90721 agtggagaca tttcctatag aagctcatta tcccctcccа ggtactatgg ctggattctc
90781 ttttgcattg gcttatctcc atgctccttc cacattacaa aatgagggct ctatcattta
90841 cataaccttg gccccttgc ttttcaatag atcttcctgc tcagctgcta ttagaatctg
90901 cctttgtatt tccaaattat atgccatttt ctctggaaga attttccagt gttccactgt
90961 ctttcttccc actattgtat ttgtataatg gcagaactgc catgagattt gggggcatga
91021 aggcacttct ttcctgagtt cagcagtgac atagagttct cttcattctc tttcatagcc
91081 tttggtcatt ttaattaaga gactcttgca ggcctctagc ccggttcact aaaatttaaa
91141 ttctctctaa tttataattt gttgacatca ttggcatcac ctcttagatg atcaaaatga
91201 caatcctata acccagcctg cctatctcag taaaacagaa agaatctact agatgttttt
91261 cagaatgtaa atagatataa catttataat gattttccta ttgtccagca aattatctcg
91321 cagttggagt cctgcaaatg ttagagacat cttgatgttt ccttcatagt cactccagag
91381 tctgttagtt cttatgtata aagaaatttc acaaagaaat ccagcttttc tcactgctaa

91441 aaggatgtgg ccttctgtcc ctaagcaaag tgacccattt aggggaggga taaaatttta
91501 gagcttatta ttggctaaaa ccctactctg gatcaaaagt ttgtttttaa agtgcattgt
91561 agattgcaga acaactatga atcactcata aagagaggta acaaagacct gaggctatat
91621 gtgtaaccag tgtattgaac aatttaaacc tgacaggtac acagagaaaa tggtgttttc
91681 tccaaccaat ggggactgag gaattatgcc ttttagaatc tccttgccct tctcaagagc
91741 aaacccttta caaactttca ggcagattcc ataatttcca ggtaatgttt agagattaaa
91801 aacccagcct gatctagttt aaaactctcc tcttacataa tttaaacctc atctgcttca
91861 ctctctccac tgccagccaa tcttccattc aggaacatgg agagtagaca aaatgggtct
91921 gctactatta tacacccttc ccttcttccc tttcctcctg ttcctcttca tctctggcat
91981 atttaaggag aagaggattt acaaggaagg cggcaaatgt gttttcctaa atggaatatg
92041 ttttagttct ttctctgtta attgttattg cttctctgac taataataat aatgttaaca
92101 attgcaaggt acattctcag tgcccagtgc catatatata tacatatata tatatatata
92161 cacatatata tatacatata tatatataca tatatatata tatatatgaa tttatttaac
92221 acccacaact caatgaaatg gatactttta ttatccccat ttcacagatg agcaaactaa
92281 tgctcagaaa ggtgcccagt ctgacacagc tagtaaatgg cagaaccggt attgaaaccc
92341 agcaggtgca gcatccaggc ttttaatgcc ttgatgggtt attaatgtct ctctattgca
92401 ggtggtacct gaatactgac tgtctcctag gacatttggg ttctttggag ggtccttcgg
92461 aagactgtgt attgcacagt gccctgatgt gggagattct ttactggttc aacctctcat
92521 aatccccagt ccttgatctc aatccctatt gaggtaacct gcaattgctt atgactgggg
92581 ttctttgtct ggtgtccagt cttcttggta acttagctac cttcatagca tccactgaac
92641 acacaggaat gtcccatgtc cctaccatcc caatggtggg gagttctatt cctggaccct
92701 ctcactctgc cctcagattg ttgcaattct ttttagacag taatattatt aaaaaaaaaa
92761 aaagacaaaa caaatgcttt ccttgtctct gagtcctagt ctcttaattc ttaggcagtt
92821 gaaaaatgac tccatgagat gtgttgttac catttacatt gtatcattca agaatgagaa
92881 gatctaggga aataattcat ccccttttctc cttatatttg ctgagatgcc cttcatcttt
92941 acttgaaggc tgagaaccaa agctatttgt ctggttatag ggcctacaaa ttgcaacaaa
93001 ggttggggtg attgtgcctt ttagtaaatt ccaaggaaaa atgtcaagtt gtatgtgtgt
93061 gtgtgtctgt gtatgtttac atatttccta cgtgtgtgtg tctgtgtgtg tgtgtttaca
93121 tgtttcctat aatcatttgt cttgcttttt gagggcattc caactactgg tggaaaaaat
93181 aaataaatac aagggggtcc atgctgtgag tagttgaaat gaaaatactg gtgttttgat
93241 gggattaatt cagtacattt ataatagact aattcaccca aaatcaactt ctaaaaccag
93301 tttgccttaa ctcacttaac tcaatttcag ttagcctgat gactattgca tctaatgttg
93361 aaaattcaga attaaaaatg aaatattggc tggatacagt ggctcatgcc tgtatcccag
93421 cactttggga ggctgaggcg ggtggataat ttgaggttgg gagttcgaga ctagcctggc
93481 caacatggtg ataccccatc tctactaaaa atacaaaaat tagccaggca gggcagcagg
93541 tgcctgtagt cccagctact caggaggctg aagcaggata atcgcttgaa cctgggaggc
93601 aaaggttaca gtgagccaag attgtgccac tgagctccag cctgggcaac agagtgagac
93661 tctgtcttga aaaaaaaaaa aaagaaaaag aaagaaagaa acatttacca aataatatgg
93721 ctgagtattt atgactaatt tttgtattgc taatacttta tcacatatag ggaatcatga

93781 gattgttaca tattgttgtg actgtctttt tctgttccag tcattttgaa cacttgcatt
93841 attctttagc caatttgtca aaaaaaaaaa gtcttttttct ttacaatttt gaatttctgc
93901 taaaaatatt tagtggaatg aaatttattc cattaaaaaa acgaaccttt tgattattat
93961 tgtctccttg ctactttcct ttattataag agtctatgaa ctctacatgt atgtgtatat
94021 atatacatat gtatgcatta accaaattag catactctca gagctcattt ctgtttagtg
94081 aggtattcgt attttaaaag aataaagaaa aatgggtccc tcttttgatc accattccat
94141 gttatttatc aagagatgta attgataaag gttttatttt gttttgtttt gagacagagt
94201 ctctctctct tcctcccaag ttggaatgca gtggtgtgtg atctcggctc attgcagcct
94261 ctgcctgagc tcaagagatc ctcctgccac agccttccaa atagctggga ctacaggtgt
94321 gtgccataac gcccagctaa tttttgtatt ttttgtaaag aaggagtttc accatgttgc
94381 tcagactggt cttgaattcc tgggctcaaa tgatcctcct gcctgggtct cccaaagtgc
94441 tggaattaca ggcatgagcc accatgcctg gccctaattg ataaagtttt aaaatgcaaa
94501 atgtgcatca tttccaaatg aatttatagt gagaatcata acattttgaa aaacagtttt
94561 caaaatgcca ctggagtgtt aacaaattaa taccatctgt gatgactttt ccattctgcc
94621 aaaacctgat aaagctctgc tgaagtaaag aaattggttt cacagagcca gcacactgaa
94681 tgggcaaaag ctggaagtat tccccttgaa aaccagaata agacaaggat gcccactctc
94741 accactccta ttcaacatag tactagaagc cctggccata gcaatcagat aagggaaaga
94801 agtaaaaggc atccaaatag gaagagggga actcaaagta tccctgtttg cagataacat
94861 gattctatat ctagaaaacc ccatagtctc tgcccaaaag ctccttgagc tgttaagcaa
94921 catcagcaaa gtttcagggt acaaaattaa tgtacaaaag tcagtaaatt cctatatacc
94981 aacaatcacc aagccaaatc agaaacacaa tcccattcac gattgccaca aaagaataaa
95041 taccgaggaa tacagctaac caggaaggtg aaagatctct gcaataagaa ttacaaaaca
95101 ctgctcaatg tgcttaaagc aatttataga ttcaatgcta ctgctatcaa acaaccaacg
95161 acattcttca cagaactaga aacaaaacta ttctaaaatt catatagaat caaaaaaggg
95221 cccaaacagc caaggcaacc ctaaacaaaa agaacaaagc tggaggaatc atgctatctt
95281 acttcaaact atactacagg actgcagtaa ccaaaacagc atggtactgg tacaaaaaca
95341 gacatataga ccactggaag agaatagaga gctcagaaat aaaaccacac acttacaacc
95401 atctagtctt aggcaaagct ggcaaaaaca ggcaatgggg aaagaatccc tatttaataa
95461 atggtgctgt gatagcaggc tagccatatg taaaagattg aagctggatc ccttccttac
95521 accatataca aaaatcaact caagatggat tatagaccta ataaaaccta aaacagtaaa
95581 cctgaaagat aacttaggaa atacattttg gccataggaa ctggcaaaaa tttcatgatg
95641 aaaatgccaa aagcacttgc agccaaagca aatctgacaa atggaactta attaaactta
95701 agagcttcta catagcaaaa gaaactatca acagagtaaa caggcaactt acagagtgga
95761 gaaaatattt acaaaccata catctgacaa aggtctaata tttcagaatc tacagggaaa
95821 ttatacatac aaggaaaaaa acaaacaacc tcatttaaaa gtgagcaaag gacataaaca
95881 gacacttttg aaaagaagac atacatgcag ccaacaagca tatgaaaaaa tgctcaatat
95941 cactaatcat tagagaaatg caaatcaaaa ccacaatgag ataccatgtc actccagtta
96001 gagtggctat tattaaaaag tcaaaacata acagatgctg tctgagacca gcctggacaa
96061 catggcaaaa cctcgtctct actagaaatc caaaagttag ccaggtgtgg tggcacatgc

96121 ctgtaatccc agctgcttgg gaggctgagg caggaaaata acttgaaccc aggaggcaga
96181 ggctgcagtg agccaagatc acaccactgc actccctcct gggccacaca gtgagactcc
96241 acctcaaaag aaataaaaaa ttaaaaaata acagacactg gcgaggttgc tgagaaaagg
96301 gaactcttat acactgctgc tggtggtgta aattagttca accactgtgg aaagcagtgt
96361 ggtaagtcct aagataacaa aaacagaact accattcgac ccagcaattc cgctactgag
96421 tatatattca aaggaatata aatcagtcta ccataaagac acatgcatgc aaatgttcgt
96481 tgcagcacta ttcataatag ccaagatgtg gaatcaacct aaatgcctat caatgacaga
96541 ttggacaaag gaaatgtggc acatatacac catggaatac tacgtggtca taaaaaataa
96601 taagatcatg tcctttgcag gaacatgtat ggaactggag gccactatcc ttagcaaact
96661 aatgcaggaa caggaaacta aatactgcat gttcccactt ataagtggga gctaaataat
96721 gagaacacat ggacagaaag aggggaacaa cagacactgg gatctacctg agggtagagg
96781 gttggagaaa ggagaggatt aggaaaaaaa aaaatagaac aactttcggg cactatggtt
96841 agtacgcggg tgatgaaata atctatacac caaactcgca agtcacaagt ttacctacac
96901 aacaaacctg aattatgtac ccccgaacct aaaatcaaag ttaaaatatt cttcaggatc
96961 actgaataaa aagctcataa agattcaaaa aagtcataca ctcaaagtta taaaaacctt
97021 ctagttacca accctcacca atctcaaaga gaatgattag aaatacaagc tcattgtatt
97081 ttaagaagat tgacctctca gagaaattca tgttacagcc cttaaaaatc ccccccaaaa
97141 taacacccaa atggatctaa aaccttcaaa acggagttag acctcaacat taggagaaat
97201 tttaatatgg caaattggtt ttagacaaag catatgtttt actgtttatt ttcgtaatga
97261 gggttgagag gacaggacga agtaaccata aagcacttgg taaagagtgt gaagttttta
97321 atttacaaga aagaaaatgg aataattcag aaatgctggt tatatcacac ccttgccggg
97381 attctcatgc cttggcagag tctgagttgg ggctgtttgt cctgggaatc acataccacc
97441 agaggagagg cgtattctcc tcagagccct gagtttttac atccgtgagc atgggcagct
97501 acataatttg cagggctagg tgttccaaaa acggtaagga tttcaaggta gggagagcag
97561 aacattaaat taagcccgag gcccttctga gtgcagatgc catgcagcta cccagggcac
97621 acagccttga ggcagccagg tctatgagaa caaccattgc ctactttctc ttctaccctc
97681 tctcctctgc atgttctttt cttttctcct tctccttctt ttttcttttt ttccaagtct
97741 gctttatgca tcttctctgt taacctccac atcttgcttt ttttttttt ttttttttt
97801 tttgagacgg agtctcgctg tcgcccaggc tggagtgcac tggcgcgatc ttggttcact
97861 gcaggctccg ccccccgggg gttcacgcca ttctcctgcc tcagcctccc acgtagcggg
97921 attacaggcg cccgccacct cgcccggcta atttttgta tttttagtag agatggggtt
97981 tcaccgtgtt agccaggatg gtctcgatct cctgacctca tgatccgccc acctcggcct
98041 tccaaagtgc tgggattaca ggcgtgagcc accgcgcccg gcccacatct tgatttctta
98101 atgtaaagtc cctgggtagc taatggaggg aaattctgag cttagatatt gccttggtgg
98161 atgttaccca tgattgactc agtttgaaaa gaacctgctt cctaaagata ctcaatattt
98221 tcttcatttc ctccgaatct gcccattaat gcagcatctg gcctcctagc agaagcggag
98281 aacttttcag aaacttagag atcagtagta tcaaaacaat ctcagccaaa gcataagatg
98341 aaaatgtact aacgttcttt cttttctcct ttaatttgac ttcctgtggg aacttccttt
98401 cctgttaata gaatggaggt aagaaactgt tattgtaaca attgtttcca atgttttgtt

98461 ttgtagggat ttcgtttgtt tgtttttgtc tgtgagaggg tcttgtgttg cccaggctgg
98521 agtgcggtgg agtatgtttt gtttttgtta tttgacatgc catttattga gtgtttacta
98581 tttgctgagc actgtaacat tttagaaact ttctaatttc taatcctttt agtaagtatg
98641 atgaagtgaa agacaggtaa cctctactga atacttacta tggatcgggc actgtgctga
98701 gcttcacatg cattatttaa atctatcttc aagacatccc catggaatgg gtattattgt
98761 tatctctatt ttgcagaaaa aaaaaataaa aaaacctaag aaagtttctt tgaactggag
98821 agttcaagtg gcttacacag ccagtaaatg ataaagttag aaatggaacc cagaactgcc
98881 aaactccccc ttatagctct aacctatata taagaaggta tcccttgcaa tataaccttt
98941 tgcaacttac agtgttttat ttgcagtact tttaaaactg accttcataa aactctatgg
99001 agtgtaatta attttaagac agcattctta gcacatagcc tacgtttaaa aacaggcagc
99061 aggatacaaa attttggtta gatagcaaaa ataagttcaa gagatttaga gtacaataca
99121 gtgactatca ttaataacaa tgtattgtat tcttgacaac cactgagaat agattttaag
99181 tgttctcatc atcagaaaat ggtaagtatg tgaggtaatg catttgttaa ttagctcaat
99241 ttagtcatcc cacaatgcgt acatgtttta aaacatcatg tggtacacaa taaaaaaaac
99301 agtttttttt aactaaaaac acctttaaa gttttactgt taaaaaggtc ttaagaaata
99361 ccatttggat gtatatattg ctctgaaaag cagtgaaaat catgatacac attatatgaa
99421 aaattaaact agttttaagt atataggata gtgatttgtc ataattgact gcattccagt
99481 ttgttaatgt ggtatcaaaa attctcagtt caaaaaaaag aaaaaattct gagtccattt
99541 tttaatctaa atattgcttt aataatttttt attaacaatt ttggagctac tgccttagca
99601 gagtaaagtt tatctaaact aaaattaata aaagtgccat ttaataaccc tccttctgaa
99661 aaaaacaggc agcaggccaa atttgtcctg tgggttgtac ttgctgaccc ctgccttgga
99721 gaataaatta tatacaaaga cactagacgc gaaagaatag aaacagttcc cgtttgcttt
99781 gaaggttgga agtagcacag aatctgtcat tacctttgtt gggaatgttc aaggagagat
99841 aaggcagttg ctaaaaaagg gaagatttgt ctgaagcaga ggagaggtac agctgtcaag
99901 tgtgcctgtg cagggaggga gggaagtaag gtgtggagtt tccactagag tcttggggtt
99961 gtcataacac aaacatgcca tggctggtca tctggaatgc ccttgggaca aaatattatg
100021 tgttcaaagg gagtagacat ctccctcaga gaaacttgaa gataacattt taaaatgttc
100081 tattgaatgt gattcatgcg tttcaaagta gagagaaata ggagtaagag gtgcagtgag
100141 aattctttac ctactccctt tgaccacata gggttgtctg ttataaaaga agttgaaaag
100201 gagatccgag atcaaatatc cattattgcc tctacaagaa agggaacttt tctgaaagag
100261 aagtcaactg agtttatatt gtaaggaggc aagagaggga ctgtttccat gtgcaatatt
100321 aactagcatt attagaagct agtctggctg atgattccga aataaccagc attctgtgaa
100381 tggatccctg tgacctctgt cccacggttc taatgagcaa caggaccagc tgcttctagt
100441 gttgccccat cagcagtacc acgaactgca ggcagagaaa cacaacttta gctggacatg
100501 gaggggtctt gtcacttaca aaagacaaca gaagacacca atggaaatta tttgcattta
100561 tctcattccc cagttcttgc tgtgagctcc ttttaaaaat gtttgaagtg atagatttag
100621 gggtttgagg gacaaaatgt tccagttggc ctctgtgtct tgcatctaga atttgatcac
100681 tgtgtaaaat tgaaggctta tatttctgca caagaggaga ggaaaaggaa gtggttgaaa
100741 cactgaaact ataggtagtt gatagataaa caaattcaga tatatataaa tttagataga

100801 tagatagata gattagatag atagatagat agatagatag atagataggt aggtagatca
100861 tcggtcttgt gtgtgcctta ccttttagag ctaatccaag cactgatata ataccaaagc
100921 caagtcctta attattccag gaacatcata gaaatgaaat gtagaaaact aataataatc
100981 atatactttg tatgtgtatg ttttttccca gcacataaag ggtttgtata agctagtggt
101041 catcaagctg ttaggaagaa aaagcaaaat taaaactaag atcttctcat ttctattcaa
101101 aacctattgt ctttttttct ttttcatttt tattttgcat tatatactta atgctgtaaa
101161 actaatgagg attcaatact agcagaaatt cagacagagg ggttcattat tagttgattg
101221 ttagtaatcc ttatctctga agttattttc attaattttt cttttgtgta ctttttctta
101281 gtttccagtt ttttaaaaaa gtgtgttttg atgtataatt aaaggaaaca tcatgaaatg
101341 tctattattt ttaaaaatac tcatggaaaa tgagtaacag catcattgaa tagttaacac
101401 atgacagcaa aacctgaatg aataattctc agctcggaga cactgagaaa tatttaattt
101461 ttacatggtg gagtttttttc tgttaagcgt aaagagtcac acatgctctt attcatcccc
101521 ctttatgccg agatattacg tcaacatgtg agaccatttc gtaaaccagt ttgagatatt
101581 tctggttact ccttattata tagtttctta aagcacagtg tagaagctgg ttagggatta
101641 attcctttcc ttcccatcct aacagtcatg gctgacacct atataacaat gacaggttaa
101701 caagagaaga gcataacaaa tatgtttgat cacagtttta cataacatgg gacccttcag
101761 aataaagacc ccagatacag ggaaagcaat cctttttttc tgagacagag tctcgctctg
101821 tcacccaggc cggagtgcag aggtgcaatc tcagctcact gcaacctctg ccccccagat
101881 tcaagtgatt ctcctgcctc agcccctcga gtagctggga ttacagatgt ccgccaccac
101941 gcccggctaa tttttatgtt tttagtagag actgggtttc tcgatgtcgg ccaggctggt
102001 ctcaaactcc tgacctcagg tgatccaccc atctcggcct cccaaagtgc tgggattaca
102061 ggtgtgagcc accacactca gccaaagcaa tccatttta tgcttaggtt caatgaagta
102121 tgaacagctg tgtagaaata tgattagaca caaagggtat gatctaatgc taacaggctg
102181 agtggggaaa ctagcccatc ctgcttgttc agatttttct cagcccctct gtgcagcact
102241 cactcctccc aggcaagagg taggatccct ctggaatgag ggtctgaatt tctttatggc
102301 caggtgttac acagaaaagc tgggggtggg tagagtaaat gtttaggttt tatggctggc
102361 cttgaggaaa aggcgttctg gtgtctgatc tgacttggag aagagggatt ctagtgtcta
102421 aggtttgcct gagggaagaa agagaggaga gacaggaggg cagaaggtct gtttctgagg
102481 ctgcttctta ggccttcacc ttggggtgtc gtttactgag cctcaacaac agcatccttg
102541 tttctgtcta attttctctg ggggttttct caccttacc ttgagaaagt ttttgtggag
102601 ttttgtgctt tcttattcaa ggccttcatt ttaaatattc ccaacaaaca aagggataca
102661 gtaaaactca tgttggctaa ttagaaaaag gccagtatga attaaaggaa gactctatat
102721 tacaaaatat tgttttaaag tatagctgtg tttcttggaa gttcatcatt ttacctgaat
102781 gtattatatc tcattccaat gaatttgctt taaagacctg ccagtggtgg tttgtaatta
102841 tagtattaat tttttaaatt caattggggt cacgtaacaa ttttaaaatt tgacacaaat
102901 tctaatttgt ttaattttct tactttaaat tctttatata aagacaatga aaaactaaat
102961 tcgatagttg tacaaatcta aatgagaata taacttaaga gttttcttaa gtcattacta
103021 acactatgga agatctgata gaacacataa gaatatactg agaccatcac agtgcctaca
103081 cataataagt attcaatata tgtttgtcag gtgagaatat gagttgttat aattcccagc

103141 attatattaa gggaacaagt agatgtgtga agagagtacc aatagcattt tccattctcc
103201 caattgtctt cagttattat agcagataag tttttaatcc tatgtttgtg ctagcactag
103261 catttacagg tttctccctg atatatggcc cattaacaca caataatccg agttcagagt
103321 aattacttac atcattcaac agaatagatc actgaggcac tgggtgacca gttgactttc
103381 catgtgatga gacatgatga gaaaacagca aagctgaagg tgctacttgg ctcctctgga
103441 agccatattt ctgctttctc ctccctacat cactttcttt ttctttaatg gaattctagg
103501 aagatgtgtg agtgggagaa tctgagtgtg gaaggtgttg caaagatgta tatgttgtca
103561 aaaattaagg taaactatca taacacataa ataaactatg ttcctaaagc tgcaaacttt
103621 ttaggtgaga gcaattattc ttatgctcaa ttatttgtta accatcatga tgaaatgtct
103681 tccagatgca tctttgctta tatcagctta ttaactaaga gtagtcagat tctatttata
103741 atgtaaaata ttaaaaatac ccaaatctat tcagtccttc atagttccca aagctttcca
103801 catctatcgt cacatttggc cttctcaata gccctgtgga gtagctagag atgatataat
103861 tgcagctgga aatgaagaca atattcaaat ggagcgtgtc aaccaattta ctagtacaat
103921 tttctcctat ttctgagaca cagatgtgaa aaccaaaaaa aaaaagaaaa gcagaatgaa
103981 tgccaagaaa tagcatgtga ttagaaatgt tgttcatttc ttctttcagt aaaccacaga
104041 aagataacaa aggctactgc gcccagtaca gaggggaggt gtgtaatgca gtcctggcaa
104101 aagatgctct tgtttttctc aacacctcct atgcggaccc tgaggaggcc caagagctac
104161 tggtccacac ggcctggaat gaactgaaag tagtgagccc agtctgccgg ccagctgctg
104221 aggctttgtt gtgtaaccac atcttccagg agtgcagtcc tggagtagtg cctactccta
104281 ttcccatttg caggtaaaat ctcaaaaata agtcaaagga aaaattccat ttttctatct
104341 gcacaacaga aggagttttt gaaaaatgtt gtaatatgca acagtaaaag gaaaagctgg
104401 ttttcatcca aaataggagg ttaatgcctg ggtgcagtgg ctcatgcctg taatcccagc
104461 acttcgggag gccgaagtgg gtggatcact tgaggtcagg agtttaacac cagcctgtcc
104521 aacatggtga aaccccgtct ctactaaaca tacaaaaatt agccaggtgt ggtggtgcac
104581 ttgtaatccc agctactcgg gaggctgagg caggagaatc acttgaactg gggaggcaga
104641 ggttgcagtg agccgagatt gcaccactgc actccagcct gagtgttgag actctgtctc
104701 aaacaaacaa acaaatagga ggtaattaat cagacaatat ttctaccata taaatcacta
104761 aagataacct aaaatacaag tacttagaac ctctagaaaa tatcataaat ggtgtaatat
104821 tccattactc ttgttattgt tcacattatt atcatatcca taaatatccc agatttctat
104881 cagatgaaag gagaaatctt aaacatggac ctcattagta agccaagata gagaaaataa
104941 aaactgtaca ttatttgtca ataaatgaga tcatgccaag catctctgaa tgttatttta
105001 aagtacattc catccaaaat tctaagttct gatgctgttg cctcatttgg gtggttatag
105061 gaaggaatta gattataaat agatattttg ttaaactccc atacttttta aatattgaaa
105121 ttgataaatt tatgttcaat agaattatct tcatctttaa ttacttctta tgtagaaaaa
105181 aaagaatcta gtttttgagc taaatagaac aaagttcaaa tactgttagt tctgctttct
105241 cgatgtgtgt ggtcttggct aaacttcagt ttcctcatct gcacggtaga attgagagga
105301 ttaaaggaaa aatcacactc atggaatatg tcagaaacta gatagacatt gttattccta
105361 aattttctgt tgaggaaacc ccatgacaac aaccaacaca gcacatttcc acttctattt
105421 tgataaaacc agaaactatt taaatattgc aataatttga ggacactctc tatttagcat

105481 tcaataacaa cagtatggtc attaaattag agttttgtat tcctcaattt actgcaaagt
105541 ttgagggttt ggagacacta taagagtaat ataatttgtt tattcatcta agaagattgt
105601 attgtgatca ggcatgttat ctaaaaatct ctagggactt cagcattgac agaataagaa
105661 ggggaaagag aaggagagaa aaagtaaaat tactgcaaaa aaaaatggga agagtgggtg
105721 aggggcagta aaatttgttt taatagaact taagaaatac tgatgctatt tcaactgtcc
105781 ttgcagttat ttgaaaaaat agtgtctctg ttaattatca cttctttagt ttagatttct
105841 ctttcttggg cttctttata ggattctcca aaattgttta tttgacgtac tgctcaacag
105901 tgaaaatcct tttgctagaa agtagcacgt gtataataaa cagaatgtaa ccagcaaaat
105961 aaagtgacag tagattctat cagcttttcc tttagtacta ctaacataat ttgtggtggc
106021 cacgggatag ttatcatact tacacagtga cactcaggca aatcagctca acaccatgga
106081 tagatgcttg agagaaataa taattagatt agaaaaattc tctgtgtgtg tgacagccat
106141 tgtggttttc tgattacaaa acccacaaga ctccattgta taaaaaaaga acacagtact
106201 ttcattgcta aaacccagaa agttggtcac tactgaggtg tgtgtttact tatatttact
106261 tatatctata tttctgtact ctgaattcta tttcatggat ggtttctcta tttttgcatt
106321 agagactttg ggtttaatta ctgtctttat aattaatttc aatttgtgct acgaatttcg
106381 caggttttca tcttttaaaa aattattgtt tactcattat ataattattt ttattacatg
106441 ttgacattgg caaaatgttt ctaaatttca tatttaaaaa taattatata agttatataa
106501 tacaattata tattaactta acaataatta tcaataataa ttaataatta ttatattaat
106561 aataaataat acttaatatg atataactaa ttataagcta tataattata tattatagta
106621 tataacttat ataattgata taatttacaa ttatatatta attatataac atataattaa
106681 tatataatta taattatagt ttataataat ataattatat attatatagc tcactatata
106741 attattttta aatataaaat ttagaaacat tttgccaatg tccacatgta aataccattt
106801 agaatttgat cagaatgatg ctaagtttat acaattaact tagggcacag agctatattt
106861 acattactga gtattctcat ttaggagtat ggtatgccat tctttttatg tagatcttgt
106921 attatgcctg ctagtaaaat ttgatgattt ctttcttact tttttttaat taaatttatg
106981 actaggtgtg ttttatagtc attgctgttg ttgcaagagt attaattata atatagttat
107041 tacaggaggc tagaatgtcc ataaaacata gagatgcaat taattccctt gttccttatt
107101 ttaataaaac tgccattaat ttctttagaa tttgtacatt ttagagttga actatgtaat
107161 tttttggatc atattaatca gatttctaaa aatgtattct tttttttgag gtagttagtt
107221 gatagaagta taatttatat acaagaaact gtgccccttt taaccatata gttcagagtt
107281 tgacaaacgt atacaacaat gtaaccacta ccccaatcaa gacatagaat gttttcacca
107341 cccataaatt tctcttatgc tcatttcctt ctttttttttt ttttttttttt tttgtccctg
107401 ggttcaagca attctcctgt ctcagcctcc caagtagctg ggactacagg cacctgtcac
107461 caggtatttt tgtattttta gtagagatgg ggtttcacct tgttggtcag gctggtctcg
107521 aactcctgac ctcaggtgat tcacctgcct cggtctccca aagtgctgag attacaggcg
107581 tgagccaccg cgcccagccc tcttatgctc atttctaatc aacttcccat tatctctaaa
107641 ggcatcgtcg ttctgatttc tctgacaact agttttgctt gttcctgaat ctcatactca
107701 tgaaattgta taatatatac tgctttgtgt ctgacttctt ttgttcaaca tgtttttgat
107761 attcatccac attgctacat gtaacagtgg tttgttcctt ttcattgcag cttttatttg

107821 tgtggttgag atggaaatag ttatgtgaag aagtaggtag ggtcaagctc cccttcatgc
107881 tgcctaagaa ttataaagca attaatttga acaactgcag tatcaaaagg aaagttagta
107941 tagaaatgtt aggccactca agatgacaga ctcatcagcc acaacaaaaa agtcagatac
108001 cagctttaga cacaaaggat caaccaaata atttattcct gcaatttgta gtttattcca
108061 attttgtttg gtattatacc tcctaattat tgagaggaat caagtctcat caatcataaa
108121 tcattaatcc ttgccaacaa atgtgtatta ttttccattt tgttaacgag ttgttactac
108181 tatataataa agccatttca ttttattata tttatataca acaaccgctt tacagtattc
108241 tattagattt ttgattgata gtctatggtt cctctgatgg aaaaatatgg tctataaatt
108301 attatatata gtttatatat aatataaaac tataaatctt aattagattc tactctttct
108361 taattgaaat ttcagaaatt tttactagaa ttaaaattaa attttatctt catgtgctag
108421 cacaaaatac atttattaac tttccagcat ttatgtccca gatcagttta catgcctgag
108481 ccacagatgt tctttctaat cttgaaaata attcaccttt ttgaaagaaa aaaatccctt
108541 tcattgaaat gttaaattta ttagaaaatc atagttattt cctaaatcta tgtcattcac
108601 agtatacatt taaatttttt ttctaattcc cattgttatt taaataagta gttttattgg
108661 gaaaatgtta ttttttaaaa tcctcatcat caaatatttt gttcccattg aagtaagaaa
108721 atataatcta aaaatttttа cattttaata ttttatagag gttttttctc tgatatataa
108781 taataaaaat tggcatttat aaagacttag tctcttccat taacatacaa aattcatata
108841 tttatgttca atcctttctg ctcttaaatg agtattagct atttggtcca atagtttaat
108901 agtgatgcgt caaaattttc acaattgtgt ttccaagaat gttttcttgc aattctgact
108961 cctgcttttt gcaccaagaa atattaaact aaaattgaat ttactgctga taactggtaa
109021 gtttgatctt catttttttg ttatatcttt tgaaaaagtc tctaccttta ttcatcaaac
109081 tagttcagaa gttgtcaacc attttatatt ctacttctac ttgcttgtga tatttttaaa
109141 agcgtgctat cactcatggt tttctaatta ttaggttggt acaaaagtaa ttgtgttttt
109201 tttccattaa aagtaatggc aagaaccgca attacttttg ccccaaccta acataagcag
109261 tcattcaatg atgtgtgcct cttttcatga acgacatgga attttattgt ctaacaaata
109321 tttattgatc tccttctggg ctccaagtac tacactgagc atttgggata tattaatgaa
109381 cataataaac aacttatata taactttaga aggtgttaaa tgtcatggaa aaagaaaaaa
109441 ggaatgcttt aaggaagacc agaaataaca aacggagagg agaaagttgt aactttaaaa
109501 ataaggtgtt cagggtagac ttaattaagt tagcataatt gtactgaatc ttccacactt
109561 gttctttgaa actttacctg aaattatcaa ccgtatttgt attgttcaat tatattttat
109621 ttgcatatgc tcaatttttg gaacattatt cttagctttt acatttgatt tcataatcat
109681 gtataagtag atacttggag gagcttatac tatgttactt atcattgata ctcattgtca
109741 ttcatttcaa ataaaatatt tctttttctt aaattcctaa tttaaattca cttcttgttc
109801 attcatctca tctttactca tctctcattc agctggagta ggtgtttttc acatgtaaaa
109861 aaaaattctg tcattgtaca tatgtgtttt tgactgggta tttaagtctg tgttaacaca
109921 agtgttagct tttgcgttag ttctcctcac ttgtgttact tatcctcaaa actgtggact
109981 ctgaccaatt attttctggc catgttgtaa taaagaggaa gaagaaagca atcctgactt
110041 ttgttccttt gtaaggaaca ttttcctctc tccagattgt agaaagatta tttctttaat
110101 tgttgagatt caaaatattt gtaaaattca tttggggata gatttattct cattgttttc

110161 tttcatgtaa tataaataat ataaaaataa tgggtaatat gccctaaaca ttgtgccctt
110221 ttcatcttaa aaatgttttc ttataccaca tctttgatta ttttctattt tttatgtgct
110281 ctggttctct tgctaagaaa cactattatt tgattttgaa cttcttactt gctccacctt
110341 atcagttatt tcacacatta ttttcatctg tttagccctt cttgcattca gttaggtcct
110401 ttctttctgc attcaattga atatttaatt caaatttgtt tatttcttgc agtgccattt
110461 gttttctatt ttcaatgaag attgttaagt gttggtttta ttttttgtgg tttctatttt
110521 ctgtagttac ttccatgttc aaattatcct acttttttagt ctatagttca tcttgatttg
110581 ttttttcttg tgaaaaactc tgctatagag ggcatgcttt agtgcatggc aatgaaaaca
110641 aagcaaacca aaagccattc attaatgtgt tcttctgttt agaataaaaa aatttcccag
110701 gtatttgctt cttctgccta atgtggagta tggagttgtt ttcatatgtc ccatattgat
110761 ttacacttta actatgctgt ctgcgtgcaa aaaaatgtgc ttatacaacc caggggtgga
110821 accaagctaa gcaactctcc tcaggtcctt tacctgctca gaagtcttga aagccccatt
110881 atactccctt ctcccttacg cacaccaaga attataaatc ccattgtttt cttcatataa
110941 gaatatattt gcatctcatc acattcatat gcacagcctt ttattctatg catactcaat
111001 tagcacatat tggcaagtta ggaaagtagg agtgtgggaa taagtatgaa aaaagacacc
111061 attgtggcat atatatacac acacacacac acacacacac actcttacaa tttcctcctc
111121 tctgaatcct tcagatactg aataaaggac atctgctatt attatgttta atttatttaa
111181 ttatctttaa tttcctctta ttattaaccc caaatacctt aatttgaaat taaccaggtt
111241 tttcctatgc agtttgtcct attttctatc aggcttaaac aaatactaat ctgcaaaatt
111301 ccaagtagtc caattagtgt ttcttcagcc ccttcactca taatacaaca tgtagatgaa
111361 cataacagct tcatattcaa acagataata ctttggcttt ctcagatgga agcacgcaga
111421 gcaatgggac aggattccgt gcctcaaagt aagggctgag taaggaccca gatgccctcc
111481 tataagctgc cagggaggtg gtggtgttct gtttcagagg acaaagcaca cagaggccca
111541 gactgtgttc ctcgagccct acccattagc cccaagatca tagaaaaatc ttccaagctg
111601 gaaactggtt gacaatgatc ctgactttca gtaggtgtgt tttttaaact ctgtatacct
111661 ttttcctcta cctgtgttgt tatttgaata tgaagttggg agaagacata tcagagattc
111721 ccaatctaat acgttttaaa tttgacgttt ttttccctta gactagcatt aattgtgttt
111781 cacaacaaaa cgagatagca tttcatctca cgggacagta cactagattt catgaggtct
111841 catattattt acagtaaaaa gtttctttca taaacgcgct tttttcaaga acaatttacc
111901 atgatgatgt cttgaaaaca cagaatttag gctctgccac aaatttgctt taacatgtaa
111961 tgattcatca agttttgttc tccatatact attttagaga gtactgcttg gcagtaaagg
112021 agctcttctg cgcaaaagaa tggctggtaa tggaagagaa gacccacaga ggactctaca
112081 gatccgagat gcatttgctg tccgtgccag aatgcagcaa gcttcccagc atgcattggg
112141 accccacggc ctgtgccaga ctgccacatc taggtaacac agagttctcc caagactttg
112201 gaggttaaga gaaatttact attttgaaga aactaaggtg tgaacttaaa gcttctaata
112261 tttctaggca tttctaattt ttttttttttg agttctgcct tccttagata cctactagcg
112321 gaatcctaat gctatcctaa ttgtacagat tagcgtaaag atttatttca tttgctctaa
112381 aataaatgaa acagcacttt taattactgc ttgacatttt agattctttc atagggaatc
112441 ttatgagagc ttgtaacatt ttctggagtg tgtagaaaaa tggctaagaa acatcttata

112501 ttttgtcagc agagtggaat aaaggaataa agtccttttt cttagccaag aaagcatgct
112561 aaaataagac acatgtttga aaatgctgat ctcacaaaac aaaattgaat tgcttcatgt
112621 tgctttaatg aactttgttt gtaaggaact atgttgttat ccctaacagc tggtttaatt
112681 tcaaagaccc aattctttca cattcgaatg caaagaatgt tttccagttg tatattaaaa
112741 agctgagaga gaacttgcat ttcttagcac tcactctctc acagaatatg tgagatatct
112801 ggatgctcac ttaaaacaaa tttttatcct ttccccttca gattataaca aagaaaacct
112861 aaaaagtaag taattgtgtt tgtgcccttg aaaccttatg tgtatgtaat tggattcatg
112921 catgtgtgtt tacacttata tttcctgatg cccagaacag aatgtacagc cgctctcaaa
112981 gtcttctcac catactcatc cagggtataa catgagggaa aatcatggaa ggtctcagtt
113041 tataactttt aattagaccg tagagagtac catatttagt gagtcataca aatgctatct
113101 cccacctcaa ggtttttagt ctgttttatt tcttatatgg ctataagtaa gccaaattta
113161 aaatgtcacc ttttgatttt atattcttga ttcagtataa tctaattatg tatagatgaa
113221 acccaacatt tatttcttca ttgagccaat tcatgatctt catttgtgac aatagatccc
113281 tcttttggaa gttaggtatt tttttaagac agctgatttc cagtataaag tttataggat
113341 caaatcaaat ggctttaaaa aggtcatcac aaaaatctct gggaaagaat tcaagaaggt
113401 tgcttgaaaa gggatgtcgt acaaaataac ttgtatcaga tagtgcttta acctgtcaga
113461 atgcagaaat cctcaggatg aaattagaaa agcttttcat gtcaactaac ttcctctggt
113521 ctcagcgttc taaggcttaa atcacactta cttcctgtaa tacatattcc agccctaatc
113581 tcctctgcat ttgactaggt gccaggactt gattttacca gcttgcttaa aggaccaaca
113641 cttaaaagta ttaaaagcaa gaatgctact ggtcctagtt gaattactca gaggtattaa
113701 acaagaagag ttatggaaac cttaaaaatc tattattctg gtagcctgtc aaattgttat
113761 tcccaaatcg aaggaataaa aaaaaatttc aattctttgt tatatgagca gccaaagttt
113821 actttgattg gactttgaat tgattactgt gctctttgtt atccatcgat tgctcactca
113881 tccattcaaa cattcattga gggtttgctg tgtggaagga ccagaccatt catcttaaat
113941 tagacaggaa caatacacaa aaaagcatcc acatttctgc ctttcacact aattataaag
114001 gaattttgag cagcacaaac tagctacaat aataaatttt ctagtcttta aaaaacagct
114061 ttatgaaatc ttcgatacat gtaagaaaat gagctcctaa tgtcatgaac taaccattta
114121 aactgaaagt agggcaggga atatctgaaa gtatgctcct tgagttaagg caattattat
114181 taaaagagtt ggctttagca ggtcaatagt ggagcaaaga aaacatcctt attaggcagt
114241 gtcccatatt ttataggggt gtgtaaagac cttaagtatt ttccaaagag tgtcttgatt
114301 tctgagtaaa ctctaaagaa tatcaccagc tcatttggag gggtcacaaa agagctgtta
114361 atcatttgtt tatctttgca ttatttttctt cttccttgag catagggact agaatttcag
114421 tagtttttct tttttataat ttctttggct gaagtgaaac atctttttga gcaggcaatg
114481 cctttgtgct atttacatta tttgtaagca aggattacac tattcctctc ttccgtgaga
114541 cttcacatac tttattacag aaacactcag cagtgaatct gtcttctatt tcagagcttc
114601 tgtggagaaa aggttaattt gtcttaatca ttgaaataat tacttttctc ttgaattctc
114661 tttttccttc catctttgct ctttctatac atatacatgg agaataaagg acccaatgaa
114721 tgtacccaaa tccaaactga ctagtgtgat acatacatta tctctcttaa tactcccaat
114781 agttctacaa aattaagtac tatgaacgtc ctccatttta cttacaaccc aacatgagaa

114841 agagagatta agcaatgtgt ccaattttac ccatctagta aggtgataag ccagaatttg
114901 aactgaaatc tatctgattc tggctctgtc ttcagagcca gaatgttata cctgatgcat
114961 ttctgttatt actaatgttt cttaaaaaat tccaagacct catgtgtaat aaagcttaac
115021 tgattgttta actgattcat tcttgaataa attccactac cttttcacat ttgttataat
115081 tgattattct taagaagctc taattgataa aaattttatt gttcacaatt ttaaatcacc
115141 caggccactt gatgatttga ctttttgtta acatttaaat gaatacatgc tttgtgtccc
115201 agaccatttt tccataatga tcagctacta ttttgcccac gaatgaaatc atgaagcgtc
115261 agtgtctctg tgtgtgtgtg tgtgtgtgtg tgtctgtgta aaactcatga attatttcat
115321 aatttgaaat gtggtttggg taatttttgt ggtaatatta aagttacaag ttcttagaaa
115381 attggagttt aaagtaactt taacagttat ttaatctaaa gtctcccaca atgaaagaat
115441 cttttctaga gcatctctga cagaaacatt ccattttccc tcctgaattt atttctcaat
115501 tcctttgtag aatacattaa ttatttcaac aatttagcta tgtagaacta aattctggtt
115561 ctctagaact gtcaacaact gatcttcact ctatttcttt gatttattta taatctgtat
115621 gatagtcctt aaaatatttg gagacaggca ctcaatctct ctgtagtctt ctcttcttca
115681 cattaaatat ctccaatttt taacttttтc ttttgcaact gacttccaaa atcctcacct
115741 ccatgtttac tttttactgg ctgccacaag cttgagaata tccagaactg aacacaaagc
115801 acagaacatg atctgatcag aattgcaatg caaccatatt ttctgtgata aggccttgtt
115861 cttttatgag tatagattaa actcatgcta gctgtctaat aatttcatga cattaatagc
115921 ccttctatac acatatgggt ttactgattt ccttgatttt ctaataaatt ttctactaga
115981 ccaatccaat tcataattat ttttattaca ttcttctagc atttataata atttgtactt
116041 tacatgttta gttactatgt tctatgaggc atagtgatcc aagacacttt tctttttata
116101 tgaagctctt taccaatgta aaatgtcact cttgtcttgt tttagtgctt ttagctttaa
116161 atttctagta ttaataatgg taatttttтc cttgtattta tgttaaccta gcacctcttt
116221 gttcctcttt tatttttctt ttcttataaa caacatatac ctgggtttac tccaatcaga
116281 tagccatttt ctattaatag gaggatttag cctgttcata ttttatatca caactgatat
116341 actctatttt atccctacta tcttaactgt atattttcta ttcgctttac gtttttgctt
116401 cttctttttc tttttcttta cttgttactg gttatgtttt ctccactgct aagtgaaagt
116461 cagacaccaa ttctttctac acatcgcagt gctctattta ttcttcattt ctgcccaccc
116521 catgggactt tcagaatctc caggagatcc tcagactgct tggatcttct tccttacctc
116581 ccctggtact cttaggtttc tctttgcaga gtgattctca atattgagtc ttacctagcg
116641 aattagccaa gactccaccc atcacagccc cttcacatgt atcctgaagt tattttctga
116701 ttcaattgtt attaagagtc tcctcatgta tttccttaga agggaaagtg tcttgggaga
116761 cagaatccct gaagccttgt gtgttatcaa attgttttct tttatttggg tagttgaaaa
116821 gtgtattaac tgggtatgga actcctgagt gacatttctt tgggtggttt atagatgtga
116881 tttcactctt ttctagcttc tagtgttgga agcaggtagt ctggtgtgaa tttatttttt
116941 tcctgtaagt aatttattct ttctatctag gcagaaactt tttgattttt ccctttatcc
117001 gtgatatctg tatgataaaa attgtttaat catgtgctat tgaacatctc tttccaactc
117061 catgataggg cttcatgttg ggagcttgag ataagctatg atgggaatct ttatcccatt
117121 gaaatcagga tggtagacag acctttctaa tgcaaaaagt tgatcatgct attccacctc

117181 gtaaaacact cctataagac cctccatttg ctgcagggca tagtccaaat tacttaaatt
117241 ggtatacaag gacttttatc actaaacctg atatctgcag ctttacctat agatactccc
117301 caactccaac aatgaaactt ctaggtgcac ttttagaaag gcatcacatc tgcttagttc
117361 agatcttggt atatgctatt acttctttat agaatactat ctctctaccc tgactccatt
117421 ctactctctt aattccccca tcccacacac acgtttgtgt gtgtttttt gttttgtttt
117481 gttttgtttt gttttgtttt gtttgagacg gagtctcact ctgtcgccca ggctggagtg
117541 cagtggcaca atcttggttc actgcaagct ccgcctcccg ggttcacgcc atcctcttgc
117601 ctcagcctcc cgagtagctg ggactacagg cgcccaccac catgcccagc taatttttg
117661 tatttttagt agagatgggg attcaccgtg ttagccagga tggtctcgat ctcctgacct
117721 cgtgattcac ccgccttagc ctcccaaagt gctgggatta caggcgtgag ctactgctcc
117781 cagcccacac cttttcctta gtctgttcag gttgctataa caaaatgcca cagactgggt
117841 ggcttataca cagaaattta tttctcacag ttctggagtc caagaagtcc aagatcaagg
117901 tgccagcaga tttggtatct ggtgaggacc cattcctcat agacatagct gtcttctccc
117961 tgtgtcctca catggcagaa cgggcgaggg agctttcttg gacctctttt ataagggcat
118021 taattccatt tatcaggact ctacccttat tcatttcaac acatgaatgt gggggaaaga
118081 cacaaagact cagatcatca taaccttcaa ctggttactg gctactcacc atttatgttt
118141 aacttacagt tactcactct agaaaacctt ctcagtatgt ctaaacctga gttagtgcca
118201 gccctgaacg agactcacaa gcatcgtgtt cttactactc ctataatgct tcttatattt
118261 tgttttattt ctccatttat tcacttgtgt ctcatgacaa gcaaagactt ctcatgttca
118321 ccacagtgtt ctggatacct aacagtcact attgatttag tgaatgcatt tacatatgga
118381 tgaatgagtg tataaactcc cgtagtgttc agaggaaaag aatcaagaca gaaaattggt
118441 gagagaaaag ataaaaagga aaaagaatga cgattcaaag tgatccttta gacccaaaga
118501 gatcattgat gtagttcaag ggaagatcag atcaaatcag aagcagtcat caaggaataa
118561 caaaacaaaa ctatcttgaa ggaaagaaac atttaaatcc ataaagcaaa attattgttc
118621 caactatgtc atttcttgca ttttaaaaaa actcactaaa tcatcataga tttttctttt
118681 aacatgacag taaattctac tttctgattc tttttagaaa aactaacctt atatttacca
118741 gtgaaattac actaccaact ttactaatta cattatattc cctcacatgt tatatatggt
118801 gtgagatgct ctgtaaactc caaatacaaa aatagttatt tctccctatc ttttaataat
118861 tgttccaact ttattattag cagaaagcaa agctcgtcaa tttaagccac cccctaccac
118921 caccacccac ccatcttaga tcgagaaaac ttgggatgac tcagtccaaa gagaatcaga
118981 ctagctttca agtcagtcag agaggaacct ggtcagtctg ttgagtccac cactcctgtg
119041 gtgccggatg aggcatgctg tcactgatct tgcgcagatg ttttattgct gtgctgatgt
119101 tcttccagtt ccaggtgcct gcctgagtca cagtggtgac caggcctggc atccgcaggc
119161 ttcagaatca cttgcttagc cattggtact cagggcataa tcactgggtc cacttcatgt
119221 atgactaaga agtcatacat gagcgtctct tgtagcctcc aattttgcaa gtgccctatt
119281 tcaaatgctt taggcatcta ctgccataaa ggttttattt tgactttgta atatgttata
119341 ttaatatgtc cccttctatt aaatcattat tctctgacta tgatgtagtc agttgctaat
119401 atttcgttta ggatcttcta aacttaggtt gtataatcta tgtatgctct tttcttctgt
119461 gctaacattg ccaggttgtg atattggtat tataataatt tctaaaataa tttgaaagaa

119521 ttttctctta ctggaacata ttataaatat ggaaatttta tctctttcaa gactaaaaga
119581 atgtctttta taatgtgatg acttaaaaat ctagtttcct gcctatggta atatttatat
119641 tttctaatgc ttcaaatttg gggattaata tgttcctatc attttcctta aggtgtgaaa
119701 tataataatt acacattatt ttaattaact ttgaatctgt tataactttt ttatcatttc
119761 taatttttctg tttgtacctt ttctctttaa ttaaaattcc attgattaga ctactatatg
119821 aatatttata aaaccaacta ttgatctttt aattctatca tttgtgttac gtgtattcta
119881 acttattaac ttctgcttgt gtatggctgt tactttatta cctattatct tttgttttct
119941 gtagttattg tttcttaccc aaagtcttgg gttaaatgtt cagttcattt actttcattc
120001 ttttttatct agtggaagga gataacacta tgactttatc tttgagcaca actttggcta
120061 aataaaatac acactattaa gaggcttgtg tctaatctat aactatagtt actctctagt
120121 ttttgatcaa aaagtcattg atttttttct ttttaaaaat gtcccattgg attttattta
120181 atctattatt aattgcactt tggccattaa gtagatatgc ataatttctg cctttaaaat
120241 ttattgagat taatccacaa atatttgaaa ggaaggttta ttctctattt ttgggtacaa
120301 aggtcattct tagctattaa aacattgttg ctgattattt taaaatactc tgtatccctg
120361 tttttgtctt tactcaatct gttaagagga tttaaatgtg attaataagg ttcttttaat
120421 acatatacaa tggactttgt actctacaaa tagtggtatg agtatggcat cttttggttt
120481 ccaacagtaa tgctgatttt actttataca tatcacatcg gccttttaaa ttgaagtttg
120541 acaggagttc agtttttaga tgaattaact tctcatttgt ctcctaatat tttcattttt
120601 catcttcttt catgattttt cttctgtttg taaactgaca gtaaatgtat ataaaagctc
120661 agctctagac aatcctgatg tcaagtgtaa ttatgtgaaa atattttatt tgataatttc
120721 catgatttat gtcaggtcat agataatatg attcagtata aatggcacca gcccaagatc
120781 tacatttatc tcagaaaaaa aaaacctatt tcctctctct gagtctcatc tttaaaattc
120841 tattattcta taagctggat ttacttacaa ctagacctta ctgaacttta taaatatata
120901 accagggaga acctgataca taaatatatt attatcatga aatttatttt actgattgct
120961 taaatacaaa aaattgcttc ttaaaggttt gagaatgaat gaaataatta ttctttactt
121021 acagcattcc caccaatgac gtcctcaaag ccaagtgtgg acattccaaa tctgccttcc
121081 tcctcctctt cttccttctc tgtctcacct acatactcca tgactgtaat aatctccatc
121141 atgtccagct ttgcaatatt tgtgcttctt accataacta ctctctattg ctgccgaaga
121201 agaaaacaat ggaaaaataa gaaaaggtga gattctagtt tcagctaacc atgtgtagta
121261 atattttaaa gccttgtgtt ttatggagtt ggtatgacgt gaggaatata tatgacactg
121321 caactctcta aatatatccg tagccctgct ttaaaattaa gcacccccat catgatcttt
121381 acaaatgtca atgacttttt ggcatgggat caaatcaaat gccctagggt tactgtttca
121441 caaaaggtaa aatctaaaca ataatttgga ggaaaatggc tattcctgct ccttgtcttc
121501 tcctcaggcc tgttgccatt gctggcttgg agagctaaac atttctgaga aaatgtgcct
121561 tttgactcta gaccaaacaa aatattttat tgctctcaaa acgaaggatc tttggctgcc
121621 ttagtataac ttgttttcat tactcttaaa tgccatattt cttagaatct aagtctaagt
121681 acaaagatct aacctgcttc tgagctcatt cctgatcttg cctgtcttgc ctgcagagaa
121741 tcagcagcag taaccctcac cacactgcct tctgagctct tactagatag acttcatccc
121801 aaccccatgt accagaggat gccgctcctt ctgaacccca aattgctcag cctggagtat

121861 ccaaggaata acattgaata tgtgagagac atcggagagg gagcgtttgg aagggtgttt
121921 caagcaaggt aaagttacct atggaaaaaa aaactccatt gaaatatgtt atgtctgaaa
121981 agctaccaaa ctattagctt ggtatatata taatattagc tttatatata tatacacaca
122041 catatatata tatatatcaa gctaatgata tagtacatat atatgtacac tgtgtgtgta
122101 tatatatata cacacacaca tatacatata tacacacagt gtaatataca gtattatata
122161 gtattaatac aatattatat atgtattata tggtaataat atactatata aaatagtttt
122221 tatcaagtta gttaattctg gccaggtgcg gtggctcgtg cctgtaatcc cagcactttg
122281 ggaggctgag gcgggaggat caccttagtc aggaattcaa gaccagcctg gccaacatgg
122341 cgaaaccccg tctctactaa aaatacaaaa ttgagccagg catggtggtg cacaactgta
122401 gtcctagcta ctcgggagtc tgaggcagaa gaattgcttg aagccggaag acagaggttg
122461 cagtgagcca agatcgcgcc actgcactcc agcctgggtg acagagcaag actctgtctc
122521 aaaaaaaaaa aaaaaaagaa aagaaaaact agttaattct ttacatcatt aaccttattt
122581 gtattgcata atacacttca aatcttaatt tcccctcttt gctggaaaac agtagcctat
122641 atggagataa tatattttac tgcacttaaa ataggtaatt tattggagat gtaaatgtgt
122701 cttcacttct acgattttta aattataaga aattagtaat atagttcaat aatatttcct
122761 tttcaggaaa gaatttacca tatattttta atcataattt cttacattgt tttaaataac
122821 tccttacatt ataatataat gtatagatat taagtagatg ttcatgaaat gacaaacaga
122881 aaaggaataa aaaggcaaaa atttataaaa aatgagctca agaaaggagt atgtattagg
122941 gccaatatta gcctatgtat cacctttgtg cgaattggaa taaaataccc tttctgctgc
123001 atggatatgg ctccacagac acacagctga gccagagaat atgaatttgg ttttaatctc
123061 caactggcac ttcggcctgg tgctcttggg caagacacaa cttaatctcc acccatggtg
123121 gccctggcgt agaggttaca tgaatagtga aaatctcaca caaacatgtc ttggaaacca
123181 aaatttgcaa ggcaccactt taggctcaat ggagggtaca aagatgagta agccatagtt
123241 cctacgtcat ggaatttaga ttctggacaa agattaaaag gttaggatgt ggctgggcgc
123301 gatggctcac acctgtaatc cccgcagttt gggaggccga ggtggtcata tcacgaggtc
123361 aggagattga gaccatcctg gctaacacag tgaaaccctg tctctactaa aaatacaaaa
123421 aattagccag gtgtggtggc gggtgcctgt agacccagct actcaggagg ctgaggcagg
123481 agaatggtgt gaacccagta tgtggagctt gcagtgagcc tagatcatgc cactgcactc
123541 cagcctggat gacagagtga gactctgtct caaaaaaaaa aaaaaaaaaa aaggttagga
123601 tggcaatgat aatcctattg ggggtgtata cttcagaatt cctataattt gtaaataatg
123661 catctttcaa acttcattgt ttgaaattgt tgaaaataac accagtgatt tttattagtt
123721 gacatcaagg agttttaagt atgttgtctt tctttgattc tgtggctctg ggaaaggctg
123781 cgtgagactt aaccagcctt ttacacaggg gaggtgggag gatatgtata aatgtgggta
123841 ggtataaaga tatgatgtcc atgatctttg gtttcttttt caataaatgt atctctcagg
123901 gcaccaggct tacttcccta tgaacctttc actatggtgg cagtaaagat gctcaaagaa
123961 gaagcctcgg cagatatgca agcggacttt cagagggagg cagccctcat ggcagaattt
124021 gacaacccta acattgtgaa gctattaggt atgaaaatac aagtgaggat atgtatttca
124081 tcagaaaaca gaggctttcc aagtttttct ccccttgttc gtgctttttc cttttctcct
124141 tgatcagtga gacgtttcag ttccttttca aatttagctt cttcaccttg gtctatccca

124201 accctatagg acattcatgg cttaatggat tatccctctt taaattcatc acttcaattt
124261 gtctctgtct ttgctgcctc ctatttataa aaatgtttaa aatgtcccca ttgtaaaaaa
124321 ttaatactgc ttctccatca caaaatttat caatattgaa aagtctatat attttactta
124381 ttttgtttct cctctttctt ccctaactag aatgtcatga gcagcgattt gtatcttttc
124441 tgttcattgt tgagttccag tttattccca gattcataaa ttcaacacaa attttacaaa
124501 tatttagttt gtattaatta cacagcaatt aataaaactt ttcaaaaatc tgtgctctcg
124561 gctgggagca gtggctcatg cctataatct cagcacttta ggaggccgag gcaggcagat
124621 cacttgaggt caggagtttg acaccagcct ggcgaacaag gtgaaatccc atctctacta
124681 aaaatagaaa aattagctgg gtgtggtggt gtgggcctgt aatcctagct actcgggagg
124741 ctgaggcatg agaatcgctt acaccggggg ggcagaggtt gcagtaagcc aagattgcac
124801 cactgcacca cagcctgggt gacagagtga gattccatct ttaaaaaagg aagaaaaaaa
124861 aaatctgtgc tctcatagag catacattca ctctatatga ggagacagat aataaaaaaa
124921 aaacaaaaat atgggatgct ggatattaag ttctacagac tttttaaagt gttaaagcag
124981 agaagttgga atgtgagcta caaagtttga agacttcagt gaaaatatta catttatata
125041 aagacctggc agaggcaagg gaataacagt gtggatatct tgggaaagaa cattccaaaa
125101 agaatgagaa gcatttgcaa aggtactgtg gcaagagcag atgtggcatg cttgaggaat
125161 agcaaggaga tgaatgtggc tggagcagag tgaaagatgg ggagagttat caaagatgag
125221 atcagagagg taatggggga ggtaggcagg tcctgtcagg ccttattaaa aacattggct
125281 tttaatctaa gttgggaaac aaatggagag tttcagccaa gacatgacat gacacaactc
125341 acatttttc agatcttctc tggctgcttt cttgagcatt gcatgaaggg aagcaatgaa
125401 atcaggaaga cagtaaacag gtattgcaat gatgcagcaa gagaagatga tggcatgggc
125461 caggtggtgg tagtgaagat cgtgagaagt gattctcttc catgtgtaat gtgaaagtag
125521 agccaaataa tttgctgaca gaccaaatat gagatgtgca aaaaagggaa aagtcaaaga
125581 tagtatcgaa gtatttggct gtgcagatga gtgaatggag gtgccattgg ctgagttgag
125641 gaatactcag aaggaacagg ttcctttagt ggagagagtg ggaattcatt taaagatgtg
125701 gtttttgtcc aggcactgtg gctcacgcct gtaatttcaa cactttgtga ggccgaggcg
125761 agcagatcac ctgaggtcag gaattcgaga ctagcctggc caacatggtg aaaccccatc
125821 tctactaaaa atacaaaaat tagccgggtg tggtggcaca cgcttgtaat cccagctgct
125881 tgagaggctg aagcaggaga attgcttgaa cctgggaggc ggaggttgca gtgagccgag
125941 attgtgccat tgcactccag cctgtgtgac agagtgagac tccatctggg aaaaaaaaaa
126001 gacgtgtttt ttggcgatgc ttattcaaca tccacatgat ccacatgaag ttaaggatgc
126061 atgtggatat ggaggcctag agttctggta aggatgatct ggttagacat gaatccaagg
126121 ctattgcagt acacagagta tttaaagcca tgaggttgag taagacacct aagtatggag
126181 aaagcaagcc agaacagaga agaggtccaa ggaccaaggc ctggagcatt ccagtattta
126241 gtgtgagaaa gaggagatga acaagaaaaa caaactaaaa acgagcaacc aatgaaatag
126301 aagtaaatca agagagtgtg gtgtcctgga tgtcaaatga agtattttaa ataggtgaaa
126361 gtgagcatgt catatgcatt aagtcaagtg agaggaggac tataaagtga ccttgaattt
126421 gtaaacatgg atgttcactg gtaaccccga gaagagaggt ttcttaggaa tgttgggggc
126481 agaggaaatg taagtgagct caaaagaaga ggaagagaaa atctggagaa aaagtataaa

126541 caacttgttt tgccataaag gtgaaccaag gaacatggat agagctgaag ggggcagaaa
126601 gaagcatgct tcctttcatg tggaagtaat agcacatttg taaattaatg agaatgatcc
126661 cgtaaagaga aaaattgatg acagggttgg caaatagtgg aagtaacatc tttgaacagt
126721 gagagggaat ggaatcttgg cactgttgga tggattggcc tttgtaaaga gaatgctcag
126781 atcaaccata gtaataagag agaattggct ggagattgta gccagtctct tctgattgat
126841 ttagttttct ctgtgaggta ggaatcaaga tctcatctga gggtgaggaa tgggagaaga
126901 gttgaagatt tgaggaaaga gaagaaataa attgtcatct aagaaaatcc atttttacat
126961 aaaatataaa atggactaga gaaacataat atgattggca agaacattaa aagcttactt
127021 gaaattagag attacacatt taacatgaga ctggtcagca tggttgtgta tttatccaaa
127081 tgctgccagc tgggcataga ctcgttaaga ggagttaaat tttaccagaa ttagcatttt
127141 gccacacaag taagttgaag tcaaattgag gcaaataaga gaggtgtatg caaaggagtg
127201 attattatga ttgatcaagg aacttaagct gtttaaggaa ggaagacaaa acgtgaagaa
127261 agtagggatc attaaaaggg ggtaggatca atagattaaa agtttcaggg ggaggagcca
127321 agatggccga ataggaacag ctccggtcta cagctcccag cgtgagcgac gcagaagacg
127381 ggtgatttct gcatttccat ctgaggtacc gggttcatct cactagggag tgccagacag
127441 tgggcgcagg ccagtgtgtg tgcgcaccgt gcgcgagccg aagcagggcg aggcattgcc
127501 tcacctggga agcgcaaggg gtcagggagt tccctttctg agtcaaagaa aggggtgacg
127561 gacgcacctg gaaaatcggg tcactcccac ccgaatattg cgcttttcag accggcttaa
127621 gaaacggcgc accacgagac tatatcccac acctggctcg gagggtccta cgcccacgga
127681 atctcgctga ttgctagcac agcagtctga gaccaaactg caaggcggca acggggctgg
127741 gggaggggcg cccgccattg cccaggcttg cttaggtaaa caaagcagcc aggaagctcg
127801 aactgggtgg agcccaccac agctcaagga ggcctgcctg cctctgtagg ctccacctct
127861 gggggcaggg cacagacaaa caaaaagaca gcagtaacct ctgcagactt aagtgtccct
127921 gtctgacagc tttgaagaga gcagtggttc tcccagcacg cagctggaga tctgagaacg
127981 ggcagactgc ctcctcaagt gggtccctga cccctgaccc ccgagcagcc taactgggag
128041 gcacccccca gcaggggcac actgacacct cacacagcag ggtattccaa cagacctgca
128101 gctgagggtc ctgtctgtta gaaggaaaac taacaaccag aaaggacatc tacaccgaaa
128161 acccatctgt acatcaccat catcaaagac caaaagtaga taaaaccaca aagatgggga
128221 aaaaacagaa cagaaaaact ggaaactcta aaacgcagag cgcctctcct cctccaaagg
128281 aacgcagttc ctcaccagca acagaacaaa gctggatgga gaatgatttt gacgagctga
128341 gagaagaagg cttcagacga tcaaattact ctgagctacg ggaggacatt caaaccaaag
128401 gcaaagaagt tgaaaacttt gaaaaaaatt tagaagaatg tataactaga ataaccaata
128461 cagagaagtg cttaaaggag ctgatggagc tgaaaaccaa ggctcgagaa ctacgtgaag
128521 aatgcagaag cctcaggagc cgatgcgatc aactggaaga aagggtatca gcaatggaag
128581 atgaaatgaa tgaaatgaag cgagaaggga agtttagaga aaaaagaata aaaagaaatg
128641 agcaaagcct ccaagaaata tgggactatg tgaaaagacc aaatctacgt ctgattggtg
128701 tacctgaaag tgatgtggag aatggaacca agttggaaaa cactctgcag gatattatcc
128761 aggagaactt ccccaatcta gcaaggcagg ccaacgttca gattcaggaa atacagagaa
128821 tgccacaaag atactcctcg agaagagcaa ctccaagaca cataattgtc agattcacca

128881 aagttgaaat gaaggaaaaa atgttaaggg cagccagaga gaaaggtcgg gttaccctca
128941 aaggaaagcc catcagacta acagcggatc tctcggcaga aaccctacaa gccagaagag
129001 agtgggggcc aatattcaac attcttaaag aaaagaattt tcaacccaga atttcatatc
129061 cagccaaact aagcttcata agtgaaggag aaataaaata ctttatagac aagcaaatgc
129121 tgagagattt tgtcaccacc aggcctgccc taaaagagct cctgaaggaa gcactaaaca
129181 tggaaaggaa caaccggtac cagccgctgc aaaatcatgc caaaatgtaa agaccatcga
129241 gactaggaag aaactgcatc aactaatgag caaaatcacc agctaacatc ataatgacag
129301 gatcaaattc acacataaca atattaactt taaatataaa tggactaaat tctgcaatta
129361 aaagacacag actggcaagt tggataaaga gtcaagaccc atcagtgtgc tgtattcagg
129421 aaacccatct catgtgcaga gacacacata ggctcaaaat aaaaggatgg aggaagatct
129481 accaagccaa tggaaaacaa aaaaaggcag gggttgcaat cctagtctct gataaaacag
129541 actttaaacc aacaaagatc aaaagagaca aagaaggcca ttacataatg gtaaagggat
129601 caattcaaca agaggagcta actatcctaa atatttatgc acccaataca ggagcaccca
129661 gattcataaa gcaagtcctg agtgacctac aaagagactt agactcccac acattaataa
129721 tgggagactt taacacccca ctgtcaacat tagacagatc aacaagacag aaagtcaaca
129781 aggataccca ggaattgaac tcagctctgc accaagcaga cctaatagac atctacagaa
129841 ctctccaccc caaatcaaca gaatatacat ttttttcagc accacaccac acctattcca
129901 aaattgacca catagttgga agtaaagctc tcctcagcaa atgtaaaaga acagaaatta
129961 taacaaacta tctctcagac cacagtgcaa tcaaactaga actcaggatt aagaatctca
130021 ctcaaagcca ctcaactaca tggaaactga acaacctgct cctgaatgac tactgggtat
130081 agaacgaaat gaaggcagaa ataaagatgt tctttgaaac caacgagaac aaagacacca
130141 cataccagaa tctctgggac gcattcaaag cagtgtgtag agggaaattt atagcactaa
130201 atgcctacaa gagaaagcag gaaagatcca aaattgacac cctaacatca caattaaaag
130261 aactagaaaa gcaagagcaa acacattcaa aagctagcag aaggcaagaa ataactaaaa
130321 tcagagcaga actgaaggaa atagagacac aaaaaaccct tcaaaaaatc aatgaatcca
130381 ggagctggtt ttttgaaagg atcaacaaaa ttgatagacc gctagcaaga ctaataaaga
130441 aaaaaagaga gaagaatcaa atagacacaa taaaaaatga taaaggggat atcaccaccg
130501 atcccacaga aatacaaact accatcagag aatactacaa acacctctac gcaaataaac
130561 tagaaaatct agaagaaatg gatacattcc tcgacacata cactctccca agactaaacc
130621 aggaagaagt tgaatctctg aatagaccaa taacaggctc tgaaattgtg gcaataatca
130681 atagtttacc aaccaaaaag agtccaggac cagatggatt cacagctgaa ttctaccaga
130741 ggtacaagga ggaactggta ccattccttc tgaaactatt ccaatcaata gaaaaagagg
130801 gaatcctccc taactcattt tatgaggcca gcatcattct gataccaaag ccgggcagag
130861 acacaaccaa aaaagagaat tttagaccaa tatccttgat gaacattgat gcaaaaatcc
130921 tcaataaaat actggcaaac cgaatccagc agcacatcaa aaagcttatc caccatgatc
130981 aagtgggctt catccctggg atgcaaggct ggttcaatat acgcaaatca ataaatgtaa
131041 tccagcatat aaacagagcc aaagacaaaa accacatgat tatctcaata gatgcagaaa
131101 aagcctttga caaaattcaa caacccttca tgctaaaaac tctcaataaa ttaggtattg
131161 atgggacgta tttcaaaata ataagagcta tctatgacaa acccacagcc aatatcatac

131221 tgaatgggca aaaactggaa gcattccctt tgaaaattgg cacaagacag ggatgccctc
131281 tctcaccgct cctattcaac atagtgttgg aagttctggc cagggcaatc aggcaggaga
131341 aggaaataaa gggtattcaa ttaggaaaag aggaagtcaa attgtccctg tttgcagacg
131401 acatgattgt ttatctagaa aaccccatcg tctcagccca aaatctcctt aagctgataa
131461 gcaacttcag caaagtctca ggatacaaaa tcaatgtaca aaaatcacaa gcattcttat
131521 acaccaacaa cagacaaaca gagagccaaa tcatgagtga acttccattc acaattgctt
131581 caaagagaat aaaataccta ggaatccaac ttacaaggga tgtgaaggac ctcttcaagg
131641 agaactacaa accactgctc aaggaaataa aagaggacac aaacaaatgg aagaacattc
131701 catgctcatg ggtaggaaga atcaatatcg tgaaaatggc catactgccc aaggtaattt
131761 acagattcaa tgccatcccc atcaagctac caatgacttt cttcacagaa ttggaaaaaa
131821 ctactttaaa gttcatatgg aaccaaaaaa gagcccgcat cgccaagtca atcctaagcc
131881 aaaagaacaa agctggaggc atcacactac ctgacttcaa actatactac aaggctacag
131941 taaccaaaac agcatggtac tggtaccaaa acagagatat agatcaatgg aagagaacag
132001 agccctcaga aataatgccg catatctaca actatctgat ctttgacaaa cctgagaaaa
132061 acaagcaatg gggaaaggat tccctattta ataaatggtg ctgggaaaac tggctagcca
132121 tatgtagaaa gctgaaactg gatcccttcc ttacacctta tacaaaaatc aattcaagat
132181 ggattaaaga tttaaacgtt agacctaaaa ccataaaaac cctagaagaa aacctaggca
132241 ttaccattca ggacataggc gtgggcaagg acttcatgtc caaaacacca aaagcaatgg
132301 caacaaaagc caaaattgac aaatgggatc taattaaact caagagcttc tgcacagcaa
132361 aagaaactac catcagagtg aacaggcaac ctacaaaatg ggagaaaatt ttcgcaacct
132421 actcatctga caaagggcta atatccagaa tctacaatga actcaaacaa atttacaaga
132481 aaaaaacaaa caaccccatc aaaaagtggg cgaaggacat gaacagacac ttctcaaaag
132541 aagacattta tgcagccaaa aaacacatga agaaatgctc atcatcactg gccatcagag
132601 aaatgcaaat caaaaccact atgagatatc atctcacacc agttagaatg gcaatcatta
132661 aaaagtcagg aaacaacagg tgctggagag gatgcggaga aataggaaca cttttacact
132721 gttggtggga ctgtaaacta gttcaaccat tgtggaagtc agtgtggcga ttcctcaggg
132781 atctagaact agaaatacca tttgacccag ccatcccatt actgggtata tacccaaagg
132841 actataaatc atgctgctat aaagacacat gcacacgtat gtttattgcg gcactattca
132901 caatagcaaa gacttggaac caacccaaat gtccaacaat gatagactgg attaagaaaa
132961 tgtggcacat atacaccatg gaatactatg cagccataaa aaatgatgag ttcatgtcct
133021 ttgtagggac atggatgaaa ttggaaacca tcattctcag taaactatcg caagaacaaa
133081 aaaccaaaca ccgcatattc tcactcatag gtgggaattg aacaatgaga tcacatggac
133141 acaggaaggg gaatatcaca ctctggggac tgtggtgggg tcaggggagg ggggagggat
133201 agcattggga gatataccta atgctagatg acacgttagt gggtgcagcg caccagcatg
133261 gcacatgtat acatatgtaa ctaacctgca caatgtgcac atgtacccta aaacttagag
133321 tataacaaaa aaataaaaaa ataaaaaata aaaaataaat gcatgaatac ccaaaaaaaa
133381 aaaaaaaaaa aaaaaaaaga aggcatttca gcatgcaaac aagtaatact tttaggaatt
133441 acactgactt cattgtaatg cataggaaaa ataaataatt cacaaataaa aaacaaacaa
133501 acaaaaaaaa agtttcagtg gggtcaaagg atttttagag ttagggcagt cgaggcagtg

133561 aactagggtg aaaaagggag gaagtgatga acaacaggta gagtaactga aaatgagatt
133621 atgggaggta tacaaatgta tggaatgaca aagtcagggg tatgacaatg tgagtgatta
133681 gctgaagttg ggcagaggtc taaggaaagg aagtaaagta atttagtggt caggatattg
133741 gaaggaatct agataaatat taaaagcaag aatttctata gtagtatctc gaatagtttc
133801 tggcacattg taggcactct ataaatattt gttcaataaa tgaataaacg atattaagta
133861 cataacaatt catcttgaaa acacttcttc catttcctca actcctaaac attcatttat
133921 tcattcttca tcacacaaaa atctgaatct ggcttctgcc ccctaccctc cttatttact
133981 ttctcaaata gtatacattt agtcattaaa caaacataca tacatgcata ttttcaagat
134041 tatcaagcaa ttcctgtttc aacttttctt aaaatgttga ctctgtattc gtatacagtt
134101 tataacatcc tgaattcctg aaattgattc aaacagaaac tatgtacagt tttccaattt
134161 aaccacagta gcatgcttat acatcactac ttggagtttt ctctcatttt tattgtccaa
134221 caagaactga aacttatgtt gccgtttgtt aaatgctata tctaaattcc atttggatat
134281 ccaatgaaca caggttctat tttttatcaa gtatacataa gcagtaatca ttcatgcaag
134341 tgattccact actctcatag tttcttgtaa gttaatccca gtgaaataag atgacaatag
134401 tggaagaaag gggaattggg aaaatccata aaattcactt ctatcaataa aagaaatcta
134461 ctttgtttta tatatttgat acatcagcca cttattgaac atgttcgtat cttaaaaatt
134521 gtttcccttt tattgaaatc ctagtggata atggttttgt agtcataaat tgggaaaaat
134581 ggtataacta aagaaatatg cagaatttta gaatgggagt aggcattgaa tattatagac
134641 tcttacggaa tattctggca gtggagcaaa cagtagaaca atcaggtgag attattcatt
134701 gaagatgtca tgctaaagtt taaagacatg gcttgggcta ggcatgaggt tttcttatgc
134761 ccatccatct atgcatccat ccttaaatct atccatgcat ccacctatgc attaattcat
134821 ccatccaccc atcaacatat attgaaaacc catagtgagc catgtgtagt attagacctg
134881 aggttacaag gatgaataaa atacagtctt cctctcaata attattatat tttgaagtcc
134941 cacctaagag ttgggttgga gtaattacaa tatagaaaac attttgaggt cttaaataaa
135001 tgtatataca tatataattg taaattatat ctatacacat gtatatataa ttgttcataa
135061 taatcacaaa gtagaaatct tttgtatagt attttcttta tcagagtgga aaatttcatt
135121 aaatcaattt agttcaaaac tttatttctc agagaaatat tttgtcattt ttttccagta
135181 taagaaatta tttttaaatc aactcaacca gcataacaat ggtaaagcca gttgatgaga
135241 taggtaagtc cctgttaact aaagattatc caaaaaggat cccacagaag aaacttctaa
135301 gtattatcca gttggtattt ctttatttttt tccctttagt ttacagaaat gtgctaattg
135361 aggtccttgg aattaaaaat taatgccaaa ataaataagc caagatagca gtattcctca
135421 tttctcctct ttttcaaaca gatactttta acttttgcct gaaaaaaccc aatagatcta
135481 ataatctatt tttaagatga tgtgaaatta tgcccatctt atctaatatt ccaagttctc
135541 cagtttccct ctcaaatata tcaagacttt aagatttgaa aatgatcttc tggctttaaa
135601 tctaagactt tatttatatt aacttttttg gtagcatgaa cattgtaaaa cctaaatttc
135661 aaaatgtttt actgcagcaa cttaaatact tcatctaaga cacttgaatt gtatttgtta
135721 ttgtttccaa acttgataca tctttcttat taacatcctt catagaagta aacagaaaca
135781 gacagcaatt acattacata ctcagagcaa gcatccattc ataaattaac tcaccaaaca
135841 ttatgaggca tctgctctgc cagacacgtg gtaggtgtgg ggaattttta aagaagaata

135901 aggttcaatc tctcctttca aagtgctaaa acgttgggga gaaacctcaa atagtcaaat
135961 gattataaaa taggatggta ggttctctgt gaaaggatga cagtaggaaa atctaacagt
136021 tactggaagg atcaggagct gaggcaccct agggagagtg ataaactgaa tcttaaaggc
136081 aaagaggaga tgtttaggca gagaaatagg gtcagggttc aaccatggtg ttgtcaacaa
136141 aaaaccaggg cctccagatt tcagagagaa gagccactcc agagaactga tacaccatgt
136201 acttatatgc accatgaact tgatgcacca tgtacgatgt acttatgaca agtgcccagg
136261 acaacagcgc tctgctggaa gtcctcaaaa actttagcca agggacagaa accccactac
136321 ccagagtgca tttcctagct gagactcctt ttgtgttgtg attaaaagga tacaaatatt
136381 aaaaaacaaa catacgacaa caacaacaaa aaacagggct tcatatgttc tgacatggtc
136441 gtttgctttt ggagtgctct ttccattgtt tcattgtaga aactgagact aacagggatg
136501 gtcttttggt tccaggagtg tgtgctgtcg ggaagccaat gtgcctgctc tttgaataca
136561 tggcctatgg tgacctcaat gagttcctcc gcagcatgtc ccctcacacc gtgtgcagcc
136621 tcagtcacag tgacttgtct atgagggctc aggtctccag ccctgggccc ccacccctct
136681 cctgtgctga gcagctttgc attgccaggc aggtggcagc tggcatggct tacctctcag
136741 aacgtaagtt tgttcaccga gatttagcca ccaggaactg cctggtgggc gagaacatgg
136801 tggtgaaaat tgccgacttt ggcctctcca ggaacatcta ctcagcagac tactacaaag
136861 ctaatgaaaa cgacgctatc cctatccgtt ggatgccacc agagtccatt ttttataacc
136921 gctacactac agagtctgat gtgtgggcct atggcgtggt cctctgggag atcttctcct
136981 atggcctgca gccctactat gggatggccc atgaggaggt catttactac gtgcgagatg
137041 gcaacatcct ctcctgccct gagaactgcc ccgtggagct gtacaatctc atgcgtctat
137101 gttggagcaa gctgcctgca gacagaccca gtttcaccag tattcaccga attctggaac
137161 gcatgtgtga gagggcagag ggaactgtga gtgtctaagg ttgaagacgt tcaaataaaa
137221 tgctgcagtt tcctctcaga ctctgtgagc caggggaatc ctacaccaga ggcccaacaa
137281 gacccacata ggaaagagta agagtaaaca tgagtagtgt gttgtttgct tcccagggag
137341 agcaaagaca gtgcaaaacc catgtggtag acggacccat tgaaagccag tgattggaaa
137401 cacaggctag gaaatgtgtc agataatgga gacaactatt cttcttcatg aaggtttgta
137461 atacacactg cacagggaag aatgtcatcc tgttcagttt ccaaagtagc tggtcacaga
137521 gtaaagctct gctgtattaa attttaatat gaaatgggat tcagagcttc atttttaat
137581 tgagttaatt cctgtccatt gtgaaagtag cttaatcgtc atgtaagaca cttaggtgaa
137641 gtacagaaaa ctaaaaagaa ggaaaagcca ctcattctgt ctccccccaa agacgagtct
137701 tagtgtttta ttaaatcttt cttgcattta atgcataatt ttatatttgt ttgtattctg
137761 cagagttgtg gttacatttt attgatagag ggtttctaag gaatgaaaca gcaaatcagc
137821 aagcctgtaa ctctgagttc ccttttctgt cctgtgcccc tccttttttc ctttctgtgc
137881 atttgtcatg aattaagtct gcttatttta ttcctccagt tttcttgaaa caagtttttg
137941 tatcttactg atttaccttt tcctttaaaa attgtattgg tatcttttcc attgctttaa
138001 tctttatttc ttcttctttc caggacttct gtccttttt agttattaag ctatttttt
138061 cttttatttc attcatgtaa taaacactct ggcagaaata ataacatttt aaataccatt
138121 gtagattgat atgtatatgc cttttgcaaa gtattactat ttttcctgca tttgcctttg
138181 aagccacaca tttcaacatt ctcacctatt aatattatta ctagagtcta tttaaatctc

138241 ttaaaccata atttataata tgagatttca caagatacac ttgtggctct gagttatttc
138301 aaaactgata tttctgtgca ttctgacatt ttattccttt tagaaacaaa ttcagttggc
138361 tgtagaatta atatcgttct gcttaacaac tttgtgcatg acatattaac tgattttgtt
138421 gtatttcatg atttaaaaaa aaaagcagca gctctggaac tcagattcct gggggttcag
138481 atttttttctc agtggatcct cacacaatac atctttatct aagtccatac atgatctgag
138541 tttatttctg atatagcagg aacccaaatt ctcctgaaaa cgaacaggga agagaaaata
138601 acagtctact ctataccagc ttatcttaat tcagactaat tggtagttag ggcattggag
138661 gaatggtgtg aattcttgaa agtagatttt cgctgtctgc tggaaaactc tgcctgaaat
138721 ccccaaatct gcctcatgta acagcttgac atctttggtg ggaaacctgc catttcttat
138781 tcatagtgtc tccaggcaac caagacaaaa atgtagaaat tttcctagac tttgccctct
138841 ctttcatcat cagttttcta ttagttttac ttcctaaaat cctcctgctg acatcctctt
138901 cccttcaacc caagagccaa tgactcaacc tctaccgttg cccaccctgt ctattagctg
138961 gccttcctct catttcagac ctgaacagat tctgtaggat acaacgacag taaggcggtc
139021 cttagtcaca gttctggttc ataaatagcg aggtcagcat ttaggactga gacctaaaga
139081 agtgcttcag ataaaaatca tgagtctaag tccaaaattg atactgtaat ccaaatgact
139141 gaataaagaa taaagttgca gcgtgtgtct aaagcagaaa gtcaagatgc caacaaagca
139201 gaaaagttgg agagggccac cagcaagtct agaacttgag catagatatc catggcttat
139261 tttagatggt tcatgtatgc tctgcaaaat tcaaagacag cttcgggctt tctccgctga
139321 taaagttttg ttgtaaaaga cagacataga agtcaggctg acagaaaata gagtaacagt
139381 aatcataaaa attataatat cagctagcat ttattgaaat cttaccatgt gtattctgag
139441 gcctttaaat atatgaactt aaacctcaca acatccctgt aatgttggta ctatcattat
139501 atacatttta gttttgcttt gttttgtttt gtttttgaga cggagtctcg ctctgtcgcc
139561 caggctggag tgcagtggca cgatcttggc tcactgcaag ctcagcctcc aacagtcaca
139621 gagagattgt gcaactggcc cgagtgcaca cagcaacaga gcctactttt tgaccaaaag
139681 aggccgaatt ctcaaccact atactgtaga gcctctgtac atgatagaag caataactga
139741 acctcagtaa ctctgtggaa gtgatttgta atttgcatgt cgtttcaagc acactctata
139801 tctatatttt attctattaa cttcctaagt ctttttaatg aatagcaaaa aaagtatatt
139861 tcagcattat caatttaagt taatcataac atctaatagg tgacatgttt atttttttcat
139921 gagttctaat tacattttca agttaagatc actgacttat tccctaagtg ctcgatctaa
139981 tgttctgaat cacaggagta tagatgcatt attcaccaat attgtttact tttttaaata
140041 agatttttt tcatggtaga atcatcatat acattcaaaa aggtagacaa aagagagaca
140101 ctcacagtgt cactgttacc aagtgccagg acagatatca gtaaggcacc agcagtcatt
140161 tttagtgatc aaataccaaa catggtaaga taccagagta tttttcacat gacacccaaa
140221 aacatattct ctgctatcgt ggtagagcag aaaaagaaca ctttcttttc attttacagt
140281 atattacgaa cctgttccac gtcattaaat attcttctaa aaacccaatt ttggaataat
140341 attctatttt attcatatac tgtaatttag ctaatcaatc ttgtattttt gaacatttag
140401 gtttttttcca atttttatca ttataaaaaa tgctgtaatt aacatcctta tttgttcatg
140461 tccacatttc tttttatgaa aattcagaga aaggaaatgt ctggaccaaa tggcatgtac
140521 aatattaaca cttctgttat gtggtttcat attctgcaga aatattactg ccacttctac

140581 attgtacaag agatctcata gccctaaaca tttgctttca tagataattt tctgtttttt
140641 agaaatcttt tgtctctttg gttatagaaa aagagaacct ctttttaatt ttatttttta
140701 aattactagt caggttgaat gtttcttgtt cctaggtcat taacagtttt tattttggca
140761 attgtctaca gcccattttt ctgctgtgtt cattttctaa tcgaattatg ggatttatct
140821 tgtaaaaagc ctattaagcc tttttcatac tttacacaag agatcacatc tacttacttt
140881 accttaaaat aacatttact tattttctta taaaagtaat atattatgtt tgaaaagaaa
140941 aataatatgc aataatatac aataatatgt ataatcataa tagacaataa taaaaatgaa
141001 aaaacaccaa ccagaggtaa ttaacattaa catcataata ttcttccagg ctttttcaga
141061 tagacaggta ggtaagtagg ttggtaggta aatagataga tagatgatac atagagagag
141121 atagatagat aatttaaaca aaaataagat catactgcta cattacttca agccttgctt
141181 ttatcactta atatatctta aacatcttct acatgaacaa gtattcatgt gcaacattaa
141241 ttttgatggt tgaatagtat tatacagatt tatcgtaatt gacataacta ttctactgtt
141301 agacatttgg tttatttcta tttttccatt ataaaatgta atgtttggat catcctgttg
141361 ctaaattttg taagcattta tcttaagtga tttctttagc tataactcct agaagtgaaa
141421 tttctagatt aaaggataaa tgcactttta atacttttta aatatattaa aaaattacct
141481 tcctgaatta ttttattaac atgtacctct cctagtcaga taagacagcc catttatttc
141541 agtctcacca atactgagta tagcatttta atcattgcca atataatagc taatagctta
141601 aagttatttc atagcttata tttacacttc tttaaatact aataaaattg aacattgttt
141661 aatgttttga ggatacttga ttggtgattt gcctcctact attatttttc tactgggtat
141721 atctttttct tgttgctttg taagagcact ttatatatta aggagttaaa ttttgtgata
141781 tatgtttcaa ctacttttat catgttaaaa atatagactt ctatttgtct tttattgtag
141841 gttttatcaa tcagaaaaga atgttgactt ttccgtccat tcagatgatt gtggcttttt
141901 tccctaatgg atttgttaat atgttcaatt gtatgaattt atttcctaat gtagcgatat
141961 ccttgtcttc taggaataaa ctttttgggc gaatcatatc aatcttctac ttaactacca
142021 aattaattta catatatttg catcaatatt aagttcataa aattaaaagt ttatcatttt
142081 catctctgtt agagttttgt attggcatta gcatttgtat tagcattgta ttaggaaaaa
142141 ctcaggagtt tttctctata atcttggtta gtttatttt aaataattgt tatttatgaa
142201 agtaatacat aaaaatgttg tttaaaaaaa ctcacaagag ggtaaaaatt aaaaaaataa
142261 taaaagttcc cttcttcctt ttcatctcta gtcccagcct aagtgctaac cacttcaccc
142321 atttatagtg ttagttcttc tggtgattac cagtgcaatt ctaacaaata ggtttgcatt
142381 tctctttctg aattgatcaa ttttttaaaa atatgcagca ctctgactca aactcccttt
142441 ctttttcctg agatatgtta acttctaatg ttatattgtt tatcacaact ttcacaaata
142501 tttctaaata aaggttacct actgattctg gattgtgcta cataaaatta gagcttccaa
142561 atttccctcc atcacttctc cctgctctct actctcacaa tcagtcaact atacacctat
142621 ttctacgctg tcaactatat gttcatttct atgaatctgt aatatttgca ttttgttctg
142681 gaacaaatta agatttaggt gctttgacta gattgattct aaacatcaaa aaacaaaaat
142741 aaaatatctg caattatgtg atcatgtatt tatgcattgc caaataatgg tattccatta
142801 ttttaatttg ataagataaa tttaatatac attaattctt atttcctcta ttttatggaa
142861 gaaatatttt taaaaatcac aaaactttta cattcgcttc tcttcctgat atttatttt

142921 ccttttttctt ctgcctctct tctttcgtgc ccttttttcc gaaaattatt ttgatgattt
142981 tttttattca ccatacataa ttacaaatga agagttgctc tggttcgtat tggtagtaga
143041 agtggggtcc ctttgctgtt ttgttggtat attcacccag tgtgacctct tttccgtggg
143101 atggctacct ctgggctctg attatgtggc tcatagggaa gtataggcag cctgagtcag
143161 aatccccaca gttccaaagt gatggaagac tgtactctga gatacaatat tttgacgtat
143221 ttcactccca gggagagcta cttgctattc tttcactgct tccattaccc aaaagagtat
143281 gatattctcc ccatttttctg tattgcctca cacctaggac ccttcaaacc cacaccaacg
143341 acctctcagg caaattgatc tattcagata gcagtttaca gggatagaca tgaggcctct
143401 tggcccacct gctctataca caatcttcta gtcgaccatc ctgattgaca acccacagcc
143461 cacccctgtc tctgtatttg ctgactcaga gcatggagac tttatacatg tgaaatcaca
143521 tctcccctcc cctcacgctt ggcttgtgtg tattgcaaaa gctgcaattt agtttttcct
143581 gtgccttgtc ttacccatgg ataagaacac taagatactt tccgcttttt gaatatttgt
143641 caaagtgatg gcacttggat tggtttcagc atgtacatag attgattctt attcatatac
143701 atttactgtc atattgggga aatcttgagg ggaaaagaaa agcctcttac taccatgttc
143761 atcaagagtc ctctctggaa tagttgaaat agtttaggag ttatcggttc actccttcgt
143821 cttgtttgcc tccagatttc ttttttcctt cttttcctgt ttcttaatgt tggaacagcc
143881 cacacctcaa tccttggatg acatctccct tttatctgta ttcatcccta gtgatctctt
143941 ctggttgcaa ggctataaat gccatctgta tgctgagatt tttttatttt tagttcaaac
144001 ctctctcccc aactttacac tcacatttct aactgtgtgt tatagatgat agctttagat
144061 tctcctcctc aggactaggc tttctgcttg atctaggagc aaagctgaaa actgctatgg
144121 agcttggtgt tgccttgata ccgaggagga gtctcagagc ctctccagtg caaatacaca
144181 cttgcagtgt cctagtgctg ctgacttacg tactcattct aaagagggta gattgtatcc
144241 attttaatag ctctcaatac ccttgcccat tcccattaca gctggcagaa attccccagc
144301 tgcaaatggg ttgcatttat ctgttaccca ttcctgattt gcagcacgat tgactgtttc
144361 cttttctgcg tggtctatgt gtcactccat gagaatctgg gagaggagaa ctcgatatgg
144421 tgctcattcc atcattttaa ccatagtgtt ctttattgtg aagaggtatc ccggttagag
144481 tggagtcaaa gctttatagc aagtgtattt caggtaacta ttcttttact tgtttcagat
144541 ctatttcagt agcacagcca ccaagataga acacttataa gcccttattt tggtatagat
144601 caccagagaa accactcacc actcgcactt ggccttcagt actgagtcat tacatattgg
144661 aaggtcagaa actacatcaa caggaaagac ccataggtgt gggggtctga tatatttgcc
144721 agtacatttc ttatcattac aaacaaagat ttatgtgtgt ctagatgt

hu6-75; SEQ ID NO: 78
G*C*T *A*G*G *G*T*G *G*T*C *T*T*T *T*A*G *A*A*A *T*G*C *A
*represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2’-MOE modified sugar.

hu6-69; SEQ ID NO: 79
G*G*T *C*A*A *G*C*T *A*G*G *G*T*G *G*T*C *T*T*T *T*A*G *A

hu6-58; SEQ ID NO: 80
C*T*G *C*A*G *G*A*A *A*T*G *G*T*C *A*A*G *C*T*A *G*G*G *T

hu6-39; SEQ ID NO: 81
G*A*A *G*T*G *G*T*G *A*G*T *G*A*C *G*C*T *C*C*T *G*C*A *G

hu6-27; SEQ ID NO: 82
G*T*T *A*G*G *A*A*G *A*C*A *G*A*A *G*T*G *G*T*G *A*G*T *G

hu6-12; SEQ ID NO: 83
A*T*C *C*T*G *G*C*A *A*A*A *A*C*T *G*T*T *A*G*G *A*A*G *A

hu610; SEQ ID NO: 84
G*T*G *G*G*A *T*T*C *A*G*G *A*G*C *C*C*G *C*A*G *G*A*T *C

hu619; SEQ ID NO: 85
G*G*T *G*A*C *A*T*T *G*T*G *G*G*A *T*T*C *A*G*G *A*G*C *C

hu628; SEQ ID NO: 86
G*G*A *G*C*C *A*A*A *G*G*T *G*A*C *A*T*T *G*T*G *G*G*A *T

hu637; SEQ ID NO: 87
G*G*T *C*A*C *A*A*A *G*G*A *G*C*C *A*A*A *G*G*T *G*A*C *A

hu646; SEQ ID NO: 88
A*C*A *G*T*G *C*A*G *G*G*T *C*A*C *A*A*A *G*G*A *G*C*C *A

hu656; SEQ ID NO: 89
C*T*G *T*T*G *C*T*G *T*A*C *A*G*T *G*C*A *G*G*G *T*C*A *C

hu669; SEQ ID NO: 90
G*G*G *A*C*A *G*G*A *A*T*G *C*C*T *G*T*T *G*C*T *G*T*A *C

hu681; SEQ ID NO: 91
C*A*G *G*T*G *A*T*G *G*T*G *G*G*G *A*C*A *G*G*A *A*T*G *C

hu693; SEQ ID NO: 92
C*C*G *T*T*T *T*C*A *A*T*C *C*A*G *G*T*G *A*T*G *G*T*G *G

hu6110; SEQ ID NO: 93

T*G*A *C*A*C *T*C*A *C*A*G *C*A*T *T*T*C *C*G*T *T*T*T *C

hu6125; SEQ ID NO: 94

A*A*G *T*C*C *C*C*A *C*A*C *A*C*A *T*G*A *C*A*C *T*C*A *C

hu6139; SEQ ID NO: 95

G*G*T *C*T*T *C*C*C *C*A*G *A*C*A *A*G*T *C*C*C *C*A*C *A

hu7-75; SEQ ID NO: 96
A*C*T *A*T*G *T*C*A *G*T*A *G*A*T *T*T*G *A*A*G *G*G*A *A

hu7-66; SEQ ID NO: 97
T*C*C *C*A*C *T*A*T *A*C*T *A*T*G *T*C*A *G*T*A *G*A*T *T

hu7-53; SEQ ID NO: 98
T*C*A *G*T*C *A*A*G *G*A*T *T*T*C *C*C*A *C*T*A *T*A*C *T

hu7-45; SEQ ID NO: 99
A*A*A *A*G*A *A*C*T *C*A*G *T*C*A *A*G*G *A*T*T *T*C*C *C

hu7-33; SEQ ID NO: 100
G*T*A *A*A*G *G*A*A *A*A*T *A*A*A *A*G*A *A*C*T *C*A*G *T

hu7-22; SEQ ID NO: 101
A*A*C *C*T*G *A*C*A *G*A*G *T*A*A *A*G*G *A*A*A *A*T*A *A

hu7-10; SEQ ID NO: 102
G*G*A *C*C*C *A*G*A *A*G*A *A*A*C *C*T*G *A*C*A *G*A*G *T

hu73; SEQ ID NO: 103
C*A*C *T*C*T *C*T*T *G*A*A *T*G*G *A*C*C *C*A*G *A*A*G *A

hu717; SEQ ID NO: 104
C*A*C *T*C*G *G*T*C *T*T*T *C*A*C *A*C*T *C*T*C *T*T*G *A

hu730; SEQ ID NO: 105
G*T*C *T*T*G *A*G*T *C*A*A *T*C*A *C*T*C *G*G*T *C*T*T *T

hu744; SEQ ID NO: 106
G*A*T *A*A*A *C*A*G *C*T*G *C*A*G *T*C*T *T*G*A *G*T*C *A

hu758; SEQ ID NO: 107
A*G*T *C*C*T *G*G*C *T*T*G *G*T*G *A*T*A *A*A*C *A*G*C *T

hu766; SEQ ID NO: 108
A*T*G *T*G*T *A*G*A *G*T*C *C*T*G *G*C*T *T*G*G *T*G*A *T

hu776; SEQ ID NO: 109
G*T*A *G*C*T *A*T*G *C*A*T *G*T*G *T*A*G *A*G*T *C*C*T *G

hu785; SEQ ID NO: 110
T*G*C *T*T*A *T*T*G *G*T*A *G*C*T *A*T*G *C*A*T *G*T*G *T

hu796; SEQ ID NO: 111
A*C*T *T*C*T *C*C*C *C*A*T *G*C*T *T*A*T *T*G*G *T*A*G *C

hu7111; SEQ ID NO: 112
C*C*T *T*G*G *C*A*G *T*A*C *T*G*A *A*C*T *T*C*T *C*C*C *C

hu7136; SEQ ID NO: 113
C*C*T *G*C*T *A*T*G *C*T*G *A*T*G *G*T*G *G*C*T *G*C*A *G

hu7146; SEQ ID NO: 114
G*G*G *C*A*T *C*C*T *A*C*C *T*G*C *T*A*T *G*C*T *G*A*T *G

hu7158; SEQ ID NO: 115
G*C*A *A*A*T *G*T*G *A*A*G *G*G*G *C*A*T *C*C*T *A*C*C *T

MuSK HUMAN_Ig3_Domain (SEQ ID NO: 116)
ARILRAPESHNVTFGSFVTLHCTATGIPVPTITWIENGNAVSSGSIQESVKDRVIDSRLQLFITKPGLYTCIATN
KHGEKFSTAKAAATIS

MuSK MOUSE Ig3 Domain (SEQ ID NO: 117)
ARILRAPESHNVTFGSFVTLRCTAIGIPVPTISWIENGNAVSSGSIQESVKDRVIDSRLQLFITKPGLYTCIATN
KHGEKFSTAKAAATVS

MuSK 34 (spanning the exon/exon junction 3-4) Forward
CCTGCAAGTGAAGATGAAACCTAAA (SEQ ID NO: 118)

MuSK 34 (spanning the exon/exon junction 3-4) Reverse
ATGAATCCTCAAGCTCCCAGA(SEQ ID NO: 119)

MuSK 67 (spanning the exon/exon junction 6-7) Forward
GGCTCCTGAATCCCACAATG (SEQ ID NO: 120)

MuSK 67 (spanning the exon/exon junction 6-7) Reverse
GAATGGACCCAGAAGAAACAGCA(SEQ ID NO: 121)

GAPDH (HKG) Forward
CCTCAACGACCACTTTGTCA(SEQ ID NO: 122)

GAPDH (HKG) Reverse
TTACTCCTTGGAGGCCATGT(SEQ ID NO: 123)

YWHAZ (HKG) Forward
CGAAGCTGAAGCAGGAGAAG(SEQ ID NO: 124)

YWHAZ (HKG) Reverse
TTTGTGGGACAGCATGGATG(SEQ ID NO: 125)

Region 1 – MuSK Exon 7

ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATTGACTCAA
GAC (SEQ ID NO: 126)

Oligonucleotide Bld51 (SEQ ID NO: 127)
TTGAATGGACCCAGAAGAAA

Oligonucleotide Bld52 (SEQ ID NO: 128)
CTTGAATGGACCCAGAAGAA

Oligonucleotide Bld53 (SEQ ID NO: 129)
TCTTGAATGGACCCAGAAGA

Oligonucleotide Bld54 (SEQ ID NO: 130)
CTCTTGAATGGACCCAGAAG

Oligonucleotide Bld55 (SEQ ID NO: 131)
TCTCTTGAATGGACCCAGAA

Oligonucleotide Bld56 (SEQ ID NO: 132)
CTCTCTTGAATGGACCCAGA

Oligonucleotide Bld57 (SEQ ID NO: 133)
ACTCTCTTGAATGGACCCAG

Oligonucleotide Bld58 (SEQ ID NO: 134)
CACTCTCTTGAATGGACCCA

Oligonucleotide Bld59 (SEQ ID NO: 135)
ACACTCTCTTGAATGGACCC

Oligonucleotide Bld60 (SEQ ID NO: 136)
CACACTCTCTTGAATGGACC

Oligonucleotide Bld61 (SEQ ID NO: 137)

TCACACTCTCTTGAATGGAC

Oligonucleotide Bld62 (SEQ ID NO: 138)

TTCACACTCTCTTGAATGGA

Oligonucleotide Bld63 (SEQ ID NO: 139)

TTTCACACTCTCTTGAATGG

Oligonucleotide Bld64 (SEQ ID NO: 140)

CTTTCACACTCTCTTGAATG

Oligonucleotide Bld65 (SEQ ID NO: 141)

TCTTTCACACTCTCTTGAAT

Oligonucleotide Bld66 (SEQ ID NO: 142)

GTCTTTCACACTCTCTTGAA

Bld51; SEQ ID NO: 143
T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A

Bld52; SEQ ID NO: 144
C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A

Bld53; SEQ ID NO: 145
T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A

Bld54; SEQ ID NO: 146
C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G

Bld55; SEQ ID NO: 147
T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A

Bld56; SEQ ID NO: 148
C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A

Bld57; SEQ ID NO: 149
A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G

Bld58; SEQ ID NO: 150
C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A

Bld59; SEQ ID NO: 151
A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C

Bld60; SEQ ID NO: 152
C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C

Bld61; SEQ ID NO: 153
T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C

Bld62; SEQ ID NO: 154
T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A

Bld63; SEQ ID NO: 155
T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G

Bld64; SEQ ID NO: 156
C*T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G

Bld65; SEQ ID NO: 157
T*C*T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T

Bld66; SEQ ID NO: 158
G*T*C*T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A

Oligonucleotide Bld25-1 (SEQ ID NO: 159)

CCAGAAGAAACCTGACAGAGTAAAG

Oligonucleotide Bld25-2 (SEQ ID NO: 160)

ACCCAGAAGAAACCTGACAGAGTAA

Oligonucleotide Bld25-3 (SEQ ID NO: 161)

ATGGACCCAGAAGAAACCTGACAGA

Oligonucleotide Bld25-4 (SEQ ID NO: 162)

GAATGGACCCAGAAGAAACCTGACA

Oligonucleotide Bld25-5 (SEQ ID NO: 163)

CTTGAATGGACCCAGAAGAAACCTG

Oligonucleotide Bld26-1 (SEQ ID NO: 164)

CTCTTGAATGGACCCAGAAGAAACC

Oligonucleotide Bld26-2 (SEQ ID NO: 165)

CTCTCTTGAATGGACCCAGAAGAAA

Oligonucleotide Bld26-3 (SEQ ID NO: 166)

CACACTCTCTTGAATGGACCCAGAA

Oligonucleotide Bld26-4 (SEQ ID NO: 167)

TTCACACTCTCTTGAATGGACCCAG

Bld25-1; SEQ ID NO: 168
C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T*A*A*A*G*

Bld25-2; SEQ ID NO: 169
A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T*A*A*

Bld25-3; SEQ ID NO: 170
A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*

Bld25-4; SEQ ID NO: 171
G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*

Bld25-5; SEQ ID NO: 172
C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*

Bld26-1; SEQ ID NO: 173
C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*

Bld26-2; SEQ ID NO: 174
C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*

Bld26-3; SEQ ID NO: 175
C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*

Bld26-4; SEQ ID NO: 176

T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*

Oligonucleotide Bld25-A (SEQ ID NO: 177)
ACCCAGAAGAAACCTGACAGAGT

Oligonucleotide Bld25-B (SEQ ID NO: 178)
CCAGAAGAAACCTGACAGAGT

Oligonucleotide Bld25-C (SEQ ID NO: 179)
GGACCCAGAAGAAACCTGACAGA

Oligonucleotide Bld25-D (SEQ ID NO: 180)
ACCCAGAAGAAACCTGACAGA

Oligonucleotide Bld25-E (SEQ ID NO: 181)
GGACCCAGAAGAAACCTGACA

Oligonucleotide Bld25-5-A (SEQ ID NO: 182)
GAATGGACCCAGAAGAAACCTGA

Oligonucleotide Bld25-5-B (SEQ ID NO: 183)
ATGGACCCAGAAGAAACCTGA

Oligonucleotide Bld25-5-C (SEQ ID NO: 184)
TTGAATGGACCCAGAAGAAACCT

Oligonucleotide Bld25-5-D (SEQ ID NO: 185)
GAATGGACCCAGAAGAAACCT

Oligonucleotide Bld25-5-E (SEQ ID NO: 186)
TTGAATGGACCCAGAAGAAAC

Oligonucleotide Bld26-2-A (SEQ ID NO: 187)
CTCTTGAATGGACCCAGAAGAAA

Oligonucleotide Bld26-2-B (SEQ ID NO: 188)
CTTGAATGGACCCAGAAGAAA

Oligonucleotide Bld26-2-C (SEQ ID NO: 189)

CTCTCTTGAATGGACCCAGAAGA

Oligonucleotide Bld26-2-D (SEQ ID NO: 190)

CTCTCTTGAATGGACCCAGAA

Oligonucleotide Bld26-B (SEQ ID NO: 191)

CTCTTGAATGGACCCAGAAGA

Oligonucleotide Bld26-C (SEQ ID NO: 192)

CACTCTCTTGAATGGACCCAGAA

Oligonucleotide Bld26-D (SEQ ID NO: 193)

CACTCTCTTGAATGGACCCAG

Bld25-A; SEQ ID NO: 194
A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T

Bld25-B; SEQ ID NO: 195
C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T

Bld25-C; SEQ ID NO: 196
G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A

Bld25-D; SEQ ID NO: 197
A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A

Bld25-E; SEQ ID NO: 198
G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A

Bld25-5-A; SEQ ID NO: 199
G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A

Bld25-5-B; SEQ ID NO: 200
A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A

Bld25-5-C; SEQ ID NO: 201
T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T

Bld25-5-D; SEQ ID NO: 202
G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T

Bld25-5-E; SEQ ID NO: 203
T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C

Bld26-2-A; SEQ ID NO: 204
C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A

Bld26-2-B; SEQ ID NO: 205
C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A

Bld26-2-C; SEQ ID NO: 206
C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A

Bld26-2-D; SEQ ID NO: 207
C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A

Bld26-B; SEQ ID NO: 208
C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A

Bld26-C; SEQ ID NO: 209
C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A

Bld26-D; SEQ ID NO: 210
C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G

Region 2 – MuSK Exon 7
GGGGAGAAGTTCAGTACTGCCAAGGCTGCAGCCACCATCAGCATAGCAGGTAGGATGCCCCT
TCACATTTG (SEQ ID NO: 211)

SEQ ID NO: 212
TTTCTTCTGGGTCCATTCAA

SEQ ID NO: 213
TTCTTCTGGGTCCATTCAAG

SEQ ID NO: 214
TCTTCTGGGTCCATTCAAGA

SEQ ID NO: 215

CTTCTGGGTCCATTCAAGAG

SEQ ID NO: 216
TTCTGGGTCCATTCAAGAGA

SEQ ID NO: 217
TCTGGGTCCATTCAAGAGAG

SEQ ID NO: 218
CTGGGTCCATTCAAGAGAGT

SEQ ID NO: 219
TGGGTCCATTCAAGAGAGTG

SEQ ID NO: 220
GGGTCCATTCAAGAGAGTGT

SEQ ID NO: 221
GGTCCATTCAAGAGAGTGTG

SEQ ID NO: 222
GTCCATTCAAGAGAGTGTGA

SEQ ID NO: 223
TCCATTCAAGAGAGTGTGAA

SEQ ID NO: 224
CCATTCAAGAGAGTGTGAAA

SEQ ID NO: 225
CATTCAAGAGAGTGTGAAAG

SEQ ID NO: 226
ATTCAAGAGAGTGTGAAAGA

SEQ ID NO: 227

TTCAAGAGAGTGTGAAAGAC

SEQ ID NO: 228
CTTTACTCTGTCAGGTTTCTTCTGG

SEQ ID NO: 229
TTACTCTGTCAGGTTTCTTCTGGGT

SEQ ID NO: 230
TCTGTCAGGTTTCTTCTGGGTCCAT

SEQ ID NO: 231
TGTCAGGTTTCTTCTGGGTCCATTC

SEQ ID NO: 232
CAGGTTTCTTCTGGGTCCATTCAAG

SEQ ID NO: 233
GGTTTCTTCTGGGTCCATTCAAGAG

SEQ ID NO: 234
TTTCTTCTGGGTCCATTCAAGAGAG

SEQ ID NO: 235
TTCTGGGTCCATTCAAGAGAGTGTG

SEQ ID NO: 236
CTGGGTCCATTCAAGAGAGTGTGAA

SEQ ID NO: 237
ACTCTGTCAGGTTTCTTCTGGGT

SEQ ID NO: 238
ACTCTGTCAGGTTTCTTCTGG

SEQ ID NO: 239
TCTGTCAGGTTTCTTCTGGGTCC

SEQ ID NO: 240
TCTGTCAGGTTTCTTCTGGGT

SEQ ID NO: 241
TGTCAGGTTTCTTCTGGGTCC

SEQ ID NO: 242
TCAGGTTTCTTCTGGGTCCATTC

SEQ ID NO: 243
TCAGGTTTCTTCTGGGTCCAT

SEQ ID NO: 244
AGGTTTCTTCTGGGTCCATTCAA

SEQ ID NO: 245
AGGTTTCTTCTGGGTCCATTC

SEQ ID NO: 246
GTTTCTTCTGGGTCCATTCAA

SEQ ID NO: 247
TTTCTTCTGGGTCCATTCAAGAG

SEQ ID NO: 248
TTTCTTCTGGGTCCATTCAAG

SEQ ID NO: 249
TCTTCTGGGTCCATTCAAGAGAG

SEQ ID NO: 250
TTCTGGGTCCATTCAAGAGAG

SEQ ID NO: 251
TCTTCTGGGTCCATTCAAGAG

SEQ ID NO: 252

TTCTGGGTCCATTCAAGAGAGTG

SEQ ID NO: 253

CTGGGTCCATTCAAGAGAGTG

EQUIVALENTS

[0531] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the present invention is not intended to be limited to the above Description, but rather is as set forth in the following claims:

CLAIMS

1. An oligonucleotide composition, comprising plurality of oligonucleotides:
the oligonucleotide composition being characterized in that, when it is contacted with a MuSK transcript in a transcript splicing system, relative amounts of transcripts that do and do not include Ig3 domain-encoding sequences are altered as compared with such relative amounts observed under reference conditions selected from the group consisting of absence of the composition, presence of a reference composition, and combinations thereof.

2. The composition of claim 1, wherein the oligonucleotides mediate skipping of at least one exon of the MuSK gene.

3. The composition of claim 2, wherein the exon skipping lowers levels of mRNAs encoding MuSK protein form that participate in BMP signaling compared with levels observed absent the exon skipping.

4. The composition of claim 3, wherein the MuSK protein form participating in BMP signaling is or comprises a MuSK protein form that forms a MuSK/BMP complex.

5. The composition of claim 4, wherein the exon skipping reduces the level and/or activity of a MuSK/BMP complex.

6. The composition of any one of claims 2-5, wherein the at least one skipped exon is selected from the group consisting of exons 3, 4, 6, and 7.

7. The composition of any one of the preceding claims, wherein the relative amounts are amounts of transcripts including exons 6 and 7 relative to those lacking exons 6 and 7.

8. The composition of any one of the preceding claims, wherein the relative amounts are amounts of transcripts including exons 3 and 4 relative to those lacking exons 6 and 7.

9. The composition of any one of the preceding claims, wherein the alteration comprises skipping one or more of exons 6 and 7 of MuSK.

10. The composition of any one of the preceding claims, wherein the alteration comprises skipping one or more of exons 3 and 4 of MuSK.

11. The composition of any one of the preceding claims, wherein the alteration comprises skipping one or more of exons 6 and 7 of MuSK, but skipping none of exons 3 and 4 of MuSK.

12. The composition of any one of claims 1-11, wherein MuSK splicing is altered in that level of MuSK transcripts including exons 6 and 7 is decreased or level of MuSK protein forms including sequences encoded by exons 6 and 7 is decreased, or both.

13. The composition of any one of claims 1-11, wherein MuSK splicing is altered in that level of MuSK transcripts including exons 3 and 4 is decreased or level of MuSK protein forms including sequences encoded by exons 3 and 4 is decreased, or both.

14. The composition of any one of claims 1-11, wherein MuSK splicing is altered in that level of MuSK transcripts including exons 6 and 7 is increased or level of MuSK protein forms including sequences encoded by exons 6 and 7 is increased, or both.

15. The composition of any one of claims 1-11, wherein MuSK splicing is altered in that level of MuSK transcripts including exons 3 and 4 is increased or level of MuSK protein forms including sequences encoded by exons 3 and 4 is increased, or both.

16. The composition of any one of claims 1-12, wherein MuSK splicing is altered in that level of MuSK transcripts including exons 3 and 4 remains substantially unchanged and level of MuSK transcripts including exons 6 and 7 is decreased.

17. The composition of any one of claims 1-12 and 16, wherein MuSK splicing is altered in that level of MuSK protein forms including sequences encoded by exons 3 and 4 remains substantially unchanged and level of MuSK protein forms including sequences encoded by exons 6 and 7 is decreased.

18. The composition of any one of claims 1-12 and 16-17, wherein MuSK splicing is altered in that total level of MuSK transcripts remained substantially unchanged and level of MuSK transcripts including exons 6 and 7 is decreased.

19. The composition of any one of claims 1-11, wherein the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 2 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both.

20. The composition of any one of claims 1-11, wherein the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 3 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both.

21. The composition of any one of claims 1-11, wherein the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 4 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both.

22. The composition of any one of claims 1-11, wherein the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 5 fold greater than the decrease observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both.

23. The composition of any one of claims 1-11, wherein the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases at a level at least 10 fold greater than the decrease

observed for the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both.

24. The composition of any one of claims 1-11, wherein the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

25. The composition of any one of claims 1-11, wherein the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 70% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

26. The composition of any one of claims 1-11, wherein the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 80% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

27. The composition of any one of claims 1-11, wherein the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 90% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 40%.

28. The composition of any one of claims 1-11, wherein the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 30%.

29. The composition of any one of claims 1-11, wherein the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 20%.

30. The composition of any one of claims 1-11, wherein the level of MuSK transcripts including exons 6 and 7 or the level of MuSK protein forms including sequences encoded by exons 6 and 7, or both, decreases by greater than 60% and the level of MuSK transcripts including exons 3 and 4 or the level of MuSK protein forms including sequences encoded by exons 3 and 4, or both, decreases by less than 10%.

31. The composition of any one of the preceding claims, wherein the base sequence of the oligonucleotide comprises a sequence having no more than 5 mismatches from a 18-25 base long portion of the MuSK gene or its complement.

32. The composition of any one of the preceding claims, wherein the oligonucleotides target a region on the MuSK genomic sequence corresponding to positions 83776-83800 and/or 83854-83878 of SEQ ID NO: 77.

33. The composition of any one of the preceding claims, wherein the oligonucleotides target a region on the MuSK genomic sequence within or comprising at least a portion of sequence ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGATTGACTCAAGAC (region 1, SEQ ID: 126).

34. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% identical to region 1, SEQ ID: 126.

35. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126.

36. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to no more than 30 consecutive bases of region 1, SEQ ID: 126.

37. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126.

38. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 19 consecutive bases of region 1, SEQ ID: 126.

39. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 20 consecutive bases of region 1, SEQ ID: 126.

40. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 21 consecutive bases of region 1, SEQ ID: 126.

41. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 22 consecutive bases of region 1, SEQ ID: 126.

42. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 23 consecutive bases of region 1, SEQ ID: 126.

43. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 24 consecutive bases of region 1, SEQ ID: 126.

44. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 25 consecutive bases of region 1, SEQ ID: 126.

45. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 26 consecutive bases of region 1, SEQ ID: 126.

46. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 27 consecutive bases of region 1, SEQ ID: 126.

47. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 28 consecutive bases of region 1, SEQ ID: 126.

48. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 29 consecutive bases of region 1, SEQ ID: 126.

49. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 30 consecutive bases of region 1, SEQ ID: 126.

50. The composition of any one of the preceding claims, wherein the oligonucleotides target a region on the MUSK genomic sequence within or comprising at least a portion of sequence

GGGGAGAAGTTCAGTACTGCCAAGGCTGCAGCCACCATCAGCATAGCAGGTAG GATGCCCCTTCACATTTG (region 2, SEQ ID 211).

51. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% identical to region 2, SEQ ID: 211.

52. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of egion 2, SEQ ID: 211.

53. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to no more than 30 consecutive bases of egion 2, SEQ ID: 211.

54. The composition of any one of the preceding claims, wherein the oligonucleotides target a portion of MUSK transcript comprising a sequence that is identical to 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of egion 2, SEQ ID: 211.

55. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to a sequence within or comprising at least a portion of ACTCTGTCAGGTTTCTTCTGGGTCCATTCAAGAGAGTGTGAAAGACCGAGTGAT TGACTCAAGAC (region 1, SEQ ID: 126).

56. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to a sequence that is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% identical to region 1 (SEQ ID: 126).

57. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126)

that includes at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1 (SEQ ID: 126).

58. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a sequence that is at least 95% identical to a portion of region 1(SEQ ID: 126) that includes at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1 (SEQ ID: 126).

59. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 20 consecutive bases of region 1 (SEQ ID: 126).

60. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 21 consecutive bases of region 1 (SEQ ID: 126).

61. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 22 consecutive bases of region 1 (SEQ ID: 126).

62. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1 (SEQ ID: 126) that includes at least 23 consecutive bases of region 1 (SEQ ID: 126).

63. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1, SEQ ID: 126 that includes at least 24 consecutive bases of region 1, SEQ ID: 126.

64. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1, SEQ ID: 126 that includes at least 25 consecutive bases of region 1, SEQ ID: 126.

65. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a sequence that is at least 90% identical to a portion of region 1, SEQ ID: 126 that includes at least 26 consecutive bases of region 1, SEQ ID: 126.

66. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to at least 10, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126.

67. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to no more than 30 consecutive bases of region 1, SEQ ID: 126.

68. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive bases of region 1, SEQ ID: 126.

69. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to 19 consecutive bases of region 1, SEQ ID: 126.

70. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to 20 consecutive bases of region 1, SEQ ID: 126.

71. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to 21 consecutive bases of region 1, SEQ ID: 126.

72. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to 22 consecutive bases of region 1, SEQ ID: 126.

73. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to 23 consecutive bases of region 1, SEQ ID: 126.

74. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to 24 consecutive bases of region 1, SEQ ID: 126.

75. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to 25 consecutive bases of region 1, SEQ ID: 126.

76. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to 26 consecutive bases of region 1, SEQ ID: 126.

77. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to 27 consecutive bases of region 1, SEQ ID: 126.

78. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to 28 consecutive bases of region 1, SEQ ID: 126.

79. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to 29 consecutive bases of region 1, SEQ ID: 126.

80. The composition of any one of the preceding claims, wherein the oligonucleotide comprises a nucleic acid strand that is complementary to 30 consecutive bases of region 1, SEQ ID: 126.

81. The composition of any one of the preceding claims, where the oligonucleotide has a length of 25 bases.

82. The composition of any one of claims 1-32, where the oligonucleotide has a length of 24 bases.

83. The composition of any one of claims 1-32, where the oligonucleotide has a length of 23 bases.

84. The composition of any one of claims 1-32, where the oligonucleotide has a length of 22 bases.

85. The composition of any one of claims 1-32, where the oligonucleotide has a length of 21 bases.

86. The composition of any one of claims 1-32, where the oligonucleotide has a length of 20 bases.

87. The composition of any one of claims 1-32, where the oligonucleotide has a length of 19 bases.

88. The composition of any one of claims 1-32, where the oligonucleotide has a length of 18 bases.

89. The composition of any one of claims 1-32, where the oligonucleotide has a length of 17 bases.

90. The composition of any one of claims 1-32, where the oligonucleotide has a length of 16 bases.

91. The composition of any one of claims 1-32, where the oligonucleotide has a length of 15 bases.

92. The composition of any one of claims 1-32, where the oligonucleotide has a length of less than about 50 bases.

93. The composition of any one of claims 1-32, where the oligonucleotide has a length of less than about 40 bases.

94. The composition of any one of claims 1-32, where the oligonucleotide has a length of less than about 30 bases.

95. The composition of any one of claims 1-32, where the oligonucleotide has a length of more than about 10 bases.

96. The composition of any one of claims 1-32, where the oligonucleotide has a length of more than about 15 bases.

97. The composition of any one of claims 1-32, where the oligonucleotide has a length of more than about 20 bases.

98. The composition of any one of claims 1-32, wherein the base sequence of the oligonucleotide comprises from 5' to 3':

SEQ ID	Oligo ID	5' to 3' Sequence
1	Bld1	GCTAGGGTGGTCTTTTAGAAATGCA
2	Bld2	GGTCAAGCTAGGGTGGTCTTTTAGA
3	Bld3	CTGCAGGAAATGGTCAAGCTAGGGT
4	Bld4	GAAGTGGTGAGTGACGCTCCTGCAG
5	Bld5	GTTAGGAAGACAGAAGTGGTGAGTG
6	Bld6	ATCCTGGCAAAAACTGTTAGGAAGA
7	Bld7	GTGGGATTCAGGAGCCCGCAGGATC
8	Bld8	GGTGACATTGTGGGATTCAGGAGCC
9	Bld9	GGAGCCAAAGGTGACATTGTGGGAT

10	Bld10	GGTCACAAAGGAGCCAAAGGTGACA
11	Bld11	ACAGTGCAGGGTCACAAAGGAGCCA
12	Bld12	CTGTTGCTGTACAGTGCAGGGTCAC
13	Bld13	GGGACAGGAATGCCTGTTGCTGTAC
14	Bld14	CAGGTGATGGTGGGGACAGGAATGC
15	Bld15	CCGTTTTCAATCCAGGTGATGGTGG
16	Bld16	TGACACTCACAGCATTTCCGTTTTC
17	Bld17	AAGTCCCCACACACATGACACTCAC
18	Bld18	GGTCTTCCCCAGACAAGTCCCCACA
19	Bld19	ACTATGTCAGTAGATTTGAAGGGAA
20	Bld20	TCCCACTATACTATGTCAGTAGATT
21	Bld21	TCAGTCAAGGATTTCCCACTATACT
22	Bld22	AAAAGAACTCAGTCAAGGATTTCCC
23	Bld23	GTAAAGGAAAATAAAAGAACTCAGT
24	Bld24	AACCTGACAGAGTAAAGGAAAATAA
25	Bld25	GGACCCAGAAGAAACCTGACAGAGT
26	Bld26	CACTCTCTTGAATGGACCCAGAAGA
27	Bld27	CACTCGGTCTTTCACACTCTCTTGA
28	Bld28	GTCTTGAGTCAATCACTCGGTCTTT
29	Bld29	GATAAACAGCTGCAGTCTTGAGTCA
30	Bld30	AGTCCTGGCTTGGTGATAAACAGCT
31	Bld31	ATGTGTAGAGTCCTGGCTTGGTGAT
32	Bld32	GTAGCTATGCATGTGTAGAGTCCTG
33	Bld33	TGCTTATTGGTAGCTATGCATGTGT
34	Bld34	ACTTCTCCCCATGCTTATTGGTAGC
35	Bld35	CCTTGGCAGTACTGAACTTCTCCCC
36	Bld36	CCTGCTATGCTGATGGTGGCTGCAG
37	Bld37	GGGCATCCTACCTGCTATGCTGATG
38	Bld38	GCAAATGTGAAGGGGCATCCTACCT
127	Bld51	TTGAATGGACCCAGAAGAAA
128	Bld52	CTTGAATGGACCCAGAAGAA

129	Bld53	TCTTGAATGGACCCAGAAGA
130	Bld54	CTCTTGAATGGACCCAGAAG
131	Bld55	TCTCTTGAATGGACCCAGAA
132	Bld56	CTCTCTTGAATGGACCCAGA
133	Bld57	ACTCTCTTGAATGGACCCAG
134	Bld58	CACTCTCTTGAATGGACCCA
135	Bld59	ACACTCTCTTGAATGGACCC
136	Bld60	CACACTCTCTTGAATGGACC
137	Bld61	TCACACTCTCTTGAATGGAC
138	Bld62	TTCACACTCTCTTGAATGGA
139	Bld63	TTTCACACTCTCTTGAATGG
140	Bld64	CTTTCACACTCTCTTGAATG
141	Bld65	TCTTTCACACTCTCTTGAAT
142	Bld66	GTCTTTCACACTCTCTTGAA
159	Bld25-1	CCAGAAGAAACCTGACAGAGTAAAG
160	Bld25-2	ACCCAGAAGAAACCTGACAGAGTAA
161	Bld25-3	ATGGACCCAGAAGAAACCTGACAGA
162	Bld25-4	GAATGGACCCAGAAGAAACCTGACA
163	Bld25-5	CTTGAATGGACCCAGAAGAAACCTG
164	Bld26-1	CTCTTGAATGGACCCAGAAGAAACC
165	Bld26-2	CTCTCTTGAATGGACCCAGAAGAAA
166	Bld26-3	CACACTCTCTTGAATGGACCCAGAA
167	Bld26-4	TTCACACTCTCTTGAATGGACCCAG
177	Bld25-A	ACCCAGAAGAAACCTGACAGAGT
178	Bld25-B	CCAGAAGAAACCTGACAGAGT
179	Bld25-C	GGACCCAGAAGAAACCTGACAGA
180	Bld25-D	ACCCAGAAGAAACCTGACAGA
181	Bld25-E	GGACCCAGAAGAAACCTGACA
182	Bld25-5-A	GAATGGACCCAGAAGAAACCTGA
183	Bld25-5-B	ATGGACCCAGAAGAAACCTGA
184	Bld25-5-C	TTGAATGGACCCAGAAGAAACCT

185	Bld25-5-D	GAATGGACCCAGAAGAAACCT
186	Bld25-5-E	TTGAATGGACCCAGAAGAAAC
187	Bld26-2-A	CTCTTGAATGGACCCAGAAGAAA
188	Bld26-2-B	CTTGAATGGACCCAGAAGAAA
189	Bld26-2-C	CTCTCTTGAATGGACCCAGAAGA
190	Bld26-2-D	CTCTCTTGAATGGACCCAGAA
191	Bld26-B	CTCTTGAATGGACCCAGAAGA
192	Bld26-C	CACTCTCTTGAATGGACCCAGAA, or
193	Bld26-D	CACTCTCTTGAATGGACCCAG.

99. The composition of any one of claims 1-32, wherein the oligonucleotide is complementary to a nucleotide sequence that is at least 90% identical to any one of SEQ ID NOs: 39-76 and 212-253.

100. The composition of any one of the preceding claims, wherein the oligonucleotides comprise one or more types of base modifications, sugar modification, and internucleotidic linkage modifications.

101. The composition of any one of the preceding claims, wherein the oligonucleotides comprise non-natural sugar moieties, or non-natural internucleotidic linkages, or both.

102. The composition of claim 100 or 101, wherein the oligonucleotides comprise internucleotidic linkage modifications.

103. The composition of claim 102, wherein the internucleotidic linkages of the oligonucleotide comprise natural phosphate, phosphorothioate, or phosphodithioate linkages.

104. The composition of claim 103, wherein each internucleotidic linkage of the oligonucleotide is a phosphorothioate linkage.

105. The composition of claim 103, wherein each internucleotidic linkage of the oligonucleotide is a natural phosphate linkage.

106. The composition of claim 103, wherein the oligonucleotide comprises at least one natural phosphate linkage and at least one phosphodithioate linkage.

107. The composition of claim 103 or 106, wherein at least 50%, 60%, 70%, 80%, 90%, 94%, or 95% of internucleotidic linkages of the oligonucleotide are phosphodithioate linkages.

108. The composition of claim 103 or 106, wherein at least 50%, 60%, 70%, 80%, 90%, 94%, or 95% of internucleotidic linkages of the oligonucleotide are natural phosphate linkages.

109. The composition of any one of claims 100-104, wherein the oligonucleotides comprise sugar modification.

110. The composition of claim 105, wherein the modified sugar moiety has a 2'-modification.

111. The composition of claim 105, wherein the modified sugar moiety comprises a bicyclic sugar modification.

112. The composition of claim 110, wherein the modified sugar moiety comprises a 2'-modification, wherein a 2'-modification is 2'-OR^1, wherein R^1 is optionally substituted C_{1-6} alkyl.

113. The composition of claim 112, wherein the modified sugar moiety comprises a 2'-modification, wherein a 2'-modification is 2'-MOE.

114. The composition of claim 112, wherein the modified sugar moiety comprises a 2'-modification, wherein a 2'-modification is 2'-OMe.

115. The composition of any one of claims 100-114, wherein the oligonucleotides comprise 2'-OH sugar (RNA sugar).

116. The composition of any one of claims 100-115, wherein the oligonucleotides comprise 2'-H sugar (DNA sugar).

117. The composition of any one of claims 100-116, wherein the oligonucleotides comprise 2'-MOE sugar.

118. The composition of any one of claims 100-117, wherein the oligonucleotides comprise 2'-OMe sugar.

119. The composition of claim 112, wherein each sugar of the oligonucleotide is a 2'-MOE modified sugar.

120. The composition of claim 112, wherein each sugar of the oligonucleotide is a 2'-OMe modified sugar.

121. The composition of claim 112, wherein each sugar of the oligonucleotide is a 2'-H sugar.

122. The composition of claim 112, wherein each sugar of the oligonucleotide is a 2'-OH sugar.

123. The composition of any one of claims 100-116, wherein the oligonucleotides comprise at least one 2'-MOE sugar and at least one 2'-OH sugar (RNA sugar).

124. The composition of any one of claims 100-116, wherein the oligonucleotides comprise at least one 2'-MOE sugar and at least one 2'-H sugar (DNA sugar).

125. The composition of any one of the preceding claims, wherein the oligonucleotide has the structure from 5’ to 3’of:

Oligo ID	SEQ ID NO:	5’ to 3’ Sequence
Bld1	78	G*C*T*A*G*G*G*T*G*G*T*C*T*T*T*T*A*G*A*A*A*T*G*C*A
Bld2	79	G*G*T*C*A*A*G*C*T*A*G*G*G*T*G*G*T*C*T*T*T*T*A*G*A
Bld3	80	C*T*G*C*A*G*G*A*A*A*T*G*G*T*C*A*A*G*C*T*A*G*G*G*T
Bld4	81	G*A*A*G*T*G*G*T*G*A*G*T*G*A*C*G*C*T*C*C*T*G*C*A*G
Bld5	82	G*T*T*A*G*G*A*A*G*A*C*A*G*A*A*G*T*G*G*T*G*A*G*T*G
Bld6	83	A*T*C*C*T*G*G*C*A*A*A*A*A*C*T*G*T*T*A*G*G*A*A*G*A
Bld7	84	G*T*G*G*G*A*T*T*C*A*G*G*A*G*C*C*C*G*C*A*G*G*A*T*C
Bld8	85	G*G*T*G*A*C*A*T*T*G*T*G*G*G*A*T*T*C*A*G*G*A*G*C*C
Bld9	86	G*G*A*G*C*C*A*A*A*G*G*T*G*A*C*A*T*T*G*T*G*G*G*A*T
Bld10	87	G*G*T*C*A*C*A*A*A*G*G*A*G*C*C*A*A*A*G*G*T*G*A*C*A
Bld11	88	A*C*A*G*T*G*C*A*G*G*G*T*C*A*C*A*A*A*G*G*A*G*C*C*A
Bld12	89	C*T*G*T*T*G*C*T*G*T*A*C*A*G*T*G*C*A*G*G*G*T*C*A*C
Bld13	90	G*G*G*A*C*A*G*G*A*A*T*G*C*C*T*G*T*T*G*C*T*G*T*A*C
Bld14	91	C*A*G*G*T*G*A*T*G*G*T*G*G*G*G*A*C*A*G*G*A*A*T*G*C
Bld15	92	C*C*G*T*T*T*T*C*A*A*T*C*C*A*G*G*T*G*A*T*G*G*T*G*G
Bld16	93	T*G*A*C*A*C*T*C*A*C*A*G*C*A*T*T*T*C*C*G*T*T*T*T*C
Bld17	94	A*A*G*T*C*C*C*C*A*C*A*C*A*C*A*T*G*A*C*A*C*T*C*A*C
Bld18	95	G*G*T*C*T*T*C*C*C*C*A*G*A*C*A*A*G*T*C*C*C*C*A*C*A
Bld19	96	A*C*T*A*T*G*T*C*A*G*T*A*G*A*T*T*T*G*A*A*G*G*G*A*A
Bld20	97	T*C*C*C*A*C*T*A*T*A*C*T*A*T*G*T*C*A*G*T*A*G*A*T*T
Bld21	98	T*C*A*G*T*C*A*A*G*G*A*T*T*T*C*C*C*A*C*T*A*T*A*C*T
Bld22	99	A*A*A*A*G*A*A*C*T*C*A*G*T*C*A*A*G*G*A*T*T*T*C*C*C
Bld23	100	G*T*A*A*A*G*G*A*A*A*A*T*A*A*A*A*G*A*A*C*T*C*A*G*T
Bld24	101	A*A*C*C*T*G*A*C*A*G*A*G*T*A*A*A*G*G*A*A*A*A*T*A*A
Bld25	102	G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T
Bld26	103	C*A*C*T*C*T*C*T*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A
Bld27	104	C*A*C*T*C*G*G*T*C*T*T*T*C*A*C*A*C*T*C*T*C*T*T*T*G*A

Bld28	105	G*T*C*T*T*G*A*G*T*C*A*A*T*C*A*C*T*C*G*G*T*C*T*T*T
Bld29	106	G*A*T*A*A*A*C*A*G*C*T*G*C*A*G*T*C*T*T*G*A*G*T*C*A
Bld30	107	A*G*T*C*C*T*G*G*C*T*T*G*G*T*G*A*T*A*A*A*C*A*G*C*T
Bld31	108	A*T*G*T*G*T*A*G*A*G*T*C*C*T*G*G*C*T*T*G*G*T*G*A*T
Bld32	109	G*T*A*G*C*T*A*T*G*C*A*T*G*T*G*T*A*G*A*G*T*C*C*T*G
Bld33	110	T*G*C*T*T*A*T*T*G*G*T*A*G*C*T*A*T*G*C*A*T*G*T*G*T
Bld34	111	A*C*T*T*C*T*C*C*C*C*A*T*G*C*T*T*A*T*T*G*G*T*A*G*C
Bld35	112	C*C*T*T*G*G*C*A*G*T*A*C*T*G*A*A*C*T*T*C*T*C*C*C*C
Bld36	113	C*C*T*G*C*T*A*T*G*C*T*G*A*T*G*G*T*G*G*C*T*G*C*A*G
Bld37	114	G*G*G*C*A*T*C*C*T*A*C*C*T*G*C*T*A*T*G*C*T*G*A*T*G
Bld38	115	G*C*A*A*A*T*G*T*G*A*A*G*G*G*G*C*A*T*C*C*T*A*C*C*T,
Bld51	143	T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A
Bld52	144	C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A
Bld53	145	T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A
Bld54	146	C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G
Bld55	147	T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A
Bld56	148	C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A
Bld57	149	A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G
Bld58	150	C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A
Bld59	151	A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C
Bld60	152	C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C
Bld61	153	T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C
Bld62	154	T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A
Bld63	155	T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G
Bld64	156	C*T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G
Bld65	157	T*C*T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T
Bld66	158	G*T*C*T*T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A
Bld25-1	168	C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T*A*A*A*G*
Bld25-2	169	A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T*A*A*
Bld25-3	170	A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*
Bld25-4	171	G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*

Bld25-5	172	C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*
Bld26-1	173	C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*
Bld26-2	174	C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*
Bld26-3	175	C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*
Bld26-4	176	T*T*C*A*C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*
Bld25-A	194	A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T
Bld25-B	195	C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A*G*T
Bld25-C	196	G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A
Bld25-D	197	A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A*G*A
Bld25-E	198	G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A*C*A
Bld25-5-A	199	G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A
Bld25-5-B	200	A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T*G*A
Bld25-5-C	201	T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T
Bld25-5-D	202	G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C*C*T
Bld25-5-E	203	T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A*C
Bld26-2-A	204	C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A
Bld26-2-B	205	C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A*A*A
Bld26-2-C	206	C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A
Bld26-2-D	207	C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A
Bld26-B	208	C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A*G*A
Bld26-C	209	C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G*A*A, or
Bld26-D	210	C*A*C*T*C*T*C*T*T*G*A*A*T*G*G*A*C*C*C*A*G.

wherein * represents a phosphorothioate linkage, and each sugar of the oligonucleotides is a 2'-MOE modified sugar.

126. An oligonucleotide composition comprising a mixture of two or more oligonucleotides according to any one of claims 1-120.

127. The composition of claim 126, wherein the composition comprises oligonucleotides that target regions of the MuSK genomic sequence that correspond to positions 83776-83800 and/or 83854-83878 of SEQ ID NO: 77.

128. A pharmaceutical composition comprising a therapeutically effective amount of an oligonucleotide, and at least one pharmaceutically acceptable inactive ingredient selected from pharmaceutically acceptable diluents, pharmaceutically acceptable excipients, and pharmaceutically acceptable carriers, wherein the oligonucleotide is an oligonucleotide of any one of claims 1-127.

129. The composition of any one of claims 1-128, wherein the oligonucleotides are formulated a nanocarrier.

130. The composition of any one of claims 129, wherein the oligonucleotides are formulated in lipid nano-particles (LNPs).

131. The composition of composition of any one of claims 1-128, wherein the oligonucleotides are covalently conjugated to an additional moiety selected from lipids (for example, cholesterol), peptides, aptamers, antibodies, and sugars (for example, N-acetylgalactosamine (GalNAc).

132. The composition of composition of claim 131, wherein the oligonucleotides are covalently conjugated to N-acetylgalactosamine (GalNAc).

133. A method of altering relative amounts of MuSK spliced transcripts, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of claims 1-132.

134. The method of claim 133, wherein the alteration of MuSK spliced transcripts being characterized in that, the ratio of MuSK transcripts containing Ig3 domain-encoding sequences to MuSK transcription containing no Ig3 domain-encoding sequences is increased.

135. The method of claim 133, wherein the alteration of MuSK spliced transcripts being characterized in that, the ratio of MuSK transcripts containing Ig3 domain-encoding sequences to MuSK transcription containing no Ig3 domain-encoding sequences decreases.

136. The method of claim 133, wherein the alteration of MuSK spliced transcripts being characterized in that MuSK transcripts containing Ig3 domain-encoding sequences decreases and level of total MuSK transcripts remains substantially the same.

137. The method of claim 133, wherein the alteration of MuSK spliced transcripts is characterized in that, the level of MuSK transcripts including exons 6 and 7 decreases or level of MuSK protein forms including sequences encoded by exons 6 and 7 decreases, or both.

138. The method of claim 133, wherein the alteration of MuSK spliced transcripts being characterized in that, level of MuSK transcripts including exons 6 and 7 is increased or level of MuSK protein forms including sequences encoded by exons 6 and 7 is increased, or both.

139. The method of any one of claims 133 and 136-138, wherein the alteration of MuSK spliced transcripts is characterized in that, the level of MuSK transcripts including exons 3 and 4 decreases or level of MuSK protein forms including sequences encoded by exons 3 and 4 decreases, or both.

140. The method of any one of claims 133 and 136-138, wherein the alteration of MuSK spliced transcripts is characterized in that, the level of MuSK transcripts including exons 3 and 4 is increased or level of MuSK protein forms including sequences encoded by exons 3 and 4 is increased, or both.

141. The method of any one of claims 133, and 136-138, wherein the alteration of MuSK spliced transcripts being characterized in that, the level of MuSK transcripts including exons 3 and 4 remains substantially the same, or level of MuSK protein forms including sequences encoded by exons 3 and 4 remains substantially the same, or both.

142. The method of any one of claims 133 and 136-138, wherein the alteration of MuSK spliced transcripts are characterized in that,

the level of MuSK transcripts including exons 3 and 4 remains substantially the same, or level of MuSK protein forms including sequences encoded by exons 3 and 4 remains substantially the same, or both; and

the level of MuSK transcripts including exons 6 and 7 decreases or level of MuSK protein forms including sequences encoded by exons 6 and 7 decreases, or both.

143. A method of treating a subject suffering from one or more features of neurodegenerative diseases, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of claims 1-132.

144. A method of increasing neurogenesis, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of claims 1-132.

145. A method of treating a subject suffering from one or more features of neuromuscular dysfunction or a muscular dystrophy, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of claims 1-132.

146. A method of increasing muscle regeneration and/or muscle growth, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of claims 1-132.

147. A method of treating muscle fibrosis, the method comprising a step of administering to a subject a pharmaceutical composition that comprises or delivers a composition of any one of claims 1-132.

148. The method of any one of claims 142 and 145, wherein the subject is at risk of, or afflicted with, a disease or disorder selected from the group consisting of: neuromuscular

dysfunction, neurodegenerative disorder, cardiac disorder, and diseases characterized by muscle wasting.

149. The method of claim 148, wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's Disease (AD), Parkinson's disease, dementia (e.g., Frontotemporal dementia), stroke, Major Depressive Disorder (MDD), bipolar disorder, Schizophrenia, Post-Traumatic Stress Disorder (PTSD), substance-related and addictive disorders (e.g., chronic cocaine use and lifelong cigarette smoking), Temporal-Lobe Epilepsy, Hippocampal Sclerosis, Niemann Pick Type C, Diabetes-mediated hippocampal neuronal loss, brain injury (e.g., traumatic and/or anoxic brain injury), and Huntington's disease.

150. The method of claim 149, wherein the neurodegenerative disease is Alzheimer's Disease (AD).

151. The method of claim 148, wherein the neuromuscular dysfunction is a muscular dystrophy selected from the group consisting of: Becker, Congenital, Distal, Duchenne, Emery-Dreifuss, Facioscapulohumeral, Limb-girdle, Myotonic, and Oculo-pharyngeal muscular dystrophy.

152. The method of claim 151 wherein the cardiac disorder is myocardial infarction or cardiomyopathy.

153. The method of any one of claims 142-145, wherein the subject is in need of enhanced muscle regeneration and/or growth following a condition selected from the group consisting of: surgery, trauma and prolonged immobilization.

154. The method of claim 153, wherein the prolonged immobilization results from bed-rest or casting.

155. The method of any one of claims 143-145, wherein the subject is at risk of, or afflicted with, sarcopenia.

156. The method of any one of claims 143-145, wherein the subject is at risk of, or afflicted with, muscle fibrosis resulting from a disease or condition selected from the group consisting of: trauma, heritable disease, muscle disorder, and aging.

157. The method of claim 156, wherein the trauma is the result of a condition selected from the group consisting of: radiation treatment, crush injury, laceration, and amputation.

158. The method of claim 156, wherein the heritable disease or muscle disorder selected from the group consisting of: Congenital Muscular Dystrophy, Duchenne Muscular Dystrophy, Becker's Muscular Dystrophy; Amyotrophic Lateral Sclerosis (ALS), and age-associate sarcopenia.

159. The method of any one of claims 145-158, wherein the composition is delivered to the CNS.

160. The method of any one of claims 144-158, wherein the composition is delivered to the cerebrospinal fluid.

161. The method of any one of claims 144-158, wherein the composition is delivered to the muscle.

162. The method of any one of claims 144-158, wherein the composition is delivered to the liver.

163. The method of any one of claims 144-158, wherein the composition can be formulated for systemic or localized administration.

164. The method of claim 163, wherein the composition is formulated for delivery by a route selected from intravenous injection, intravenous infusion, intramuscular injection, intrathecal administration, oral administration, buccal administration, inhalation, nasal administration, topical administration, ophthalmic administration or otic administration.

165. The method of claim 164, wherein the composition is formulated for delivery by intramuscular administration.

166. The method of claim 164, wherein the composition is formulated for delivery by intravenous administration.

167. The method of claim 164, wherein the composition is formulated for delivery by oral administration.




RNA Sequence
Exon-skipping ASO
MuSK-FL
MuSK-Δlg3
... exon 4 exon 5 exon 6 exon 7 exon 8 exon 9 ...
... exon 4 exon 5 exon 8 exon 9 ...
Protein
IG1
IG2
IG3
FZ
CRD
BMP
Outcomes
BMP Signal
Neurogenesis and Cognition
BMP Signal
Neurogenesis and Cognition

FIG. 1



Our objective: Identify ASOs that reduce the level of 6-7 containing MuSK (FL) but maintain the total MuSK levels.

FIG. 2



MuSK/YWHAZ - LHCN-M2 - Taqman
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Contro...
Contro...
SMN-AS1
SMN-AS1
SMN-AS1
SMN-AS1
MuSK/YWHAZ - LHCN-M2 - Sybrgreen
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Ctrl
Ctrl
SMN-AS1
SMN-AS1
SMN-AS1
SMN-AS1

FIG. 3




FIG. 4



Human mRNA
5′ 3′
ASOs 3′ 5
1d1
1d2
1d3
1d4
1d5
1d6
1d7
1d8
1d9
1d10
1d11
1d12
1d13
1d14
1d15
1d16
1d17
1d18

FIG. 5



control
Bld1
Bld2
Bld3
Bld4
Bld6
Bld7
Bld9
Bld11
Bld12
Bld13
Bld14
Bld15
Bld16
Bld17

FIG. 6



MuSK34/HKG 100nM
MuSK67/HKG 100nM
MuSK34/HKG 50nM
MuSK67/HKG 50nM
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
1pre
2pre
3pre
4pre
5pre
6pre
7pre
8pre
9pre
10pre
11pre
12pre
13pre
14pre
15pre
16pre
17pre
18pre

FIG. 7



Human mRNA
5′3′
ASOs 3′5
B1d1
B1d2
B1d3
B1d4
B1d5
B1d6
B1d7
B1d8
B1d9
B1d10
B1d11
B1d12
B1d13
B1d14
B1d15
B1d16
B1d17
B1d18

FIG. 8



Human mRNA 5' 3' ASOs 3' 5'
B1d19
B1d20
B1d21
B1d22
B1d23
B1d24
B1d25
B1d26
B1d27
B1d28
B1d29
B1d30
B1d31
B1d32
B1d33
B1d34
B1d35
B1d36
B1d37
B1d38

FIG. 9



control
Bld19
Bld20
Bld21
Bld22
Bld29
Bld30
Bld31
Bld32
Bld33
Bld34

FIG. 10



MuSK34/HKG 100nM
MuSK67/HKG 100nM
MuSK34/HKG 50nM
MuSK67/HKG 50nM

FIG. 11



Human mRNA 5' 3' ASOs 3' 5'
B1d19
B1d20
B1d21
B1d22
B1d23
B1d24
B1d25
B1d26
B1d27
B1d28
B1d29
B1d30
B1d31
B1d32
B1d33
B1d34
B1d35
B1d36
B1d37
B1d38

FIG. 12



A Bld25
B Bld26
C Bld27
D Bld28
E Bld35
F Bld38
MuSK34
MuSK67
IC50 = 11.5nM
→ MuSK34 75%
IC50 = 11.4 nM
→ MuSK34 84%
IC50 = 14 nM
→ MuSK34 76%
IC50 = 15.8 nM
→ MuSK34 85%
IC50 = 125nM
→ MuSK34 62%
IC50 = 55nM
→ MuSK34 77%
Relative gene expression
Concentration (nM)

FIG. 13



A Bld25
B Bld26
MuSK34
MuSK67
Relative gene expression
Concentration (nM)
5nM
7.5nM
12.5nM
25nM
40.0
0.0
0.2
0.4
0.6
0.8
1.0
1.2

FIG. 14



Total MuSK
Ig3 domain
72%
6%
Gene expression
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Untreated
Bld25+Bld26

FIG. 15



A
2500
800
350
hu7-10 ctrl
hu7-10 5nM
hu7-10 25nM
hu73 ctrl
hu73 5nM
hu73 25nM
LoNB
Short
B
2500
800
350
hu7-10 ctrl
1-FL-977
2/3- Δ8
738/708
B'
hu7-10 25nM
1-Δig3 (Δ6,7)
687
2/3-Δig3
(Δ(5+),6,7,8)
453

FIG. 16

Human mRNA 5'3'	...GACTGAGTTCTTTTATTTTCCTTTACTCTGTCAG
ASOs 3'5':	
B1d51	AAAGAAGACCCAGGTAAGTT
B1d52	AAGAAGACCCAGGTAAGTTC
B1d53	AGAAGACCCAGGTAAGTTCT
B1d54	GAAGACCCAGGTAAGTTCTC
B1d55	AAGACCCAGGTAAGTTCTCT
B1d56	AGACCCAGGTAAGTTCTCTC
B1d57	GACCCAGGTAAGTTCTCTCA
B1d58	ACCCAGGTAAGTTCTCTCAC
B1d59	CCCAGGTAAGTTCTCTCACA
B1d60	CCAGGTAAGTTCTCTCACAC
B1d61	CAGGTAAGTTCTCTCACACT
B1d62	AGGTAAGTTCTCTCACACTT
B1d63	GGTAAGTTCTCTCACACTTT
B1d64	GTAAGTTCTCTCACACTTTC
B1d65	TAAGTTCTCTCACACTTTCT
B1d66	AAGTTCTCTCACACTTTCTG

FIG. 17



A
Gene expression – ASO at 12.5 nM
Total MuSK
Ig3 domain
2
1.5
1
0.5
0
T5pIB
Z5pIB
E5pIB
4SpIB
5SpIB
9SpIB
S5pIB
Z5pIB
6SpIB
8SpIB
09pIB
T9pIB
Z9pIB
E9pIB
4GpIB
S9pIB
99pIB
B
Gene expression – ASO at 100 nM
2
1.5
1
0.5
0
T5pIB
Z5pIB
E5pIB
4SpIB
5SpIB
9SpIB
S5pIB
Z5pIB
6SpIB
8SpIB
09pIB
T9pIB
Z9pIB
E9pIB
4GpIB
S9pIB
99pIB

FIG. 18



region1
exon7
Human mRNA 5'3'
GACTGAGTTCTTTTATTTTCCTTTACTCTGTCAG
ASOs 3'5':
Bld25-1
GAAATGAGACAGTCCAAAGAAGACC
Bld25-2
AATGAGACAGTCCAAAGAAGACCCA
Bld25
TGAGACAGTCCAAAGAAGACCCAGG
Bld25-3
AGACAGTCCAAAGAAGACCCAGGTA
Bld25-4
ACAGTCCAAAGAAGACCCAGGTAAG
Bld25-5
GTCCAAAGAAGACCCAGGTAAGTTC
Bld26-1
CCAAAGAAGACCCAGGTAAGTTCTC
Bld26-2
AAAGAAGACCCAGGTAAGTTCTCTC
Bld26
AGAAGACCCAGGTAAGTTCTCTCAC
Bld26-3
AAGACCCAGGTAAGTTCTCTCACAC
Bld26-4
GACCCAGGTAAGTTCTCTCACACTT
Bld27
AGTTCTCTCACACTTTCTGGCTCAC
Bld28
TTTCTGGCTCACTAACTGAGTTCTG
region2
exon7
Human mRNA 5'3'
Bld35
CCCCTCTTCAAGTCATGACGGTTCC
Bld38
TCCATCCTACGGGGAAGTGTAAACG

FIG. 19



A
25 mers - MuSK67
gene expression - MuSK67
ASO concentration (nM)
B
25 mers - MuSK34
gene expression - MuSK34
ASO concentration (nM)
Bld25-1
Bld25-2
Bld25
Bld25-3
Bld25-4
Bld25-5
Bld26-1
Bld26-2
Bld26
Bld26-3
Bld26-4
Bld27
Bld28
Bld35
Bld38

FIG. 20



A
25 mers - MuSK67
gene expression - MuSK67
ASO concentration (nM)
Bid25
Bid25-3
Bid25-4
Bid25-5
Bid26-2
Bid26
Bid26-4
B
25 mers - MuSK34
gene expression - MuSK34
ASO concentration (nM)

FIG. 21



A
Bid25 - 24h
B
Bid25-5 24h
Total MuSK
Ig3 domain
C
Bid25 - 48h
D
Bid25-5 - 48h
% of correction
ASO concentration [nM]

FIG. 22

Human mRNA 5′3′	GACTGAGTTCTTTTATTTTCCTTTACTCTGTCAG[redacted]
ASOs 3′5:	
Bld25	TGAGACAGTCCAAAGAAGACCCAGG
Bld25-A	TGAGACAGTCCAAAGAAGACCCA
Bld25-B	TGAGACAGTCCAAAGAAGACC
Bld25-C	AGACAGTCCAAAGAAGACCCAGG
Bld25-D	AGACAGTCCAAAGAAGACCCA
Bld25-E	ACAGTCCAAAGAAGACCCAGG
Bld25-5	GTCCAAAGAAGACCCAGGTAAGTTC
Bld25-5-A	AGTCCAAAGAAGACCCAGGTAAG
Bld25-5-B	AGTCCAAAGAAGACCCAGGTA
Bld25-5-C	TCCAAAGAAGACCCAGGTAAGTT
Bld25-5-D	TCCAAAGAAGACCCAGGTAAG
Bld25-5-E	CAAAGAAGACCCAGGTAAGTT
Bld26-2	AAAGAAGACCCAGGTAAGTTCTCTC
Bld26-2-A	AAAGAAGACCCAGGTAAGTTCTC
Bld26-2-B	AAAGAAGACCCAGGTAAGTTC
Bld26-2-C	AGAAGACCCAGGTAAGTTCTCTC
Bld26-2-D	AAGACCCAGGTAAGTTCTCTC
Bld26	AGAAGACCCAGGTAAGTTCTCTCAC
Bld26-B	AGAAGACCCAGGTAAGTTCTC
Bld26-C	AAGACCCAGGTAAGTTCTCTCAC
Bld26-D	GACCCAGGTAAGTTCTCTCAC

FIG. 23



MuSK34 - MuSK67
Bid25 A
Bid25 B
Bid25 C
Bid25 D
Bid25 E
% of correction
ASO concentration [nM]

FIG. 24



MuSK34 - MuSK67
Bld23-5-A
Bld23-5-B
Bld23-5-C
Bld23-5-D
Bld23-5-E
% of correction
ASO concentration [nM]

FIG. 25



Variant1, NM_005592.4, full length: 972b – Δlg3: 687b
AF006464.1
Exon 3
Exon 4
Exon 5
Exon 6
Exon 7
Exon 8
Exon 9/RV
Variant2, NM_001166280.2, full length: 738b – Δlg3: 453b
BC109098.1, Strausberg et al., PNAS December 24, 2002 99 (26) 16899-16903; https://doi.org/10.1073/pnas.242603899
Exon 3
Exon 4
Exon 5
Exon 6
Exon 7
Exon 9/RV
Variant3, NM_001166281.2, full length: 708b – Δlg3: 423b
BC109099.1, Strausberg et al., PNAS December 24, 2002 99 (26) 16899-16903; https://doi.org/10.1073/pnas.242603899
Exon 3
Exon 4
Exon 5
Exon 6
Exon 7
Exon 9/RV
Exon size (bp): 17 128 142 30 125 160 7 264 129

FIG. 26



Bld25
Intensity – Arbitrary units
2.5
2
1.5
1
0.5
0
C1
C2
C3
Bld25 Bld25 Bld25
1 2 3
upper band MuSK
lower band MuSK
4/5/6/7/EWS/8/9
4/5/6/7/EWS/8/9
4/5/6/7/EWS/8/9*
MuSK39
4/5/6/7/EWS/8/9
4/5/6/7/EWS/8/9
4/5/6/7/EWS/8/9*
YWHAZ
Bld25-5
2
1.5
1
0.5
0
C1
C2
C3
Bld25-5 Bld25-5 Bld25-5
1 2 3
4/5/6/7/EWS/8/9
4/5/6/7/EWS/8/9
4/5/6/7/EWS/8/9*

FIG. 27



Sequence of the first band with Bolden ASO:




FIG. 28



Scale 50um
Day 2
Day 3
Day 4
Day 5
untreated
+ siRNA
Scale 50um
+ siRNA
Day 5
untreated

FIG. 29